CINXE.COM

<!DOCTYPE html><html lang="en"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width"/><script src="https://cmp.osano.com/6olh2SicG0V81Mlk/1f9d883d-3834-40b9-9a96-6f89a1cda98b/osano.js"></script><title>Biosimilars</title><meta name="description" content="The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates."/><meta property="og:url" content="https://www.ajmc.com/compendium/biosimilars "/><meta property="og:title" content="Biosimilars"/><meta property="og:image" content="https://s3.amazonaws.com/mjhlifesciences.com/sitelogos/AJMC_1200x637.png"/><meta property="og:site_name" content="AJMC"/><meta property="og:description" content="The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates."/><meta name="twitter:card" content="summary"/><meta name="twitter:title" content="Biosimilars"/><meta name="twitter:image" content="https://s3.amazonaws.com/mjhlifesciences.com/sitelogos/AJMC_1200x637.png"/><meta name="twitter:site" content="@@AJMC_Journal"/><meta name="twitter:description" content="The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates."/><meta name="robots" content="max-image-preview:large"/><meta name="robots" content="max-video-preview:-1"/><link rel="preconnect dns-prefetch" href="https://cmp.osano.com"/><link rel="preconnect dns-prefetch" href="https://res.lassomarketing.io"/><link rel="preconnect dns-prefetch" href="https://www.lightboxcdn.com"/><link rel="preconnect dns-prefetch" href="https://pub.doubleverify.com"/><link rel="preconnect dns-prefetch" href="https://cdn.doubleverify.com"/><link rel="preconnect dns-prefetch" href="https://cdn.segment.com"/><link rel="preconnect dns-prefetch" href="https://securepubads.g.doubleclick.net"/><link rel="preconnect dns-prefetch" href="https://pagead2.googlesyndication.com"/><link rel="preconnect dns-prefetch" href="https://cdn.sanity.io"/><link rel="preconnect dns-prefetch" href="https://www.google-analytics.com"/><link rel="preconnect dns-prefetch" href="https://www.googletagmanager.com"/><link rel="preconnect dns-prefetch" href="https://player.vimeo.com"/><link rel="preconnect dns-prefetch" href="https://youtube.com"/><link rel="preconnect dns-prefetch" href="https://connect.facebook.net"/><link rel="preconnect dns-prefetch" href="https://www.facebook.com"/><link rel="preconnect dns-prefetch" href="https://static.ads-twitter.com"/><link rel="preconnect dns-prefetch" href="https://ad.doubleclick.net"/><link rel="preload" href="https://securepubads.g.doubleclick.net/tag/js/gpt.js"/><link rel="preload" href="https://pub.doubleverify.com/signals/pub.js#ctx=20083417&cmp=DV464021"/><link rel="icon" href="/favicon.ico"/><script async="" src="https://securepubads.g.doubleclick.net/tag/js/gpt.js"></script><script src="https://pub.doubleverify.com/signals/pub.js#ctx=20083417&cmp=DV464021"></script><script src="https://one.ajmc.com/tagmanager/scripts/one.js"></script><script>window.dataLayer = window.dataLayer || []; window.dataLayer.push({ event: "page_dimensions", pageTitle: "Biosimilars", dimension9: "compendium/biosimilars", dimension11: "", dimension12: "", dimension13: "", dimension14: "", dimension15: "compendium/biosimilars", dimension18: "", dimension19: "", dimension20: "", });</script><script type="module"> (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-NK5KQXS'); </script><script type="module"> var ALGOLIA_INSIGHTS_SRC = "https://cdn.jsdelivr.net/npm/search-insights@2.4.0"; !function(e,a,t,n,s,i,c){e.AlgoliaAnalyticsObject=s,e[s]=e[s]||function(){ (e[s].queue=e[s].queue||[]).push(arguments)},i=a.createElement(t),c=a.getElementsByTagName(t)[0], i.async=1,i.src=n,c.parentNode.insertBefore(i,c) }(window,document,"script",ALGOLIA_INSIGHTS_SRC,"aa");</script><link rel="canonical" href="https://www.ajmc.com/compendium/biosimilars"/><meta name="next-head-count" content="10"/><script async="" type="text/javascript" src="https://www.lightboxcdn.com/static/lightbox_mjh.js"></script><script defer="" src="https://res.lassomarketing.io/scripts/lasso-imp-id-min.js" type="text/javascript"></script> <script defer="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js"></script> <script type="module"> !function(){var analytics=window.analytics=window.analytics||[];if(!analytics.initialize)if(analytics.invoked)window.console&&console.error&&console.error("Segment snippet included twice.");else{analytics.invoked=!0;analytics.methods=["trackSubmit","trackClick","trackLink","trackForm","pageview","identify","reset","group","track","ready","alias","debug","page","once","off","on","addSourceMiddleware","addIntegrationMiddleware","setAnonymousId","addDestinationMiddleware"];analytics.factory=function(e){return function(){var t=Array.prototype.slice.call(arguments);t.unshift(e);analytics.push(t);return analytics}};for(var e=0;e<analytics.methods.length;e++){var key=analytics.methods[e];analytics[key]=analytics.factory(key)}analytics.load=function(key,e){var t=document.createElement("script");t.type="text/javascript";t.async=!0;t.src="https://cdn.segment.com/analytics.js/v1/" + key + "/analytics.min.js";var n=document.getElementsByTagName("script")[0];n.parentNode.insertBefore(t,n);analytics._loadOptions=e};analytics.SNIPPET_VERSION="4.13.1"; window.LassoImpressionID = lassoImpID(); analytics.load("BBbKMoOjmhsxPnbd2nO6osz3zq67DzuN"); analytics.page({ 'LassoImpressionID': window.LassoImpressionID }); }}(); </script> <link rel="preload" href="/_next/static/css/a929bdd3e91026fa.css" as="style"/><link rel="stylesheet" href="/_next/static/css/a929bdd3e91026fa.css" data-n-g=""/><link rel="preload" href="/_next/static/css/1fd9d1dcb68b7a42.css" as="style"/><link rel="stylesheet" href="/_next/static/css/1fd9d1dcb68b7a42.css" data-n-p=""/><link rel="preload" href="/_next/static/css/73c00cd95dc66651.css" as="style"/><link rel="stylesheet" href="/_next/static/css/73c00cd95dc66651.css" data-n-p=""/><link rel="preload" href="/_next/static/css/0f1de527bcd6b2b3.css" as="style"/><link rel="stylesheet" href="/_next/static/css/0f1de527bcd6b2b3.css" data-n-p=""/><noscript data-n-css=""></noscript><script defer="" nomodule="" src="/_next/static/chunks/polyfills-c67a75d1b6f99dc8.js"></script><script src="/_next/static/chunks/webpack-961be11aea234f76.js" defer=""></script><script src="/_next/static/chunks/framework-45ce3d09104a2cae.js" defer=""></script><script src="/_next/static/chunks/main-c1ce322a402d266c.js" defer=""></script><script src="/_next/static/chunks/pages/_app-4bfd1e1c0348d790.js" defer=""></script><script src="/_next/static/chunks/8eec4907-bd18a9d50c17fbc1.js" defer=""></script><script src="/_next/static/chunks/065a3ddb-42216585c327b2a5.js" defer=""></script><script src="/_next/static/chunks/9814d858-cb162ab048445baf.js" defer=""></script><script src="/_next/static/chunks/69bd6bf3-c7219ac9ecb38ac9.js" defer=""></script><script src="/_next/static/chunks/f36c6662-e730e1316f9aa347.js" defer=""></script><script src="/_next/static/chunks/72585f70-0d4479e14d41a365.js" defer=""></script><script src="/_next/static/chunks/59b4e022-07228b5f1b83aaf8.js" defer=""></script><script src="/_next/static/chunks/aeb74aa0-4e0b515016d20a9f.js" defer=""></script><script src="/_next/static/chunks/e893f787-08b93252db7fc864.js" defer=""></script><script src="/_next/static/chunks/e1efa4cc-06e900eb45581c19.js" defer=""></script><script src="/_next/static/chunks/c8eae200-9f0c2beb62006a40.js" defer=""></script><script src="/_next/static/chunks/a29ae703-70c961c34719afa8.js" defer=""></script><script src="/_next/static/chunks/4592-37f767f9d2e595fc.js" defer=""></script><script src="/_next/static/chunks/1212-e69ee8c76b24c02a.js" defer=""></script><script src="/_next/static/chunks/4179-91956f2d2c4bf724.js" defer=""></script><script src="/_next/static/chunks/9879-c84885d45ee98d34.js" defer=""></script><script src="/_next/static/chunks/9355-c793747e2dd7fab4.js" defer=""></script><script src="/_next/static/chunks/3499-b4daf1c9382343af.js" defer=""></script><script src="/_next/static/chunks/4386-1eb6319d7e5f2437.js" defer=""></script><script src="/_next/static/chunks/8421-a4cb4c694745bc83.js" defer=""></script><script src="/_next/static/chunks/8412-bd07abe8ce76d08f.js" defer=""></script><script src="/_next/static/chunks/430-ec5773e97694cd78.js" defer=""></script><script src="/_next/static/chunks/173-14593f6d6b9517b7.js" defer=""></script><script src="/_next/static/chunks/7707-0911877d2791a102.js" defer=""></script><script src="/_next/static/chunks/475-8933b8b0e2730387.js" defer=""></script><script src="/_next/static/chunks/9323-fbb62165c37c2d73.js" defer=""></script><script src="/_next/static/chunks/4978-6a483c0f48f7ecb4.js" defer=""></script><script src="/_next/static/chunks/4063-f338377ebed73baf.js" defer=""></script><script src="/_next/static/chunks/pages/%5B...slug%5D-1b8b61a43bc98d83.js" defer=""></script><script src="/_next/static/IRrGcHGbYOSE-7JrEGg8a/_buildManifest.js" defer=""></script><script src="/_next/static/IRrGcHGbYOSE-7JrEGg8a/_ssgManifest.js" defer=""></script><style id="__jsx-1661e6713d4eb9b5">.leaderboardAdWrapper.jsx-1661e6713d4eb9b5{min-height:90px;background:#fff}.leaderboardAdWrapper.jsx-1661e6713d4eb9b5 .AD728x90.jsx-1661e6713d4eb9b5{}@media screen and (min-width:768px){.leader-fixed.jsx-1661e6713d4eb9b5{position:fixed;margin-top:1rem;z-index:999999}}.leaderboardAdWrapper.jsx-1661e6713d4eb9b5 .AD728x90.jsx-1661e6713d4eb9b5 div[id*="google_ads_iframe"].jsx-1661e6713d4eb9b5:empty{height:0px!important}@media screen and (max-width:668px){.leaderboardAdWrapper.jsx-1661e6713d4eb9b5{min-height:0px;position:fixed;background:white;left:0;right:0;top:55px;padding-top:.5rem;padding-bottom:.25rem;z-index:9999}}</style><style id="__jsx-1215160397">.bottomDiv.jsx-1215160397{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-1215160397::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-1215160397::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-1215160397{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-1215160397{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-1215160397{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore0undefined.jsx-1215160397:hover{background:var(--secondary)}.view-more-wrap0undefined.jsx-1215160397{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap0undefined.jsx-1215160397:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-1215160397{background-position:right bottom}.text-white.jsx-1215160397{color:var(--primary)}</style><style id="__jsx-1637274924">.bottomDiv.jsx-1637274924{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-1637274924::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-1637274924::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-1637274924{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-1637274924{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-1637274924{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore1undefined.jsx-1637274924:hover{background:var(--secondary)}.view-more-wrap1undefined.jsx-1637274924{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap1undefined.jsx-1637274924:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-1637274924{background-position:right bottom}.text-white.jsx-1637274924{color:var(--primary)}</style><style id="__jsx-286612495">.bottomDiv.jsx-286612495{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-286612495::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-286612495::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-286612495{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-286612495{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-286612495{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore2undefined.jsx-286612495:hover{background:var(--secondary)}.view-more-wrap2undefined.jsx-286612495{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap2undefined.jsx-286612495:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-286612495{background-position:right bottom}.text-white.jsx-286612495{color:var(--primary)}</style><style id="__jsx-2915913710">.bottomDiv.jsx-2915913710{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-2915913710::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-2915913710::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-2915913710{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-2915913710{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-2915913710{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore3undefined.jsx-2915913710:hover{background:var(--secondary)}.view-more-wrap3undefined.jsx-2915913710{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap3undefined.jsx-2915913710:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-2915913710{background-position:right bottom}.text-white.jsx-2915913710{color:var(--primary)}</style><style id="__jsx-2363373513">.bottomDiv.jsx-2363373513{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-2363373513::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-2363373513::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-2363373513{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-2363373513{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-2363373513{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore4undefined.jsx-2363373513:hover{background:var(--secondary)}.view-more-wrap4undefined.jsx-2363373513{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap4undefined.jsx-2363373513:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-2363373513{background-position:right bottom}.text-white.jsx-2363373513{color:var(--primary)}</style><style id="__jsx-19ede9f0a5a45918">.jsx-19ede9f0a5a45918::-webkit-scrollbar{display:none}</style><style id="__jsx-2785488040">.bottomDiv.jsx-2785488040{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-2785488040::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-2785488040::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-2785488040{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-2785488040{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-2785488040{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore5undefined.jsx-2785488040:hover{background:var(--secondary)}.view-more-wrap5undefined.jsx-2785488040{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap5undefined.jsx-2785488040:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-2785488040{background-position:right bottom}.text-white.jsx-2785488040{color:var(--primary)}</style><style id="__jsx-1434825611">.bottomDiv.jsx-1434825611{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-1434825611::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-1434825611::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-1434825611{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-1434825611{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-1434825611{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore6undefined.jsx-1434825611:hover{background:var(--secondary)}.view-more-wrap6undefined.jsx-1434825611{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap6undefined.jsx-1434825611:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-1434825611{background-position:right bottom}.text-white.jsx-1434825611{color:var(--primary)}</style><style id="__jsx-4064126826">.bottomDiv.jsx-4064126826{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-4064126826::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-4064126826::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-4064126826{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-4064126826{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-4064126826{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore7undefined.jsx-4064126826:hover{background:var(--secondary)}.view-more-wrap7undefined.jsx-4064126826{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap7undefined.jsx-4064126826:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-4064126826{background-position:right bottom}.text-white.jsx-4064126826{color:var(--primary)}</style><style id="__jsx-187450181">.bottomDiv.jsx-187450181{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-187450181::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-187450181::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-187450181{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-187450181{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-187450181{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore8undefined.jsx-187450181:hover{background:var(--secondary)}.view-more-wrap8undefined.jsx-187450181{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap8undefined.jsx-187450181:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-187450181{background-position:right bottom}.text-white.jsx-187450181{color:var(--primary)}</style><style id="__jsx-609564708">.bottomDiv.jsx-609564708{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-609564708::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-609564708::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-609564708{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-609564708{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-609564708{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore9undefined.jsx-609564708:hover{background:var(--secondary)}.view-more-wrap9undefined.jsx-609564708{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap9undefined.jsx-609564708:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-609564708{background-position:right bottom}.text-white.jsx-609564708{color:var(--primary)}</style><style id="__jsx-229659467">.bottomDiv.jsx-229659467{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-229659467::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-229659467::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-229659467{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-229659467{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-229659467{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore02bfeb2a2-17ae-49a2-9a42-f5875df7fb07.jsx-229659467:hover{background:var(--secondary)}.view-more-wrap02bfeb2a2-17ae-49a2-9a42-f5875df7fb07.jsx-229659467{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap02bfeb2a2-17ae-49a2-9a42-f5875df7fb07.jsx-229659467:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-229659467{background-position:right bottom}.text-white.jsx-229659467{color:var(--primary)}</style><style id="__jsx-ad50481d5ee26850">@media(min-width:980px)and (max-width:1200px){.article-detail.jsx-ad50481d5ee26850{width:47%}}@media(min-width:1201px)and (max-width:1400px){.article-detail.jsx-ad50481d5ee26850{width:55%}}</style></head><body><div id="__next" data-reactroot=""><div class="-mb-6"><div id="frame-nav" class="sticky top-0 z-[999999]"><div class="h-full w-full"><nav role="navigation" class=" w-full mx-auto hidden lg:block bg-white shadow-md relative"><div class="bg-primary" id="topnav"><div class="container px-4 relative justify-between h-16 flex items-center md:items-stretch mx-auto "><div class="h-full flex items-center flex-1 justify-between mr-4"><a role="img" aria-label="logo" class="focus:outline-none relative h-12 w-40 mr-6 flex items-center" href="/"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;object-position:left"/><noscript><img sizes="100vw" srcSet="/_next/image?url=%2Fajmc_logo_inverted.png&w=640&q=75 640w, /_next/image?url=%2Fajmc_logo_inverted.png&w=750&q=75 750w, /_next/image?url=%2Fajmc_logo_inverted.png&w=828&q=75 828w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1080&q=75 1080w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1200&q=75 1200w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1920&q=75 1920w, /_next/image?url=%2Fajmc_logo_inverted.png&w=2048&q=75 2048w, /_next/image?url=%2Fajmc_logo_inverted.png&w=3840&q=75 3840w" src="/_next/image?url=%2Fajmc_logo_inverted.png&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;object-position:left" loading="lazy"/></noscript></span></a><div class="hidden md:block"><div class="bg-primary py-2 whitespace-nowrap"><div class="mx-auto md:max-w-4xl lg:max-w-5xl xl:max-w-7xl "><div class="flex gap-4 items-end"><div class=" isolate z-[10000] " data-headlessui-state=""><button class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center tracking-normal capitalize text-white" type="button" aria-expanded="false" data-headlessui-state="">News<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><div class="sr-only"><a href="/news" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">All News</a><a href="/press-release" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Press Releases</a><a href="/approvals-launches" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Product Approvals and Launches</a></div></div><div class=" isolate z-[10000] " data-headlessui-state=""><button class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center tracking-normal capitalize text-white" type="button" aria-expanded="false" data-headlessui-state="">Video<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><div class="sr-only"><a href="/video-hub" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">All Video Types</a><a href="/interviews" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">AJMC TV</a><a href="/guidelines" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Guidelines</a><a href="/insights" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Insights</a><a href="/onlocation" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">OnLocation</a><a href="/payer-perspectives" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Payer Perspectives</a><a href="/peer-exchange" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Peer Exchange</a><a href="/post-conference-perspectives" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Post Conference Perspectives</a><a href="/stakeholder-summit" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Stakeholder Summit</a></div></div><a class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center text-sm tracking-normal capitalize text-white" href="/podcasts">Podcasts</a><div class=" isolate z-[10000] " data-headlessui-state=""><button class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center tracking-normal capitalize text-white" type="button" aria-expanded="false" data-headlessui-state="">Conferences<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><div class="sr-only"><a href="/latest-conference" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Conference Coverage</a><a href="/conference" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Conference Listing</a><a href="/post-conference-perspectives" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Post Conference Perspectives</a></div></div><div class=" isolate z-[10000] " data-headlessui-state=""><button class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center tracking-normal capitalize text-white" type="button" aria-expanded="false" data-headlessui-state="">Journals<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><div class="sr-only"><a href="/publications" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">All Journals</a><a href="/publications/issue" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">The American Journal of Managed Care</a><a href="/publications/ajac" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Population Health, Equity & Outcomes</a><a href="/publications/evidence-based-oncology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Evidence-Based Oncology</a><a href="/supplement" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">About Supplements and Featured Publications</a><a href="/publications/supplement" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Supplements and Featured Publications Issues</a><a href="/submit-a-manuscript" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Submit a Manuscript</a></div></div><div class=" isolate z-[10000] " data-headlessui-state=""><button class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center tracking-normal capitalize text-white" type="button" aria-expanded="false" data-headlessui-state="">Events<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><div class="sr-only"><a href="/ivbmevents" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Institute for Value-Based Medicine</a><a href="https://pcoc.ajmc.com/" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Patient-Centered Oncology Care</a></div></div><div class=" isolate z-[10000] " data-headlessui-state=""><button class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center tracking-normal capitalize text-white" type="button" aria-expanded="false" data-headlessui-state="">Resources<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><div class="sr-only"><a href="/interactive-tools" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Interactive Tools</a><a href="/formulary" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Formulary Central</a><a href="/clinical-spotlight" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Clinical Spotlight</a><a href="/custom-email" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Microsites</a><a href="/sponsored" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Sponsored Content</a></div></div><a class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center text-sm tracking-normal capitalize text-white" href="/continuing-education">CE</a><div class=" isolate z-[10000] " data-headlessui-state=""><button class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center tracking-normal capitalize text-white" type="button" aria-expanded="false" data-headlessui-state="">About AJMC<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><div class="sr-only"><a href="/editorial" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">AJMC Staff</a><a href="/anniversary" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Anniversary</a><a href="/about/seema-sonnad-nomination" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Seema Sonnad Award</a><a href="/partners" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Strategic Alliance Partners</a></div></div></div></div></div></div></div><div class="md:flex items-center justify-end hidden"><div class="flex items-center"><div class="md:pr-10 lg:pr-0 h-full flex items-center"><button class="w-6 h-6 relative"><svg xmlns="http://www.w3.org/2000/svg" class="text-white stroke-current icon icon-tabler icon-tabler-search" viewBox="0 0 24 24" stroke-width="1.5" stroke="currentColor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"></path><circle cx="10" cy="10" r="7"></circle><line x1="21" y1="21" x2="15" y2="15"></line></svg></button><div class="hidden bg-secondary p-4 rounded shadow-lg top-16 right-0 overflow-hidden absolute grid place-items-center z-[99999] "><form method="GET" action="/search"><div class="relative"><div class="text-gray-600 absolute ml-3 inset-0 m-auto lg:w-4 lg:h-4 md:w-6 md:h-6"><button aria-label="submit" type="submit" class="absolute block inset-0"><svg xmlns="http://www.w3.org/2000/svg" class="text-gray-600 stroke-current icon icon-tabler icon-tabler-search" viewBox="0 0 24 24" stroke-width="2" stroke="currentColor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"></path><circle cx="10" cy="10" r="7"></circle><line x1="21" y1="21" x2="15" y2="15"></line></svg></button></div><input type="text" required="" name="searchTerm" class="block border border-gray-200 focus:outline-none focus:border-indigo-700 lg:w-48 xl:w-64 rounded text-sm text-gray-800 pl-8 py-2" placeholder="Search"/></div></form></div></div></div><a href="https://one.ajmc.com/subscribe" class="bg-subscribe-btn rounded text-white py-1.5 px-3 text-[14px] ml-4 uppercase font-semibold">Subscribe</a></div></div></div><div class="bg-white" id="bottomnav"><div style="max-height:60px" class="px-4 transition-all container justify-between h-14 flex items-center md:items-stretch mx-auto"><div class="h-full w-full flex items-center justify-between relative"><div class="flex flex-row gap-2 mr-4"><div class="relative"><div class="block"><div class=""><div class="mx-auto md:max-w-4xl lg:max-w-5xl xl:max-w-7xl "><div class="flex gap-4 justify-start"><div class=" isolate z-[9999] " data-headlessui-state=""><button class="focus:outline-none rounded font-medium cursor-pointer h-full flex items-center text-xs md:text-sm h-[34px] px-2 py-2 md:px-4 tracking-normal capitalize brightness-[85%] bg-primary text-gray-50 lg:min-w-[140px] justify-between" type="button" aria-expanded="false" data-headlessui-state="">Specialty Area<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><nav role="navigation" aria-label="Specialty Area" class="sr-only"><div><a href="/compendium/biosimilars" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Biosimilars</a></div><div><a href="/compendium/cardiorenalmetabolic" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Cardiorenalmetabolic</a><a href="/compendium/cardiovascular" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Cardiovascular</a><a href="/compendium/ckd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Chronic Kidney Disease</a><a href="/compendium/diabetes" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Diabetes</a><a href="/compendium/heart-failure" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Heart Failure</a><a href="/compendium/type1diabetes" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Type 1 Diabetes</a></div><div><a href="/compendium/dermatology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Dermatology</a><a href="/compendium/alopecia" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Alopecia</a><a href="/compendium/atopic-dermatitis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Atopic Dermatitis</a><a href="/compendium/psoriasis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Psoriasis</a></div><div><a href="/compendium/gastroenterology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Gastroenterology</a></div><div><a href="/compendium/hematology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Hematology</a><a href="/compendium/all" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">ALL/AML</a><a href="/compendium/cll" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">CLL/SLL</a><a href="/compendium/gvhd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">GVHD</a><a href="/compendium/hemophilia" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Hemophilia</a><a href="/compendium/multiple-myeloma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Multiple Myeloma</a><a href="/compendium/myelodysplastic-syndromes" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Myelodysplastic Syndromes</a><a href="/compendium/mpn" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Myeloproliferative Neoplasms</a><a href="/compendium/nhl" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Non-Hodgkin Lymphoma</a><a href="/compendium/rareblood" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Rare Blood</a></div><div><a href="/compendium/hepatology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Hepatology</a><a href="/compendium/liver-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Liver</a></div><div><a href="/compendium/immunology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Immunology</a><a href="/compendium/autoimmune" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Autoimmune</a><a href="/compendium/Inflammation" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Inflammation</a><a href="/compendium/lupus" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Lupus</a><a href="/compendium/myasthenia-gravis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Myasthenia Gravis</a></div><div><a href="/compendium/infectious-disease" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Infectious Disease</a><a href="/compendium/covid-19" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">COVID-19</a><a href="/compendium/hiv" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">HIV</a><a href="/compendium/rsv" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">RSV</a><a href="/compendium/vaccines" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Vaccines</a></div><div><a href="/compendium/mash" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">MASH</a></div><div><a href="/compendium/mental-health" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Mental Health</a><a href="/compendium/mdd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Major Depressive Disorder</a><a href="/compendium/sleep" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Sleep</a></div><div><a href="/compendium/neurology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Neurology</a><a href="/compendium/dmd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Duchenne Muscular Dystrophy</a><a href="/compendium/epilepsy" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Epilepsy</a><a href="/compendium/multiple-sclerosis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Multiple Sclerosis</a><a href="/compendium/parkinson" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Parkinson Disease</a></div><div><a href="/compendium/obesity" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Obesity</a></div><div><a href="/compendium/oncology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Oncology</a><a href="/compendium/breast-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Breast Cancer</a><a href="/compendium/cholangiocarcinoma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Cholangiocarcinoma</a><a href="/compendium/colorectal-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Colorectal Cancer</a><a href="/compendium/immuno-oncology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Immuno-Oncology</a><a href="/compendium/liver-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Liver Cancer</a><a href="/compendium/nsclc" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Non–Small Cell Lung Cancer</a><a href="/compendium/ovarian-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Ovarian Cancer</a><a href="/compendium/prostate-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Prostate Cancer</a><a href="/compendium/skincancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Skin Cancer</a><a href="/compendium/lung-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Small Cell Lung Cancer</a><a href="/compendium/soft-tissue-sarcoma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Soft Tissue Sarcoma</a></div><div><a href="/compendium/ophthalmology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Ophthalmology</a></div><div><a href="/compendium/pulmonology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Pulmonology</a><a href="/compendium/copd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">COPD</a><a href="/compendium/pah" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Pulmonary Arterial Hypertension</a></div><div><a href="/compendium/raredisease" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Rare Disease</a><a href="/compendium/sma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Spinal Muscular Atrophy</a></div><div><a href="/compendium/respiratory" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Respiratory</a><a href="/compendium/asthma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Asthma</a><a href="/compendium/ipf" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Idiopathic Pulmonary Fibrosis</a></div><div><a href="/compendium/rheumatology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Rheumatology</a></div><div><a href="/compendium/womens-health" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Women's Health</a></div></nav></div></div></div></div></div></div><div class="relative"><div class="block"><div class=""><div class="mx-auto md:max-w-4xl lg:max-w-5xl xl:max-w-7xl "><div class="flex gap-4 justify-start"><div class=" isolate z-[9999] " data-headlessui-state=""><button class="focus:outline-none rounded font-medium cursor-pointer h-full flex items-center text-xs md:text-sm h-[34px] px-2 py-2 md:px-4 tracking-normal capitalize brightness-[85%] bg-primary text-gray-50 lg:min-w-[140px] justify-between" type="button" aria-expanded="false" data-headlessui-state="">Topics<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><nav role="navigation" aria-label="Topics" class="sr-only"><div><a href="/compendium/biosimilars" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Biosimilars</a></div><div><a href="/topic/center-on-health-equity-and-access" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Center on Health Equity & Access</a></div><div><a href="/compendium/digital-health" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Digital Health</a></div><div><a href="/formulary" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Formulary</a></div><div><a href="/compendium/gene-therapy" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Gene Therapy</a></div><div><a href="/guidelines" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Guidelines</a></div><div><a href="/topic/healthcare-cost" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Health Care Cost</a></div><div><a href="/topic/healthcare-delivery" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Health Care Delivery</a></div><div><a href="/topic/insurance" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Insurance</a></div><div><a href="/topic/policy" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Policy</a></div><div><a href="/compendium/population" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Population Health</a></div><div><a href="/approvals-launches" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Product Approvals and Launches</a></div><div><a href="/topic/technology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Technology</a></div><div><a href="/topic/value-based-care" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Value-Based Care</a></div></nav></div></div></div></div></div></div></div><div class="flex flex-1 items-center gap-3 overflow-hidden justify-start"><span class="text-md font-semibold whitespace-pre !text-primary filter brightness-75">Spotlight</span><ul id="spotlight-links" class="flex gap-2 h-4 overflow-hidden flex-wrap"><li class="text-xs pt-0.5 whitespace-pre cursor-pointer hover:underline text-gray-800"><a href="/ivbmevents?display=home">Free In-Person Regional Events Focused on Oncology and Population Health</a></li></ul></div></div></div></div></nav><nav class="lg:hidden"><div class="w-full shadow-md bg-primary sticky top-0 z-40"><div class="flex mx-auto container"><div class=" py-4 flex items-stretch justify-between mx-4 items-center w-full"><div class="flex items-center justify-end"><div class="flex items-center"><div class="h-full flex items-center"><button id="menu" aria-label="open menu" aria-expanded="false" class="focus:outline-none focus:ring-2 focus:ring-gray-700 rounded-md text-white"><svg width="30" height="30" viewBox="0 0 24 24" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M21 10H3" stroke="#fff" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"></path><path d="M21 6H3" stroke="#fff" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"></path><path d="M21 14H3" stroke="#fff" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"></path><path d="M21 18H3" stroke="#fff" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"></path></svg></button></div></div></div><div aria-label="logo" role="img" tabindex="0" class="focus:outline-none relative h-10 w-40"><a role="img" aria-label="logo" class="focus:outline-none relative h-12 w-40 mr-6 flex items-center" href="/"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;object-position:center"/><noscript><img sizes="100vw" srcSet="/_next/image?url=%2Fajmc_logo_inverted.png&w=640&q=75 640w, /_next/image?url=%2Fajmc_logo_inverted.png&w=750&q=75 750w, /_next/image?url=%2Fajmc_logo_inverted.png&w=828&q=75 828w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1080&q=75 1080w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1200&q=75 1200w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1920&q=75 1920w, /_next/image?url=%2Fajmc_logo_inverted.png&w=2048&q=75 2048w, /_next/image?url=%2Fajmc_logo_inverted.png&w=3840&q=75 3840w" src="/_next/image?url=%2Fajmc_logo_inverted.png&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;object-position:center" loading="lazy"/></noscript></span></a></div><div class="relative w-8 h-8 my grid items-center"><a class="absolute lg:hidden inset-0 mt-1" href="/search"><svg xmlns="http://www.w3.org/2000/svg" class="text-white stroke-current icon icon-tabler icon-tabler-search" viewBox="0 0 24 24" stroke-width="1.5" stroke="currentColor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"></path><circle cx="10" cy="10" r="7"></circle><line x1="21" y1="21" x2="15" y2="15"></line></svg></a></div></div></div><div style="max-height:50px" class="bg-white px-4 transition-all h-12 md:items-stretch mx-auto" id="bottomnav-mobile"><div class="container justify-between h-12 flex items-center md:items-stretch mx-auto"><div class="h-full w-full flex items-center justify-between relative"><div class="flex flex-1 justify-center xs:justify-start items-center relative group h-full z-50 gap-2"><div class="z-1 relative"><div class="block"><div class=""><div class="mx-auto md:max-w-4xl lg:max-w-5xl xl:max-w-7xl "><div class="flex gap-4 justify-start"><div class=" isolate z-[9999] " data-headlessui-state=""><button class="focus:outline-none rounded font-medium cursor-pointer h-full flex items-center text-xs md:text-sm h-[34px] px-2 py-2 md:px-4 tracking-normal capitalize brightness-[85%] bg-primary text-gray-50 lg:min-w-[140px] justify-between" type="button" aria-expanded="false" data-headlessui-state="">Specialty Area<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><nav role="navigation" aria-label="Specialty Area" class="sr-only"><div><a href="/compendium/biosimilars" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Biosimilars</a></div><div><a href="/compendium/cardiorenalmetabolic" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Cardiorenalmetabolic</a><a href="/compendium/cardiovascular" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Cardiovascular</a><a href="/compendium/ckd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Chronic Kidney Disease</a><a href="/compendium/diabetes" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Diabetes</a><a href="/compendium/heart-failure" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Heart Failure</a><a href="/compendium/type1diabetes" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Type 1 Diabetes</a></div><div><a href="/compendium/dermatology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Dermatology</a><a href="/compendium/alopecia" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Alopecia</a><a href="/compendium/atopic-dermatitis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Atopic Dermatitis</a><a href="/compendium/psoriasis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Psoriasis</a></div><div><a href="/compendium/gastroenterology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Gastroenterology</a></div><div><a href="/compendium/hematology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Hematology</a><a href="/compendium/all" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">ALL/AML</a><a href="/compendium/cll" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">CLL/SLL</a><a href="/compendium/gvhd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">GVHD</a><a href="/compendium/hemophilia" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Hemophilia</a><a href="/compendium/multiple-myeloma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Multiple Myeloma</a><a href="/compendium/myelodysplastic-syndromes" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Myelodysplastic Syndromes</a><a href="/compendium/mpn" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Myeloproliferative Neoplasms</a><a href="/compendium/nhl" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Non-Hodgkin Lymphoma</a><a href="/compendium/rareblood" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Rare Blood</a></div><div><a href="/compendium/hepatology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Hepatology</a><a href="/compendium/liver-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Liver</a></div><div><a href="/compendium/immunology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Immunology</a><a href="/compendium/autoimmune" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Autoimmune</a><a href="/compendium/Inflammation" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Inflammation</a><a href="/compendium/lupus" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Lupus</a><a href="/compendium/myasthenia-gravis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Myasthenia Gravis</a></div><div><a href="/compendium/infectious-disease" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Infectious Disease</a><a href="/compendium/covid-19" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">COVID-19</a><a href="/compendium/hiv" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">HIV</a><a href="/compendium/rsv" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">RSV</a><a href="/compendium/vaccines" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Vaccines</a></div><div><a href="/compendium/mash" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">MASH</a></div><div><a href="/compendium/mental-health" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Mental Health</a><a href="/compendium/mdd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Major Depressive Disorder</a><a href="/compendium/sleep" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Sleep</a></div><div><a href="/compendium/neurology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Neurology</a><a href="/compendium/dmd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Duchenne Muscular Dystrophy</a><a href="/compendium/epilepsy" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Epilepsy</a><a href="/compendium/multiple-sclerosis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Multiple Sclerosis</a><a href="/compendium/parkinson" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Parkinson Disease</a></div><div><a href="/compendium/obesity" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Obesity</a></div><div><a href="/compendium/oncology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Oncology</a><a href="/compendium/breast-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Breast Cancer</a><a href="/compendium/cholangiocarcinoma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Cholangiocarcinoma</a><a href="/compendium/colorectal-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Colorectal Cancer</a><a href="/compendium/immuno-oncology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Immuno-Oncology</a><a href="/compendium/liver-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Liver Cancer</a><a href="/compendium/nsclc" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Non–Small Cell Lung Cancer</a><a href="/compendium/ovarian-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Ovarian Cancer</a><a href="/compendium/prostate-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Prostate Cancer</a><a href="/compendium/skincancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Skin Cancer</a><a href="/compendium/lung-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Small Cell Lung Cancer</a><a href="/compendium/soft-tissue-sarcoma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Soft Tissue Sarcoma</a></div><div><a href="/compendium/ophthalmology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Ophthalmology</a></div><div><a href="/compendium/pulmonology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Pulmonology</a><a href="/compendium/copd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">COPD</a><a href="/compendium/pah" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Pulmonary Arterial Hypertension</a></div><div><a href="/compendium/raredisease" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Rare Disease</a><a href="/compendium/sma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Spinal Muscular Atrophy</a></div><div><a href="/compendium/respiratory" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Respiratory</a><a href="/compendium/asthma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Asthma</a><a href="/compendium/ipf" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Idiopathic Pulmonary Fibrosis</a></div><div><a href="/compendium/rheumatology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Rheumatology</a></div><div><a href="/compendium/womens-health" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Women's Health</a></div></nav></div></div></div></div></div></div><div class="z-1 relative"><div class="block"><div class=""><div class="mx-auto md:max-w-4xl lg:max-w-5xl xl:max-w-7xl "><div class="flex gap-4 justify-start"><div class=" isolate z-[9999] " data-headlessui-state=""><button class="focus:outline-none rounded font-medium cursor-pointer h-full flex items-center text-xs md:text-sm h-[34px] px-2 py-2 md:px-4 tracking-normal capitalize brightness-[85%] bg-primary text-gray-50 lg:min-w-[140px] justify-between" type="button" aria-expanded="false" data-headlessui-state="">Topics<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><nav role="navigation" aria-label="Topics" class="sr-only"><div><a href="/compendium/biosimilars" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Biosimilars</a></div><div><a href="/topic/center-on-health-equity-and-access" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Center on Health Equity & Access</a></div><div><a href="/compendium/digital-health" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Digital Health</a></div><div><a href="/formulary" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Formulary</a></div><div><a href="/compendium/gene-therapy" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Gene Therapy</a></div><div><a href="/guidelines" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Guidelines</a></div><div><a href="/topic/healthcare-cost" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Health Care Cost</a></div><div><a href="/topic/healthcare-delivery" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Health Care Delivery</a></div><div><a href="/topic/insurance" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Insurance</a></div><div><a href="/topic/policy" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Policy</a></div><div><a href="/compendium/population" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Population Health</a></div><div><a href="/approvals-launches" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Product Approvals and Launches</a></div><div><a href="/topic/technology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Technology</a></div><div><a href="/topic/value-based-care" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Value-Based Care</a></div></nav></div></div></div></div></div></div></div></div></div></div></div><div class="fixed top-0 w-[85vw] h-full transform -translate-x-full z-40 transition duration-300 lg:hidden min-h-screen bg-primary shadow-lg" id="mobile-nav"><div class="w-full h-full shadow-lg z-40 fixed overflow-y-auto top-0 flex-col justify-between xl:hidden pb-4 transition duration-500 ease-in-out"><div class="px-5 h-full"><div class="flex flex-col justify-between h-full w-full"><div><div class="mt-6 flex w-full items-center justify-between"><div class="border-b border-gray-200 pb-2 flex items-center justify-between w-full"><div aria-label="logo" role="img" tabindex="0" class="focus:outline-none relative h-16 w-40 "><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;object-position:left"/><noscript><img sizes="100vw" srcSet="/_next/image?url=%2Fajmc_logo_inverted.png&w=640&q=75 640w, /_next/image?url=%2Fajmc_logo_inverted.png&w=750&q=75 750w, /_next/image?url=%2Fajmc_logo_inverted.png&w=828&q=75 828w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1080&q=75 1080w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1200&q=75 1200w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1920&q=75 1920w, /_next/image?url=%2Fajmc_logo_inverted.png&w=2048&q=75 2048w, /_next/image?url=%2Fajmc_logo_inverted.png&w=3840&q=75 3840w" src="/_next/image?url=%2Fajmc_logo_inverted.png&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;object-position:left" loading="lazy"/></noscript></span></div><button aria-label="close menu" class="focus:outline-none focus:ring-2 rounded-md text-white pl-8 font-bold"><svg width="18" height="18" viewBox="0 0 14 14" fill="#fff" xmlns="http://www.w3.org/2000/svg"><path d="M13 1L1 13" stroke="#fff" stroke-linecap="round" stroke-width="2" stroke-linejoin="round"></path><path d="M1 1L13 13" stroke="#fff" stroke-linecap="round" stroke-width="2" stroke-linejoin="round"></path></svg></button></div></div><ul role="list" class="flex flex-1 flex-col gap-y-7 mt-6"><li><ul role="list" class="-mx-2 space-y-1"><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>Spotlight</button></div></li><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>News</button></div></li><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>Video</button></div></li><li><a class="hover:bg-gray-500 block rounded-md py-2 pr-2 pl-10 text-sm leading-6 font-semibold text-gray-50" href="/podcasts"><span>Podcasts</span></a></li><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>Conferences</button></div></li><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>Journals</button></div></li><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>Events</button></div></li><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>Resources</button></div></li><li><a class="hover:bg-gray-500 block rounded-md py-2 pr-2 pl-10 text-sm leading-6 font-semibold text-gray-50" href="/continuing-education"><span>CE</span></a></li><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>About AJMC</button></div></li><li><a class="hover:bg-gray-500 block rounded-md py-2 pr-2 pl-10 text-sm leading-6 font-semibold text-gray-50" href="https://one.ajmc.com/subscribe"><span>Subscribe</span></a></li></ul></li></ul><div class="flex md:hidden mt-4 items-center gap-2 mt-6 pt-6 border-t"><a rel="noreferrer noopener" target="_blank" href="https://www.facebook.com/TheAmericanJournalOfManagedCare"><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 448 512" color="#fff" style="color:#fff" height="24" width="24" xmlns="http://www.w3.org/2000/svg"><path d="M400 32H48A48 48 0 0 0 0 80v352a48 48 0 0 0 48 48h137.25V327.69h-63V256h63v-54.64c0-62.15 37-96.48 93.67-96.48 27.14 0 55.52 4.84 55.52 4.84v61h-31.27c-30.81 0-40.42 19.12-40.42 38.73V256h68.78l-11 71.69h-57.78V480H400a48 48 0 0 0 48-48V80a48 48 0 0 0-48-48z"></path></svg></a><a rel="noreferrer noopener" target="_blank" href="https://twitter.com/AJMC_Journal"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" width="21" height="21" viewBox="12.65 12.65 118.02 118.02"><g transform="translate(1.4065934065934016 1.4065934065934016) scale(2.81 2.81)"><path d="M 11 4 C 7.134 4 4 7.134 4 11 L 4 39 C 4 42.866 7.134 46 11 46 L 39 46 C 42.866 46 46 42.866 46 39 L 46 11 C 46 7.134 42.866 4 39 4 L 11 4 z M 13.085938 13 L 21.023438 13 L 26.660156 21.009766 L 33.5 13 L 36 13 L 27.789062 22.613281 L 37.914062 37 L 29.978516 37 L 23.4375 27.707031 L 15.5 37 L 13 37 L 22.308594 26.103516 L 13.085938 13 z M 16.914062 15 L 31.021484 35 L 34.085938 35 L 19.978516 15 L 16.914062 15 z" fill="#FFFFFF"></path></g></svg></a><a rel="noreferrer noopener" target="_blank" href="https://www.linkedin.com/company/american-journal-of-managed-care/"><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 448 512" color="#fff" style="color:#fff" height="27" width="27" xmlns="http://www.w3.org/2000/svg"><path d="M416 32H31.9C14.3 32 0 46.5 0 64.3v383.4C0 465.5 14.3 480 31.9 480H416c17.6 0 32-14.5 32-32.3V64.3c0-17.8-14.4-32.3-32-32.3zM135.4 416H69V202.2h66.5V416zm-33.2-243c-21.3 0-38.5-17.3-38.5-38.5S80.9 96 102.2 96c21.2 0 38.5 17.3 38.5 38.5 0 21.3-17.2 38.5-38.5 38.5zm282.1 243h-66.4V312c0-24.8-.5-56.7-34.5-56.7-34.6 0-39.9 27-39.9 54.9V416h-66.4V202.2h63.7v29.2h.9c8.9-16.8 30.6-34.5 62.9-34.5 67.2 0 79.7 44.3 79.7 101.9V416z"></path></svg></a><a rel="noreferrer noopener" target="_blank" href="https://www.instagram.com/ajmcjournal/"><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 448 512" color="#fff" style="color:#fff" height="24" width="24" xmlns="http://www.w3.org/2000/svg"><path d="M224,202.66A53.34,53.34,0,1,0,277.36,256,53.38,53.38,0,0,0,224,202.66Zm124.71-41a54,54,0,0,0-30.41-30.41c-21-8.29-71-6.43-94.3-6.43s-73.25-1.93-94.31,6.43a54,54,0,0,0-30.41,30.41c-8.28,21-6.43,71.05-6.43,94.33S91,329.26,99.32,350.33a54,54,0,0,0,30.41,30.41c21,8.29,71,6.43,94.31,6.43s73.24,1.93,94.3-6.43a54,54,0,0,0,30.41-30.41c8.35-21,6.43-71.05,6.43-94.33S357.1,182.74,348.75,161.67ZM224,338a82,82,0,1,1,82-82A81.9,81.9,0,0,1,224,338Zm85.38-148.3a19.14,19.14,0,1,1,19.13-19.14A19.1,19.1,0,0,1,309.42,189.74ZM400,32H48A48,48,0,0,0,0,80V432a48,48,0,0,0,48,48H400a48,48,0,0,0,48-48V80A48,48,0,0,0,400,32ZM382.88,322c-1.29,25.63-7.14,48.34-25.85,67s-41.4,24.63-67,25.85c-26.41,1.49-105.59,1.49-132,0-25.63-1.29-48.26-7.15-67-25.85s-24.63-41.42-25.85-67c-1.49-26.42-1.49-105.61,0-132,1.29-25.63,7.07-48.34,25.85-67s41.47-24.56,67-25.78c26.41-1.49,105.59-1.49,132,0,25.63,1.29,48.33,7.15,67,25.85s24.63,41.42,25.85,67.05C384.37,216.44,384.37,295.56,382.88,322Z"></path></svg></a><a rel="noreferrer noopener" target="_blank" href="/rss"></a></div></div></div></div></div></div></nav></div></div><div class="container top-ad-div px-4 mx-auto pl-2 pr-2 sm:h-[98px] sm:w-[728px]"><div id="leaderboardWrapper" class="jsx-1661e6713d4eb9b5 leaderboardAdWrapper mx-auto mt-1 flex min-h-0 md:min-h-[90px] justify-center items-center flex-col relative z-[99999] "><div class="jsx-1661e6713d4eb9b5 bg-white md:-translate-x-4"><div class="jsx-1661e6713d4eb9b5 text-[8px] text-center text-gray-600 hidden relative">Advertisement</div><div id="div-gpt-ad-top" class="jsx-1661e6713d4eb9b5 AD728x90 mx-auto text-center x"></div></div></div></div><hr class="mt-8 pt-8 -mb-4 pb-0"/><div id="biosimilars" class="container mx-auto flex m-1 min-h-[57vh] px-4"><div class="flex-auto w-[calc(100%-300px)] pr-0 md:pr-6 mt-16 sm:mt-0"><div class="pb-24 my-2"><div class="flex"><h1 class="text-[19px] mt-1 md:mt-0 md:text-3xl mb-2">Biosimilars</h1><div class="flex justify-center px-0 -mt-1 sm:-mt-2 align-center"></div></div><div class="w-full mb-2 border border-secondary"></div><div id="description-summary" class="text-sm text-gray-500"><div class="blockText_blockContent__TbCXh"><p class="pb-2">The <em>AJMC</em><sup class="text-inherit">®</sup> Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.</p></div><div class="clear-both"></div></div><div class="border-b-[2px] border-[#EEE] "><div class="m-2"><div class="hidden xs:flex justify-between items-center"><h2 class="text-3xl">Latest News</h2></div><div class="xs:my-6 my-4 xs:block hidden"><div class="flex"><div class="flex sm:pr-[35px] pr-[20px] flex-col w-[40%] border-r-[2px] border-[#EEE]"><div class="lg:h-[220px] h-[170px] relative bg-default-logo-background "><a class="0 w-full" href="/view/fda-approves-celltrion-s-tocilizumab-anoh-biosimilar-to-actemra"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-contain" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fa0cb6495daeaee9e3fb7822d0e083c4ace68041e-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fa0cb6495daeaee9e3fb7822d0e083c4ace68041e-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fa0cb6495daeaee9e3fb7822d0e083c4ace68041e-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fa0cb6495daeaee9e3fb7822d0e083c4ace68041e-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fa0cb6495daeaee9e3fb7822d0e083c4ace68041e-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fa0cb6495daeaee9e3fb7822d0e083c4ace68041e-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fa0cb6495daeaee9e3fb7822d0e083c4ace68041e-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fa0cb6495daeaee9e3fb7822d0e083c4ace68041e-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fa0cb6495daeaee9e3fb7822d0e083c4ace68041e-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-contain" loading="lazy"/></noscript></span></a></div><div class="border-t-gray-100 border-t-2 flex-auto py-2 "><span class="text-sm text-gray-500 py-2">January 31st 2025</span><div class="py-3"><a class="lg:text-[20px] text-[19px] font-[500]" href="/view/fda-approves-celltrion-s-tocilizumab-anoh-biosimilar-to-actemra">FDA Approves Celltrion’s Tocilizumab-anoh, Biosimilar to Actemra</a></div><div class="pb-2"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/cameron-santoro"><i>Cameron Santoro</i></a></span></div></div><a href="/view/fda-approves-celltrion-s-tocilizumab-anoh-biosimilar-to-actemra"><a href="/view/fda-approves-celltrion-s-tocilizumab-anoh-biosimilar-to-actemra"><p class="mt-1 text-gray-800 text-[13px] line-clamp-6 text-hidden">Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, potentially expanding treatment access for patients. </p></a></a></div></div><div class="flex-wrap w-[60%] flex "><a class="flex w-[50%] flex-col sm:pl-[35px] pl-[20px] pb-[35px] " href="/view/embracing-eom-enhancing-collaboration-and-cost-management-dr-kirollos-hanna"><div class="w-full lg:h-[134px] h-[100px] relative bg-default-logo-background "><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="lg:object-cover object-contain " style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff698018f94ae99ba6f548f81a15462f47765951b-1280x720.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff698018f94ae99ba6f548f81a15462f47765951b-1280x720.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff698018f94ae99ba6f548f81a15462f47765951b-1280x720.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff698018f94ae99ba6f548f81a15462f47765951b-1280x720.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff698018f94ae99ba6f548f81a15462f47765951b-1280x720.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff698018f94ae99ba6f548f81a15462f47765951b-1280x720.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff698018f94ae99ba6f548f81a15462f47765951b-1280x720.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff698018f94ae99ba6f548f81a15462f47765951b-1280x720.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff698018f94ae99ba6f548f81a15462f47765951b-1280x720.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="lg:object-cover object-contain " loading="lazy"/></noscript></span></div><div class="border-t-gray-100 border-t-2 pt-2 pb-2 flex-auto "><a href="/view/embracing-eom-enhancing-collaboration-and-cost-management-dr-kirollos-hanna"><span class="text-sm text-gray-500">January 29th 2025</span></a><div><a class="text-[14px]" href="/view/embracing-eom-enhancing-collaboration-and-cost-management-dr-kirollos-hanna"><p class="line-clamp-4 text-hidden font-[500]">Embracing EOM, Enhancing Collaboration and Cost Management: Dr Kirollos Hanna</p></a></div><div class="py-2"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/kyle-munz"><i>Kyle Munz</i></a></span><span class="text-md "><span class="mr-1 italic"><br/></span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/kirollow-hanna-pharmd"><i>Kirollos Hanna, PharmD</i></a></span></div></div></div></a><a class="flex w-[50%] flex-col sm:pl-[35px] pl-[20px] pb-[35px] " href="/view/ustekinumab-biosimilar-launches-in-france-shifts-the-autoimmune-disease-market"><div class="w-full lg:h-[134px] h-[100px] relative bg-default-logo-background "><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="lg:object-cover object-contain " style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F67ae50f595958a4eed000662539d417cc02de7f4-4230x2815.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F67ae50f595958a4eed000662539d417cc02de7f4-4230x2815.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F67ae50f595958a4eed000662539d417cc02de7f4-4230x2815.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F67ae50f595958a4eed000662539d417cc02de7f4-4230x2815.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F67ae50f595958a4eed000662539d417cc02de7f4-4230x2815.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F67ae50f595958a4eed000662539d417cc02de7f4-4230x2815.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F67ae50f595958a4eed000662539d417cc02de7f4-4230x2815.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F67ae50f595958a4eed000662539d417cc02de7f4-4230x2815.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F67ae50f595958a4eed000662539d417cc02de7f4-4230x2815.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="lg:object-cover object-contain " loading="lazy"/></noscript></span></div><div class="border-t-gray-100 border-t-2 pt-2 pb-2 flex-auto "><a href="/view/ustekinumab-biosimilar-launches-in-france-shifts-the-autoimmune-disease-market"><span class="text-sm text-gray-500">January 27th 2025</span></a><div><a class="text-[14px]" href="/view/ustekinumab-biosimilar-launches-in-france-shifts-the-autoimmune-disease-market"><p class="line-clamp-4 text-hidden font-[500]">Ustekinumab Biosimilar Launches in France, Shifts the Autoimmune Disease Market</p></a></div><div class="py-2"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/cameron-santoro"><i>Cameron Santoro</i></a></span></div></div></div></a><a class="flex w-[50%] flex-col sm:pl-[35px] pl-[20px] pb-[35px] " href="/view/biosimilar-market-share-growth-and-price-trends-in-q1-2025"><div class="w-full lg:h-[134px] h-[100px] relative bg-default-logo-background "><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="lg:object-cover object-contain " style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb0ba6e9ce73571eb664a160694081ebd5573c86c-8191x4672.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb0ba6e9ce73571eb664a160694081ebd5573c86c-8191x4672.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb0ba6e9ce73571eb664a160694081ebd5573c86c-8191x4672.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb0ba6e9ce73571eb664a160694081ebd5573c86c-8191x4672.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb0ba6e9ce73571eb664a160694081ebd5573c86c-8191x4672.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb0ba6e9ce73571eb664a160694081ebd5573c86c-8191x4672.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb0ba6e9ce73571eb664a160694081ebd5573c86c-8191x4672.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb0ba6e9ce73571eb664a160694081ebd5573c86c-8191x4672.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb0ba6e9ce73571eb664a160694081ebd5573c86c-8191x4672.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="lg:object-cover object-contain " loading="lazy"/></noscript></span></div><div class="border-t-gray-100 border-t-2 pt-2 pb-2 flex-auto "><a href="/view/biosimilar-market-share-growth-and-price-trends-in-q1-2025"><span class="text-sm text-gray-500">January 23rd 2025</span></a><div><a class="text-[14px]" href="/view/biosimilar-market-share-growth-and-price-trends-in-q1-2025"><p class="line-clamp-4 text-hidden font-[500]">Biosimilar Market Share: Growth and Price Trends in Q1 2025</p></a></div><div class="py-2"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/cameron-santoro"><i>Cameron Santoro</i></a></span></div></div></div></a><a class="flex w-[50%] flex-col sm:pl-[35px] pl-[20px] pb-[35px] " href="/view/patent-litigation-impacts-on-us-biosimilar-market-entry"><div class="w-full lg:h-[134px] h-[100px] relative bg-default-logo-background "><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="lg:object-cover object-contain " style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F35552823be3bf28539562545d1d65e2aad82fe15-8256x5504.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F35552823be3bf28539562545d1d65e2aad82fe15-8256x5504.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F35552823be3bf28539562545d1d65e2aad82fe15-8256x5504.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F35552823be3bf28539562545d1d65e2aad82fe15-8256x5504.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F35552823be3bf28539562545d1d65e2aad82fe15-8256x5504.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F35552823be3bf28539562545d1d65e2aad82fe15-8256x5504.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F35552823be3bf28539562545d1d65e2aad82fe15-8256x5504.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F35552823be3bf28539562545d1d65e2aad82fe15-8256x5504.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F35552823be3bf28539562545d1d65e2aad82fe15-8256x5504.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="lg:object-cover object-contain " loading="lazy"/></noscript></span></div><div class="border-t-gray-100 border-t-2 pt-2 pb-2 flex-auto "><a href="/view/patent-litigation-impacts-on-us-biosimilar-market-entry"><span class="text-sm text-gray-500">January 22nd 2025</span></a><div><a class="text-[14px]" href="/view/patent-litigation-impacts-on-us-biosimilar-market-entry"><p class="line-clamp-4 text-hidden font-[500]">Patent Litigation Impacts on US Biosimilar Market Entry</p></a></div><div class="py-2"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/cameron-santoro"><i>Cameron Santoro</i></a></span></div></div></div></a></div></div></div><div class="xs:hidden block"><div class="jsx-19ede9f0a5a45918 py-4 relative px-0"><div class="flex justify-between items-center py-1 space-x-4 border-0 select-none"><div class="w-full xs:my-6 my-4 #000 text-3xl">Latest News</div></div><div style="scroll-snap-type:none" class="jsx-19ede9f0a5a45918 flex items-start overflow-x-auto space-x-4 py-4 relative mx-auto w-[calc(100%-64px)]"><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-1215160397 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/fda-approves-celltrion-s-tocilizumab-anoh-biosimilar-to-actemra"><div class="jsx-1215160397 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-1215160397 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fa0cb6495daeaee9e3fb7822d0e083c4ace68041e-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fa0cb6495daeaee9e3fb7822d0e083c4ace68041e-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fa0cb6495daeaee9e3fb7822d0e083c4ace68041e-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fa0cb6495daeaee9e3fb7822d0e083c4ace68041e-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fa0cb6495daeaee9e3fb7822d0e083c4ace68041e-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fa0cb6495daeaee9e3fb7822d0e083c4ace68041e-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fa0cb6495daeaee9e3fb7822d0e083c4ace68041e-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fa0cb6495daeaee9e3fb7822d0e083c4ace68041e-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fa0cb6495daeaee9e3fb7822d0e083c4ace68041e-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-1215160397 content-wrap"><span class="jsx-1215160397 py-3 text-sm text-gray-500 text-left"><i class="jsx-1215160397">January 31st 2025</i></span><div class="jsx-1215160397 w-full h-fit mb-4"><p class="jsx-1215160397 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">FDA Approves Celltrion’s Tocilizumab-anoh, Biosimilar to Actemra</p></div><div class="jsx-1215160397 pb-2 text-left ]"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/cameron-santoro"><i>Cameron Santoro</i></a></span></div></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-1637274924 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/embracing-eom-enhancing-collaboration-and-cost-management-dr-kirollos-hanna"><div class="jsx-1637274924 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-1637274924 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff698018f94ae99ba6f548f81a15462f47765951b-1280x720.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff698018f94ae99ba6f548f81a15462f47765951b-1280x720.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff698018f94ae99ba6f548f81a15462f47765951b-1280x720.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff698018f94ae99ba6f548f81a15462f47765951b-1280x720.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff698018f94ae99ba6f548f81a15462f47765951b-1280x720.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff698018f94ae99ba6f548f81a15462f47765951b-1280x720.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff698018f94ae99ba6f548f81a15462f47765951b-1280x720.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff698018f94ae99ba6f548f81a15462f47765951b-1280x720.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff698018f94ae99ba6f548f81a15462f47765951b-1280x720.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-1637274924 content-wrap"><span class="jsx-1637274924 py-3 text-sm text-gray-500 text-left"><i class="jsx-1637274924">January 29th 2025</i></span><div class="jsx-1637274924 w-full h-fit mb-4"><p class="jsx-1637274924 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Embracing EOM, Enhancing Collaboration and Cost Management: Dr Kirollos Hanna</p></div><div class="jsx-1637274924 pb-2 text-left ]"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/kyle-munz"><i>Kyle Munz</i></a></span><span class="text-md "><span class="mr-1 italic"><br/></span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/kirollow-hanna-pharmd"><i>Kirollos Hanna, PharmD</i></a></span></div></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-286612495 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/ustekinumab-biosimilar-launches-in-france-shifts-the-autoimmune-disease-market"><div class="jsx-286612495 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-286612495 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F67ae50f595958a4eed000662539d417cc02de7f4-4230x2815.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F67ae50f595958a4eed000662539d417cc02de7f4-4230x2815.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F67ae50f595958a4eed000662539d417cc02de7f4-4230x2815.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F67ae50f595958a4eed000662539d417cc02de7f4-4230x2815.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F67ae50f595958a4eed000662539d417cc02de7f4-4230x2815.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F67ae50f595958a4eed000662539d417cc02de7f4-4230x2815.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F67ae50f595958a4eed000662539d417cc02de7f4-4230x2815.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F67ae50f595958a4eed000662539d417cc02de7f4-4230x2815.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F67ae50f595958a4eed000662539d417cc02de7f4-4230x2815.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-286612495 content-wrap"><span class="jsx-286612495 py-3 text-sm text-gray-500 text-left"><i class="jsx-286612495">January 27th 2025</i></span><div class="jsx-286612495 w-full h-fit mb-4"><p class="jsx-286612495 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Ustekinumab Biosimilar Launches in France, Shifts the Autoimmune Disease Market</p></div><div class="jsx-286612495 pb-2 text-left ]"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/cameron-santoro"><i>Cameron Santoro</i></a></span></div></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-2915913710 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/biosimilar-market-share-growth-and-price-trends-in-q1-2025"><div class="jsx-2915913710 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-2915913710 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb0ba6e9ce73571eb664a160694081ebd5573c86c-8191x4672.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb0ba6e9ce73571eb664a160694081ebd5573c86c-8191x4672.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb0ba6e9ce73571eb664a160694081ebd5573c86c-8191x4672.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb0ba6e9ce73571eb664a160694081ebd5573c86c-8191x4672.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb0ba6e9ce73571eb664a160694081ebd5573c86c-8191x4672.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb0ba6e9ce73571eb664a160694081ebd5573c86c-8191x4672.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb0ba6e9ce73571eb664a160694081ebd5573c86c-8191x4672.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb0ba6e9ce73571eb664a160694081ebd5573c86c-8191x4672.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb0ba6e9ce73571eb664a160694081ebd5573c86c-8191x4672.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-2915913710 content-wrap"><span class="jsx-2915913710 py-3 text-sm text-gray-500 text-left"><i class="jsx-2915913710">January 23rd 2025</i></span><div class="jsx-2915913710 w-full h-fit mb-4"><p class="jsx-2915913710 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Biosimilar Market Share: Growth and Price Trends in Q1 2025</p></div><div class="jsx-2915913710 pb-2 text-left ]"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/cameron-santoro"><i>Cameron Santoro</i></a></span></div></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-2363373513 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/patent-litigation-impacts-on-us-biosimilar-market-entry"><div class="jsx-2363373513 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-2363373513 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F35552823be3bf28539562545d1d65e2aad82fe15-8256x5504.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F35552823be3bf28539562545d1d65e2aad82fe15-8256x5504.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F35552823be3bf28539562545d1d65e2aad82fe15-8256x5504.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F35552823be3bf28539562545d1d65e2aad82fe15-8256x5504.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F35552823be3bf28539562545d1d65e2aad82fe15-8256x5504.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F35552823be3bf28539562545d1d65e2aad82fe15-8256x5504.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F35552823be3bf28539562545d1d65e2aad82fe15-8256x5504.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F35552823be3bf28539562545d1d65e2aad82fe15-8256x5504.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F35552823be3bf28539562545d1d65e2aad82fe15-8256x5504.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-2363373513 content-wrap"><span class="jsx-2363373513 py-3 text-sm text-gray-500 text-left"><i class="jsx-2363373513">January 22nd 2025</i></span><div class="jsx-2363373513 w-full h-fit mb-4"><p class="jsx-2363373513 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Patent Litigation Impacts on US Biosimilar Market Entry</p></div><div class="jsx-2363373513 pb-2 text-left ]"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/cameron-santoro"><i>Cameron Santoro</i></a></span></div></div></div></div></a></div></div></div></div></div><div class="border-b-[2px] border-[#EEE] "><div class="jsx-19ede9f0a5a45918 py-4 relative px-0"><div class="flex justify-between items-center py-1 space-x-4 border-0 select-none"><div class="w-[70%] mr-3 xs:my-6 my-4 #000 text-3xl">Video Series</div><a href="/video-series" class="w-[30%] text-right text-[#0AA2BE] text-[16px] underline"><span>View All</span></a></div><div style="scroll-snap-type:none" class="jsx-19ede9f0a5a45918 flex items-start overflow-x-auto space-x-4 py-4 relative mx-auto w-[calc(100%-64px)]"><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-1215160397 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/evaluating-biosimilar-programs-and-formularies"><div class="jsx-1215160397 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-1215160397 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png%2FOubre_HS.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png%2FOubre_HS.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png%2FOubre_HS.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png%2FOubre_HS.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png%2FOubre_HS.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png%2FOubre_HS.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png%2FOubre_HS.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png%2FOubre_HS.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png%2FOubre_HS.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-1215160397 content-wrap"><span class="jsx-1215160397 py-3 text-sm text-gray-500 text-left"><i class="jsx-1215160397">November 16th 2021</i></span><div class="jsx-1215160397 w-full h-fit mb-4"><p class="jsx-1215160397 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Evaluating Biosimilar Programs and Formularies</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-1637274924 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/integrating-biosimilars-for-hcps-into-electronic-health-records-and-in-clinical-pathways-care-plans"><div class="jsx-1637274924 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-1637274924 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg%2FMicrosoftTeams-image.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg%2FMicrosoftTeams-image.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg%2FMicrosoftTeams-image.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg%2FMicrosoftTeams-image.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg%2FMicrosoftTeams-image.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg%2FMicrosoftTeams-image.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg%2FMicrosoftTeams-image.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg%2FMicrosoftTeams-image.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg%2FMicrosoftTeams-image.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-1637274924 content-wrap"><span class="jsx-1637274924 py-3 text-sm text-gray-500 text-left"><i class="jsx-1637274924">November 16th 2021</i></span><div class="jsx-1637274924 w-full h-fit mb-4"><p class="jsx-1637274924 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Integrating Biosimilars for HCPs, into Electronic Health Records, and in Clinical Pathways/Care Plans</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-286612495 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/tracking-usage-and-monitoring-the-impact-of-biosimilars"><div class="jsx-286612495 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-286612495 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png%2FOubre_HS.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png%2FOubre_HS.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png%2FOubre_HS.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png%2FOubre_HS.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png%2FOubre_HS.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png%2FOubre_HS.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png%2FOubre_HS.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png%2FOubre_HS.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png%2FOubre_HS.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-286612495 content-wrap"><span class="jsx-286612495 py-3 text-sm text-gray-500 text-left"><i class="jsx-286612495">November 9th 2021</i></span><div class="jsx-286612495 w-full h-fit mb-4"><p class="jsx-286612495 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Tracking Usage and Monitoring the Impact of Biosimilars</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-2915913710 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/protocols-and-laws-for-transitioning-to-biosimilars"><div class="jsx-2915913710 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-2915913710 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg%2FMicrosoftTeams-image.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg%2FMicrosoftTeams-image.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg%2FMicrosoftTeams-image.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg%2FMicrosoftTeams-image.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg%2FMicrosoftTeams-image.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg%2FMicrosoftTeams-image.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg%2FMicrosoftTeams-image.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg%2FMicrosoftTeams-image.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg%2FMicrosoftTeams-image.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-2915913710 content-wrap"><span class="jsx-2915913710 py-3 text-sm text-gray-500 text-left"><i class="jsx-2915913710">November 9th 2021</i></span><div class="jsx-2915913710 w-full h-fit mb-4"><p class="jsx-2915913710 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Protocols and Laws for Transitioning to Biosimilars</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-2363373513 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/transitioning-to-a-biosimilar-program"><div class="jsx-2363373513 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-2363373513 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png%2FOubre_HS.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png%2FOubre_HS.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png%2FOubre_HS.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png%2FOubre_HS.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png%2FOubre_HS.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png%2FOubre_HS.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png%2FOubre_HS.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png%2FOubre_HS.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png%2FOubre_HS.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-2363373513 content-wrap"><span class="jsx-2363373513 py-3 text-sm text-gray-500 text-left"><i class="jsx-2363373513">November 2nd 2021</i></span><div class="jsx-2363373513 w-full h-fit mb-4"><p class="jsx-2363373513 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Transitioning to a Biosimilar Program</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-2785488040 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/increased-use-of-biosimilars"><div class="jsx-2785488040 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-2785488040 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png%2FOubre_HS.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png%2FOubre_HS.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png%2FOubre_HS.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png%2FOubre_HS.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png%2FOubre_HS.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png%2FOubre_HS.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png%2FOubre_HS.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png%2FOubre_HS.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png%2FOubre_HS.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-2785488040 content-wrap"><span class="jsx-2785488040 py-3 text-sm text-gray-500 text-left"><i class="jsx-2785488040">November 2nd 2021</i></span><div class="jsx-2785488040 w-full h-fit mb-4"><p class="jsx-2785488040 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Increased Use of Biosimilars</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-1434825611 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/optimizing-transitions-to-biosimilars"><div class="jsx-1434825611 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-1434825611 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg%2FMicrosoftTeams-image.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg%2FMicrosoftTeams-image.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg%2FMicrosoftTeams-image.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg%2FMicrosoftTeams-image.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg%2FMicrosoftTeams-image.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg%2FMicrosoftTeams-image.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg%2FMicrosoftTeams-image.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg%2FMicrosoftTeams-image.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg%2FMicrosoftTeams-image.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-1434825611 content-wrap"><span class="jsx-1434825611 py-3 text-sm text-gray-500 text-left"><i class="jsx-1434825611">October 26th 2021</i></span><div class="jsx-1434825611 w-full h-fit mb-4"><p class="jsx-1434825611 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Optimizing Transitions to Biosimilars</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-4064126826 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/optimizing-transitions-to-biosimilars-continued"><div class="jsx-4064126826 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-4064126826 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg%2FMicrosoftTeams-image.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg%2FMicrosoftTeams-image.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg%2FMicrosoftTeams-image.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg%2FMicrosoftTeams-image.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg%2FMicrosoftTeams-image.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg%2FMicrosoftTeams-image.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg%2FMicrosoftTeams-image.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg%2FMicrosoftTeams-image.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg%2FMicrosoftTeams-image.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-4064126826 content-wrap"><span class="jsx-4064126826 py-3 text-sm text-gray-500 text-left"><i class="jsx-4064126826">October 26th 2021</i></span><div class="jsx-4064126826 w-full h-fit mb-4"><p class="jsx-4064126826 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Optimizing Transitions to Biosimilars Continued</p></div></div></div></a></div></div></div><div class="border-b-[2px] border-[#EEE] "><div class="jsx-19ede9f0a5a45918 py-4 relative px-0"><div class="flex justify-between items-center py-1 space-x-4 border-0 select-none"><div class="w-[70%] mr-3 xs:my-6 my-4 #000 text-3xl">Video Interviews</div><a href="/interviews" class="w-[30%] text-right text-[#0AA2BE] text-[16px] underline"><span>View All</span></a></div><div style="scroll-snap-type:none" class="jsx-19ede9f0a5a45918 flex items-start overflow-x-auto space-x-4 py-4 relative mx-auto w-[calc(100%-64px)]"><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-1215160397 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/best-practices-for-employers-to-maximize-uptake-of-biosimilars"><div class="jsx-1215160397 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-1215160397 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7e8db2a7450136a10fd1d2663574e5a9c7826d7d-1920x1080.png%2FMarketing%2520Image%2520(5).png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7e8db2a7450136a10fd1d2663574e5a9c7826d7d-1920x1080.png%2FMarketing%2520Image%2520(5).png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7e8db2a7450136a10fd1d2663574e5a9c7826d7d-1920x1080.png%2FMarketing%2520Image%2520(5).png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7e8db2a7450136a10fd1d2663574e5a9c7826d7d-1920x1080.png%2FMarketing%2520Image%2520(5).png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7e8db2a7450136a10fd1d2663574e5a9c7826d7d-1920x1080.png%2FMarketing%2520Image%2520(5).png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7e8db2a7450136a10fd1d2663574e5a9c7826d7d-1920x1080.png%2FMarketing%2520Image%2520(5).png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7e8db2a7450136a10fd1d2663574e5a9c7826d7d-1920x1080.png%2FMarketing%2520Image%2520(5).png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7e8db2a7450136a10fd1d2663574e5a9c7826d7d-1920x1080.png%2FMarketing%2520Image%2520(5).png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7e8db2a7450136a10fd1d2663574e5a9c7826d7d-1920x1080.png%2FMarketing%2520Image%2520(5).png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-1215160397 content-wrap"><span class="jsx-1215160397 py-3 text-sm text-gray-500 text-left"><i class="jsx-1215160397">February 10th 2025</i></span><div class="jsx-1215160397 w-full h-fit mb-4"><p class="jsx-1215160397 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Best Practices for Employers to Maximize Uptake of Biosimilars</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-1637274924 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/the-economic-impact-of-biosimilars"><div class="jsx-1637274924 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-1637274924 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7e8db2a7450136a10fd1d2663574e5a9c7826d7d-1920x1080.png%2FMarketing%2520Image%2520(5).png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7e8db2a7450136a10fd1d2663574e5a9c7826d7d-1920x1080.png%2FMarketing%2520Image%2520(5).png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7e8db2a7450136a10fd1d2663574e5a9c7826d7d-1920x1080.png%2FMarketing%2520Image%2520(5).png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7e8db2a7450136a10fd1d2663574e5a9c7826d7d-1920x1080.png%2FMarketing%2520Image%2520(5).png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7e8db2a7450136a10fd1d2663574e5a9c7826d7d-1920x1080.png%2FMarketing%2520Image%2520(5).png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7e8db2a7450136a10fd1d2663574e5a9c7826d7d-1920x1080.png%2FMarketing%2520Image%2520(5).png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7e8db2a7450136a10fd1d2663574e5a9c7826d7d-1920x1080.png%2FMarketing%2520Image%2520(5).png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7e8db2a7450136a10fd1d2663574e5a9c7826d7d-1920x1080.png%2FMarketing%2520Image%2520(5).png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7e8db2a7450136a10fd1d2663574e5a9c7826d7d-1920x1080.png%2FMarketing%2520Image%2520(5).png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-1637274924 content-wrap"><span class="jsx-1637274924 py-3 text-sm text-gray-500 text-left"><i class="jsx-1637274924">February 10th 2025</i></span><div class="jsx-1637274924 w-full h-fit mb-4"><p class="jsx-1637274924 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">The Economic Impact of Biosimilars</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-286612495 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/biosimilars-are-getting-a-foothold-and-becoming-preferred-says-dr-james-chambers"><div class="jsx-286612495 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-286612495 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff28ae1dc3219faac65fe94e1cf673b17d8bcd3a8-1280x719.png%2FJames%2520Chambers%2520Nexus%25202024.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff28ae1dc3219faac65fe94e1cf673b17d8bcd3a8-1280x719.png%2FJames%2520Chambers%2520Nexus%25202024.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff28ae1dc3219faac65fe94e1cf673b17d8bcd3a8-1280x719.png%2FJames%2520Chambers%2520Nexus%25202024.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff28ae1dc3219faac65fe94e1cf673b17d8bcd3a8-1280x719.png%2FJames%2520Chambers%2520Nexus%25202024.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff28ae1dc3219faac65fe94e1cf673b17d8bcd3a8-1280x719.png%2FJames%2520Chambers%2520Nexus%25202024.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff28ae1dc3219faac65fe94e1cf673b17d8bcd3a8-1280x719.png%2FJames%2520Chambers%2520Nexus%25202024.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff28ae1dc3219faac65fe94e1cf673b17d8bcd3a8-1280x719.png%2FJames%2520Chambers%2520Nexus%25202024.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff28ae1dc3219faac65fe94e1cf673b17d8bcd3a8-1280x719.png%2FJames%2520Chambers%2520Nexus%25202024.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff28ae1dc3219faac65fe94e1cf673b17d8bcd3a8-1280x719.png%2FJames%2520Chambers%2520Nexus%25202024.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-286612495 content-wrap"><span class="jsx-286612495 py-3 text-sm text-gray-500 text-left"><i class="jsx-286612495">November 13th 2024</i></span><div class="jsx-286612495 w-full h-fit mb-4"><p class="jsx-286612495 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Biosimilars Are Getting a Foothold and Becoming Preferred, Says Dr James Chambers</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-2915913710 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/removing-need-for-switching-studies-could-change-payer-perspectives-of-biosimilars"><div class="jsx-2915913710 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-2915913710 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff28ae1dc3219faac65fe94e1cf673b17d8bcd3a8-1280x719.png%2FJames%2520Chambers%2520Nexus%25202024.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff28ae1dc3219faac65fe94e1cf673b17d8bcd3a8-1280x719.png%2FJames%2520Chambers%2520Nexus%25202024.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff28ae1dc3219faac65fe94e1cf673b17d8bcd3a8-1280x719.png%2FJames%2520Chambers%2520Nexus%25202024.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff28ae1dc3219faac65fe94e1cf673b17d8bcd3a8-1280x719.png%2FJames%2520Chambers%2520Nexus%25202024.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff28ae1dc3219faac65fe94e1cf673b17d8bcd3a8-1280x719.png%2FJames%2520Chambers%2520Nexus%25202024.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff28ae1dc3219faac65fe94e1cf673b17d8bcd3a8-1280x719.png%2FJames%2520Chambers%2520Nexus%25202024.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff28ae1dc3219faac65fe94e1cf673b17d8bcd3a8-1280x719.png%2FJames%2520Chambers%2520Nexus%25202024.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff28ae1dc3219faac65fe94e1cf673b17d8bcd3a8-1280x719.png%2FJames%2520Chambers%2520Nexus%25202024.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff28ae1dc3219faac65fe94e1cf673b17d8bcd3a8-1280x719.png%2FJames%2520Chambers%2520Nexus%25202024.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-2915913710 content-wrap"><span class="jsx-2915913710 py-3 text-sm text-gray-500 text-left"><i class="jsx-2915913710">November 5th 2024</i></span><div class="jsx-2915913710 w-full h-fit mb-4"><p class="jsx-2915913710 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Removing Need for Switching Studies Could Change Payer Perspectives of Biosimilars</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-2363373513 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/role-of-the-pharmacist-in-the-care-team-to-contain-costs-in-oncology"><div class="jsx-2363373513 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-2363373513 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff698018f94ae99ba6f548f81a15462f47765951b-1280x720.png%2FKirollos%2520Hanna-09-2024.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff698018f94ae99ba6f548f81a15462f47765951b-1280x720.png%2FKirollos%2520Hanna-09-2024.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff698018f94ae99ba6f548f81a15462f47765951b-1280x720.png%2FKirollos%2520Hanna-09-2024.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff698018f94ae99ba6f548f81a15462f47765951b-1280x720.png%2FKirollos%2520Hanna-09-2024.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff698018f94ae99ba6f548f81a15462f47765951b-1280x720.png%2FKirollos%2520Hanna-09-2024.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff698018f94ae99ba6f548f81a15462f47765951b-1280x720.png%2FKirollos%2520Hanna-09-2024.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff698018f94ae99ba6f548f81a15462f47765951b-1280x720.png%2FKirollos%2520Hanna-09-2024.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff698018f94ae99ba6f548f81a15462f47765951b-1280x720.png%2FKirollos%2520Hanna-09-2024.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff698018f94ae99ba6f548f81a15462f47765951b-1280x720.png%2FKirollos%2520Hanna-09-2024.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-2363373513 content-wrap"><span class="jsx-2363373513 py-3 text-sm text-gray-500 text-left"><i class="jsx-2363373513">September 28th 2024</i></span><div class="jsx-2363373513 w-full h-fit mb-4"><p class="jsx-2363373513 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Role of the Pharmacist in the Care Team to Contain Costs in Oncology</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-2785488040 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/private-label-biosimilars"><div class="jsx-2785488040 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-2785488040 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F70743c5a831ed6464c87b7ead422566b0dc3e8ec-1920x1080.png%2FMarketingWS%2520(30).png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F70743c5a831ed6464c87b7ead422566b0dc3e8ec-1920x1080.png%2FMarketingWS%2520(30).png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F70743c5a831ed6464c87b7ead422566b0dc3e8ec-1920x1080.png%2FMarketingWS%2520(30).png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F70743c5a831ed6464c87b7ead422566b0dc3e8ec-1920x1080.png%2FMarketingWS%2520(30).png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F70743c5a831ed6464c87b7ead422566b0dc3e8ec-1920x1080.png%2FMarketingWS%2520(30).png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F70743c5a831ed6464c87b7ead422566b0dc3e8ec-1920x1080.png%2FMarketingWS%2520(30).png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F70743c5a831ed6464c87b7ead422566b0dc3e8ec-1920x1080.png%2FMarketingWS%2520(30).png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F70743c5a831ed6464c87b7ead422566b0dc3e8ec-1920x1080.png%2FMarketingWS%2520(30).png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F70743c5a831ed6464c87b7ead422566b0dc3e8ec-1920x1080.png%2FMarketingWS%2520(30).png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-2785488040 content-wrap"><span class="jsx-2785488040 py-3 text-sm text-gray-500 text-left"><i class="jsx-2785488040">July 23rd 2024</i></span><div class="jsx-2785488040 w-full h-fit mb-4"><p class="jsx-2785488040 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Private Label Biosimilars</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-1434825611 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/dr-kimberly-maxfield-discusses-fda-actions-since-bsufa-iii-reauthorization"><div class="jsx-1434825611 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-1434825611 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4cf6cb481888a7102b78a253bb317a345b32d0d3-2880x1603.png%2FScreen%2520Shot%25202023-10-20%2520at%25204.36.04%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4cf6cb481888a7102b78a253bb317a345b32d0d3-2880x1603.png%2FScreen%2520Shot%25202023-10-20%2520at%25204.36.04%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4cf6cb481888a7102b78a253bb317a345b32d0d3-2880x1603.png%2FScreen%2520Shot%25202023-10-20%2520at%25204.36.04%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4cf6cb481888a7102b78a253bb317a345b32d0d3-2880x1603.png%2FScreen%2520Shot%25202023-10-20%2520at%25204.36.04%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4cf6cb481888a7102b78a253bb317a345b32d0d3-2880x1603.png%2FScreen%2520Shot%25202023-10-20%2520at%25204.36.04%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4cf6cb481888a7102b78a253bb317a345b32d0d3-2880x1603.png%2FScreen%2520Shot%25202023-10-20%2520at%25204.36.04%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4cf6cb481888a7102b78a253bb317a345b32d0d3-2880x1603.png%2FScreen%2520Shot%25202023-10-20%2520at%25204.36.04%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4cf6cb481888a7102b78a253bb317a345b32d0d3-2880x1603.png%2FScreen%2520Shot%25202023-10-20%2520at%25204.36.04%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4cf6cb481888a7102b78a253bb317a345b32d0d3-2880x1603.png%2FScreen%2520Shot%25202023-10-20%2520at%25204.36.04%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-1434825611 content-wrap"><span class="jsx-1434825611 py-3 text-sm text-gray-500 text-left"><i class="jsx-1434825611">November 19th 2023</i></span><div class="jsx-1434825611 w-full h-fit mb-4"><p class="jsx-1434825611 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Dr Kimberly Maxfield Discusses FDA Actions Since BsUFA III Reauthorization</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-4064126826 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/dr-sophia-humphreys-speaks-on-biosimilars-in-formulary-management"><div class="jsx-4064126826 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-4064126826 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb0d5d3aac945a97b5115f78767fa29ef92b0ae9d-1280x720.jpg%2FHumphreys%2520Thumbnail.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb0d5d3aac945a97b5115f78767fa29ef92b0ae9d-1280x720.jpg%2FHumphreys%2520Thumbnail.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb0d5d3aac945a97b5115f78767fa29ef92b0ae9d-1280x720.jpg%2FHumphreys%2520Thumbnail.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb0d5d3aac945a97b5115f78767fa29ef92b0ae9d-1280x720.jpg%2FHumphreys%2520Thumbnail.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb0d5d3aac945a97b5115f78767fa29ef92b0ae9d-1280x720.jpg%2FHumphreys%2520Thumbnail.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb0d5d3aac945a97b5115f78767fa29ef92b0ae9d-1280x720.jpg%2FHumphreys%2520Thumbnail.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb0d5d3aac945a97b5115f78767fa29ef92b0ae9d-1280x720.jpg%2FHumphreys%2520Thumbnail.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb0d5d3aac945a97b5115f78767fa29ef92b0ae9d-1280x720.jpg%2FHumphreys%2520Thumbnail.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb0d5d3aac945a97b5115f78767fa29ef92b0ae9d-1280x720.jpg%2FHumphreys%2520Thumbnail.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-4064126826 content-wrap"><span class="jsx-4064126826 py-3 text-sm text-gray-500 text-left"><i class="jsx-4064126826">November 15th 2023</i></span><div class="jsx-4064126826 w-full h-fit mb-4"><p class="jsx-4064126826 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Dr Sophia Humphreys Speaks on Biosimilars in Formulary Management</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-187450181 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/dr-jorge-garcia-speaks-about-ambulatory-drug-infusion-infusion-therapy"><div class="jsx-187450181 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-187450181 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3c11f2c8755afdbeab5b3972676e6e3032424159-1280x720.jpg%2FGarcia%2520Thumbnail.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3c11f2c8755afdbeab5b3972676e6e3032424159-1280x720.jpg%2FGarcia%2520Thumbnail.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3c11f2c8755afdbeab5b3972676e6e3032424159-1280x720.jpg%2FGarcia%2520Thumbnail.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3c11f2c8755afdbeab5b3972676e6e3032424159-1280x720.jpg%2FGarcia%2520Thumbnail.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3c11f2c8755afdbeab5b3972676e6e3032424159-1280x720.jpg%2FGarcia%2520Thumbnail.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3c11f2c8755afdbeab5b3972676e6e3032424159-1280x720.jpg%2FGarcia%2520Thumbnail.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3c11f2c8755afdbeab5b3972676e6e3032424159-1280x720.jpg%2FGarcia%2520Thumbnail.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3c11f2c8755afdbeab5b3972676e6e3032424159-1280x720.jpg%2FGarcia%2520Thumbnail.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3c11f2c8755afdbeab5b3972676e6e3032424159-1280x720.jpg%2FGarcia%2520Thumbnail.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-187450181 content-wrap"><span class="jsx-187450181 py-3 text-sm text-gray-500 text-left"><i class="jsx-187450181">November 10th 2023</i></span><div class="jsx-187450181 w-full h-fit mb-4"><p class="jsx-187450181 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Dr Jorge Garcia Speaks About Ambulatory Drug Infusion, Infusion Therapy</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-609564708 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/dr-kimberly-maxfield-highlights-fda-s-education-efforts-to-increase-biosimilar-comfort"><div class="jsx-609564708 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-609564708 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4cf6cb481888a7102b78a253bb317a345b32d0d3-2880x1603.png%2FScreen%2520Shot%25202023-10-20%2520at%25204.36.04%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4cf6cb481888a7102b78a253bb317a345b32d0d3-2880x1603.png%2FScreen%2520Shot%25202023-10-20%2520at%25204.36.04%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4cf6cb481888a7102b78a253bb317a345b32d0d3-2880x1603.png%2FScreen%2520Shot%25202023-10-20%2520at%25204.36.04%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4cf6cb481888a7102b78a253bb317a345b32d0d3-2880x1603.png%2FScreen%2520Shot%25202023-10-20%2520at%25204.36.04%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4cf6cb481888a7102b78a253bb317a345b32d0d3-2880x1603.png%2FScreen%2520Shot%25202023-10-20%2520at%25204.36.04%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4cf6cb481888a7102b78a253bb317a345b32d0d3-2880x1603.png%2FScreen%2520Shot%25202023-10-20%2520at%25204.36.04%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4cf6cb481888a7102b78a253bb317a345b32d0d3-2880x1603.png%2FScreen%2520Shot%25202023-10-20%2520at%25204.36.04%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4cf6cb481888a7102b78a253bb317a345b32d0d3-2880x1603.png%2FScreen%2520Shot%25202023-10-20%2520at%25204.36.04%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4cf6cb481888a7102b78a253bb317a345b32d0d3-2880x1603.png%2FScreen%2520Shot%25202023-10-20%2520at%25204.36.04%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-609564708 content-wrap"><span class="jsx-609564708 py-3 text-sm text-gray-500 text-left"><i class="jsx-609564708">October 22nd 2023</i></span><div class="jsx-609564708 w-full h-fit mb-4"><p class="jsx-609564708 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Dr Kimberly Maxfield Highlights FDA's Education Efforts to Increase Biosimilar Comfort</p></div></div></div></a></div></div></div><div class="border-b-[2px] border-[#EEE] "><div class="jsx-19ede9f0a5a45918 py-4 relative px-0"><div class="flex justify-between items-center py-1 space-x-4 border-0 select-none"><div class="w-[70%] mr-3 xs:my-6 my-4 #000 text-3xl">Podcasts</div><a href="/podcasts" class="w-[30%] text-right text-[#0AA2BE] text-[16px] underline"><span>View All</span></a></div><div style="scroll-snap-type:none" class="jsx-19ede9f0a5a45918 flex items-start overflow-x-auto space-x-4 py-4 relative mx-auto w-[calc(100%-64px)]"><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-1215160397 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/how-health-care-institutions-can-leverage-biosimilars-to-generate-savings"><div class="jsx-1215160397 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-1215160397 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4a316e64089806bda54f9d53f783fa1d7a93a6b5-1280x720.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4a316e64089806bda54f9d53f783fa1d7a93a6b5-1280x720.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4a316e64089806bda54f9d53f783fa1d7a93a6b5-1280x720.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4a316e64089806bda54f9d53f783fa1d7a93a6b5-1280x720.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4a316e64089806bda54f9d53f783fa1d7a93a6b5-1280x720.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4a316e64089806bda54f9d53f783fa1d7a93a6b5-1280x720.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4a316e64089806bda54f9d53f783fa1d7a93a6b5-1280x720.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4a316e64089806bda54f9d53f783fa1d7a93a6b5-1280x720.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4a316e64089806bda54f9d53f783fa1d7a93a6b5-1280x720.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-1215160397 content-wrap"><span class="jsx-1215160397 py-3 text-sm text-gray-500 text-left"><i class="jsx-1215160397">August 17th 2022</i></span><div class="jsx-1215160397 w-full h-fit mb-4"><p class="jsx-1215160397 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">How Health Care Institutions Can Leverage Biosimilars to Generate Savings</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-1637274924 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/biosimilar-whisky-this-expert-says-it-s-doable-no-aging-required"><div class="jsx-1637274924 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-1637274924 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4a316e64089806bda54f9d53f783fa1d7a93a6b5-1280x720.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4a316e64089806bda54f9d53f783fa1d7a93a6b5-1280x720.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4a316e64089806bda54f9d53f783fa1d7a93a6b5-1280x720.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4a316e64089806bda54f9d53f783fa1d7a93a6b5-1280x720.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4a316e64089806bda54f9d53f783fa1d7a93a6b5-1280x720.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4a316e64089806bda54f9d53f783fa1d7a93a6b5-1280x720.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4a316e64089806bda54f9d53f783fa1d7a93a6b5-1280x720.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4a316e64089806bda54f9d53f783fa1d7a93a6b5-1280x720.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F4a316e64089806bda54f9d53f783fa1d7a93a6b5-1280x720.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-1637274924 content-wrap"><span class="jsx-1637274924 py-3 text-sm text-gray-500 text-left"><i class="jsx-1637274924">June 14th 2022</i></span><div class="jsx-1637274924 w-full h-fit mb-4"><p class="jsx-1637274924 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Biosimilar Whisky? This Expert Says It’s Doable, No Aging Required</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-286612495 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/exploring-2022-trends-in-health-and-hospital-drug-spending-with-vizient"><div class="jsx-286612495 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-286612495 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fbe0b7b58876ac810caae8ed95b44a57df5c930dd-800x400.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fbe0b7b58876ac810caae8ed95b44a57df5c930dd-800x400.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fbe0b7b58876ac810caae8ed95b44a57df5c930dd-800x400.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fbe0b7b58876ac810caae8ed95b44a57df5c930dd-800x400.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fbe0b7b58876ac810caae8ed95b44a57df5c930dd-800x400.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fbe0b7b58876ac810caae8ed95b44a57df5c930dd-800x400.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fbe0b7b58876ac810caae8ed95b44a57df5c930dd-800x400.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fbe0b7b58876ac810caae8ed95b44a57df5c930dd-800x400.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fbe0b7b58876ac810caae8ed95b44a57df5c930dd-800x400.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-286612495 content-wrap"><span class="jsx-286612495 py-3 text-sm text-gray-500 text-left"><i class="jsx-286612495">August 10th 2021</i></span><div class="jsx-286612495 w-full h-fit mb-4"><p class="jsx-286612495 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden"> Exploring 2022 Trends in Health and Hospital Drug Spending With Vizient</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-2915913710 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/biosimilars-are-being-approved-but-not-reaching-the-market"><div class="jsx-2915913710 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-2915913710 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-2915913710 content-wrap"><span class="jsx-2915913710 py-3 text-sm text-gray-500 text-left"><i class="jsx-2915913710">July 17th 2019</i></span><div class="jsx-2915913710 w-full h-fit mb-4"><p class="jsx-2915913710 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Biosimilars Are Being Approved but Not Reaching the Market</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-2363373513 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/progress-in-the-us-with-biosimilars-but-opportunities-remain"><div class="jsx-2363373513 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-2363373513 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-2363373513 content-wrap"><span class="jsx-2363373513 py-3 text-sm text-gray-500 text-left"><i class="jsx-2363373513">January 9th 2019</i></span><div class="jsx-2363373513 w-full h-fit mb-4"><p class="jsx-2363373513 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Progress in the US With Biosimilars, but Opportunities Remain</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-2785488040 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/podcast-this-week-in-managed-caremdashstates-gain-power-to-alter-aca-offerings-and-other-health-news"><div class="jsx-2785488040 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-2785488040 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-2785488040 content-wrap"><span class="jsx-2785488040 py-3 text-sm text-gray-500 text-left"><i class="jsx-2785488040">October 27th 2018</i></span><div class="jsx-2785488040 w-full h-fit mb-4"><p class="jsx-2785488040 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Podcast: This Week in Managed Care—States Gain Power to Alter ACA Offerings and Other Health News</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-1434825611 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/podcast-this-week-in-managed-caremdashverma-on-health-data-and-other-health-news"><div class="jsx-1434825611 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-1434825611 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-1434825611 content-wrap"><span class="jsx-1434825611 py-3 text-sm text-gray-500 text-left"><i class="jsx-1434825611">March 10th 2018</i></span><div class="jsx-1434825611 w-full h-fit mb-4"><p class="jsx-1434825611 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Podcast: This Week in Managed Care&mdash;Verma on Health Data and Other Health News</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-4064126826 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/the-state-of-biosimilars-in-the-united-states-center-for-biosimilars-peer-exchange"><div class="jsx-4064126826 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-4064126826 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-4064126826 content-wrap"><span class="jsx-4064126826 py-3 text-sm text-gray-500 text-left"><i class="jsx-4064126826">January 24th 2018</i></span><div class="jsx-4064126826 w-full h-fit mb-4"><p class="jsx-4064126826 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">The State of Biosimilars in the United States: The Center for Biosimilars® Peer Exchange</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-187450181 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/podcast-this-week-in-managed-caremdashnew-voluntary-payment-model-and-other-health-news"><div class="jsx-187450181 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-187450181 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-187450181 content-wrap"><span class="jsx-187450181 py-3 text-sm text-gray-500 text-left"><i class="jsx-187450181">January 13th 2018</i></span><div class="jsx-187450181 w-full h-fit mb-4"><p class="jsx-187450181 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Podcast: This Week in Managed Care&mdash;New Voluntary Payment Model and Other Health News</p></div></div></div></a></div></div></div><div class="border-b-[2px] border-[#EEE] my-4"><div class="jsx-19ede9f0a5a45918 py-4 relative px-0"><div class="flex justify-between items-center py-1 space-x-4 border-0 select-none"><div class="w-[70%] mr-3 xs:my-6 my-4 #000 text-3xl">Continuing Medical Education</div><a href="/continuing-education" class="w-[30%] text-right text-[#0AA2BE] text-[16px] underline"><span>View All</span></a></div><div style="scroll-snap-type:none" class="jsx-19ede9f0a5a45918 flex items-start overflow-x-auto space-x-4 py-4 relative mx-auto w-[calc(100%-64px)]"><a target="_blank" style="scroll-snap-align:center;text-decoration:none" class="jsx-229659467 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="https://www.pharmacytimes.org/courses/new-and-approved-fdas-2024-drug-lineup?utm_source=undefined&utm_medium=undefined&utm_campaign=cmeDeck"><div class="jsx-229659467 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-229659467 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Ff1up0oihf0qd-PTCE_FDA-PT_Article_012725v2_800x385.png&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Ff1up0oihf0qd-PTCE_FDA-PT_Article_012725v2_800x385.png&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Ff1up0oihf0qd-PTCE_FDA-PT_Article_012725v2_800x385.png&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Ff1up0oihf0qd-PTCE_FDA-PT_Article_012725v2_800x385.png&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Ff1up0oihf0qd-PTCE_FDA-PT_Article_012725v2_800x385.png&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Ff1up0oihf0qd-PTCE_FDA-PT_Article_012725v2_800x385.png&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Ff1up0oihf0qd-PTCE_FDA-PT_Article_012725v2_800x385.png&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Ff1up0oihf0qd-PTCE_FDA-PT_Article_012725v2_800x385.png&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Ff1up0oihf0qd-PTCE_FDA-PT_Article_012725v2_800x385.png&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-229659467 content-wrap"><span class="jsx-229659467 py-3 text-sm text-gray-500 text-left"><i class="jsx-229659467">February 17th 2025</i></span><div class="jsx-229659467 w-full h-fit mb-4"><p class="jsx-229659467 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">New and Approved: FDA’s 2024 Drug Lineup</p></div><div class="jsx-229659467 text-left text-[12px] text-[#000] py-6">1.5 Credits / General Pharmacy</div></div></div></a></div></div></div><div class="flex items-center space-x-4 border-0 border-b border-secondary select-none py-1"><h2 class="text-3xl text-primary">More News</h2></div><div class="flex flex-wrap w-full pb-4"><div class="jsx-ad50481d5ee26850 w-full h-full"><div><div><div class="text-[8px] text-center text-gray-500 hidden">Advertisement</div><div id="div-gpt-ad-infeed-1"></div></div></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/the-future-of-pharmacy-trends-threats-transformations"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/4d2b1e0a5fb7993e065301c6d238736aeb12075e-5760x3840.jpg?fit=crop&auto=format" alt="Pharmaceutical industry. | Image Credit: Africa Studio - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">January 10th 2025</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/the-future-of-pharmacy-trends-threats-transformations">The Future of Pharmacy: Trends, Threats, Transformations</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/cameron-santoro">Cameron Santoro</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/the-future-of-pharmacy-trends-threats-transformations"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">The pharmaceutical landscape enters 2025 with a mix of challenges and opportunities, with the potential to shape the future of drug access and affordability for patients across the nation. </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/top-5-biosimilar-articles-of-2024"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/0fa217cda72fba54cc623e6430e8ea59cecb406a-3187x1625.png?fit=crop&auto=format" alt="The top 5 biosimilar articles touch on the growing biosimilar landscape, including recent FDA approvals, patent disputes, cost-saving potential, and challenges in market entry." width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">December 28th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/top-5-biosimilar-articles-of-2024">Top 5 Biosimilar Articles of 2024</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/cameron-santoro">Cameron Santoro</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/top-5-biosimilar-articles-of-2024"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">The top 5 biosimilar articles touch on the growing biosimilar landscape, including recent FDA approvals, patent disputes, cost-saving potential, and challenges in market entry.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex md:hidden justify-center items-center"></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/5-key-drug-approvals-and-crls-in-2024"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/b0002ea79080e3493345e3c993b00be4690f0087-4279x2706.jpg?fit=crop&auto=format" alt="Paper with FDA approved on top of a magnifying glass and a keyboard | Image Credit: Pawel - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">December 27th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/5-key-drug-approvals-and-crls-in-2024">5 Key Drug Approvals and CRLs in 2024</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/laura-joszt">Laura Joszt, MA</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/5-key-drug-approvals-and-crls-in-2024"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">In 2024, multiple drugs received complete response letters (CRLs), sometimes unrelated to the safety and efficacy of the drug, but patients with schizophrenia gained the first new treatment with a new mechanism of action in decades.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/fda-approves-seventh-ustekinumab-biosimilar-to-reference-stelara"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/ca845f7e6dfc35ab2f006b74744bb6c3a34fff11-5500x4093.jpg?fit=crop&auto=format" alt="FDA approval with stamp. | Image Credit: Surendra - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">December 20th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/fda-approves-seventh-ustekinumab-biosimilar-to-reference-stelara">FDA Approves Seventh Ustekinumab Biosimilar to Reference Stelara</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/cameron-santoro">Cameron Santoro</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/fda-approves-seventh-ustekinumab-biosimilar-to-reference-stelara"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">The FDA granted approval to Steqeyma (ustekinumab-stba) for inflammatory conditions, making it the seventh biosimilar to reference Stelara after a year of multiple ustekinumab biosimilar approvals.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/uptake-of-rituximab-biosimilars-in-medicare-and-medicaid-in-2019-2022"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png?fit=crop&auto=format" alt="AJMC" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">December 16th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/uptake-of-rituximab-biosimilars-in-medicare-and-medicaid-in-2019-2022">Uptake of Rituximab Biosimilars in Medicare and Medicaid in 2019-2022</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/jingjing-qian-phd">Jingjing Qian, PhD</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/uptake-of-rituximab-biosimilars-in-medicare-and-medicaid-in-2019-2022"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Significant uptake of rituximab biosimilars in Medicare and Medicaid occurred within the first 4 years of marketing in the US.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/from-approval-to-practice-addressing-the-hurdles-in-biosimilar-integration"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/50d700b88aa9af2c75864177d43c5651d055284b-1200x697.jpg?fit=crop&auto=format" alt="Seattle Washington skyline | Image Credit: © espiegle - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">December 12th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/from-approval-to-practice-addressing-the-hurdles-in-biosimilar-integration">From Approval to Practice: Addressing the Hurdles in Biosimilar Integration</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/skylar-jeremias">Skylar Jeremias</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/from-approval-to-practice-addressing-the-hurdles-in-biosimilar-integration"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Recent discussions at an Institute for Value-Based Medicine event highlighted the significant potential of biosimilars in reshaping the health care landscape, despite facing considerable barriers to adoption.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div><div><div class="text-[8px] text-center text-gray-500 hidden">Advertisement</div><div id="div-gpt-ad-infeed-7"></div></div></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/policy-proposals-aim-to-stimulate-the-long-term-sustainability-of-infused-biosimilars"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/7cad58a0175282b6a9e2f0292dc22ac8b8dc9d40-3600x2401.jpg?fit=crop&auto=format" alt="Health Policy. | Image Credit: Mohamad Zaki - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">December 4th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/policy-proposals-aim-to-stimulate-the-long-term-sustainability-of-infused-biosimilars">Policy Proposals Aim to Stimulate the Long-Term Sustainability of Infused Biosimilars</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/cameron-santoro">Cameron Santoro</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/policy-proposals-aim-to-stimulate-the-long-term-sustainability-of-infused-biosimilars"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Panelists proposed policy solutions to ensure long-term sustainability of infused biosimilars amid current challenges, including average sales price erosion and reimbursement issues.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/fda-approves-sixth-ustekinumab-biosimilar-yesintek"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/2f366a4ab7421a6a697b539c22b8aedf46713899-6000x4000.jpg?fit=crop&auto=format" alt="FDA approval. | Image Credit: syahrir - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">December 2nd 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/fda-approves-sixth-ustekinumab-biosimilar-yesintek">FDA Approves Sixth Ustekinumab Biosimilar, Yesintek</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/skylar-jeremias">Skylar Jeremias</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/fda-approves-sixth-ustekinumab-biosimilar-yesintek"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">The approval of Yesintek (ustekinumab-kfce), the sixth biosimilar to reference Stelara, will be used to treat patients with various immunology conditions, including psoriatic arthritis and inflammatory bowel disease.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex md:hidden justify-center items-center"></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/addressing-patent-hurdles-payer-barriers-and-interchangeability"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/acfa79aea9d4d9915415c5b57644f564014a966a-6760x4171.jpg?fit=crop&auto=format" alt="Patient access to medication. | Image Credit: Supatman - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">November 22nd 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/addressing-patent-hurdles-payer-barriers-and-interchangeability">Addressing Patent Hurdles, Payer Barriers, and Interchangeability</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/cameron-santoro">Cameron Santoro</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/addressing-patent-hurdles-payer-barriers-and-interchangeability"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Global Biosimilars Week discussed issues in biosimilar adoption and called for reforms to streamline processes, foster competition, and increase biosimilar access for patients.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/financial-incentives-drive-biosimilar-adoption-in-japan"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/dfa1025ae10a86f9ce44cdc2182c02e7a8c82f5d-4924x3288.jpg?fit=crop&auto=format" alt="Health care expenses. | Image Credit: izzuan - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">November 20th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/financial-incentives-drive-biosimilar-adoption-in-japan">Financial Incentives Drive Biosimilar Adoption in Japan</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/cameron-santoro">Cameron Santoro</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/financial-incentives-drive-biosimilar-adoption-in-japan"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Financial incentives provided to hospitals in Japan led to a significant increase in biosimilar oncology drug prescriptions.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/fda-q-a-addressing-biosimilar-safety-ai-in-drug-development-and-supply-chain-challenges"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/ebfb40d061db8cb94776018fe5f4c50f7871539b-5293x3529.jpg?fit=crop&auto=format" alt="FDA logo and website | Image credit: Postmodern Studio - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">November 6th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/fda-q-a-addressing-biosimilar-safety-ai-in-drug-development-and-supply-chain-challenges">FDA Q&A: Addressing Biosimilar Safety, AI in Drug Development, and Supply Chain Challenges</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/skylar-jeremias">Skylar Jeremias</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/fda-q-a-addressing-biosimilar-safety-ai-in-drug-development-and-supply-chain-challenges"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">In a Q&A, an FDA spokesperson discusses efforts to reduce misinformation about biosimilars through education, the agency’s collaboration with global regulators to streamline development, and its work to address drug shortages while emphasizing safety, efficacy, and public trust.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/biosimilar-aflibercept-p041-as-effective-safe-as-originator-in-namd"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/d2cd5de30ba7677ccd28c41ab29de29b346bdf3c-7689x5128.jpg?fit=crop&auto=format" alt="Retinal condition | Image Credit: Yakobchuk Olena - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">October 30th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/biosimilar-aflibercept-p041-as-effective-safe-as-originator-in-namd">Biosimilar Aflibercept P041 as Effective, Safe as Originator in nAMD</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/cameron-santoro">Cameron Santoro</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/biosimilar-aflibercept-p041-as-effective-safe-as-originator-in-namd"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Biosimilar aflibercept (P041) demonstrated comparable safety and efficacy to the originator aflibercept (Eylea) in treating patients with retinal conditions like neovascular age-related macular degeneration (nAMD).</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div><div><div class="text-[8px] text-center text-gray-500 hidden">Advertisement</div><div id="div-gpt-ad-infeed-13"></div></div></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/exploring-the-complexities-of-biosimilars-and-interchangeability"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/0d5a24832621e6f9d53f32a6423b928fb5b1679b-6011x3452.jpg?fit=crop&auto=format" alt="health policy chart | Image credit: JOURNEY STUDIO7 - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">October 30th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/exploring-the-complexities-of-biosimilars-and-interchangeability">Exploring the Complexities of Biosimilars and Interchangeability</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/skylar-jeremias">Skylar Jeremias</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/exploring-the-complexities-of-biosimilars-and-interchangeability"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">A panel of industry experts discussed the complexities of biosimilars and interchangeability, emphasizing the challenges in adoption, the need for regulatory and legislative solutions, and the importance of education to combat misinformation.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/biosimilars-expand-access-and-reduce-costs-in-oncology-immunology"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/7fc5480ec7e34a8f5b00fd8c0b3f673a38015d46-5184x3456.jpg?fit=crop&auto=format" alt="Cost of health care | Image Credit: Scott Hales - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">October 28th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/biosimilars-expand-access-and-reduce-costs-in-oncology-immunology">Biosimilars Expand Access and Reduce Costs in Oncology, Immunology</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/cameron-santoro">Cameron Santoro</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/biosimilars-expand-access-and-reduce-costs-in-oncology-immunology"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Biosimilars offer significant cost-saving potential while expanding patient access, particularly in oncology and immunology.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/samsung-bioepis-reports-2024-biosimilar-market-growth-trends"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/c0595641740ddb95dbc346b73a0a63639345e1ea-7008x4672.jpg?fit=crop&auto=format" alt="Market share increase | Image Credit: Kiattisak - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">October 15th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/samsung-bioepis-reports-2024-biosimilar-market-growth-trends">Samsung Bioepis Reports 2024 Biosimilar Market Growth Trends</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/cameron-santoro">Cameron Santoro</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/samsung-bioepis-reports-2024-biosimilar-market-growth-trends"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Adalimumab biosimilar market shares have steadily increased, but challenges remain due to pricing strategies and limited government support, according to the Samsung Bioepis report.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/fda-approves-imuldosa-a-fifth-biosimilar-to-stelara"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/140642b191f4ee4e4895ffeda9ce6e76c770dfe2-1200x700.jpg?fit=crop&auto=format" alt="FDA approve graphic on screen over a doctor | Image credit: wladimir1804 - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">October 11th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/fda-approves-imuldosa-a-fifth-biosimilar-to-stelara">FDA Approves Imuldosa, a Fifth Biosimilar to Stelara</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/skylar-jeremias">Skylar Jeremias</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/fda-approves-imuldosa-a-fifth-biosimilar-to-stelara"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex md:hidden justify-center items-center"></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/blue-shield-of-california-lowers-humira-biosimilar-costs-challenges-pbm-pricing"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/21c4db2b1f658d537c0a022c79b65c35f7d39b8e-3888x2592.jpg?fit=crop&auto=format" alt="Cost reduction in health care. | Image Credit: wladimir1804 - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">October 7th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/blue-shield-of-california-lowers-humira-biosimilar-costs-challenges-pbm-pricing">Blue Shield of California Lowers Humira Biosimilar Costs, Challenges PBM Pricing</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/cameron-santoro">Cameron Santoro</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/blue-shield-of-california-lowers-humira-biosimilar-costs-challenges-pbm-pricing"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Blue Shield of California will offer an adalimumab biosimilar at a price that is 75% less than the reference product Humira for the monthly dose.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/fourth-ustekinumab-biosimilar-otulfi-approved-in-us"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/60acf610ed5d8534057fb31e98f029c28409bcc1-1200x738.jpg?fit=crop&auto=format" alt="Blue FDA approved stamp | Image credit: cartoon-stock - adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">October 2nd 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/fourth-ustekinumab-biosimilar-otulfi-approved-in-us">Fourth Ustekinumab Biosimilar, Otulfi, Approved in US</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/laura-joszt">Laura Joszt, MA</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/fourth-ustekinumab-biosimilar-otulfi-approved-in-us"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Otulfi from Formycon and Fresenius Kabi was approved simultaneously in the US and the European Union. In the US, it will launch in February 2025.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div><div><div class="text-[8px] text-center text-gray-500 hidden">Advertisement</div><div id="div-gpt-ad-infeed-19"></div></div></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/biosimilar-follitropin-alfa-offers-fertility-savings-in-france"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/8dde0bb2ca949518399ff30fcdce451a7f607d87-4993x3317.jpg?fit=crop&auto=format" alt="Follitropin alfa | Image Credit: cristianstorto - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">September 30th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/biosimilar-follitropin-alfa-offers-fertility-savings-in-france">Biosimilar Follitropin Alfa Offers Fertility Savings in France</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/cameron-santoro">Cameron Santoro</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/biosimilar-follitropin-alfa-offers-fertility-savings-in-france"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">A French study found that follitropin alfa, a biosimilar fertility drug, is more cost-effective compared with its originator, leading to potential savings for both patients and the health care system. </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/report-highlights-biosimilars-savings-but-high-out-of-pocket-costs-for-patients"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/4d51334652648b7d20b479e8ff9a35a3962ea6df-4896x3264.jpg?fit=crop&auto=format" alt="Cost savings | Image credit: joyfotoliakid - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">September 27th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/report-highlights-biosimilars-savings-but-high-out-of-pocket-costs-for-patients">Report Highlights Biosimilars Savings, but High Out-of-Pocket Costs for Patients</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/julia-bonavitacola">Julia Bonavitacola</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/report-highlights-biosimilars-savings-but-high-out-of-pocket-costs-for-patients"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Out-of-pocket costs for biosimilars and generics are still high for patients despite these drugs leading to estimated savings of $445 billion in 2023.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/drug-survival-of-biosimilars-originator-tnf-inhibitors-similar"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/17e1a80a0af08634c1c58ed128411771f0bb71f1-1280x807.jpg?fit=crop&auto=format" alt="Rows of identical clear vials | Image credit: nordroden - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">September 4th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/drug-survival-of-biosimilars-originator-tnf-inhibitors-similar">Drug Survival of Biosimilars, Originator TNF Inhibitors Similar</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/laura-joszt">Laura Joszt, MA</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/drug-survival-of-biosimilars-originator-tnf-inhibitors-similar"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">The rates of discontinuation due to inefficacy or adverse events for biosimilars and originators of etanercept and adalimumab were similar, according to an analysis of a prospective registry.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/biosimilar-updates-celltrion-costco-partnership-amgen-sues-samsung-bioepis-denosumab-results"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/1b666f2bfe935d0536114ee5e312d8f5c043a68c-1280x756.jpg?fit=crop&auto=format" alt="White piggy bank next to a stethoscope with health icons above it | Image credit: Kiattisak - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">August 25th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/biosimilar-updates-celltrion-costco-partnership-amgen-sues-samsung-bioepis-denosumab-results">Biosimilar Updates: Celltrion, Costco Partnership; Amgen Sues Samsung Bioepis; Denosumab Results</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/skylar-jeremias">Skylar Jeremias</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/biosimilar-updates-celltrion-costco-partnership-amgen-sues-samsung-bioepis-denosumab-results"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Celltrion's adalimumab-aaty biosimilar is now accessible for all Costco members, while Amgen sues Samsung Bioepis over the latter’s denosumab biosimilar candidate, and GlycoNex progresses its denosumab biosimilar SPD8 to phase 3 trials.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/biosimilar-uptake-lags-in-us-despite-potential-cost-savings"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/4b5dea1abd963d1413ab85a5ad21a6b7ca30e788-4853x2720.jpg?fit=crop&auto=format" alt="Interest rates control inflation | Image Credit: Thongdee - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">August 16th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/biosimilar-uptake-lags-in-us-despite-potential-cost-savings">Biosimilar Uptake Lags in US Despite Potential Cost Savings</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/cameron-santoro">Cameron Santoro</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/biosimilar-uptake-lags-in-us-despite-potential-cost-savings"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Delayed biosimilar uptake in the US is driven by payer, provider, and patient barriers, but targeted interventions can help boost utilization and savings.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/biosimilars-and-employers-strategies-for-success"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/bac9119d52d062950c417fc4c28b4780940ac404-225x225.jpg?fit=crop&auto=format" alt="Kathy Oubre, MS | Image: LinkedIn" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">August 16th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/biosimilars-and-employers-strategies-for-success">Biosimilars and Employers: Strategies for Success</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/kathy-oubre-ms">Kathy Oubre, MS</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/biosimilars-and-employers-strategies-for-success"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">This article first appeared on The Center for Biosimilars®.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div><div><div class="text-[8px] text-center text-gray-500 hidden">Advertisement</div><div id="div-gpt-ad-infeed-25"></div></div></div><div class="jsx-ad50481d5ee26850 flex md:hidden justify-center items-center"></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/fda-approves-biosimilar-enzeevu-for-eye-conditions"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/01db92ab6c03e1018494ce00a2848e9bd662af7d-1200x629.jpg?fit=crop&auto=format" alt="eye and tech | Image credit: eevl - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">August 13th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/fda-approves-biosimilar-enzeevu-for-eye-conditions">FDA Approves Biosimilar Enzeevu for Eye Conditions</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/skylar-jeremias">Skylar Jeremias</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/fda-approves-biosimilar-enzeevu-for-eye-conditions"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">The FDA approved Sandoz’ Enzeevu, the fourth aflibercept biosimilar to be approved for Americans with age-related macular degeneration and other retinal eye diseases.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/first-aflibercept-biosimilars-approved-in-us"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/7edc257aff3f99bf7ce8baf67cd930524592e5ee-1280x813.jpg?fit=crop&auto=format" alt="Close of up of an older woman's eye | Image credit: Syda Productions - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">May 20th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/first-aflibercept-biosimilars-approved-in-us">First Aflibercept Biosimilars Approved in US</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/skylar-jeremias">Skylar Jeremias</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/first-aflibercept-biosimilars-approved-in-us"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">The FDA approved the first 2 biosimilars referencing aflibercept (Eylea). However, patent litigation has left it unclear when the biosimilars will come to market.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/budget-impact-analysis-of-biosimilar-natalizumab-in-the-us"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png?fit=crop&auto=format" alt="AJMC" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">May 17th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/budget-impact-analysis-of-biosimilar-natalizumab-in-the-us">Budget Impact Analysis of Biosimilar Natalizumab in the US</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/edward-li-pharmd-mph">Edward Li, PharmD, MPH</a><span class="jsx-ad50481d5ee26850 mr-1 ml-[1px]"> </span><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/adrian-goh-mec">Adrian Goh, MEc</a><span class="jsx-ad50481d5ee26850 mr-1 ml-[1px]"> </span><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/soni-gupta-mec">Soni Gupta, MEc</a><span class="jsx-ad50481d5ee26850 mr-1 ml-[1px]"> </span><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/marion-schauf-dipl-kff">Marion Schauf, Dipl-Kff</a><span class="jsx-ad50481d5ee26850 mr-1 ml-[1px]"> </span><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/anna-chen-pharmd-ms">Anna Chen, PharmD, MS</a><span class="jsx-ad50481d5ee26850 mr-1 ml-[1px]"> </span><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/daniel-m-hartung-pharmd-mph">Daniel M. Hartung, PharmD, MPH</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/budget-impact-analysis-of-biosimilar-natalizumab-in-the-us"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/radiographic-progression-low-for-high-risk-patients-with-axspa-on-both-secukinumab-and-an-adalimumab-biosimilar"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/fafb1b7e7ca04361c98cf0f8b2f5890932aba302-5616x3744.jpg?fit=crop&auto=format" alt="Woman sitting on bed with back pain illustrated by a highlighted spine | Image credit: WavebreakMediaMicro - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">April 12th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/radiographic-progression-low-for-high-risk-patients-with-axspa-on-both-secukinumab-and-an-adalimumab-biosimilar">Radiographic Progression Low for High-Risk Patients With axSpA on Both Secukinumab and an Adalimumab Biosimilar</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/kimberly-rath-pharmd">Kimberly Rath, PharmD</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/radiographic-progression-low-for-high-risk-patients-with-axspa-on-both-secukinumab-and-an-adalimumab-biosimilar"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Patients with radiographic axial spondyloarthritis (ax-SpA) and a high risk of radiographic progression had similar low progression on both secukinumab and an adalimumab biosimilar.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/fda-approves-first-2-denosumab-biosimilars"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/bf365d9c6f891c03e1fc1d99398a075dea15607e-3508x2480.jpg?fit=crop&auto=format" alt="FDA approval stamp in red | Image credit: chrisdorney - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">March 5th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/fda-approves-first-2-denosumab-biosimilars">FDA Approves First 2 Denosumab Biosimilars</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/laura-joszt">Laura Joszt, MA</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/fda-approves-first-2-denosumab-biosimilars"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Wyost and Jubbonti were approved as interchangeable biosimilars for Xgeva and Prolia; however, there is no launch date yet pending litigation with the maker of the reference products.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/navigating-the-biosimilar-frontier-opportunities-and-challenges-in-2024"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/8f2665e13dc96affc156be2470971e666473ce82-1280x792.jpg?fit=crop&auto=format" alt="Doctor stacking wooden blocks with health care icons | image credit: REDPIXEL - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">January 14th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/navigating-the-biosimilar-frontier-opportunities-and-challenges-in-2024">Navigating the Biosimilar Frontier: Opportunities and Challenges in 2024 </a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/jayne-hornung">Jayne Hornung</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/navigating-the-biosimilar-frontier-opportunities-and-challenges-in-2024"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Biosimilars offer substantial promise for a new era of accessibility and affordability for patients and the broader health care industry, but better understanding of these products from payers and providers is necessary for biosimilars to reach their full potential in the US.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div></div><div class="w-full text-center flex justify-center pb-24"><a class="px-4 py-2 border-y border-r bg-primary text-white" href="/compendium/biosimilars?page=1">1</a><a class="px-4 py-2 border-y border-r " href="/compendium/biosimilars?page=2">2</a><a class="px-4 py-2 border-y border-r " href="/compendium/biosimilars?page=3">3</a><a class="px-4 py-2 border-y border-r " href="/compendium/biosimilars?page=4">4</a><a class="px-4 py-2 border-y border-r " href="/compendium/biosimilars?page=5">5</a><a class="px-4 py-2 border-y border-r " href="/compendium/biosimilars?page=6">6</a><a class="px-4 py-2 border-y border-r " href="/compendium/biosimilars?page=7">7</a><a class="px-4 py-2 border-y border-r " href="/compendium/biosimilars?page=8">8</a><div class="px-4 py-2 border-y border-r">...</div><a class="px-4 py-2 border-y border-r" href="/compendium/biosimilars?page=19">19</a><a class="px-4 py-2 border-y border-r" href="/compendium/biosimilars?page=2">></a></div></div></div><div class="flex-none w-[300px] z-[9999] relative hidden md:block"><div style="top:5rem" class="sticky custom-spacing"><div class="collapse-container " style="overflow:hidden;max-height:900px;transition:max-height .4s ease-in-out"></div></div></div></div><div id="div-gpt-ad-pixel" style="width:1px;height:1px" class=""></div><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-NK5KQXS" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript><div id="footerOuterWrap" class=" mx-auto flex"><div class="bg-[#00598D] xl:w-[70%] w-[70%] py-12 pl-auto"><div class="xxl:w-[75%] w-[90%] ml-auto"><div><span style="box-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%"><span style="box-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%"><img style="display:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0" alt="" aria-hidden="true" src="data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27300%27%20height=%2744%27/%3e"/></span><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" srcSet="/_next/image?url=%2Fan_mjhls_brand_ko.png&w=384&q=75 1x, /_next/image?url=%2Fan_mjhls_brand_ko.png&w=640&q=75 2x" src="/_next/image?url=%2Fan_mjhls_brand_ko.png&w=640&q=75" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" loading="lazy"/></noscript></span></div><div class="flex"><div class="flex justify-between pt-6"><div class="w-[40%]"><div class="text-footer-text-color text-xs"><p>2 Commerce Drive<br/>Suite 100<br/>Cranbury, NJ 08512</p></div><div class="self-start py-6" style="display:flex;flex-wrap:wrap"><a rel="noreferrer noopener" class="pr-1" target="_blank" href="https://www.facebook.com/TheAmericanJournalOfManagedCare"><p> <svg width='25px' height='25px' viewBox='0 0 512 512' version='1.1' xmlns='http://www.w3.org/2000/svg'> <g id='Page-1' stroke='none' strokeWidth='1' fill='none' fillRule='evenodd'> <g id='facebook' fill='#FFFFFF' fillRule='nonzero'> <path d='M512,256 C512,114.6 397.4,0 256,0 C114.6,0 0,114.6 0,256 C0,397.4 114.6,512 256,512 C257.5,512 259,512 260.5,511.9 L260.5,312.7 L205.5,312.7 L205.5,248.6 L260.5,248.6 L260.5,201.4 C260.5,146.7 293.9,116.9 342.7,116.9 C366.1,116.9 386.2,118.6 392,119.4 L392,176.6 L358.4,176.6 C331.9,176.6 326.7,189.2 326.7,207.7 L326.7,248.5 L390.2,248.5 L381.9,312.6 L326.7,312.6 L326.7,502.1 C433.7,471.4 512,372.9 512,256 Z' id='Path' /> </g> </g> </svg> </p></a><a rel="noreferrer noopener" class="pr-1" href="https://twitter.com/AJMC_Journal"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" width="25" height="25" viewBox="1.41 1.41 252.9 252.9"><g transform="translate(1.4065934065934016 1.4065934065934016) scale(2.81 2.81)"><polygon points="24.89,23.01 57.79,66.99 65.24,66.99 32.34,23.01" fill="#FFFFFF" transform="matrix(1 0 0 1 0 0)"></polygon><path d="M 45 0 L 45 0 C 20.147 0 0 20.147 0 45 v 0 c 0 24.853 20.147 45 45 45 h 0 c 24.853 0 45 -20.147 45 -45 v 0 C 90 20.147 69.853 0 45 0 z M 56.032 70.504 L 41.054 50.477 L 22.516 70.504 h -4.765 L 38.925 47.63 L 17.884 19.496 h 16.217 L 47.895 37.94 l 17.072 -18.444 h 4.765 L 50.024 40.788 l 22.225 29.716 H 56.032 z" fill="#FFFFFF" transform="matrix(1 0 0 1 0 0)" stroke-linecap="round"></path></g></svg></a><a rel="noreferrer noopener" class="pr-1" target="_blank" href="https://www.linkedin.com/company/american-journal-of-managed-care/"><p> <svg width='25px' height='25px' viewBox='0 0 512 512' version='1.1' xmlns='http://www.w3.org/2000/svg'> <g id='Page-1' stroke='none' strokeWidth='1' fill='none' fillRule='evenodd'> <g id='linkedin' fill='#FFFFFF' fillRule='nonzero'> <path d='M256,0 C114.636719,0 0,114.636719 0,256 C0,397.363281 114.636719,512 256,512 C397.363281,512 512,397.363281 512,256 C512,114.636719 397.363281,0 256,0 Z M181.609375,387 L119.261719,387 L119.261719,199.425781 L181.609375,199.425781 L181.609375,387 Z M150.4375,173.8125 L150.03125,173.8125 C129.109375,173.8125 115.578125,159.410156 115.578125,141.410156 C115.578125,123.003906 129.523438,109 150.851562,109 C172.179688,109 185.304688,123.003906 185.710938,141.410156 C185.710938,159.410156 172.179688,173.8125 150.4375,173.8125 Z M406.421875,387 L344.082031,387 L344.082031,286.652344 C344.082031,261.433594 335.054688,244.234375 312.496094,244.234375 C295.273438,244.234375 285.015625,255.835938 280.507812,267.035156 C278.859375,271.042969 278.457031,276.644531 278.457031,282.25 L278.457031,387 L216.113281,387 C216.113281,387 216.929688,217.023438 216.113281,199.425781 L278.457031,199.425781 L278.457031,225.984375 C286.742188,213.203125 301.566406,195.023438 334.644531,195.023438 C375.664062,195.023438 406.421875,221.832031 406.421875,279.445312 L406.421875,387 Z' id='Shape' /> </g> </g> </svg> </p></a><a rel="noreferrer noopener" class="pr-1" target="_blank" href="https://www.instagram.com/ajmcjournal/"><p> <svg width='25px' height='25px' viewBox='0 0 512 512' version='1.1' xmlns='http://www.w3.org/2000/svg'> <g id='Page-1' stroke='none' strokeWidth='1' fill='none' fillRule='evenodd'> <g id='instagram' fill='#FFFFFF' fillRule='nonzero'> <path d='M305,256 C305,283.0625 283.0625,305 256,305 C228.9375,305 207,283.0625 207,256 C207,228.9375 228.9375,207 256,207 C283.0625,207 305,228.9375 305,256 Z' id='Path' /> <path d='M370.59375,169.304688 C368.238281,162.921875 364.480469,157.144531 359.597656,152.402344 C354.855469,147.519531 349.082031,143.761719 342.695312,141.40625 C337.515625,139.394531 329.734375,137 315.402344,136.347656 C299.898438,135.640625 295.25,135.488281 256,135.488281 C216.746094,135.488281 212.097656,135.636719 196.597656,136.34375 C182.265625,137 174.480469,139.394531 169.304688,141.40625 C162.917969,143.761719 157.140625,147.519531 152.402344,152.402344 C147.519531,157.144531 143.761719,162.917969 141.402344,169.304688 C139.390625,174.484375 136.996094,182.269531 136.34375,196.601562 C135.636719,212.101562 135.484375,216.75 135.484375,256.003906 C135.484375,295.253906 135.636719,299.902344 136.34375,315.40625 C136.996094,329.738281 139.390625,337.519531 141.402344,342.699219 C143.761719,349.085938 147.515625,354.859375 152.398438,359.601562 C157.140625,364.484375 162.914062,368.242188 169.300781,370.597656 C174.480469,372.613281 182.265625,375.007812 196.597656,375.660156 C212.097656,376.367188 216.742188,376.515625 255.996094,376.515625 C295.253906,376.515625 299.902344,376.367188 315.398438,375.660156 C329.730469,375.007812 337.515625,372.613281 342.695312,370.597656 C355.515625,365.652344 365.648438,355.519531 370.59375,342.699219 C372.605469,337.519531 375,329.738281 375.65625,315.40625 C376.363281,299.902344 376.511719,295.253906 376.511719,256.003906 C376.511719,216.75 376.363281,212.101562 375.65625,196.601562 C375.003906,182.269531 372.609375,174.484375 370.59375,169.304688 L370.59375,169.304688 Z M256,331.484375 C214.308594,331.484375 180.511719,297.691406 180.511719,256 C180.511719,214.308594 214.308594,180.515625 256,180.515625 C297.6875,180.515625 331.484375,214.308594 331.484375,256 C331.484375,297.691406 297.6875,331.484375 256,331.484375 Z M334.46875,195.171875 C324.726562,195.171875 316.828125,187.273438 316.828125,177.53125 C316.828125,167.789062 324.726562,159.890625 334.46875,159.890625 C344.210938,159.890625 352.109375,167.789062 352.109375,177.53125 C352.105469,187.273438 344.210938,195.171875 334.46875,195.171875 Z' id='Shape' /> <path d='M256,0 C114.636719,0 0,114.636719 0,256 C0,397.363281 114.636719,512 256,512 C397.363281,512 512,397.363281 512,256 C512,114.636719 397.363281,0 256,0 Z M402.113281,316.605469 C401.402344,332.253906 398.914062,342.9375 395.28125,352.289062 C387.644531,372.035156 372.035156,387.644531 352.289062,395.28125 C342.941406,398.914062 332.253906,401.398438 316.609375,402.113281 C300.933594,402.828125 295.925781,403 256.003906,403 C216.078125,403 211.074219,402.828125 195.394531,402.113281 C179.75,401.398438 169.0625,398.914062 159.714844,395.28125 C149.902344,391.589844 141.019531,385.804688 133.675781,378.324219 C126.199219,370.984375 120.414062,362.097656 116.722656,352.289062 C113.089844,342.941406 110.601562,332.253906 109.890625,316.609375 C109.167969,300.929688 109,295.921875 109,256 C109,216.078125 109.167969,211.070312 109.886719,195.394531 C110.597656,179.746094 113.082031,169.0625 116.714844,159.710938 C120.40625,149.902344 126.195312,141.015625 133.675781,133.675781 C141.015625,126.195312 149.902344,120.410156 159.710938,116.71875 C169.0625,113.085938 179.746094,110.601562 195.394531,109.886719 C211.070312,109.171875 216.078125,109 256,109 C295.921875,109 300.929688,109.171875 316.605469,109.890625 C332.253906,110.601562 342.9375,113.085938 352.289062,116.714844 C362.097656,120.40625 370.984375,126.195312 378.328125,133.675781 C385.804688,141.019531 391.59375,149.902344 395.28125,159.710938 C398.917969,169.0625 401.402344,179.746094 402.117188,195.394531 C402.832031,211.070312 403,216.078125 403,256 C403,295.921875 402.832031,300.929688 402.113281,316.605469 L402.113281,316.605469 Z' id='Shape' /> </g> </g> </svg> </p></a><a rel="noreferrer noopener" class="pr-1" target="_blank" href="/rss"><p><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:svgjs="http://svgjs.com/svgjs" version="1.1" width="25px" height="25px" x="0" y="0" viewBox="0 0 512 512" style="enable-background:new 0 0 512 512" xml:space="preserve"> <g> <path xmlns="http://www.w3.org/2000/svg" d="m437.019531 74.980469c-48.351562-48.351563-112.640625-74.980469-181.019531-74.980469s-132.667969 26.628906-181.019531 74.980469c-48.351563 48.351562-74.980469 112.640625-74.980469 181.019531s26.628906 132.667969 74.980469 181.019531c48.351562 48.351563 112.640625 74.980469 181.019531 74.980469s132.667969-26.628906 181.019531-74.980469c48.351563-48.351562 74.980469-112.640625 74.980469-181.019531s-26.628906-132.667969-74.980469-181.019531zm-267.757812 292.957031c-13.730469 0-24.90625-11.171875-24.90625-24.90625s11.175781-24.90625 24.90625-24.90625c13.734375 0 24.90625 11.171875 24.90625 24.90625s-11.171875 24.90625-24.90625 24.90625zm80.277343 4.925781c-8.28125 0-15-6.714843-15-15 0-44.171875-35.9375-80.109375-80.109374-80.109375-8.285157 0-15-6.71875-15-15 0-8.285156 6.714843-15 15-15 60.714843 0 110.109374 49.394532 110.109374 110.109375 0 8.285157-6.714843 15-15 15zm67.09375 0c-8.285156 0-15-6.714843-15-15 0-81.167969-66.035156-147.203125-147.203124-147.203125-8.285157 0-15-6.714844-15-15s6.714843-15 15-15c97.710937 0 177.203124 79.492188 177.203124 177.203125 0 8.285157-6.714843 15-15 15zm66.292969 0c-8.28125 0-15-6.714843-15-15 0-117.722656-95.773437-213.496093-213.496093-213.496093-8.285157 0-15-6.714844-15-15 0-8.285157 6.714843-15 15-15 65.039062 0 126.1875 25.328124 172.179687 71.316406 45.988281 45.992187 71.316406 107.140625 71.316406 172.179687 0 8.285157-6.714843 15-15 15zm0 0" fill="#ffffff" data-original="#000000" style=""/> </g> </svg></p></a></div><div class="text-footer-text-color text-xs"><p>© 2025 MJH Life Sciences<sup>®</sup> and AJMC®.<br/> All rights reserved.</p></div></div><div class="flex flex-row flex-wrap self-start w-[60%]"><div class="w-[50%] pb-3 px-2 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_self" href="/about-us">About</a></div><div class="w-[50%] pb-3 px-2 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_self" href="/contactus">Contact</a></div><div class="w-[50%] pb-3 px-2 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_self" href="/editorial-boards">Editorial Boards</a></div><div class="w-[50%] pb-3 px-2 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_self" href="/advertise">Advertise</a></div><div class="w-[50%] pb-3 px-2 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_blank" href="https://www.mjhlifesciences.com/ccpa?domain=www.ajmc.com">Do Not Sell My Information</a></div><div class="w-[50%] pb-3 px-2 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_self" href="/terms">Terms & Conditions</a></div><div class="w-[50%] pb-3 px-2 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_self" href="/privacy">Privacy Policy</a></div></div><div class="flex items-start mr-6 lg:mr-10"><span style="box-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%"><span style="box-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%"><img style="display:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0" alt="" aria-hidden="true" src="data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27251%27%20height=%2768%27/%3e"/></span><img alt="AJMC Managed Markets Network Logo" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="AJMC Managed Markets Network Logo" srcSet="/_next/image?url=%2FAJMC_MMN_logo_light.png&w=256&q=75 1x, /_next/image?url=%2FAJMC_MMN_logo_light.png&w=640&q=75 2x" src="/_next/image?url=%2FAJMC_MMN_logo_light.png&w=640&q=75" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" loading="lazy"/></noscript></span></div></div></div></div></div><div class="w-[30%] bg-[#003767] flex items-center justify-center "><div class="flex flex-col justify-between "><a target="_self" rel="noopener noreferrer" class="my-2 px-8" href="/topic/center-on-health-equity-and-access"><span style="box-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%"><span style="box-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%"><img style="display:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0" alt="" aria-hidden="true" src="data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27315%27%20height=%2777%27/%3e"/></span><img alt="CH Logo" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="CH Logo" srcSet="/_next/image?url=%2FCHA_Logo.png&w=384&q=75 1x, /_next/image?url=%2FCHA_Logo.png&w=640&q=75 2x" src="/_next/image?url=%2FCHA_Logo.png&w=640&q=75" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" loading="lazy"/></noscript></span></a><a target="_blank" rel="noopener noreferrer" class="my-2 px-8" href="https://www.centerforbiosimilars.com/"><span style="box-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%"><span style="box-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%"><img style="display:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0" alt="" aria-hidden="true" src="data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27315%27%20height=%2777%27/%3e"/></span><img alt="Center for Biosimilars Logo" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="Center for Biosimilars Logo" srcSet="/_next/image?url=%2FCB.png&w=384&q=75 1x, /_next/image?url=%2FCB.png&w=640&q=75 2x" src="/_next/image?url=%2FCB.png&w=640&q=75" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" loading="lazy"/></noscript></span></a></div></div></div></div></div><script id="__NEXT_DATA__" type="application/json">{"props":{"pageProps":{"pageProps":{},"cache":{"main_menu":[{"subQuery":[{"name":"All News","_id":"1376963d-32e8-4647-bb5e-59c984e35893","_updatedAt":"2020-04-14T13:30:35Z","is_active":true,"_type":"mainNavigation","navParent":{"_ref":"e8c503ba-34b9-43d5-8ce1-e8603c4e4b6b","_type":"reference"},"_rev":"sBk7YzjWMuBuhiatU3YIhQ","url":"/news","children":[],"_createdAt":"2020-04-14T13:30:35Z"},{"navParent":{"_ref":"e8c503ba-34b9-43d5-8ce1-e8603c4e4b6b","_type":"reference"},"_type":"mainNavigation","is_active":true,"_rev":"QxOJBWa4XErmibN6Cb5OcA","name":"Press Releases","_updatedAt":"2020-04-14T13:30:57Z","_id":"2af5da5e-78c2-42c8-90b8-3900f8c89889","url":"/press-release","_createdAt":"2020-04-14T13:30:57Z","children":[]},{"url":"/approvals-launches","is_active":true,"_rev":"jvOgZ3KZdbRHfWlt9ePmOA","children":[],"name":"Product Approvals and Launches","_updatedAt":"2022-01-07T20:44:44Z","_createdAt":"2021-07-29T12:15:49Z","_type":"mainNavigation","_id":"854a1ad1-9831-4387-bda9-ffb93a074ace","navParent":{"_ref":"e8c503ba-34b9-43d5-8ce1-e8603c4e4b6b","_type":"reference"}}],"_type":"mainNavigation","_updatedAt":"2020-04-14T13:26:21Z","_rev":"Yw6MEKZDMdk6hC2JCRdGN7","navParent":null,"sortOrder":1,"name":"News","_id":"e8c503ba-34b9-43d5-8ce1-e8603c4e4b6b","is_active":true,"_createdAt":"2020-04-14T13:26:14Z"},{"_id":"821e259a-db55-4862-985a-5cd089bbf894","_rev":"rcwwj6TiN2Q0ymhqDzIFjO","_type":"mainNavigation","navParent":null,"subQuery":[{"sortOrder":1,"_updatedAt":"2024-05-24T16:52:54Z","navParent":{"_type":"reference","_ref":"821e259a-db55-4862-985a-5cd089bbf894"},"name":"All Video Types","_type":"mainNavigation","url":"/video-hub","is_active":true,"_createdAt":"2024-05-24T16:37:06Z","_rev":"rcwwj6TiN2Q0ymhqDzJ8ty","_id":"f51d85fa-cabc-4c7d-85d0-11301088b7f6","children":[]},{"navParent":{"_ref":"821e259a-db55-4862-985a-5cd089bbf894","_type":"reference"},"_createdAt":"2024-05-24T16:38:14Z","_type":"mainNavigation","is_active":true,"name":"AJMC TV","_updatedAt":"2024-05-28T19:38:54Z","url":"/interviews","_rev":"LJrwYxwtzLC9JsOYMk8TBr","children":[],"_id":"a99a3683-5173-46b3-94b0-21b7d6b06a24"},{"_rev":"4IWvQAHLC63503PAHcJfUU","_type":"mainNavigation","children":[],"_createdAt":"2025-02-14T19:40:54Z","name":"Guidelines","_updatedAt":"2025-02-14T19:41:11Z","url":"/guidelines","_id":"9affe463-8f89-4d72-b806-62281069ebba","is_active":true,"navParent":{"_ref":"821e259a-db55-4862-985a-5cd089bbf894","_type":"reference"}},{"_rev":"Yw6MEKZDMdk6hC2JCRda8Z","_type":"mainNavigation","is_active":true,"children":[],"navParent":{"_ref":"821e259a-db55-4862-985a-5cd089bbf894","_type":"reference"},"_createdAt":"2020-04-14T13:43:45Z","name":"Insights","_id":"b03ccbf6-6387-48de-8edc-4f1f23debe40","_updatedAt":"2020-04-14T13:43:45Z","url":"/insights"},{"navParent":{"_ref":"821e259a-db55-4862-985a-5cd089bbf894","_type":"reference"},"_id":"f3d69d10-636b-4927-8ff4-4f54fabc940a","_rev":"k6N5FycA5UhVnvpzSEa3Rp","name":"OnLocation","children":[],"_type":"mainNavigation","_updatedAt":"2020-04-14T13:44:19Z","is_active":true,"_createdAt":"2020-04-14T13:44:19Z","url":"/onlocation"},{"_updatedAt":"2022-10-05T15:29:11Z","_createdAt":"2022-10-05T15:29:11Z","_rev":"37PW14Mg02p9z7FTF1SGE9","url":"/payer-perspectives","is_active":true,"navParent":{"_ref":"821e259a-db55-4862-985a-5cd089bbf894","_type":"reference"},"_type":"mainNavigation","name":"Payer Perspectives","_id":"d4e3d69c-8a07-4191-af89-27d7e838af08","children":[]},{"url":"/peer-exchange","navParent":{"_ref":"821e259a-db55-4862-985a-5cd089bbf894","_type":"reference"},"children":[],"_createdAt":"2020-04-14T13:44:43Z","_type":"mainNavigation","_rev":"VdTcsTJkAuZveXGf2i9Pes","name":"Peer Exchange","_id":"8f602f1e-1840-4c32-8cdb-9a26d6c0e873","_updatedAt":"2020-04-14T13:44:43Z","is_active":true},{"name":"Post Conference Perspectives","_updatedAt":"2024-05-24T18:27:43Z","url":"/post-conference-perspectives","_createdAt":"2024-05-24T18:27:43Z","_rev":"Jz2W7keLhiw1UYkGHgA51N","_id":"0f532685-cd4c-4350-89cd-b8a388e6495b","children":[],"_type":"mainNavigation","is_active":true,"navParent":{"_ref":"821e259a-db55-4862-985a-5cd089bbf894","_type":"reference"}},{"navParent":{"_ref":"821e259a-db55-4862-985a-5cd089bbf894","_type":"reference"},"_type":"mainNavigation","_updatedAt":"2020-12-01T22:43:26Z","children":[],"_id":"bbc55ff8-1532-475e-9f51-f9d5eb39e369","_createdAt":"2020-12-01T22:43:10Z","_rev":"y3lsbm3yQTliOnC9CU5TiR","url":"/stakeholder-summit","is_active":true,"name":"Stakeholder Summit"}],"_updatedAt":"2024-05-24T16:36:15Z","is_active":true,"_createdAt":"2020-04-14T13:26:30Z","sortOrder":2,"name":"Video"},{"name":"Podcasts","_id":"4939ee15-ae6f-4aba-8481-9ee27ce729d3","_updatedAt":"2024-05-24T16:41:18Z","is_active":true,"subQuery":[],"sortOrder":3,"_type":"mainNavigation","url":"/podcasts","_createdAt":"2024-05-24T16:40:58Z","_rev":"rcwwj6TiN2Q0ymhqDzIUb7","navParent":null},{"_rev":"rcwwj6TiN2Q0ymhqDzIVAU","_type":"mainNavigation","_id":"6841664a-93f2-4f56-8760-836ec9c7b483","_updatedAt":"2024-05-24T16:41:40Z","_createdAt":"2020-04-14T13:27:01Z","sortOrder":4,"is_active":true,"name":"Conferences","navParent":null,"subQuery":[{"_createdAt":"2020-06-12T15:17:29Z","sortOrder":1,"_id":"f45b532b-23e3-4b44-8d7f-2f3c13c9ae81","_rev":"pI9SawGKsTP14Lioy589Kx","_updatedAt":"2020-08-21T22:11:23Z","url":"/latest-conference","children":[],"_type":"mainNavigation","is_active":true,"navParent":{"_ref":"6841664a-93f2-4f56-8760-836ec9c7b483","_type":"reference"},"name":"Conference Coverage"},{"is_active":true,"_createdAt":"2020-06-12T15:18:28Z","url":"/conference","_type":"mainNavigation","_id":"004461ae-46cb-45ef-916e-f03c6d99d6d3","_updatedAt":"2020-06-12T15:19:26Z","sortOrder":2,"name":"Conference Listing","children":[],"navParent":{"_ref":"6841664a-93f2-4f56-8760-836ec9c7b483","_type":"reference"},"_rev":"FxFuWbqTkFGbPWgBBSR6xp"},{"_createdAt":"2024-07-03T19:00:13Z","sortOrder":3,"_type":"mainNavigation","name":"Post Conference Perspectives","children":[],"_rev":"ZU3dXbR1BZtBbbPuRGxz53","is_active":true,"navParent":{"_ref":"6841664a-93f2-4f56-8760-836ec9c7b483","_type":"reference"},"_id":"a006d0df-0cc9-4386-abfb-b1931a3918d4","_updatedAt":"2024-07-03T19:00:13Z","url":"/post-conference-perspectives"}]},{"_type":"mainNavigation","is_active":true,"navParent":null,"_updatedAt":"2024-05-24T16:41:49Z","_createdAt":"2020-04-14T13:27:20Z","sortOrder":5,"subQuery":[{"_rev":"rcwwj6TiN2Q0ymhqDzIVyQ","_id":"48193abd-ecf4-4c90-b0ae-984ca2be88c9","url":"/publications","children":[],"is_active":true,"_createdAt":"2020-05-04T21:06:00Z","sortOrder":1,"_type":"mainNavigation","name":"All Journals","_updatedAt":"2024-05-24T16:42:23Z","navParent":{"_ref":"94f13109-c3cc-47b5-bf49-96ed727c8150","_type":"reference"}},{"is_active":true,"_type":"mainNavigation","navParent":{"_ref":"94f13109-c3cc-47b5-bf49-96ed727c8150","_type":"reference"},"children":[],"name":"The American Journal of Managed Care","_updatedAt":"2024-05-24T16:42:39Z","url":"/publications/issue","_createdAt":"2020-04-14T13:55:29Z","sortOrder":2,"_rev":"rcwwj6TiN2Q0ymhqDzIWug","_id":"08081ddf-ffd8-4b17-a2ff-dfe6a0ac64a3"},{"url":"/publications/ajac","sortOrder":3,"_rev":"4fso9RuTzczLhlxmnMQ1bu","_type":"mainNavigation","name":"Population Health, Equity \u0026 Outcomes","_id":"47782239-2714-4bd1-99e6-750443bd39ea","_updatedAt":"2024-09-16T13:23:11Z","is_active":true,"children":[],"navParent":{"_ref":"94f13109-c3cc-47b5-bf49-96ed727c8150","_type":"reference"},"_createdAt":"2020-04-14T13:56:01Z"},{"name":"Evidence-Based Oncology","navParent":{"_ref":"94f13109-c3cc-47b5-bf49-96ed727c8150","_type":"reference"},"children":[],"_rev":"uJbbwQWkLESsncBrcLL4uf","_createdAt":"2020-04-14T13:56:21Z","_type":"mainNavigation","_id":"b99cc54f-5801-46e9-bd20-e690623ed12c","_updatedAt":"2024-05-24T16:43:12Z","url":"/publications/evidence-based-oncology","is_active":true,"sortOrder":4},{"navParent":{"_type":"reference","_ref":"94f13109-c3cc-47b5-bf49-96ed727c8150"},"name":"About Supplements and Featured Publications","_rev":"rcwwj6TiN2Q0ymhqDzIY1L","_type":"mainNavigation","_id":"6e7e3485-ef8b-40e3-8320-3c434df6bbb5","_updatedAt":"2024-05-24T16:43:26Z","url":"/supplement","is_active":true,"children":[],"_createdAt":"2024-05-23T20:59:41Z","sortOrder":5},{"name":"Supplements and Featured Publications Issues","_id":"a2112c87-8e92-4b64-b42d-3117117f67a3","_createdAt":"2020-04-14T13:56:51Z","_type":"mainNavigation","_updatedAt":"2024-05-24T16:43:32Z","_rev":"uJbbwQWkLESsncBrcLL5w0","url":"/publications/supplement","is_active":true,"navParent":{"_type":"reference","_ref":"94f13109-c3cc-47b5-bf49-96ed727c8150"},"sortOrder":6,"children":[]},{"_type":"mainNavigation","name":"Submit a Manuscript","_updatedAt":"2024-05-24T16:43:38Z","is_active":true,"_id":"fa8c9edc-3d32-4e9e-b68b-47d5c15694a5","_createdAt":"2023-03-14T13:29:11Z","_rev":"rcwwj6TiN2Q0ymhqDzIYDp","navParent":{"_ref":"94f13109-c3cc-47b5-bf49-96ed727c8150","_type":"reference"},"children":[],"url":"/submit-a-manuscript","sortOrder":7}],"_rev":"uJbbwQWkLESsncBrcLL0hr","name":"Journals","_id":"94f13109-c3cc-47b5-bf49-96ed727c8150"},{"is_active":true,"_createdAt":"2020-04-14T13:27:17Z","navParent":null,"_type":"mainNavigation","_id":"ad5c19be-040c-4ea8-b639-807f54c9a1aa","_updatedAt":"2020-05-08T20:03:10Z","sortOrder":6,"subQuery":[{"is_active":true,"_createdAt":"2024-05-24T16:44:43Z","_rev":"Jz2W7keLhiw1UYkGHgA4Yf","_type":"mainNavigation","_updatedAt":"2024-05-24T18:26:23Z","children":[],"name":"Institute for Value-Based Medicine","url":"/ivbmevents","navParent":{"_ref":"ad5c19be-040c-4ea8-b639-807f54c9a1aa","_type":"reference"},"_id":"de4fe195-3db9-4d12-842d-f26100fbea5b"},{"url":"https://pcoc.ajmc.com/","_type":"mainNavigation","name":"Patient-Centered Oncology Care","_id":"dddfc37d-8958-4e0a-91e3-0634bb6502a3","is_active":true,"children":[],"navParent":{"_type":"reference","_ref":"ad5c19be-040c-4ea8-b639-807f54c9a1aa"},"_createdAt":"2024-05-24T16:45:02Z","_rev":"Jz2W7keLhiw1UYkGHgA4eP","_updatedAt":"2024-05-24T18:26:42Z"}],"url":"/events","_rev":"8ZvheBjSwe5Dc4gCmgsR0M","name":"Events"},{"sortOrder":7,"_rev":"rcwwj6TiN2Q0ymhqDzIdco","name":"Resources","_id":"86b03e38-f3d2-41d1-89e7-c3175c571a55","is_active":true,"navParent":null,"_createdAt":"2020-04-14T13:29:34Z","_type":"mainNavigation","_updatedAt":"2024-05-24T16:45:37Z","subQuery":[{"sortOrder":1,"_createdAt":"2020-04-14T13:51:39Z","name":"Interactive Tools","_updatedAt":"2024-05-24T16:46:13Z","navParent":{"_ref":"86b03e38-f3d2-41d1-89e7-c3175c571a55","_type":"reference"},"is_active":true,"url":"/interactive-tools","_type":"mainNavigation","children":[],"_rev":"rcwwj6TiN2Q0ymhqDzIfXP","_id":"4a08b5fc-379c-4952-bec1-0d9dacb11170"},{"_rev":"4IWvQAHLC63503PAHcJhJi","_id":"db1214fd-aa4d-4f12-a6f5-72d7e3927ce9","is_active":true,"navParent":{"_ref":"86b03e38-f3d2-41d1-89e7-c3175c571a55","_type":"reference"},"url":"/formulary","sortOrder":3,"name":"Formulary Central","children":[],"_createdAt":"2025-02-14T19:41:37Z","_type":"mainNavigation","_updatedAt":"2025-02-14T19:42:02Z"},{"children":[],"_id":"43960f88-0c8d-404b-b9d9-d90432c2c516","navParent":{"_ref":"86b03e38-f3d2-41d1-89e7-c3175c571a55","_type":"reference"},"name":"Clinical Spotlight","_updatedAt":"2024-05-23T20:32:07Z","is_active":true,"_type":"mainNavigation","url":"/clinical-spotlight","_createdAt":"2020-10-16T13:03:47Z","_rev":"rcwwj6TiN2Q0ymhqDyFVrf"},{"is_active":true,"_type":"mainNavigation","url":"/custom-email","_createdAt":"2024-05-24T16:46:44Z","_id":"38aa3af0-8a34-4ae6-898c-37214580d384","_updatedAt":"2024-05-24T16:46:44Z","name":"Microsites","_rev":"rcwwj6TiN2Q0ymhqDzIhDR","children":[],"navParent":{"_ref":"86b03e38-f3d2-41d1-89e7-c3175c571a55","_type":"reference"}},{"navParent":{"_ref":"86b03e38-f3d2-41d1-89e7-c3175c571a55","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDzIiDr","name":"Sponsored Content","is_active":true,"_type":"mainNavigation","_id":"d0b0683f-18e1-4e75-89fd-fb4e578a562f","_updatedAt":"2024-05-24T16:47:05Z","url":"/sponsored","children":[],"_createdAt":"2024-05-24T16:47:05Z"}]},{"_type":"mainNavigation","sortOrder":8,"is_active":true,"_rev":"LtkInV1jlQdtEIFjVpi9sG","_updatedAt":"2024-08-27T15:31:04Z","url":"/continuing-education","name":"CE","_id":"621fccf5-dcdb-40a9-af70-9bf3ccf79278","navParent":null,"subQuery":[],"_createdAt":"2020-04-14T14:00:08Z"},{"navParent":null,"subQuery":[{"children":[],"_createdAt":"2024-05-24T19:05:57Z","_rev":"Jz2W7keLhiw1UYkGHgBp6D","_updatedAt":"2024-05-24T19:05:57Z","url":"/editorial","is_active":true,"name":"AJMC Staff","_type":"mainNavigation","navParent":{"_ref":"c14e4637-909c-4bf6-bf81-64eeb6005352","_type":"reference"},"_id":"be637b3b-f72a-4049-91b8-409809b2d815"},{"navParent":{"_ref":"c14e4637-909c-4bf6-bf81-64eeb6005352","_type":"reference"},"children":[],"_id":"5298152f-5135-4c2c-a46e-a14ad0300bf4","is_active":true,"_createdAt":"2024-05-24T16:48:30Z","_rev":"rcwwj6TiN2Q0ymhqDzIn5Y","name":"Anniversary","_updatedAt":"2024-05-24T16:48:30Z","_type":"mainNavigation","url":"/anniversary"},{"_updatedAt":"2024-07-23T13:38:48Z","url":"/about/seema-sonnad-nomination","_type":"mainNavigation","children":[],"name":"Seema Sonnad Award","navParent":{"_type":"reference","_ref":"c14e4637-909c-4bf6-bf81-64eeb6005352"},"is_active":true,"_id":"28d33143-d9a9-45bd-af63-bed8d2198118","_createdAt":"2024-05-24T18:24:23Z","_rev":"AGf4LvcO2r7q1La1cjR7dD"},{"is_active":true,"_rev":"uJbbwQWkLESsncBrcLLVEZ","_id":"acb7dc53-dfab-462a-b2e9-b0cfc8675da4","url":"/partners","children":[],"_createdAt":"2024-05-24T16:49:00Z","_type":"mainNavigation","name":"Strategic Alliance Partners","_updatedAt":"2024-05-24T16:49:00Z","navParent":{"_ref":"c14e4637-909c-4bf6-bf81-64eeb6005352","_type":"reference"}}],"_id":"c14e4637-909c-4bf6-bf81-64eeb6005352","_updatedAt":"2024-05-24T16:48:11Z","is_active":true,"_createdAt":"2024-05-24T16:48:11Z","sortOrder":9,"_rev":"rcwwj6TiN2Q0ymhqDzIlc0","name":"About AJMC","_type":"mainNavigation"},{"_updatedAt":"2024-03-11T14:58:15Z","url":"https://one.ajmc.com/subscribe","name":"Subscribe","_id":"1e279576-0b33-4e57-8782-b6b1edbf68da","blank":true,"subQuery":[],"_createdAt":"2020-06-22T20:56:33Z","_rev":"gFXie0Ldruy1o91XppbLLd","_type":"mainNavigation","is_active":true,"sortOrder":9,"navParent":null}],"sub_menu":[{"is_active":true,"_createdAt":"2020-04-14T14:04:25Z","_rev":"Jz2W7keLhiw1UYkGHfbRHa","navParent":null,"sortOrder":1,"_type":"subNavigation","name":"Specialty Area","_id":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_updatedAt":"2024-05-24T05:08:37Z","url":"/compendium","subQuery":[{"children":[],"name":"Biosimilars","is_active":true,"_createdAt":"2024-05-24T05:06:44Z","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_type":"subNavigation","_rev":"Jz2W7keLhiw1UYkGHfbM3A","_updatedAt":"2024-05-24T05:06:44Z","_id":"aa3904f3-c0d8-495d-a77f-afcc41f27045","url":"/compendium/biosimilars"},{"_rev":"aW9ZvtW6d5z6x1Negj6Jxc","name":"Cardiorenalmetabolic","url":"/compendium/cardiorenalmetabolic","children":[{"_createdAt":"2024-05-24T05:30:54Z","_rev":"Jz2W7keLhiw1UYkGHfbquf","_type":"subNavigation","name":"Cardiovascular","_id":"c3566f20-e7c6-4b38-bf9f-7d52055698b1","url":"/compendium/cardiovascular","is_active":true,"navParent":{"_ref":"6c47e32a-ae7f-4f3a-92e2-c99d54ae28ab","_type":"reference"},"_updatedAt":"2024-05-24T05:30:54Z"},{"is_active":true,"_createdAt":"2024-05-24T05:32:42Z","_type":"subNavigation","name":"Chronic Kidney Disease","_updatedAt":"2024-05-24T05:32:42Z","navParent":{"_ref":"6c47e32a-ae7f-4f3a-92e2-c99d54ae28ab","_type":"reference"},"_rev":"Jz2W7keLhiw1UYkGHfbumO","_id":"f3a69e16-dc38-4135-886e-d70e18532bf4","url":"/compendium/ckd"},{"_rev":"Jz2W7keLhiw1UYkGHfbrEl","_id":"79c02dc8-3c2d-451b-9797-008b25d61d4d","_updatedAt":"2024-05-24T05:31:14Z","is_active":true,"navParent":{"_ref":"6c47e32a-ae7f-4f3a-92e2-c99d54ae28ab","_type":"reference"},"name":"Diabetes","url":"/compendium/diabetes","_createdAt":"2024-05-24T05:31:14Z","_type":"subNavigation"},{"navParent":{"_ref":"6c47e32a-ae7f-4f3a-92e2-c99d54ae28ab","_type":"reference"},"_createdAt":"2024-05-24T05:31:38Z","_rev":"Jz2W7keLhiw1UYkGHfbrQF","name":"Heart Failure","_id":"84c7dd54-fb21-4bc5-86bc-9bbf39a7f836","is_active":true,"_updatedAt":"2024-05-24T05:31:38Z","url":"/compendium/heart-failure","_type":"subNavigation"},{"url":"/compendium/type1diabetes","is_active":true,"_createdAt":"2024-05-24T05:32:00Z","_updatedAt":"2024-05-24T05:32:00Z","name":"Type 1 Diabetes","_id":"aadd9bdc-4dd1-4ac1-be4f-2afb4315b6cb","navParent":{"_ref":"6c47e32a-ae7f-4f3a-92e2-c99d54ae28ab","_type":"reference"},"_rev":"Jz2W7keLhiw1UYkGHfbsbS","_type":"subNavigation"}],"is_active":true,"_updatedAt":"2025-01-17T17:17:34Z","_createdAt":"2024-05-24T05:30:27Z","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_type":"subNavigation","_id":"6c47e32a-ae7f-4f3a-92e2-c99d54ae28ab"},{"_rev":"Jz2W7keLhiw1UYkGHfbSVf","_type":"subNavigation","_id":"7599f50b-36ff-42a5-8d72-82814db9b988","url":"/compendium/dermatology","is_active":true,"_updatedAt":"2024-05-24T05:10:35Z","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"name":"Dermatology","_createdAt":"2024-05-24T05:10:35Z","children":[{"_createdAt":"2024-05-23T21:42:49Z","_id":"04523862-a8a1-4626-b288-95b3d4114267","navParent":{"_ref":"7599f50b-36ff-42a5-8d72-82814db9b988","_type":"reference"},"_rev":"Jz2W7keLhiw1UYkGHfbTPe","_type":"subNavigation","name":"Alopecia","_updatedAt":"2024-05-24T05:12:43Z","url":"/compendium/alopecia","is_active":true},{"is_active":true,"navParent":{"_ref":"7599f50b-36ff-42a5-8d72-82814db9b988","_type":"reference"},"_createdAt":"2024-05-24T05:12:02Z","_type":"subNavigation","url":"/compendium/atopic-dermatitis","_rev":"Jz2W7keLhiw1UYkGHfbSvV","name":"Atopic Dermatitis","_id":"637a0b1e-1b12-42bf-81a3-e6db5a997021","_updatedAt":"2024-05-24T05:12:02Z"},{"_type":"subNavigation","name":"Psoriasis","_id":"a9dcce80-4f29-488e-b7ef-51f0fb562a5a","_updatedAt":"2024-05-24T05:12:36Z","is_active":true,"_rev":"Jz2W7keLhiw1UYkGHfbTJu","url":"/compendium/psoriasis","navParent":{"_ref":"7599f50b-36ff-42a5-8d72-82814db9b988","_type":"reference"},"_createdAt":"2024-05-24T05:12:30Z"}]},{"_id":"3c425964-bf72-4f93-bfbc-4d44d42dc2fe","_rev":"I64rexdokWxpEDPZsg5Lox","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_createdAt":"2024-11-25T15:12:24Z","name":"Gastroenterology","children":[],"_type":"subNavigation","url":"/compendium/gastroenterology","_updatedAt":"2024-11-25T15:12:43Z","is_active":true},{"is_active":true,"name":"Hematology","_id":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","_updatedAt":"2024-05-24T05:13:48Z","url":"/compendium/hematology","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_rev":"Jz2W7keLhiw1UYkGHfbU3q","children":[{"navParent":{"_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","_type":"reference"},"_id":"d79f2b30-e7f2-4915-bef8-1a73a9190a91","_updatedAt":"2024-05-29T15:28:26Z","url":"/compendium/all","is_active":true,"_createdAt":"2024-05-29T15:28:26Z","_rev":"Iat2IZiT321TmGHwkF66wB","_type":"subNavigation","name":"ALL/AML"},{"_id":"664a6ece-64dd-41f8-87a0-7f5a47323c3b","_updatedAt":"2024-05-29T15:27:46Z","url":"/compendium/cll","_createdAt":"2024-05-29T15:26:57Z","_type":"subNavigation","_rev":"Iat2IZiT321TmGHwkF65Md","name":"CLL/SLL","is_active":true,"navParent":{"_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","_type":"reference"}},{"name":"GVHD","_updatedAt":"2024-05-29T15:28:51Z","url":"/compendium/gvhd","_createdAt":"2024-05-29T15:28:51Z","navParent":{"_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","_type":"reference"},"_rev":"Iat2IZiT321TmGHwkF67tn","_type":"subNavigation","_id":"32cf626c-1ce6-4fb5-9dd7-088522dc46e6","is_active":true},{"navParent":{"_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","_type":"reference"},"_createdAt":"2024-05-24T05:14:15Z","_rev":"Jz2W7keLhiw1UYkGHfbUDt","_updatedAt":"2024-05-24T05:14:15Z","is_active":true,"_type":"subNavigation","name":"Hemophilia","_id":"4dd2ce64-8f4d-4285-bc1a-ec40ffc99b51","url":"/compendium/hemophilia"},{"navParent":{"_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","_type":"reference"},"_createdAt":"2024-05-24T05:45:17Z","_rev":"Iat2IZiT321TmGHwkF6NtX","name":"Multiple Myeloma","_updatedAt":"2024-05-29T15:35:07Z","is_active":true,"_type":"subNavigation","_id":"84e2d674-0fe1-4bd1-9d97-2f8bc8589ba0","url":"/compendium/multiple-myeloma"},{"is_active":true,"_createdAt":"2024-05-24T05:45:36Z","_rev":"Iat2IZiT321TmGHwkF6a5X","_type":"subNavigation","name":"Myelodysplastic Syndromes","_id":"3a327f90-a5fc-4d87-9a18-02f54cb40b8e","navParent":{"_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","_type":"reference"},"_updatedAt":"2024-05-29T15:35:22Z","url":"/compendium/myelodysplastic-syndromes"},{"navParent":{"_type":"reference","_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4"},"_createdAt":"2024-05-29T15:29:21Z","name":"Myeloproliferative Neoplasms","url":"/compendium/mpn","is_active":true,"_rev":"Up1TL5YPo1fhI8V2tpNnMb","_type":"subNavigation","_id":"a6003c4f-e7f0-422a-8129-49a2d78eb113","_updatedAt":"2024-06-05T20:02:27Z"},{"name":"Non-Hodgkin Lymphoma","_id":"fc247a6b-0b33-4e18-ae78-56e677c6bb18","is_active":true,"navParent":{"_type":"reference","_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4"},"_createdAt":"2024-05-24T05:43:54Z","_rev":"rmdpbbz4U7GL9ExaGp96DY","_type":"subNavigation","_updatedAt":"2024-06-25T17:42:12Z","url":"/compendium/nhl"},{"navParent":{"_type":"reference","_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4"},"_type":"subNavigation","name":"Rare Blood","_updatedAt":"2024-05-24T05:14:40Z","url":"/compendium/rareblood","is_active":true,"_createdAt":"2024-05-24T05:14:40Z","_rev":"Jz2W7keLhiw1UYkGHfbUPN","_id":"85e2fc3e-ac5c-4b47-8b14-411d730d20d9"}],"_createdAt":"2024-05-24T05:13:48Z","_type":"subNavigation"},{"is_active":true,"_createdAt":"2024-05-24T05:34:29Z","name":"Hepatology","children":[{"_rev":"Jz2W7keLhiw1UYkGHfbwkP","_type":"subNavigation","url":"/compendium/liver-cancer","is_active":true,"navParent":{"_ref":"a96e7dbc-b037-41f4-bd5e-d96abf8f3c7d","_type":"reference"},"_createdAt":"2024-05-24T05:34:54Z","name":"Liver","_id":"2aefee8c-db97-4e7d-b600-efb48e6bcb6c","_updatedAt":"2024-05-24T05:34:54Z"}],"_type":"subNavigation","url":"/compendium/hepatology","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_rev":"IZ4ZA8avncRcTDvyuUbX0o","_id":"a96e7dbc-b037-41f4-bd5e-d96abf8f3c7d","_updatedAt":"2025-01-17T17:19:10Z"},{"is_active":true,"navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_createdAt":"2024-05-24T05:23:19Z","name":"Immunology","_id":"1b1e3727-8b82-42da-9a62-b20472b9c797","url":"/compendium/immunology","children":[{"name":"Autoimmune","_id":"b3daefd0-0ac3-4be2-ad23-f9c3fa37cf37","is_active":true,"navParent":{"_ref":"1b1e3727-8b82-42da-9a62-b20472b9c797","_type":"reference"},"_createdAt":"2024-05-24T05:23:39Z","url":"/compendium/autoimmune","_rev":"Jz2W7keLhiw1UYkGHfbkp8","_type":"subNavigation","_updatedAt":"2024-05-24T05:23:39Z"},{"is_active":true,"navParent":{"_ref":"1b1e3727-8b82-42da-9a62-b20472b9c797","_type":"reference"},"_rev":"Jz2W7keLhiw1UYkGHfbkzB","name":"Inflammation","_id":"6016d41d-9d43-49fa-99b6-7caca304f30d","_createdAt":"2024-05-24T05:23:59Z","_type":"subNavigation","_updatedAt":"2024-05-24T05:23:59Z","url":"/compendium/Inflammation"},{"navParent":{"_ref":"1b1e3727-8b82-42da-9a62-b20472b9c797","_type":"reference"},"_id":"b537fcea-aea3-40ca-83c1-0907fdc9ccb5","url":"/compendium/lupus","is_active":true,"_rev":"Jz2W7keLhiw1UYkGHfbmd6","_type":"subNavigation","name":"Lupus","_updatedAt":"2024-05-24T05:24:47Z","_createdAt":"2024-05-24T05:24:47Z"},{"_rev":"Jz2W7keLhiw1UYkGHfbn7F","_id":"ef6c4efc-5932-4148-b626-cbf42e1c49c3","_createdAt":"2024-05-24T05:25:23Z","_type":"subNavigation","name":"Myasthenia Gravis","_updatedAt":"2024-05-24T05:25:23Z","url":"/compendium/myasthenia-gravis","is_active":true,"navParent":{"_ref":"1b1e3727-8b82-42da-9a62-b20472b9c797","_type":"reference"}}],"_type":"subNavigation","_rev":"Jz2W7keLhiw1UYkGHfbkam","_updatedAt":"2024-05-24T05:23:19Z"},{"_updatedAt":"2024-05-24T05:35:38Z","is_active":true,"_type":"subNavigation","name":"Infectious Disease","url":"/compendium/infectious-disease","_id":"b62af616-818b-4bda-b606-bd64287f9a85","_createdAt":"2024-05-24T05:35:38Z","_rev":"Jz2W7keLhiw1UYkGHfcA9Y","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"children":[{"is_active":true,"_createdAt":"2024-05-24T05:36:03Z","_rev":"rcwwj6TiN2Q0ymhqDyeyP3","_id":"ffcd30d0-169f-4a8f-9f01-616142f33712","url":"/compendium/covid-19","navParent":{"_ref":"b62af616-818b-4bda-b606-bd64287f9a85","_type":"reference"},"_type":"subNavigation","name":"COVID-19","_updatedAt":"2024-05-24T05:36:03Z"},{"is_active":true,"_createdAt":"2024-05-24T05:36:22Z","_rev":"Jz2W7keLhiw1UYkGHfcAxn","_type":"subNavigation","url":"/compendium/hiv","navParent":{"_ref":"b62af616-818b-4bda-b606-bd64287f9a85","_type":"reference"},"name":"HIV","_id":"a53004c6-9fe2-4b9c-a86a-ad74f9204b3a","_updatedAt":"2024-05-24T05:36:29Z"},{"_createdAt":"2024-05-24T05:37:06Z","name":"RSV","_id":"ca70e9ab-a981-4629-a766-81f7890b3977","_updatedAt":"2024-05-24T05:37:06Z","navParent":{"_ref":"b62af616-818b-4bda-b606-bd64287f9a85","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDyezNO","_type":"subNavigation","url":"/compendium/rsv","is_active":true},{"_rev":"Jz2W7keLhiw1UYkGHfcFFM","name":"Vaccines","_updatedAt":"2024-05-24T05:37:53Z","_id":"a0ec0591-b4a1-4723-b984-b681c957523f","url":"/compendium/vaccines","is_active":true,"navParent":{"_ref":"b62af616-818b-4bda-b606-bd64287f9a85","_type":"reference"},"_createdAt":"2024-05-24T05:37:53Z","_type":"subNavigation"}]},{"_rev":"aW9ZvtW6d5z6x1Negj3Mh7","name":"MASH","_id":"28c2b871-3034-43e1-b2b3-613ceefea3f1","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"children":[],"is_active":true,"_type":"subNavigation","_updatedAt":"2025-01-17T17:02:58Z","url":"/compendium/mash","_createdAt":"2025-01-15T14:59:47Z"},{"children":[{"navParent":{"_ref":"db67ff69-2c58-4931-ad3d-767a636e38b0","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDyf7Qk","_type":"subNavigation","name":"Major Depressive Disorder","_id":"efcab5a8-97d8-4f5a-ba99-0a0555531f5a","_updatedAt":"2024-05-24T05:38:58Z","is_active":true,"_createdAt":"2024-05-24T05:38:58Z","url":"/compendium/mdd"},{"is_active":true,"_createdAt":"2024-05-24T05:39:18Z","_id":"f52dbfa9-aefe-4d21-b432-7052a136ae98","url":"/compendium/sleep","navParent":{"_ref":"db67ff69-2c58-4931-ad3d-767a636e38b0","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDyf96m","_type":"subNavigation","name":"Sleep","_updatedAt":"2024-05-24T05:39:18Z"}],"_createdAt":"2024-05-24T05:38:33Z","_updatedAt":"2024-05-24T05:38:33Z","is_active":true,"navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDyf4PU","_type":"subNavigation","_id":"db67ff69-2c58-4931-ad3d-767a636e38b0","url":"/compendium/mental-health","name":"Mental Health"},{"_type":"subNavigation","children":[{"is_active":true,"_type":"subNavigation","name":"Duchenne Muscular Dystrophy","url":"/compendium/dmd","_updatedAt":"2024-05-24T05:40:18Z","navParent":{"_type":"reference","_ref":"bafe1c52-a8b5-4786-bcee-668409d14a11"},"_createdAt":"2024-05-24T05:40:18Z","_rev":"rcwwj6TiN2Q0ymhqDyfERb","_id":"3e24f5af-027e-4f0b-a7e2-a3ffaf756a35"},{"navParent":{"_type":"reference","_ref":"bafe1c52-a8b5-4786-bcee-668409d14a11"},"_type":"subNavigation","name":"Epilepsy","_id":"d4e270df-2a59-4109-a7be-9c10f80722a7","url":"/compendium/epilepsy","is_active":true,"_createdAt":"2024-05-24T05:40:30Z","_rev":"rcwwj6TiN2Q0ymhqDyfIhq","_updatedAt":"2024-05-24T05:40:38Z"},{"_rev":"rcwwj6TiN2Q0ymhqDyfJRc","_type":"subNavigation","is_active":true,"navParent":{"_ref":"bafe1c52-a8b5-4786-bcee-668409d14a11","_type":"reference"},"_createdAt":"2024-05-24T05:41:07Z","name":"Multiple Sclerosis","_id":"7539f9b5-8f2a-4e1b-a10f-8cc748cd1489","_updatedAt":"2024-05-24T05:41:07Z","url":"/compendium/multiple-sclerosis"},{"url":"/compendium/parkinson","navParent":{"_ref":"bafe1c52-a8b5-4786-bcee-668409d14a11","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDyfJiG","_id":"90ebd8e7-e6d1-4128-8010-0b205fedb430","name":"Parkinson Disease","_updatedAt":"2024-05-24T05:41:29Z","is_active":true,"_createdAt":"2024-05-24T05:41:29Z","_type":"subNavigation"}],"_id":"bafe1c52-a8b5-4786-bcee-668409d14a11","is_active":true,"_rev":"wsljz10lCZachwUMK3D8Fg","url":"/compendium/neurology","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_createdAt":"2024-05-24T05:39:38Z","name":"Neurology","_updatedAt":"2025-01-17T17:18:32Z"},{"navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"name":"Obesity","url":"/compendium/obesity","is_active":true,"_createdAt":"2024-09-04T14:25:34Z","_rev":"B2kOGngERQtEUh1WG5WXvd","_updatedAt":"2024-09-04T14:25:34Z","_type":"subNavigation","_id":"fe48de19-78d2-4ed0-83fa-8884fb340de2","children":[]},{"_type":"subNavigation","name":"Oncology","_updatedAt":"2024-05-24T05:41:55Z","url":"/compendium/oncology","_rev":"rcwwj6TiN2Q0ymhqDyfKov","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"children":[{"_rev":"rcwwj6TiN2Q0ymhqDyfMpl","_type":"subNavigation","url":"/compendium/breast-cancer","_updatedAt":"2024-05-24T05:42:17Z","is_active":true,"navParent":{"_type":"reference","_ref":"90b398eb-3349-4b6a-b205-780a34cb4717"},"_createdAt":"2024-05-24T05:42:17Z","name":"Breast Cancer","_id":"03ea9371-55cd-42e2-b300-7078b94ff467"},{"_rev":"rcwwj6TiN2Q0ymhqDyfatY","_type":"subNavigation","name":"Cholangiocarcinoma","navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_createdAt":"2024-05-24T05:42:35Z","_updatedAt":"2024-05-24T05:42:35Z","url":"/compendium/cholangiocarcinoma","is_active":true,"_id":"8b57fc91-4191-420c-a224-cb869f8fa0d7"},{"navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"name":"Colorectal Cancer","_type":"subNavigation","_id":"e45ff858-e1bc-4b4a-9398-e12877b61607","_updatedAt":"2024-05-24T05:43:23Z","url":"/compendium/colorectal-cancer","is_active":true,"_createdAt":"2024-05-24T05:43:23Z","_rev":"Jz2W7keLhiw1UYkGHfcTh6"},{"_type":"subNavigation","_id":"289f747b-dffd-4006-a27d-4933a46fd7c1","url":"/compendium/immuno-oncology","is_active":true,"_createdAt":"2024-05-24T05:44:17Z","_rev":"Jz2W7keLhiw1UYkGHfsKT5","navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"name":"Immuno-Oncology","_updatedAt":"2024-05-24T13:25:09Z"},{"navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_id":"9d17bccc-3f33-4793-90e3-0adecfa71fa1","is_active":true,"_rev":"Iat2IZiT321TmGHwkF6F4B","_type":"subNavigation","name":"Liver Cancer","_updatedAt":"2024-05-29T15:32:02Z","url":"/compendium/liver-cancer","_createdAt":"2024-05-29T15:32:02Z"},{"_rev":"Jz2W7keLhiw1UYkGHfsIwL","name":"Non–Small Cell Lung Cancer","_id":"85d30c37-d6a1-4028-9c0f-ecdf36de220d","is_active":true,"navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_createdAt":"2024-05-24T05:45:56Z","_type":"subNavigation","_updatedAt":"2024-05-24T13:24:22Z","url":"/compendium/nsclc"},{"_rev":"Jz2W7keLhiw1UYkGHfcbF4","url":"/compendium/ovarian-cancer","is_active":true,"navParent":{"_type":"reference","_ref":"90b398eb-3349-4b6a-b205-780a34cb4717"},"name":"Ovarian Cancer","_id":"5a67adcb-11d8-48a6-8c39-b2956f5f3e86","_updatedAt":"2024-05-24T05:46:17Z","_createdAt":"2024-05-24T05:46:17Z","_type":"subNavigation"},{"_rev":"rcwwj6TiN2Q0ymhqDyfmoB","_type":"subNavigation","_updatedAt":"2024-05-24T05:47:42Z","url":"/compendium/prostate-cancer","is_active":true,"navParent":{"_type":"reference","_ref":"90b398eb-3349-4b6a-b205-780a34cb4717"},"_createdAt":"2024-05-24T05:47:42Z","name":"Prostate Cancer","_id":"bcfe0d88-7498-4268-95e6-875c94a2dab5"},{"navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_createdAt":"2024-05-24T05:48:18Z","_type":"subNavigation","_id":"a3a04e72-c707-450d-b9d3-f9ebacc9f997","_updatedAt":"2024-05-24T05:48:18Z","is_active":true,"_rev":"rcwwj6TiN2Q0ymhqDyfpKE","name":"Skin Cancer","url":"/compendium/skincancer"},{"name":"Small Cell Lung Cancer","is_active":true,"_type":"subNavigation","_rev":"36ELbxF4To1FbIa7xZVI3e","_id":"89f99f56-72a9-4dcd-9d8c-3d717d66a5f0","_updatedAt":"2025-01-14T18:47:45Z","url":"/compendium/lung-cancer","navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_createdAt":"2024-05-24T05:44:58Z"},{"is_active":true,"_createdAt":"2024-05-29T15:30:06Z","_rev":"Iat2IZiT321TmGHwkF69Qd","name":"Soft Tissue Sarcoma","_updatedAt":"2024-05-29T15:30:06Z","navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_type":"subNavigation","_id":"6d1dc4b4-1be8-41ee-9bba-90ad4ce546b3","url":"/compendium/soft-tissue-sarcoma"}],"is_active":true,"_createdAt":"2024-05-24T05:41:55Z","_id":"90b398eb-3349-4b6a-b205-780a34cb4717"},{"_updatedAt":"2024-05-24T05:48:54Z","is_active":true,"name":"Ophthalmology","_id":"eee19078-eb50-46e7-a97c-8f16d79eea97","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_rev":"Jz2W7keLhiw1UYkGHfcePj","url":"/compendium/ophthalmology","_type":"subNavigation","_createdAt":"2024-05-24T05:48:54Z","children":[]},{"_id":"e6c5e55f-7a5a-4f23-add2-fbf91df76400","_updatedAt":"2025-01-17T17:19:27Z","is_active":true,"url":"/compendium/pulmonology","children":[{"name":"COPD","_id":"3a19d535-d61e-43b1-bf6a-d6ced486a0b9","_updatedAt":"2024-05-24T05:49:28Z","_type":"subNavigation","navParent":{"_type":"reference","_ref":"e6c5e55f-7a5a-4f23-add2-fbf91df76400"},"_createdAt":"2024-05-24T05:49:28Z","_rev":"rcwwj6TiN2Q0ymhqDyfrwW","url":"/compendium/copd","is_active":true},{"_id":"474080cd-4295-4a70-907d-e1fc93c435cc","_updatedAt":"2024-05-24T05:49:52Z","is_active":true,"navParent":{"_type":"reference","_ref":"e6c5e55f-7a5a-4f23-add2-fbf91df76400"},"_createdAt":"2024-05-24T05:49:52Z","_type":"subNavigation","name":"Pulmonary Arterial Hypertension","_rev":"rcwwj6TiN2Q0ymhqDyfuBv","url":"/compendium/pah"}],"navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_createdAt":"2024-05-24T05:49:11Z","_rev":"IZ4ZA8avncRcTDvyuUbYi3","_type":"subNavigation","name":"Pulmonology"},{"is_active":true,"name":"Rare Disease","_id":"de690920-3cdc-4c43-a27e-ba4e38a62059","url":"/compendium/raredisease","children":[{"navParent":{"_ref":"de690920-3cdc-4c43-a27e-ba4e38a62059","_type":"reference"},"_createdAt":"2024-05-24T05:51:19Z","_type":"subNavigation","_id":"9e780f76-2008-441b-ab5f-00d3a6d1a5b0","url":"/compendium/sma","is_active":true,"_rev":"rcwwj6TiN2Q0ymhqDyg1k4","name":"Spinal Muscular Atrophy","_updatedAt":"2024-05-24T05:51:19Z"}],"_rev":"rcwwj6TiN2Q0ymhqDyg1Ah","_type":"subNavigation","_createdAt":"2024-05-24T05:50:50Z","_updatedAt":"2024-05-24T05:50:50Z","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"}},{"children":[{"navParent":{"_type":"reference","_ref":"f2a34114-0396-44cb-b241-11ef7b175500"},"name":"Asthma","_rev":"rcwwj6TiN2Q0ymhqDyg2wy","_type":"subNavigation","_id":"b2b2802f-2918-4431-8f4f-3bc7e6e6042f","_updatedAt":"2024-05-24T05:52:02Z","url":"/compendium/asthma","is_active":true,"_createdAt":"2024-05-24T05:52:02Z"},{"is_active":true,"navParent":{"_ref":"f2a34114-0396-44cb-b241-11ef7b175500","_type":"reference"},"_rev":"5DUHcaiKRKj5c8wHOPKtuf","_id":"4dac47d5-8dd1-4e90-b4be-b6b5e605f6f5","_updatedAt":"2024-06-03T18:31:07Z","_createdAt":"2024-06-03T18:31:07Z","_type":"subNavigation","name":"Idiopathic Pulmonary Fibrosis","url":"/compendium/ipf"}],"_type":"subNavigation","_updatedAt":"2024-05-24T05:50:22Z","url":"/compendium/respiratory","is_active":true,"_createdAt":"2024-05-24T05:50:22Z","_rev":"Jz2W7keLhiw1UYkGHfcjSf","name":"Respiratory","_id":"f2a34114-0396-44cb-b241-11ef7b175500","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"}},{"_rev":"Jz2W7keLhiw1UYkGHfcm6J","_createdAt":"2024-05-24T05:52:28Z","_updatedAt":"2024-05-24T05:52:28Z","url":"/compendium/rheumatology","_id":"3ecb2952-6710-46b1-ab05-36997bfb4a33","is_active":true,"children":[],"_type":"subNavigation","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"name":"Rheumatology"},{"_createdAt":"2024-05-24T05:52:51Z","_updatedAt":"2024-05-24T05:52:51Z","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_type":"subNavigation","_id":"ead467ba-7c17-4a1b-9deb-a7af56a7366e","url":"/compendium/womens-health","_rev":"Jz2W7keLhiw1UYkGHfcmDU","name":"Women's Health","is_active":true,"children":[]}]},{"is_active":true,"navParent":null,"_id":"db56b0e2-ad58-4407-aff2-5c27cb3145c1","_updatedAt":"2024-05-23T21:04:52Z","_createdAt":"2024-05-23T20:47:34Z","sortOrder":2,"_rev":"rcwwj6TiN2Q0ymhqDyHDJ3","_type":"subNavigation","subQuery":[{"_rev":"uJbbwQWkLESsncBrcJSd1N","_updatedAt":"2024-05-23T21:05:49Z","navParent":{"_ref":"db56b0e2-ad58-4407-aff2-5c27cb3145c1","_type":"reference"},"children":[],"is_active":true,"_createdAt":"2024-05-23T21:04:56Z","_type":"subNavigation","name":"Free In-Person Regional Events Focused on Oncology and Population Health","_id":"f5b2c97b-d6d4-468b-8a9a-4814364994c8","url":"/ivbmevents?display=home"}],"name":"Spotlight"},{"url":"/topic","is_active":true,"sortOrder":2,"navParent":null,"_id":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_updatedAt":"2020-08-21T22:11:57Z","_type":"subNavigation","_createdAt":"2020-04-14T14:05:54Z","subQuery":[{"is_active":true,"_type":"subNavigation","name":"Biosimilars","_updatedAt":"2024-05-24T05:05:19Z","sortOrder":1,"_rev":"Jz2W7keLhiw1UYkGHfbHQ4","_createdAt":"2024-05-24T05:05:19Z","children":[],"_id":"43207521-4e5f-42d2-b013-34763a4d964c","url":"/compendium/biosimilars","navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"}},{"_updatedAt":"2024-06-12T13:58:35Z","is_active":true,"_rev":"N7mKycgLbGtEq6btkPIW3d","url":"/topic/center-on-health-equity-and-access","navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"name":"Center on Health Equity \u0026 Access","_type":"subNavigation","_id":"4161ff97-2901-4526-80ee-3749b6dc6345","_createdAt":"2022-12-23T21:04:41Z","children":[]},{"name":"Digital Health","_updatedAt":"2024-05-24T05:56:42Z","navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_id":"232e30a0-2f7d-4ce1-9e4d-cc0cee73b20a","url":"/compendium/digital-health","is_active":true,"_createdAt":"2024-05-24T05:56:42Z","children":[],"_type":"subNavigation","_rev":"rcwwj6TiN2Q0ymhqDygl51"},{"is_active":true,"_rev":"Jz2W7keLhiw1UYkGHfdAmX","_updatedAt":"2024-05-24T05:57:01Z","url":"/formulary","navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_createdAt":"2024-05-24T05:57:01Z","name":"Formulary","children":[],"_type":"subNavigation","_id":"3887cee2-5461-4cb3-b54f-297fcceb11ee"},{"_rev":"rcwwj6TiN2Q0ymhqDygmDl","_type":"subNavigation","navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_updatedAt":"2024-05-24T05:57:41Z","_createdAt":"2024-05-24T05:57:41Z","_id":"56aff93b-4f24-48fc-9dda-2d394397f956","url":"/compendium/gene-therapy","children":[],"name":"Gene Therapy","is_active":true},{"_updatedAt":"2024-05-24T06:00:55Z","is_active":true,"_createdAt":"2024-05-24T06:00:55Z","_rev":"rcwwj6TiN2Q0ymhqDygv9D","children":[],"_type":"subNavigation","name":"Guidelines","_id":"69723346-76b2-4896-b2d9-2db53ed5da96","url":"/guidelines","navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"}},{"_type":"subNavigation","name":"Health Care Administration","url":"/","is_active":true,"_rev":"rcwwj6TiN2Q0ymhqDz7eaC","_updatedAt":"2024-05-24T14:10:39Z","children":[{"is_active":true,"name":"Employers","_id":"83fca4ec-4ff0-4766-9e49-0376d44179e8","_updatedAt":"2024-05-24T13:53:42Z","url":"/compendium/employers","navParent":{"_ref":"cd6edcff-faa3-4bee-9071-042f8186052d","_type":"reference"},"_createdAt":"2024-05-24T05:58:26Z","_rev":"rcwwj6TiN2Q0ymhqDz6EMB","_type":"subNavigation"},{"_updatedAt":"2024-05-24T13:53:53Z","is_active":true,"_createdAt":"2024-05-24T05:58:44Z","_type":"subNavigation","name":"Medicare","_id":"5647b438-aca9-4b57-9d4d-2df660b5a6ce","navParent":{"_ref":"cd6edcff-faa3-4bee-9071-042f8186052d","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDz6F3s","url":"/compendium/medicare"},{"_type":"subNavigation","_id":"2c8ff713-9c43-4afc-aaca-e33ceb98f00c","url":"/compendium/reimbursement","is_active":true,"_createdAt":"2024-05-24T05:59:16Z","_rev":"rcwwj6TiN2Q0ymhqDz6G8S","name":"Reimbursement","_updatedAt":"2024-05-24T13:54:23Z","navParent":{"_ref":"cd6edcff-faa3-4bee-9071-042f8186052d","_type":"reference"}}],"_createdAt":"2024-05-24T13:53:24Z","_id":"cd6edcff-faa3-4bee-9071-042f8186052d","navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"}},{"children":[],"_updatedAt":"2021-02-25T17:30:59Z","url":"/topic/healthcare-cost","is_active":true,"navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_type":"subNavigation","_rev":"wx7I38TXtYeZdHCfn60Syn","name":"Health Care Cost","_id":"c9a8f6fd-0ad0-4a82-a385-13c03fe688d0","_createdAt":"2020-04-14T14:06:29Z"},{"navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"url":"/topic/healthcare-delivery","_createdAt":"2020-04-14T14:06:43Z","_id":"d01b9875-6e51-42d1-bdf5-93fd8771855c","is_active":true,"_updatedAt":"2021-02-25T17:29:58Z","_rev":"YN5IiYQkhJ3hq0R7jM8DQW","_type":"subNavigation","children":[],"name":"Health Care Delivery"},{"_updatedAt":"2022-12-21T19:05:52Z","url":"/topic/insurance","name":"Insurance","_type":"subNavigation","_id":"d8eab058-f5ec-4c42-a95a-941c0a506543","navParent":{"_type":"reference","_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2"},"_createdAt":"2020-04-14T14:07:01Z","_rev":"lslStCipHxtG437RQOGJ7p","is_active":true,"children":[]},{"url":"/topic/policy","is_active":true,"navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_createdAt":"2020-04-14T14:07:15Z","name":"Policy","_type":"subNavigation","_id":"fd066f36-78ee-4112-a121-4e02f8e45b0b","_rev":"T035zdq5xruIFPyK3OzgdQ","_updatedAt":"2020-04-14T14:07:15Z","children":[]},{"_createdAt":"2024-05-24T05:59:24Z","_id":"d7893fef-5eb0-4b2d-b13d-a0bec73b2c14","_updatedAt":"2024-05-24T06:01:29Z","children":[],"is_active":true,"navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDygvgV","_type":"subNavigation","url":"/compendium/population","name":"Population Health"},{"children":[],"_createdAt":"2024-05-24T06:01:51Z","_id":"6188ac2f-7ec8-4cbb-a154-5822f606f3fa","url":"/approvals-launches","is_active":true,"_type":"subNavigation","_updatedAt":"2024-05-24T13:24:58Z","navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"name":"Product Approvals and Launches","_rev":"Jz2W7keLhiw1UYkGHfsKLu"},{"_createdAt":"2020-04-14T14:07:28Z","_type":"subNavigation","url":"/topic/technology","navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_rev":"QxOJBWa4XErmibN6Cb5bN0","name":"Technology","_id":"4e2fe99b-3ac4-4b48-89ed-774dd51675df","is_active":true,"_updatedAt":"2020-04-14T14:07:28Z","children":[]},{"_createdAt":"2020-04-14T14:07:42Z","_id":"22bd1bd6-88a6-4278-a846-e086cf30b141","_type":"subNavigation","children":[],"is_active":true,"_rev":"T035zdq5xruIFPyK3OzhkC","name":"Value-Based Care","_updatedAt":"2020-04-14T14:07:42Z","url":"/topic/value-based-care","navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"}}],"name":"Topics","_rev":"iEeBpgQLYwZXMeCflboLMu"},{"_type":"subNavigation","_updatedAt":"2020-04-27T18:48:23Z","is_active":true,"sortOrder":3,"name":"Institute for Value-Based Medicine","_id":"6389c35d-3d2d-41db-978d-b3aa4d10cb8e","navParent":null,"subQuery":[{"_type":"subNavigation","is_active":true,"navParent":{"_ref":"6389c35d-3d2d-41db-978d-b3aa4d10cb8e","_type":"reference"},"name":"All Coverage","_createdAt":"2020-05-06T13:11:16Z","_updatedAt":"2020-05-06T13:11:16Z","url":"/ivbm","_id":"f7379c68-40be-45e4-9747-484dcec584d3","_rev":"cyKVTGb2fpu5E4X0UMrv4p","children":[]},{"url":"/ivbm/event-coverage","_rev":"k2D4PisPM2pBS5NIl95QbN","_type":"subNavigation","name":"Event Coverage","_id":"cc8a827f-3e94-413a-aa0c-0d8b40eb5f18","_createdAt":"2020-04-27T18:49:41Z","_updatedAt":"2020-04-27T18:49:41Z","is_active":true,"navParent":{"_ref":"6389c35d-3d2d-41db-978d-b3aa4d10cb8e","_type":"reference"},"children":[]},{"_createdAt":"2020-04-27T18:50:03Z","_rev":"k2D4PisPM2pBS5NIl95RlO","name":"Interviews","children":[],"is_active":true,"_updatedAt":"2020-04-27T18:50:03Z","navParent":{"_ref":"6389c35d-3d2d-41db-978d-b3aa4d10cb8e","_type":"reference"},"_type":"subNavigation","_id":"aa3f3bb8-9e8c-457d-aeb6-7b94b968395a","url":"/ivbm/interviews"},{"_rev":"XtnP0djhkej33kSTbdUgmN","_updatedAt":"2020-04-27T18:50:34Z","_createdAt":"2020-04-27T18:50:34Z","name":"News","_id":"1be7e99c-8d37-4d70-a009-67eb03fae5ba","navParent":{"_ref":"6389c35d-3d2d-41db-978d-b3aa4d10cb8e","_type":"reference"},"is_active":true,"_type":"subNavigation","url":"/ivbm/news","children":[]}],"_rev":"N0LuVAjtHhQSyVgQyS0Kyv","url":"/ivbm","_createdAt":"2020-04-27T18:48:09Z"},{"subQuery":[{"children":[],"navParent":{"_ref":"9a07b754-3383-43ac-9d2d-a370d44406d1","_type":"reference"},"url":"/about","name":"AJMC Journals","_type":"subNavigation","_rev":"NGYpFwzJghlKjBIAt48VzS","_id":"4e10ead3-6a42-43df-b251-b93b912a24cb","_updatedAt":"2020-05-07T17:05:52Z","is_active":true,"_createdAt":"2020-05-07T17:05:52Z"},{"_type":"subNavigation","url":"/anniversary","is_active":true,"_id":"4451f4fa-a919-45b4-b6e5-282668cd792e","_createdAt":"2020-04-14T14:09:38Z","name":"Anniversary","_rev":"rHX8vIEJKWyjgUO02y82fe","_updatedAt":"2020-04-14T14:09:38Z","navParent":{"_ref":"9a07b754-3383-43ac-9d2d-a370d44406d1","_type":"reference"},"children":[]},{"_updatedAt":"2020-06-09T11:44:06Z","_createdAt":"2020-04-14T14:10:37Z","children":[],"_type":"subNavigation","name":"Author Forms","navParent":{"_ref":"9a07b754-3383-43ac-9d2d-a370d44406d1","_type":"reference"},"_id":"99bccc8e-9329-496f-b588-ec3d080f0859","url":"/authorshipforms","is_active":true,"_rev":"VmKMEDy0rHs5jzhO3eZVVM"},{"_id":"518317a5-297f-4c4f-9d2a-6da7b8c98d9c","url":"/authors","is_active":true,"navParent":{"_ref":"9a07b754-3383-43ac-9d2d-a370d44406d1","_type":"reference"},"_rev":"0JTsteyxJPdyCvciQ9yBPv","_type":"subNavigation","name":"Authors","_updatedAt":"2020-05-06T12:53:11Z","_createdAt":"2020-04-14T14:10:19Z","children":[]},{"name":"Nominate a Rising Leader","navParent":{"_ref":"9a07b754-3383-43ac-9d2d-a370d44406d1","_type":"reference"},"_createdAt":"2020-06-15T17:13:51Z","_rev":"m6BzyPIGe9IGx2bV3pSCbq","_updatedAt":"2020-06-15T17:13:51Z","is_active":true,"_type":"subNavigation","_id":"a96a44c9-4d51-47c6-8f81-4263bd2f58b4","url":"/seema-sonnad-nomination","children":[]},{"children":[],"_rev":"TctAtfg0qER1kILh39bPC4","_id":"4420e458-acb4-4edb-9f33-c4fc4504ff41","url":"/submit-a-manuscript","is_active":true,"name":"Submit a Manuscript","_type":"subNavigation","_updatedAt":"2023-03-14T13:29:28Z","navParent":{"_ref":"9a07b754-3383-43ac-9d2d-a370d44406d1","_type":"reference"},"_createdAt":"2023-03-14T13:29:28Z"}],"is_active":true,"_createdAt":"2020-04-14T14:09:11Z","sortOrder":4,"_rev":"lsW1cEPdRFwwIdupAS8Stb","_type":"subNavigation","name":"About AJMC","_id":"9a07b754-3383-43ac-9d2d-a370d44406d1","_updatedAt":"2020-04-27T18:48:27Z","navParent":null}],"site_setting":{"keywords":["American Journal of Managed Care","AJMC"],"salesforceDMPId":"tr3xsudox","orangizationName":"AJMC","copyRightText":"AJMC®","footerLinks":[{"_type":"urlArray","_key":"6170fdefc8129a5a7ef9dfdd78a2573e","title":"About","url":"/about-us"},{"_type":"urlArray","_key":"281c240875d5","title":"Contact","url":"/contactus"},{"_type":"urlArray","_key":"25e9e6fb7b4422cd0ac20e1a1d993228","title":"Editorial Boards","url":"/editorial-boards"},{"url":"/advertise","_type":"urlArray","_key":"20a44c137e8d","title":"Advertise"},{"title":"Do Not Sell My Information","url":"https://www.mjhlifesciences.com/ccpa?domain=www.ajmc.com","blank":true,"_type":"urlArray","_key":"21b84fcc9b6e"},{"_type":"urlArray","_key":"2f35307aab1f","title":"Terms \u0026 Conditions","url":"/terms"},{"_type":"urlArray","_key":"50ecd8627d01","title":"Privacy Policy","url":"/privacy"}],"creativeLayout":null,"socialLinks":[{"blank":true,"_type":"urlArray","_key":"5a09ae68c48c","title":"Facebook","url":"https://www.facebook.com/TheAmericanJournalOfManagedCare"},{"blank":true,"_type":"urlArray","_key":"ad6b3d250e0b","title":"Twitter","url":"https://twitter.com/AJMC_Journal"},{"blank":true,"_type":"urlArray","_key":"7d1e53fa7d09","title":"LinkedIn","url":"https://www.linkedin.com/company/american-journal-of-managed-care/"},{"title":"Instagram","url":"https://www.instagram.com/ajmcjournal/","blank":true,"_type":"urlArray","_key":"2478204aa05c"},{"_type":"urlArray","_key":"0ba4cf990c2f","title":"RSS","url":"/rss","blank":true}],"enableSanity2":true,"_updatedAt":"2025-01-23T16:12:11Z","description":"The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.","alternateName":"The American Journal of Managed Care","creativeLayoutLatestNews":null,"name":"AJMC - Managed Care News, Research, and Expert Insights","siteURL":"www.ajmc.com","_rev":"iBzEylCaJfBlbg7ZehwyvL","_createdAt":"2020-04-14T14:14:32Z","gaID":"UA-155582410-5,UA-11140057-3","_id":"siteSettings","_type":"siteSettings"},"clinicalData":[{"identifier":"center-on-health-equity-and-access","sortOrder":null,"children":[],"_id":"4ee49086-e720-4a65-883e-4efc24de53bb","name":"Center on Health Equity \u0026 Access"},{"name":"Clinical","identifier":"clinical","sortOrder":null,"children":[],"_id":"topic_clinical"},{"identifier":"healthcare-cost","sortOrder":null,"children":[],"_id":"topic_healthcare-cost","name":"Health Care Cost"},{"_id":"topic_healthcare-delivery","name":"Health Care Delivery","identifier":"healthcare-delivery","sortOrder":null,"children":[]},{"_id":"topic_insurance","name":"Insurance","identifier":"insurance","sortOrder":null,"children":[]},{"_id":"topic_policy","name":"Policy","identifier":"policy","sortOrder":null,"children":[]},{"_id":"topic_technology","name":"Technology","identifier":"technology","sortOrder":null,"children":[]},{"sortOrder":null,"children":[],"_id":"topic_value-based-care","name":"Value-Based Care","identifier":"value-based-care"}],"seo_data":[],"recent_news":[{"_id":"2eada1ba-6694-4c11-b981-a83bacf411f1","title":"Kansas City’s TB Outbreak Can Be Contained With the Lessons From COVID-19","summary":"In this final interview clip, Michael A. Bernstein, MD, stresses the need for effective communication and proactive screening to contain the ongoing tuberculosis (TB) outbreak in Kansas City.","url":{"current":"kansas-city-s-tb-outbreak-can-be-contained-with-the-lessons-from-covid-19","_type":"slug"},"authorMapping":{"firstName":"Brooke","authorType":"author","displayName":"Brooke McCormick","_rev":"A9UM2QVfJg2GpKiBNGLBGh","_id":"00af9d05-a2c4-4451-a6d1-0e28b08cbb65","biography":[{"children":[{"_type":"span","marks":[],"text":"Brooke is an associate editor for ","_key":"8d68730a8da0"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"730c46c984c9"},{"_type":"span","marks":[],"text":"® (","_key":"0b218fbaa571"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"b1b5b3d9cff0"},{"text":"®). She joined ","_key":"7de919198f04","_type":"span","marks":[]},{"_key":"f31a60d737e2","_type":"span","marks":["em"],"text":"AJMC"},{"_type":"span","marks":[],"text":" in 2023, where she produces written content covering multiple disease states.","_key":"df11193684f8"}],"_type":"block","style":"normal","_key":"936ecf4b7f0c","markDefs":[]},{"markDefs":[],"children":[{"marks":[],"text":"","_key":"5731fbb8e0ae","_type":"span"}],"_type":"block","style":"normal","_key":"9af540ce04de"},{"markDefs":[{"blank":true,"_type":"link","href":"https://www.linkedin.com/in/brooke-mccormick-1a254b1b6/","_key":"80a1c1a9d7cd","nofollow":true}],"children":[{"_type":"span","marks":[],"text":"She has a BA in journalism from Seton Hall University. You can connect with Brooke on ","_key":"bb68b5e8ee83"},{"_type":"span","marks":["80a1c1a9d7cd"],"text":"LinkedIn","_key":"4bb222fe2840"},{"_type":"span","marks":[],"text":".","_key":"c87621477700"}],"_type":"block","style":"normal","_key":"98aee68dab9d"}],"profileImage":{"_type":"mainImage","alt":"Brooke McCormick","asset":{"_ref":"image-1fe4e81696463cdd9c1d6b62a2e47c2228d7df99-430x430-png","_type":"reference"}},"_updatedAt":"2025-01-08T16:42:13Z","lastName":"McCormick","_createdAt":"2023-06-21T17:59:19Z","_type":"author","url":{"current":"brooke-mccormick","_type":"slug"}},"contentCategory":{"_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z"},"thumbnail":{"asset":{"_ref":"image-4e67a71e53a44a0736c2c37c0e31fa17cf1c24cc-2876x1537-png","_type":"reference"},"_type":"mainImage","alt":"Dr Michael Bernstein"},"published":"2025-02-15T14:00:00.000Z","factCheckAuthorMapping":null},{"authorMapping":{"displayName":"Mary Caffrey","_createdAt":"2020-05-05T10:50:00Z","_rev":"fWre465xUeSiaQm83HJghZ","_type":"author","_id":"author_6732921f288a3775abb89da57903428b","biography":[{"markDefs":[],"children":[{"marks":[],"text":"Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (","_key":"9737335da1ed0","_type":"span"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"b8dda18bb0dc"},{"marks":[],"text":"®). She joined AJMC® in 2013 and is the primary staff editor for ","_key":"f56917041c08","_type":"span"},{"text":"Evidence-Based Oncology, ","_key":"8c710bb1d962","_type":"span","marks":["em"]},{"_type":"span","marks":[],"text":"the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for ","_key":"1b94f48924f3"},{"marks":["em"],"text":"AJMC","_key":"3c5f9805f644","_type":"span"},{"_key":"d533ba55a862","_type":"span","marks":[],"text":"®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for "},{"_type":"span","marks":["em"],"text":"AJMC","_key":"953d8c643cce"},{"_type":"span","marks":[],"text":" readers. ","_key":"182af2348b04"}],"_type":"block","style":"normal","_key":"80606b0b2412"},{"_type":"block","style":"normal","_key":"a03d32973d6e","markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/marykcaffrey/","_key":"4f88673cb2c4"}],"children":[{"text":"Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on ","_key":"c2027cf5a357","_type":"span","marks":[]},{"_type":"span","marks":["4f88673cb2c4"],"text":"LinkedIn","_key":"9737335da1ed1"},{"_type":"span","marks":[],"text":".","_key":"9737335da1ed2"}]}],"_updatedAt":"2023-10-12T05:02:06Z","url":{"current":"mary-caffrey","_type":"slug"}},"contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"_id":"4558ddec-cea0-44fa-8b00-9bc10ca97dbc","thumbnail":{"asset":{"_ref":"image-3a19b338994d57764d7f408c063ffc36b037edcc-640x410-jpg","_type":"reference"},"_type":"mainImage"},"url":{"current":"powles-highlights-transformative-benefit-of-ev-plus-pembro-while-sharing-long-term-data-for-ev-302","_type":"slug"},"published":"2025-02-15T13:42:00.000Z","title":"Powles Highlights “Transformative” Benefit of EV Plus Pembro While Sharing Long-Term Data for EV-302","summary":"The lead investigator for EV-302 said not long ago, survival of 12 to 14 months in this type of bladder cancer was considered an achievement; in this study, median overall survival was 34 months after treatment with enfortumab vedotin (EV) and pembrolizumab (pembro).","factCheckAuthorMapping":null},{"_id":"3ed48850-d9c6-4a8c-ba73-c594f3511884","summary":"City of Hope's Salvador Jaime-Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody-drug conjugate (ADC) combinations in advanced urothelial cancer. ","url":{"_type":"slug","current":"analysis-looks-at-benefits-toxicity-of-adc-combinations-in-advanced-bladder-cancer"},"factCheckAuthorMapping":null,"contentCategory":{"_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles"},"title":"Analysis Looks at Benefits, Toxicity of ADC Combinations in Advanced Bladder Cancer","thumbnail":{"_type":"mainImage","caption":"Padcev packaging | Image: Astellas/Seagen","asset":{"_ref":"image-a13ef0cd0e6b56f4e0f3835241425ff4035f5ade-600x450-jpg","_type":"reference"}},"published":"2025-02-15T04:02:00.000Z","authorMapping":{"_type":"author","_id":"author_6732921f288a3775abb89da57903428b","biography":[{"_type":"block","style":"normal","_key":"80606b0b2412","markDefs":[],"children":[{"marks":[],"text":"Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (","_key":"9737335da1ed0","_type":"span"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"b8dda18bb0dc"},{"marks":[],"text":"®). She joined AJMC® in 2013 and is the primary staff editor for ","_key":"f56917041c08","_type":"span"},{"text":"Evidence-Based Oncology, ","_key":"8c710bb1d962","_type":"span","marks":["em"]},{"_type":"span","marks":[],"text":"the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for ","_key":"1b94f48924f3"},{"marks":["em"],"text":"AJMC","_key":"3c5f9805f644","_type":"span"},{"_key":"d533ba55a862","_type":"span","marks":[],"text":"®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for "},{"_type":"span","marks":["em"],"text":"AJMC","_key":"953d8c643cce"},{"_type":"span","marks":[],"text":" readers. ","_key":"182af2348b04"}]},{"_type":"block","style":"normal","_key":"a03d32973d6e","markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/marykcaffrey/","_key":"4f88673cb2c4","nofollow":true,"blank":true}],"children":[{"text":"Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on ","_key":"c2027cf5a357","_type":"span","marks":[]},{"_type":"span","marks":["4f88673cb2c4"],"text":"LinkedIn","_key":"9737335da1ed1"},{"_type":"span","marks":[],"text":".","_key":"9737335da1ed2"}]}],"_updatedAt":"2023-10-12T05:02:06Z","url":{"current":"mary-caffrey","_type":"slug"},"displayName":"Mary Caffrey","_createdAt":"2020-05-05T10:50:00Z","_rev":"fWre465xUeSiaQm83HJghZ"}},{"published":"2025-02-14T19:58:31.989Z","factCheckAuthorMapping":null,"_id":"e8553f02-8c8e-474a-aff1-3fc1c824a93a","title":"Adults With DMD More Than Twice as Likely to Experience Fractures","summary":"Less than half of patients had undergone bone monitoring, suggesting a need for better clinical guidance and management of osteoporosis in adult men with Duchenne muscular dystrophy (DMD). ","contentCategory":{"_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles"},"thumbnail":{"_type":"mainImage","alt":"Vertebral fractures are common in glucocorticoid-associated osteoporosis and are a clinical indicator of osteoporosis in young patients. | Image credit: Hugnaka - stock.adobe.com","asset":{"_ref":"image-06061deade20b7548bf1379ea5954d86c9277e14-1200x675-jpg","_type":"reference"}},"url":{"current":"adults-with-dmd-more-than-twice-as-likely-to-experience-fractures","_type":"slug"},"authorMapping":{"_rev":"N7mKycgLbGtEq6btkTWlrd","_id":"9243ec08-02c0-4c8e-b586-619334f7f95d","profileImage":{"alt":"Rose McNulty","asset":{"_ref":"image-8445b436ab605560bc20c7e9c6f4f60912e914df-430x430-png","_type":"reference"},"_type":"mainImage"},"_updatedAt":"2024-06-13T13:26:39Z","url":{"_type":"slug","current":"rose-mcnulty"},"lastName":"McNulty","_createdAt":"2020-10-06T12:46:55Z","_type":"author","biography":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Rose is an associate editorial director at ","_key":"123612bd9b2b0"},{"_key":"2cd28f20d2b9","_type":"span","marks":["em"],"text":"The American Journal of Managed Care"},{"marks":["superscript"],"text":"®","_key":"032c8e723210","_type":"span"},{"text":" (","_key":"e2d5625eae03","_type":"span","marks":[]},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3af109dc927a"},{"_key":"1903cd426eb6","_type":"span","marks":["superscript"],"text":"®"},{"text":").","_key":"688f269c2ad0","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"3a2b873558e3"},{"markDefs":[{"href":"https://www.linkedin.com/in/rose-mcnulty-652a09126/","_key":"a1a427c7e90e","nofollow":true,"blank":true,"_type":"link"}],"children":[{"marks":[],"text":"She has a BA in journalism \u0026 media studies and Spanish from Rutgers University. You can connect with Rose on ","_key":"3abc796e3805","_type":"span"},{"marks":["a1a427c7e90e"],"text":"LinkedIn","_key":"123612bd9b2b1","_type":"span"},{"marks":[],"text":".","_key":"123612bd9b2b2","_type":"span"}],"_type":"block","style":"normal","_key":"3a18842aed2b"}],"firstName":"Rose","displayName":"Rose McNulty"}}],"latest_publications":[{"url":"kap-regarding-chatgpt-among-health-care-professionals-correspondence","factCheckBy":[{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Hinpetch Daungsupawong, PhD","firstName":"Hinpetch","lastName":"Daungsupawong","url":{"current":"hinpetch-daungsupawong-phd","_type":"slug"}},{"url":{"current":"viroj-wiwanitkit-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Viroj Wiwanitkit, MD","firstName":"Viroj","lastName":"Wiwanitkit"}],"_id":"029c0e16-5487-4d46-8669-9c80e6c775d2","issueGroup":{"_ref":"cfc4ad72-548d-4101-af2d-9fff7f70ed64","_type":"reference"},"summary":"This letter discusses previously published research that paves the way for deeper exploration of the ethical and human aspects of artificial intelligence in health care.","thumbnail":{"_type":"mainImage","alt":"AJMC","asset":{"metadata":{"dimensions":{"_type":"sanity.imageDimensions","width":778,"aspectRatio":2.0366492146596857,"height":382},"exif":{"_type":"sanity.imageExifMetadata","PixelXDimension":778,"PixelYDimension":382},"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata","palette":{"lightVibrant":{"background":"#cae1f2","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":0.93},"darkVibrant":{"background":"#044679","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.09},"lightMuted":{"population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"vibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.52,"background":"#18568d"},"dominant":{"population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"_type":"sanity.imagePalette","darkMuted":{"foreground":"#fff","title":"#fff","population":0.71,"background":"#37536a","_type":"sanity.imagePaletteSwatch"},"muted":{"foreground":"#fff","title":"#fff","population":0.38,"background":"#628cad","_type":"sanity.imagePaletteSwatch"}},"hasAlpha":true,"lqip":"data:image/png;base64,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"},"uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","mimeType":"image/png","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","_type":"sanity.imageAsset","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","size":203185,"_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","_updatedAt":"2023-07-11T20:45:56Z","extension":"png","_rev":"hiKH9HIKxNVM35TxYdonKh","assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","_createdAt":"2023-07-11T20:45:56Z","originalFilename":"AJMC_logo_NEW.png","sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6"}},"title":"KAP Regarding ChatGPT Among Health Care Professionals: Correspondence","published":"2025-02-11T14:00:00.000Z","authorDetails":[{"biography":null,"showSocialShare":null,"displayName":"Hinpetch Daungsupawong, PhD","firstName":"Hinpetch","lastName":"Daungsupawong","url":{"_type":"slug","current":"hinpetch-daungsupawong-phd"},"profileImage":null},{"showSocialShare":null,"displayName":"Viroj Wiwanitkit, MD","firstName":"Viroj","lastName":"Wiwanitkit","url":{"_type":"slug","current":"viroj-wiwanitkit-md"},"profileImage":null,"biography":null}]},{"_id":"90b5927a-b28a-40cd-a19e-2ad54b3a4de3","issueGroup":{"_ref":"cfc4ad72-548d-4101-af2d-9fff7f70ed64","_type":"reference"},"summary":"This analysis demonstrated significant variability in medical policy determinations and evidence cited for clinically relevant pharmacogenetic tests among major US health insurers and laboratory benefit managers.","authorDetails":[{"firstName":"Jai","lastName":"Patel","url":{"current":"jai-n-patel-pharmd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Jai N. Patel, PharmD"},{"showSocialShare":null,"displayName":"Lena Chaihorsky, BS","firstName":"Lena","lastName":"Chaihorsky","url":{"current":"lena-chaihorsky-bs","_type":"slug"},"profileImage":null,"biography":null},{"url":{"current":"olivia-m-dong-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Olivia M. Dong, PhD","firstName":"Olivia","lastName":"Dong"},{"displayName":"Christine Y. Lu, PhD","firstName":"Christine","lastName":"Lu","url":{"current":"christine-y-lu-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"url":{"current":"chad-moretz-scd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Chad Moretz, ScD","firstName":"Chad","lastName":"Moretz"},{"displayName":"Emily Reese, PhD, MPH","firstName":"Emily","lastName":"Reese","url":{"current":"emily-reese-phd-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"displayName":"Wrenda Teeple, PharmD","firstName":"Wrenda","lastName":"Teeple","url":{"current":"wrenda-teeple-pharmd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"displayName":"Benjamin Brown, BS","firstName":"Benjamin ","lastName":"Brown","url":{"current":"benjamin-brown-bs","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Sara Rogers, PharmD","firstName":"Sara","lastName":"Rogers","url":{"current":"sara-rogers-pharmd","_type":"slug"}}],"factCheckBy":[{"biography":null,"showSocialShare":null,"displayName":"Jai N. Patel, PharmD","firstName":"Jai","lastName":"Patel","url":{"_type":"slug","current":"jai-n-patel-pharmd"},"profileImage":null},{"firstName":"Lena","lastName":"Chaihorsky","url":{"current":"lena-chaihorsky-bs","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Lena Chaihorsky, BS"},{"url":{"current":"olivia-m-dong-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Olivia M. Dong, PhD","firstName":"Olivia","lastName":"Dong"},{"displayName":"Christine Y. Lu, PhD","firstName":"Christine","lastName":"Lu","url":{"_type":"slug","current":"christine-y-lu-phd"},"profileImage":null,"biography":null,"showSocialShare":null},{"displayName":"Chad Moretz, ScD","firstName":"Chad","lastName":"Moretz","url":{"current":"chad-moretz-scd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"url":{"current":"emily-reese-phd-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Emily Reese, PhD, MPH","firstName":"Emily","lastName":"Reese"},{"lastName":"Teeple","url":{"current":"wrenda-teeple-pharmd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Wrenda Teeple, PharmD","firstName":"Wrenda"},{"displayName":"Benjamin Brown, BS","firstName":"Benjamin ","lastName":"Brown","url":{"current":"benjamin-brown-bs","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"showSocialShare":null,"displayName":"Sara Rogers, PharmD","firstName":"Sara","lastName":"Rogers","url":{"current":"sara-rogers-pharmd","_type":"slug"},"profileImage":null,"biography":null}],"title":"Medical Policy Determinations for Pharmacogenetic Tests Among US Health Plans","thumbnail":{"_type":"mainImage","alt":"AJMC","asset":{"originalFilename":"AJMC_logo_NEW.png","extension":"png","_rev":"hiKH9HIKxNVM35TxYdonKh","assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","_createdAt":"2023-07-11T20:45:56Z","sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","metadata":{"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":778,"aspectRatio":2.0366492146596857,"height":382},"exif":{"_type":"sanity.imageExifMetadata","PixelXDimension":778,"PixelYDimension":382},"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata","palette":{"dominant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26,"background":"#9bb7cc"},"_type":"sanity.imagePalette","darkMuted":{"foreground":"#fff","title":"#fff","population":0.71,"background":"#37536a","_type":"sanity.imagePaletteSwatch"},"muted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.38,"background":"#628cad"},"lightVibrant":{"foreground":"#000","title":"#000","population":0.93,"background":"#cae1f2","_type":"sanity.imagePaletteSwatch"},"darkVibrant":{"title":"#fff","population":0.09,"background":"#044679","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26,"background":"#9bb7cc"},"vibrant":{"population":0.52,"background":"#18568d","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"}}},"uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","mimeType":"image/png","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","_updatedAt":"2023-07-11T20:45:56Z","_type":"sanity.imageAsset","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","size":203185,"_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png"}},"url":"medical-policy-determinations-for-pharmacogenetic-tests-among-us-health-plans","published":"2025-02-10T14:00:00.000Z"},{"title":"Hospitalization Patterns Among Older Patients With Cancer With and Without Dementia","summary":"Dementia was more prevalent in older patients with some cancer types, and comorbid dementia in this population was associated with unplanned or unnecessary hospitalization.","thumbnail":{"_type":"mainImage","alt":"AJMC","asset":{"extension":"png","_rev":"hiKH9HIKxNVM35TxYdonKh","assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","_createdAt":"2023-07-11T20:45:56Z","originalFilename":"AJMC_logo_NEW.png","sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","metadata":{"exif":{"_type":"sanity.imageExifMetadata","PixelXDimension":778,"PixelYDimension":382},"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata","palette":{"lightMuted":{"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26},"vibrant":{"background":"#18568d","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.52},"dominant":{"population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"_type":"sanity.imagePalette","darkMuted":{"population":0.71,"background":"#37536a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"muted":{"background":"#628cad","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.38},"lightVibrant":{"population":0.93,"background":"#cae1f2","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000"},"darkVibrant":{"population":0.09,"background":"#044679","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":778,"aspectRatio":2.0366492146596857,"height":382}},"uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","mimeType":"image/png","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","_type":"sanity.imageAsset","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","size":203185,"_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","_updatedAt":"2023-07-11T20:45:56Z"}},"url":"hospitalization-patterns-among-older-patients-with-cancer-with-and-without-dementia","published":"2025-02-07T18:00:00.000Z","_id":"86a76eae-6bea-47a1-b6d4-35fc79593c22","issueGroup":{"_ref":"cfc4ad72-548d-4101-af2d-9fff7f70ed64","_type":"reference"},"authorDetails":[{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Zhigang Xie, PhD, MPA","firstName":"Zhigang","lastName":"Xie","url":{"current":"zhigang-xie-phd-mpa","_type":"slug"}},{"displayName":"Hanadi Y. Hamadi, PhD","firstName":"Hanadi","lastName":"Hamadi","url":{"current":"hanadi-y-hamadi-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"biography":null,"showSocialShare":null,"displayName":"Elissa Barr, PhD","firstName":"Elissa","lastName":"Barr","url":{"current":"elissa-barr-phd","_type":"slug"},"profileImage":null},{"biography":null,"showSocialShare":null,"displayName":"Beomyoung Cho, PhD, MPH","firstName":"Beomyoung","lastName":"Cho","url":{"current":"beomyoung-cho-phd-mph","_type":"slug"},"profileImage":null},{"firstName":"Shraddha","lastName":"Patel","url":{"current":"shraddha-patel-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Shraddha Patel, MPH"},{"url":{"_type":"slug","current":"young-rock-hong-phd-mph"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Young-Rock Hong, PhD, MPH","firstName":"Young-Rock","lastName":"Hong"}],"factCheckBy":[{"lastName":"Xie","url":{"current":"zhigang-xie-phd-mpa","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Zhigang Xie, PhD, MPA","firstName":"Zhigang"},{"showSocialShare":null,"displayName":"Hanadi Y. Hamadi, PhD","firstName":"Hanadi","lastName":"Hamadi","url":{"_type":"slug","current":"hanadi-y-hamadi-phd"},"profileImage":null,"biography":null},{"showSocialShare":null,"displayName":"Elissa Barr, PhD","firstName":"Elissa","lastName":"Barr","url":{"current":"elissa-barr-phd","_type":"slug"},"profileImage":null,"biography":null},{"showSocialShare":null,"displayName":"Beomyoung Cho, PhD, MPH","firstName":"Beomyoung","lastName":"Cho","url":{"current":"beomyoung-cho-phd-mph","_type":"slug"},"profileImage":null,"biography":null},{"lastName":"Patel","url":{"current":"shraddha-patel-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Shraddha Patel, MPH","firstName":"Shraddha"},{"firstName":"Young-Rock","lastName":"Hong","url":{"current":"young-rock-hong-phd-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Young-Rock Hong, PhD, MPH"}]},{"issueGroup":{"_ref":"5115f1e5-56a6-462e-9219-36c2ee74bc64","_type":"reference"},"title":"MRD and Other Predictors From FELIX for Obe-Cel Success in R/R B-ALL","thumbnail":{"_type":"mainImage","alt":"Elias Jabbour, MD | Image credit: MD Anderson","caption":"Elias Jabbour, MD | Image credit: MD Anderson","asset":{"size":8344,"_updatedAt":"2025-01-22T01:39:28Z","originalFilename":"Elias Jabbour MD.jpg","mimeType":"image/jpeg","sha1hash":"d7b07ba2f95a91eead9b2ff8ea1eab8b3e1e9ff2","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/d7b07ba2f95a91eead9b2ff8ea1eab8b3e1e9ff2-360x202.jpg","path":"images/0vv8moc6/ajmc/d7b07ba2f95a91eead9b2ff8ea1eab8b3e1e9ff2-360x202.jpg","_id":"image-d7b07ba2f95a91eead9b2ff8ea1eab8b3e1e9ff2-360x202-jpg","_rev":"03H5IWZJxxErG40FSFrSh1","assetId":"d7b07ba2f95a91eead9b2ff8ea1eab8b3e1e9ff2","extension":"jpg","metadata":{"dimensions":{"height":202,"_type":"sanity.imageDimensions","width":360,"aspectRatio":1.7821782178217822},"isOpaque":true,"blurHash":"MKL;jYxvNZ%MMw%0?a%g-;IA~qWBs:aeWB","_type":"sanity.imageMetadata","palette":{"muted":{"population":1.13,"background":"#8d624f","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":0.02,"background":"#ececfc"},"darkVibrant":{"title":"#fff","population":0,"background":"#5d3626","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightMuted":{"foreground":"#000","title":"#fff","population":0.2,"background":"#c6b8b8","_type":"sanity.imagePaletteSwatch"},"vibrant":{"foreground":"#000","title":"#fff","population":0.25,"background":"#c78e77","_type":"sanity.imagePaletteSwatch"},"dominant":{"title":"#fff","population":5.59,"background":"#563d35","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"_type":"sanity.imagePalette","darkMuted":{"background":"#563d35","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":5.59}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,/9j/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAALABQDASIAAhEBAxEB/8QAGAAAAwEBAAAAAAAAAAAAAAAAAAYHBAX/xAAjEAABBAIBAwUAAAAAAAAAAAABAAIDBAURBhITIjEyQXGR/8QAFQEBAQAAAAAAAAAAAAAAAAAAAAH/xAAZEQACAwEAAAAAAAAAAAAAAAAAAQIREjL/2gAMAwEAAhEDEQA/AKrfz9jIYi9Xp9feMTg0s9QuJxKTKYziUZtwvY17yQCdkLThR2pnGPxJ0Dr7TFaAdMyIjcfT7fhXC6G6TiJsj7Uzy8MdooVHr1YBEAImfiFAf//Z"},"uploadId":"AI9UWYzlKUzpNZoSkOg0eaGj37ri4uGg","_type":"sanity.imageAsset","_createdAt":"2025-01-22T01:39:28Z"}},"published":"2025-01-22T01:20:00.000Z","factCheckBy":[{"displayName":"Mary Caffrey","firstName":null,"lastName":null,"url":{"current":"mary-caffrey","_type":"slug"},"profileImage":null,"biography":[{"_type":"block","style":"normal","_key":"80606b0b2412","markDefs":[],"children":[{"_key":"9737335da1ed0","_type":"span","marks":[],"text":"Mary Caffrey is the Executive Editor for The American Journal of Managed Care® ("},{"_type":"span","marks":["em"],"text":"AJMC","_key":"b8dda18bb0dc"},{"text":"®). She joined AJMC® in 2013 and is the primary staff editor for ","_key":"f56917041c08","_type":"span","marks":[]},{"_type":"span","marks":["em"],"text":"Evidence-Based Oncology, ","_key":"8c710bb1d962"},{"text":"the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for ","_key":"1b94f48924f3","_type":"span","marks":[]},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3c5f9805f644"},{"_type":"span","marks":[],"text":"®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for ","_key":"d533ba55a862"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"953d8c643cce"},{"_key":"182af2348b04","_type":"span","marks":[],"text":" readers. "}]},{"children":[{"_type":"span","marks":[],"text":"Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on ","_key":"c2027cf5a357"},{"marks":["4f88673cb2c4"],"text":"LinkedIn","_key":"9737335da1ed1","_type":"span"},{"marks":[],"text":".","_key":"9737335da1ed2","_type":"span"}],"_type":"block","style":"normal","_key":"a03d32973d6e","markDefs":[{"href":"https://www.linkedin.com/in/marykcaffrey/","_key":"4f88673cb2c4","nofollow":true,"blank":true,"_type":"link"}]}],"showSocialShare":null},{"showSocialShare":null,"displayName":"Elias J. Jabbour, MD","firstName":null,"lastName":null,"url":{"current":"elias-j-jabbour-md","_type":"slug"},"profileImage":null,"biography":null}],"_id":"a74e0c61-1db8-4176-a3ff-356818f8f1bc","summary":null,"url":"mrd-and-other-predictors-from-felix-for-obe-cel-success-in-r-r-b-all","authorDetails":[{"biography":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (","_key":"9737335da1ed0"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"b8dda18bb0dc"},{"_type":"span","marks":[],"text":"®). She joined AJMC® in 2013 and is the primary staff editor for ","_key":"f56917041c08"},{"text":"Evidence-Based Oncology, ","_key":"8c710bb1d962","_type":"span","marks":["em"]},{"text":"the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for ","_key":"1b94f48924f3","_type":"span","marks":[]},{"text":"AJMC","_key":"3c5f9805f644","_type":"span","marks":["em"]},{"_type":"span","marks":[],"text":"®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for ","_key":"d533ba55a862"},{"text":"AJMC","_key":"953d8c643cce","_type":"span","marks":["em"]},{"text":" readers. ","_key":"182af2348b04","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"80606b0b2412"},{"markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/marykcaffrey/","_key":"4f88673cb2c4","nofollow":true,"blank":true}],"children":[{"_type":"span","marks":[],"text":"Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on ","_key":"c2027cf5a357"},{"_key":"9737335da1ed1","_type":"span","marks":["4f88673cb2c4"],"text":"LinkedIn"},{"_type":"span","marks":[],"text":".","_key":"9737335da1ed2"}],"_type":"block","style":"normal","_key":"a03d32973d6e"}],"showSocialShare":null,"displayName":"Mary Caffrey","firstName":null,"lastName":null,"url":{"current":"mary-caffrey","_type":"slug"},"profileImage":null},{"displayName":"Elias J. Jabbour, MD","firstName":null,"lastName":null,"url":{"current":"elias-j-jabbour-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null}]},{"factCheckBy":[{"showSocialShare":null,"displayName":"Denise Tran, PharmD","firstName":"Denise","lastName":"Tran","url":{"current":"denise-tran-pharmd","_type":"slug"},"profileImage":null,"biography":null},{"firstName":"Haesuk","lastName":"Park","url":{"current":"haesuk-park-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Haesuk Park, PhD"},{"displayName":"Jordon Rabey, MS","firstName":"Jordon","lastName":"Rabey","url":{"current":"jordon-rabey-ms","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"url":{"current":"seth-killion-bs","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Seth Killion, BS","firstName":"Seth","lastName":"Killion"},{"displayName":"S. Bobby Arelli, MD","firstName":"S.","lastName":"Arelli","url":{"current":"s-bobby-arelli-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"displayName":"Elaine Murphy, BS","firstName":"Elaine","lastName":"Murphy","url":{"current":"elaine-murphy-bs","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"firstName":"Yoona","lastName":"Kim","url":{"current":"yoona-kim-pharmd-phd","_type":"slug"},"profileImage":null,"biography":[{"markDefs":[{"_key":"531fb76b610f","nofollow":true,"blank":true,"_type":"link","href":"https://www.arine.io/?utm_campaign=Public%20Relations\u0026utm_source=Bylined%20Article\u0026utm_medium=AJMC\u0026utm_content=Optimizing%20Medication%20Outcomes"}],"children":[{"_type":"span","marks":[],"text":"Yoona Kim, PharmD, PhD, is the CEO and co-founder of ","_key":"f5c43b0094150"},{"_key":"1e6470ee49ca","_type":"span","marks":["531fb76b610f"],"text":"Arine"},{"_key":"2ad98b63e1fb","_type":"span","marks":[],"text":", a next-generation medication intelligence company with a mission to solve medication mismanagement across the health care continuum. Arine’s proprietary platform pulls insights from a complex ecosystem of clinical, socioeconomic, and behavioral data to optimize patient outcomes and deliver value-based care. The technology uses predictive analytics to target care to at-risk members, develops artificial intelligence (AI)-driven personalized care plans for each patient, and uses machine learning to continuously optimize members’ medication therapy. Arine overcomes the limits of traditional, manually driven medication management approaches by making the practice scalable and allowing time-strapped health care providers to deliver care to large populations and with a far greater impact. Arine’s clients have achieved the highest quality ratings and have reduced hospital admissions by 40%."}],"_type":"block","style":"normal","_key":"bf797f939822"},{"markDefs":[],"children":[{"text":"Arine’s AI-driven technology platform is powering successful interventions that navigate complexities discussed in this article. For example, Arine’s platform identified a 67-year-old Latinx male in Medicare Advantage with diabetes and an elevated hemoglobin A","_key":"ee58d5fd8fca0","_type":"span","marks":[]},{"_type":"span","marks":["subscript"],"text":"1C","_key":"2886ba74f33e"},{"_key":"00cebefaa126","_type":"span","marks":[],"text":" at high risk for hyperglycemic crisis. He had a history of medication nonadherence and canceling appointments and expressed difficulty affording a branded diabetes medication. Arine’s platform identified a generic option, along with several other recommendations, to optimize the member’s array of medications for other comorbidities. The platform also flagged a pattern of underutilization of care, indicated by an absence of a primary care visit within the last year and connected the member to an appointment. These measures were supplemented by auto-generated Spanish-language educational materials on the importance of medications and lifestyle changes for diabetes management. Ultimately, the member was very receptive to the recommendations and started taking his medications more regularly."}],"_type":"block","style":"normal","_key":"816767524ea1"},{"style":"normal","_key":"88840c7d9452","markDefs":[],"children":[{"marks":[],"text":"Prior to Arine, Yoona has held various roles at digital health, pharma, and consulting companies. She holds a bachelor’s degree from Stanford University; a PharmD with an emphasis in health policy and management from the University of California, San Francisco; and a PhD in health economics and outcomes from the University of Texas at Austin.","_key":"9db59a3d155d0","_type":"span"}],"_type":"block"},{"markDefs":[],"children":[{"marks":[],"text":"","_key":"49f538df32460","_type":"span"}],"_type":"block","style":"normal","_key":"f9ff3fa5d2f5"}],"showSocialShare":null,"displayName":"Yoona Kim, PharmD, PhD"}],"issueGroup":{"_ref":"3be6d418-ebd1-4073-af15-1f73168f5c71","_type":"reference"},"thumbnail":{"asset":{"_type":"sanity.imageAsset","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","size":203185,"_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","_updatedAt":"2023-07-11T20:45:56Z","extension":"png","_rev":"hiKH9HIKxNVM35TxYdonKh","assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","_createdAt":"2023-07-11T20:45:56Z","originalFilename":"AJMC_logo_NEW.png","sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","metadata":{"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":778,"aspectRatio":2.0366492146596857,"height":382},"exif":{"_type":"sanity.imageExifMetadata","PixelXDimension":778,"PixelYDimension":382},"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata","palette":{"lightVibrant":{"background":"#cae1f2","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":0.93},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.09,"background":"#044679"},"lightMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26,"background":"#9bb7cc"},"vibrant":{"population":0.52,"background":"#18568d","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"dominant":{"title":"#fff","population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"_type":"sanity.imagePalette","darkMuted":{"foreground":"#fff","title":"#fff","population":0.71,"background":"#37536a","_type":"sanity.imagePaletteSwatch"},"muted":{"foreground":"#fff","title":"#fff","population":0.38,"background":"#628cad","_type":"sanity.imagePaletteSwatch"}},"hasAlpha":true},"uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","mimeType":"image/png","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png"},"_type":"mainImage","alt":"AJMC"},"url":"effects-of-individualized-nurse-led-care-plans-on-olaparib-treatment-duration","published":"2025-01-20T17:00:00.000Z","authorDetails":[{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Denise Tran, PharmD","firstName":"Denise","lastName":"Tran","url":{"current":"denise-tran-pharmd","_type":"slug"}},{"displayName":"Haesuk Park, PhD","firstName":"Haesuk","lastName":"Park","url":{"_type":"slug","current":"haesuk-park-phd"},"profileImage":null,"biography":null,"showSocialShare":null},{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Jordon Rabey, MS","firstName":"Jordon","lastName":"Rabey","url":{"current":"jordon-rabey-ms","_type":"slug"}},{"firstName":"Seth","lastName":"Killion","url":{"current":"seth-killion-bs","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Seth Killion, BS"},{"showSocialShare":null,"displayName":"S. Bobby Arelli, MD","firstName":"S.","lastName":"Arelli","url":{"current":"s-bobby-arelli-md","_type":"slug"},"profileImage":null,"biography":null},{"biography":null,"showSocialShare":null,"displayName":"Elaine Murphy, BS","firstName":"Elaine","lastName":"Murphy","url":{"current":"elaine-murphy-bs","_type":"slug"},"profileImage":null},{"lastName":"Kim","url":{"current":"yoona-kim-pharmd-phd","_type":"slug"},"profileImage":null,"biography":[{"style":"normal","_key":"bf797f939822","markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.arine.io/?utm_campaign=Public%20Relations\u0026utm_source=Bylined%20Article\u0026utm_medium=AJMC\u0026utm_content=Optimizing%20Medication%20Outcomes","_key":"531fb76b610f"}],"children":[{"text":"Yoona Kim, PharmD, PhD, is the CEO and co-founder of ","_key":"f5c43b0094150","_type":"span","marks":[]},{"_key":"1e6470ee49ca","_type":"span","marks":["531fb76b610f"],"text":"Arine"},{"_type":"span","marks":[],"text":", a next-generation medication intelligence company with a mission to solve medication mismanagement across the health care continuum. Arine’s proprietary platform pulls insights from a complex ecosystem of clinical, socioeconomic, and behavioral data to optimize patient outcomes and deliver value-based care. The technology uses predictive analytics to target care to at-risk members, develops artificial intelligence (AI)-driven personalized care plans for each patient, and uses machine learning to continuously optimize members’ medication therapy. Arine overcomes the limits of traditional, manually driven medication management approaches by making the practice scalable and allowing time-strapped health care providers to deliver care to large populations and with a far greater impact. Arine’s clients have achieved the highest quality ratings and have reduced hospital admissions by 40%.","_key":"2ad98b63e1fb"}],"_type":"block"},{"_key":"816767524ea1","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Arine’s AI-driven technology platform is powering successful interventions that navigate complexities discussed in this article. For example, Arine’s platform identified a 67-year-old Latinx male in Medicare Advantage with diabetes and an elevated hemoglobin A","_key":"ee58d5fd8fca0"},{"_type":"span","marks":["subscript"],"text":"1C","_key":"2886ba74f33e"},{"_type":"span","marks":[],"text":" at high risk for hyperglycemic crisis. He had a history of medication nonadherence and canceling appointments and expressed difficulty affording a branded diabetes medication. Arine’s platform identified a generic option, along with several other recommendations, to optimize the member’s array of medications for other comorbidities. The platform also flagged a pattern of underutilization of care, indicated by an absence of a primary care visit within the last year and connected the member to an appointment. These measures were supplemented by auto-generated Spanish-language educational materials on the importance of medications and lifestyle changes for diabetes management. Ultimately, the member was very receptive to the recommendations and started taking his medications more regularly.","_key":"00cebefaa126"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"marks":[],"text":"Prior to Arine, Yoona has held various roles at digital health, pharma, and consulting companies. She holds a bachelor’s degree from Stanford University; a PharmD with an emphasis in health policy and management from the University of California, San Francisco; and a PhD in health economics and outcomes from the University of Texas at Austin.","_key":"9db59a3d155d0","_type":"span"}],"_type":"block","style":"normal","_key":"88840c7d9452"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"49f538df32460"}],"_type":"block","style":"normal","_key":"f9ff3fa5d2f5"}],"showSocialShare":null,"displayName":"Yoona Kim, PharmD, PhD","firstName":"Yoona"}],"_id":"83a8ce9d-6abb-4501-81a9-077d46c26bf1","title":"Effects of Individualized Nurse-Led Care Plans on Olaparib Treatment Duration","summary":"A nurse-led personalized care program conducted through a specialty pharmacy prolonged medication persistence among patients with cancer receiving olaparib."},{"title":"Physiologic Insulin Resensitization Lowers Cost in Patients With Diabetes and Kidney Disease","summary":"Patients with diabetes and chronic kidney disease receiving physiologic insulin resensitization had much lower annual costs of care than similar patients not receiving it.","url":"physiologic-insulin-resensitization-lowers-cost-in-patients-with-diabetes-and-kidney-disease","factCheckBy":[{"lastName":"Villaverde","url":{"current":"zachary-villaverde-bs","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Zachary Villaverde, BS","firstName":"Zachary"},{"displayName":"Roy H. Hinman II, MD","firstName":"Roy","lastName":"Hinman","url":{"current":"roy-h-hinman-ii-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"biography":null,"showSocialShare":null,"displayName":"Richard M. Grimes, PhD","firstName":"Richard","lastName":"Grimes","url":{"current":"richard-m-grimes-phd","_type":"slug"},"profileImage":null}],"authorDetails":[{"url":{"current":"zachary-villaverde-bs","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Zachary Villaverde, BS","firstName":"Zachary","lastName":"Villaverde"},{"firstName":"Roy","lastName":"Hinman","url":{"current":"roy-h-hinman-ii-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Roy H. Hinman II, MD"},{"displayName":"Richard M. Grimes, PhD","firstName":"Richard","lastName":"Grimes","url":{"current":"richard-m-grimes-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null}],"_id":"4f36a408-190c-4587-b6a4-404014c81e1f","issueGroup":{"_type":"reference","_ref":"3be6d418-ebd1-4073-af15-1f73168f5c71"},"thumbnail":{"_type":"mainImage","alt":"AJMC","asset":{"_rev":"hiKH9HIKxNVM35TxYdonKh","assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","_createdAt":"2023-07-11T20:45:56Z","originalFilename":"AJMC_logo_NEW.png","extension":"png","sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","mimeType":"image/png","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","metadata":{"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":778,"aspectRatio":2.0366492146596857,"height":382},"exif":{"_type":"sanity.imageExifMetadata","PixelXDimension":778,"PixelYDimension":382},"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata","palette":{"lightMuted":{"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26},"vibrant":{"foreground":"#fff","title":"#fff","population":0.52,"background":"#18568d","_type":"sanity.imagePaletteSwatch"},"dominant":{"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26},"_type":"sanity.imagePalette","darkMuted":{"population":0.71,"background":"#37536a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"muted":{"background":"#628cad","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.38},"lightVibrant":{"background":"#cae1f2","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":0.93},"darkVibrant":{"title":"#fff","population":0.09,"background":"#044679","_type":"sanity.imagePaletteSwatch","foreground":"#fff"}},"hasAlpha":true},"url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","size":203185,"_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","_updatedAt":"2023-07-11T20:45:56Z","_type":"sanity.imageAsset"}},"published":"2025-01-17T14:00:00.000Z"},{"factCheckBy":[{"biography":null,"showSocialShare":null,"displayName":"Ann Haas, MS, MPH","firstName":"Ann","lastName":"Haas","url":{"current":"ann-haas-ms-mph","_type":"slug"},"profileImage":null},{"url":{"current":"denise-d-quigley-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Denise D. Quigley, PhD","firstName":"Denise","lastName":"Quigley"},{"displayName":"Amelia M. Haviland, PhD","firstName":"Amelia","lastName":"Haviland","url":{"current":"amelia-m-haviland-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"displayName":"Nate Orr, MA","firstName":"Nate","lastName":"Orr","url":{"current":"nate-orr-ma","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"biography":null,"showSocialShare":null,"displayName":"Julie Brown, BA","firstName":"Julie","lastName":"Brown","url":{"current":"julie-brown-ba","_type":"slug"},"profileImage":null},{"biography":null,"showSocialShare":null,"displayName":"Sarah Gaillot, PhD","firstName":"Sarah","lastName":"Gaillot","url":{"current":"sarah-gaillot-phd","_type":"slug"},"profileImage":null},{"showSocialShare":null,"displayName":"Marc N. Elliott, PhD","firstName":"Marc","lastName":"Elliott","url":{"current":"marc-n-elliott-phd","_type":"slug"},"profileImage":null,"biography":null}],"_id":"55d58c83-54a8-4ffd-83e6-7c1642cb2c0a","published":"2025-01-16T14:00:00.000Z","authorDetails":[{"displayName":"Ann Haas, MS, MPH","firstName":"Ann","lastName":"Haas","url":{"current":"ann-haas-ms-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Denise D. Quigley, PhD","firstName":"Denise","lastName":"Quigley","url":{"current":"denise-d-quigley-phd","_type":"slug"}},{"displayName":"Amelia M. Haviland, PhD","firstName":"Amelia","lastName":"Haviland","url":{"current":"amelia-m-haviland-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"url":{"current":"nate-orr-ma","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Nate Orr, MA","firstName":"Nate","lastName":"Orr"},{"lastName":"Brown","url":{"current":"julie-brown-ba","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Julie Brown, BA","firstName":"Julie"},{"displayName":"Sarah Gaillot, PhD","firstName":"Sarah","lastName":"Gaillot","url":{"current":"sarah-gaillot-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"displayName":"Marc N. Elliott, PhD","firstName":"Marc","lastName":"Elliott","url":{"current":"marc-n-elliott-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null}],"thumbnail":{"_type":"mainImage","alt":"AJMC","asset":{"_updatedAt":"2023-07-11T20:45:56Z","_type":"sanity.imageAsset","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","size":203185,"_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","originalFilename":"AJMC_logo_NEW.png","extension":"png","_rev":"hiKH9HIKxNVM35TxYdonKh","assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","_createdAt":"2023-07-11T20:45:56Z","sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","metadata":{"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":778,"aspectRatio":2.0366492146596857,"height":382},"exif":{"_type":"sanity.imageExifMetadata","PixelXDimension":778,"PixelYDimension":382},"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata","palette":{"darkVibrant":{"title":"#fff","population":0.09,"background":"#044679","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightMuted":{"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26},"vibrant":{"foreground":"#fff","title":"#fff","population":0.52,"background":"#18568d","_type":"sanity.imagePaletteSwatch"},"dominant":{"foreground":"#000","title":"#fff","population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch"},"_type":"sanity.imagePalette","darkMuted":{"background":"#37536a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.71},"muted":{"background":"#628cad","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.38},"lightVibrant":{"title":"#000","population":0.93,"background":"#cae1f2","_type":"sanity.imagePaletteSwatch","foreground":"#000"}},"hasAlpha":true},"uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","mimeType":"image/png","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png"}},"url":"telephone-follow-up-on-medicare-patient-surveys-remains-critical","issueGroup":{"_ref":"3be6d418-ebd1-4073-af15-1f73168f5c71","_type":"reference"},"title":"Telephone Follow-Up on Medicare Patient Surveys Remains Critical","summary":"Including a telephone component in Medicare Consumer Assessment of Healthcare Providers and Systems survey administration continues to be valuable because telephone responses comprise a substantial portion of responses for several underserved groups."},{"issueGroup":{"_ref":"5115f1e5-56a6-462e-9219-36c2ee74bc64","_type":"reference"},"summary":null,"thumbnail":{"_type":"mainImage","asset":{"_updatedAt":"2025-01-22T17:37:51Z","extension":"jpg","uploadId":"AJOmAkothnE9756fQQSjcbTCOOjl6EfV","mimeType":"image/jpeg","size":4528,"assetId":"d24a7ae4df61f95992f74a25b4d5666da68a6206","metadata":{"dimensions":{"_type":"sanity.imageDimensions","width":200,"aspectRatio":1,"height":200},"isOpaque":true,"blurHash":"e96IKkfxRiogRTWCf8fRayfP02e]t8WAt4t7fhfioeju_Lk6R$ogRn","_type":"sanity.imageMetadata","palette":{"lightVibrant":{"title":"#fff","population":0,"background":"#c4dc54","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"darkVibrant":{"background":"#0c2c44","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":79.02},"lightMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":0.14,"background":"#c5d0da"},"vibrant":{"background":"#bde428","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.02},"dominant":{"background":"#0c2c44","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":79.02},"_type":"sanity.imagePalette","darkMuted":{"background":"#334961","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.14},"muted":{"background":"#697988","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.44}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,/9j/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAAUABQDASIAAhEBAxEB/8QAGAABAAMBAAAAAAAAAAAAAAAAAAEEBgf/xAAgEAACAQQDAAMAAAAAAAAAAAAAAQIDBAUREiExE1Fh/8QAGAEBAAMBAAAAAAAAAAAAAAAAAAEDBAX/xAAZEQEBAQADAAAAAAAAAAAAAAAAAhEBElH/2gAMAwEAAhEDEQA/AOBpN+EpN+Jmgo562pW8IQx1LnFLc2TSz9tDTdhBy72+u/w3xdVvacc7OPWfSf0wXchexua6nSp/FHilxQLEKOhoACUgAB//2Q=="},"originalFilename":"ontada_logo.jpg","_rev":"z05Cxco1bGw7CBDJOjIZyP","_type":"sanity.imageAsset","sha1hash":"d24a7ae4df61f95992f74a25b4d5666da68a6206","_createdAt":"2025-01-22T17:37:51Z","_id":"image-d24a7ae4df61f95992f74a25b4d5666da68a6206-200x200-jpg","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/d24a7ae4df61f95992f74a25b4d5666da68a6206-200x200.jpg","path":"images/0vv8moc6/ajmc/d24a7ae4df61f95992f74a25b4d5666da68a6206-200x200.jpg"}},"url":"spotlight-on-access-and-equity-bispecifics-for-multiple-myeloma-in-the-community-setting","authorDetails":[{"showSocialShare":null,"displayName":"Luke Halpern","firstName":null,"lastName":null,"url":{"_type":"slug","current":"luke-halpern"},"profileImage":null,"biography":null},{"showSocialShare":true,"displayName":"Laura Joszt, MA","firstName":"Laura","lastName":"Joszt","url":{"current":"laura-joszt","_type":"slug"},"profileImage":{"_type":"mainImage","alt":"Laura Joszt headshot","asset":{"_ref":"image-93ea362164e769dfd84dca31a8b2670a1dd9092b-512x512-jpg","_type":"reference"}},"biography":[{"style":"normal","_key":"4a950aea97b3","markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/laura-joszt-05ba7116/","_key":"f77b28536a8d"},{"href":"https://twitter.com/joszt","_key":"c419f18a7ffe","_type":"link"}],"children":[{"_type":"span","marks":[],"text":"Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®’s parent company, MJH Life Sciences®, since 2011.","_key":"67a67d3764f00"}],"_type":"block"},{"markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/laura-joszt-05ba7116/","_key":"f77b28536a8d","nofollow":true,"blank":true},{"_type":"link","href":"https://twitter.com/joszt","_key":"c419f18a7ffe","nofollow":true,"blank":true}],"children":[{"text":"She has an MA in business and economic reporting from New York University. You can connect with Laura on ","_key":"48d199d8ecd5","_type":"span","marks":[]},{"_type":"span","marks":["f77b28536a8d"],"text":"LinkedIn","_key":"67a67d3764f01"},{"_type":"span","marks":[],"text":" or ","_key":"67a67d3764f02"},{"_type":"span","marks":["c419f18a7ffe"],"text":"Twitter","_key":"67a67d3764f03"},{"_type":"span","marks":[],"text":".","_key":"67a67d3764f04"}],"_type":"block","style":"normal","_key":"b28d8058b3d8"}]}],"_id":"de999a47-35fe-4e8d-8527-755d8e08ce93","title":"Spotlight on Access and Equity: Bispecifics for Multiple Myeloma in the Community Setting","published":"2025-01-11T17:28:00.000Z","factCheckBy":[{"lastName":null,"url":{"_type":"slug","current":"luke-halpern"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Luke Halpern","firstName":null},{"firstName":"Laura","lastName":"Joszt","url":{"current":"laura-joszt","_type":"slug"},"profileImage":{"_type":"mainImage","alt":"Laura Joszt headshot","asset":{"_ref":"image-93ea362164e769dfd84dca31a8b2670a1dd9092b-512x512-jpg","_type":"reference"}},"biography":[{"_type":"block","style":"normal","_key":"4a950aea97b3","markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/laura-joszt-05ba7116/","_key":"f77b28536a8d"},{"_type":"link","href":"https://twitter.com/joszt","_key":"c419f18a7ffe"}],"children":[{"_type":"span","marks":[],"text":"Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®’s parent company, MJH Life Sciences®, since 2011.","_key":"67a67d3764f00"}]},{"style":"normal","_key":"b28d8058b3d8","markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/laura-joszt-05ba7116/","_key":"f77b28536a8d"},{"href":"https://twitter.com/joszt","_key":"c419f18a7ffe","nofollow":true,"blank":true,"_type":"link"}],"children":[{"_type":"span","marks":[],"text":"She has an MA in business and economic reporting from New York University. You can connect with Laura on ","_key":"48d199d8ecd5"},{"_type":"span","marks":["f77b28536a8d"],"text":"LinkedIn","_key":"67a67d3764f01"},{"text":" or ","_key":"67a67d3764f02","_type":"span","marks":[]},{"_type":"span","marks":["c419f18a7ffe"],"text":"Twitter","_key":"67a67d3764f03"},{"text":".","_key":"67a67d3764f04","_type":"span","marks":[]}],"_type":"block"}],"showSocialShare":true,"displayName":"Laura Joszt, MA"}]},{"authorDetails":[{"firstName":"Pearl ","lastName":"Steinzor","url":{"current":"pearl-steinzor","_type":"slug"},"profileImage":{"_type":"mainImage","alt":"Pearl Steinzor","asset":{"_ref":"image-aaad3972f041cf080c4994a923d62017c74f0ac3-512x512-jpg","_type":"reference"}},"biography":null,"showSocialShare":null,"displayName":"Pearl Steinzor"}],"summary":null,"issueGroup":{"_type":"reference","_ref":"5115f1e5-56a6-462e-9219-36c2ee74bc64"},"title":"SPOTLIGHT: Cilta-Cel Shows Sustained MRD Negativity; Leads to Prolonged PFS in Multiple Myeloma","thumbnail":{"_type":"mainImage","alt":"Yi Lin, MD, PhD ","asset":{"path":"images/0vv8moc6/ajmc/74682bc40139d223bd547d491e60f19bbf4a7a89-205x246.jpg","size":4599,"extension":"jpg","_id":"image-74682bc40139d223bd547d491e60f19bbf4a7a89-205x246-jpg","_updatedAt":"2025-01-22T00:31:10Z","originalFilename":"Yi Lin MD PhD.jpg","_type":"sanity.imageAsset","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/74682bc40139d223bd547d491e60f19bbf4a7a89-205x246.jpg","_createdAt":"2025-01-22T00:31:10Z","metadata":{"hasAlpha":false,"lqip":"data:image/jpeg;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":205,"aspectRatio":0.8333333333333334,"height":246},"isOpaque":true,"blurHash":"eAEoV-x^0#Iq=F~CX9.7xuNG0gxt=FV?Eg.8n~D%WqWA-UWCS2s:V[","_type":"sanity.imageMetadata","palette":{"darkVibrant":{"title":"#fff","population":2.18,"background":"#532f27","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightMuted":{"title":"#fff","population":1.92,"background":"#a9b5b9","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"vibrant":{"population":6.83,"background":"#d5a18e","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"dominant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":6.83,"background":"#d5a18e"},"_type":"sanity.imagePalette","darkMuted":{"foreground":"#fff","title":"#fff","population":0.02,"background":"#50343d","_type":"sanity.imagePaletteSwatch"},"muted":{"background":"#a4505c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.01},"lightVibrant":{"foreground":"#000","title":"#fff","population":0,"background":"#dbae9e","_type":"sanity.imagePaletteSwatch"}}},"uploadId":"ow8Gv8Np3Nj1GOIUCHMbYvdmmOqXIgMk","_rev":"0atQJUC04BTO87jLlB2QZm","mimeType":"image/jpeg","sha1hash":"74682bc40139d223bd547d491e60f19bbf4a7a89","assetId":"74682bc40139d223bd547d491e60f19bbf4a7a89"}},"url":"spotlight-cilta-cel-shows-sustained-mrd-negativity-leads-to-prolonged-pfs-in-multiple-myeloma","published":"2025-01-09T00:20:00.000Z","factCheckBy":[{"displayName":"Pearl Steinzor","firstName":"Pearl ","lastName":"Steinzor","url":{"_type":"slug","current":"pearl-steinzor"},"profileImage":{"_type":"mainImage","alt":"Pearl Steinzor","asset":{"_ref":"image-aaad3972f041cf080c4994a923d62017c74f0ac3-512x512-jpg","_type":"reference"}},"biography":null,"showSocialShare":null}],"_id":"e7f1792f-598b-4b39-a6aa-40177d13717c"},{"issueGroup":{"_ref":"020f348b-83bc-4402-8a0e-56dfd206392b","_type":"reference"},"title":"The High Cost of Shortages of Low-Cost Chemotherapy","url":"the-high-cost-of-shortages-of-low-cost-chemotherapy","published":"2024-12-19T15:00:00.000Z","_id":"261d60f2-d321-4f0c-b80a-b02f3f9da3ba","summary":null,"thumbnail":{"alt":"chemotherapy | Image credit: Penn Medicine","asset":{"_createdAt":"2024-12-19T20:25:38Z","_id":"image-fc90c1bb74fbe4ee2cf001ef6f3c16b51ccacce4-1000x658-png","_type":"sanity.imageAsset","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/fc90c1bb74fbe4ee2cf001ef6f3c16b51ccacce4-1000x658.png","path":"images/0vv8moc6/ajmc/fc90c1bb74fbe4ee2cf001ef6f3c16b51ccacce4-1000x658.png","size":600696,"originalFilename":"CHEMO PENN MEDICINE.png","mimeType":"image/png","metadata":{"isOpaque":true,"blurHash":"VIKnbqx^%M%Mx]_4?b%MIV-=tRogNGxtxaxst7kDozt6","_type":"sanity.imageMetadata","palette":{"_type":"sanity.imagePalette","darkMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":3.26,"background":"#3c3f48"},"muted":{"foreground":"#fff","title":"#fff","population":0.63,"background":"#a98a6a","_type":"sanity.imagePaletteSwatch"},"lightVibrant":{"foreground":"#000","title":"#fff","population":0.07,"background":"#c8b386","_type":"sanity.imagePaletteSwatch"},"darkVibrant":{"population":1.52,"background":"#84723e","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":2.17,"background":"#ccc3af"},"vibrant":{"foreground":"#000","title":"#fff","population":0.08,"background":"#cdbb65","_type":"sanity.imagePaletteSwatch"},"dominant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":3.26,"background":"#3c3f48"}},"hasAlpha":false,"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":1000,"aspectRatio":1.5197568389057752,"height":658}},"sha1hash":"fc90c1bb74fbe4ee2cf001ef6f3c16b51ccacce4","assetId":"fc90c1bb74fbe4ee2cf001ef6f3c16b51ccacce4","extension":"png","_rev":"bAl93RvH29PY4NpeP8EuRS","_updatedAt":"2024-12-19T20:25:38Z","uploadId":"eCMXCsgcAvTQfUHoAFR5Dl14CWyEWapm"},"_type":"mainImage"},"authorDetails":[{"showSocialShare":null,"displayName":"Interview by Mary Caffrey","firstName":null,"lastName":null,"url":{"_type":"slug","current":"interview-by-mary-caffrey"},"profileImage":null,"biography":null}],"factCheckBy":[{"displayName":"Interview by Mary Caffrey","firstName":null,"lastName":null,"url":{"current":"interview-by-mary-caffrey","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null}]},{"_id":"cd895057-d7f7-4dac-9612-731993914702","issueGroup":{"_ref":"b0733662-6367-4a92-b97f-a3f09117b473","_type":"reference"},"thumbnail":{"_type":"mainImage","alt":"Susan Sabo-Wagner, MSN, RN, OCN, NEA-BC, leads the panel. | Image credit: Greg Smit for AJMC","caption":"Susan Sabo-Wagner, MSN, RN, OCN, NEA-BC, leads the panel. | Image credit: Greg Smit for AJMC","asset":{"_type":"sanity.imageAsset","mimeType":"image/jpeg","sha1hash":"e97c1a1352bf0f13d912b5ccefdf27200d11ec6e","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/e97c1a1352bf0f13d912b5ccefdf27200d11ec6e-7974x5319.jpg","metadata":{"isOpaque":true,"blurHash":"VjI=47gO%go}Rj_Nt7%MxuM{o~WYxuafWARjRiaeRjj[","_type":"sanity.imageMetadata","palette":{"dominant":{"title":"#fff","population":4.07,"background":"#987254","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"_type":"sanity.imagePalette","darkMuted":{"population":0.51,"background":"#31395a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"muted":{"title":"#fff","population":4.07,"background":"#987254","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightVibrant":{"foreground":"#000","title":"#000","population":2.13,"background":"#e3c7b2","_type":"sanity.imagePaletteSwatch"},"darkVibrant":{"title":"#fff","population":0.6,"background":"#582911","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightMuted":{"background":"#c7afaf","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.39},"vibrant":{"title":"#fff","population":0.16,"background":"#ca422b","_type":"sanity.imagePaletteSwatch","foreground":"#fff"}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":7974,"aspectRatio":1.4991539763113366,"height":5319}},"_rev":"bAl93RvH29PY4NpeOwJOVS","size":15130898,"_updatedAt":"2024-12-18T16:55:14Z","extension":"jpg","path":"images/0vv8moc6/ajmc/e97c1a1352bf0f13d912b5ccefdf27200d11ec6e-7974x5319.jpg","assetId":"e97c1a1352bf0f13d912b5ccefdf27200d11ec6e","_createdAt":"2024-12-18T16:55:14Z","_id":"image-e97c1a1352bf0f13d912b5ccefdf27200d11ec6e-7974x5319-jpg","uploadId":"zGjhajs8WaevHZzaU0m7jijJUWTk7r4v","originalFilename":"PCOC Day 1-256.jpg"}},"factCheckBy":[{"biography":null,"showSocialShare":null,"displayName":"Pearl Steinzor","firstName":"Pearl ","lastName":"Steinzor","url":{"_type":"slug","current":"pearl-steinzor"},"profileImage":{"_type":"mainImage","alt":"Pearl Steinzor","asset":{"_ref":"image-aaad3972f041cf080c4994a923d62017c74f0ac3-512x512-jpg","_type":"reference"}}}],"authorDetails":[{"firstName":"Pearl ","lastName":"Steinzor","url":{"current":"pearl-steinzor","_type":"slug"},"profileImage":{"_type":"mainImage","alt":"Pearl Steinzor","asset":{"_ref":"image-aaad3972f041cf080c4994a923d62017c74f0ac3-512x512-jpg","_type":"reference"}},"biography":null,"showSocialShare":null,"displayName":"Pearl Steinzor"}],"title":"Navigating Persistent Financial Toxicity in the Patient Experience","summary":null,"url":"navigating-persistent-financial-toxicity-in-the-patient-experience","published":"2024-12-18T16:20:00.000Z"},{"summary":null,"thumbnail":{"_type":"mainImage","alt":"A. Mark Fendrick, MD","asset":{"uploadId":"m7V9XtPiXtYYOT8dK5g5IcA1r8PNnvpB","_rev":"DwR10qWgSie3DjeRpieYPC","_createdAt":"2024-12-18T17:18:30Z","extension":"webp","sha1hash":"822daaa6aa904a352704626ad00be7e21e1e810e","originalFilename":"Mark Fendrick new photo 2017_i.webp","metadata":{"palette":{"darkMuted":{"foreground":"#fff","title":"#fff","population":3.15,"background":"#463837","_type":"sanity.imagePaletteSwatch"},"muted":{"title":"#fff","population":4.75,"background":"#977b73","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightVibrant":{"foreground":"#000","title":"#000","population":0.1,"background":"#f6bbad","_type":"sanity.imagePaletteSwatch"},"darkVibrant":{"foreground":"#fff","title":"#fff","population":0,"background":"#781f0c","_type":"sanity.imagePaletteSwatch"},"lightMuted":{"background":"#c69f95","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":2.05},"vibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.06,"background":"#ee7257"},"dominant":{"population":4.75,"background":"#977b73","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"_type":"sanity.imagePalette"},"hasAlpha":false,"lqip":"data:image/jpeg;base64,/9j/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAAKABQDASIAAhEBAxEB/8QAGAAAAwEBAAAAAAAAAAAAAAAAAAUGBAf/xAAlEAACAQMDAgcAAAAAAAAAAAABAgADBAUGESEScQcTFiI0QsH/xAAVAQEBAAAAAAAAAAAAAAAAAAAEA//EABkRAQADAQEAAAAAAAAAAAAAAAEAAhEDIf/aAAwDAQACEQMRAD8AttL5lBcVbYOUbo6gRzuYuzF/XW8qu9zVY0mDKGXaIdPE+o7fn7CUeU92onDcjymOx7Q6bYI7mlednJmreI6qwBrncDmE5FkvlHt+mEu2RyDKD7P/2Q==","dimensions":{"_type":"sanity.imageDimensions","width":1024,"aspectRatio":2,"height":512},"isOpaque":true,"blurHash":"MNKdJL-U0~9Fn4~qRj%MIUR,yDM{oLa#sS","_type":"sanity.imageMetadata"},"mimeType":"image/webp","size":26588,"assetId":"822daaa6aa904a352704626ad00be7e21e1e810e","_id":"image-822daaa6aa904a352704626ad00be7e21e1e810e-1024x512-webp","_type":"sanity.imageAsset","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/822daaa6aa904a352704626ad00be7e21e1e810e-1024x512.webp","path":"images/0vv8moc6/ajmc/822daaa6aa904a352704626ad00be7e21e1e810e-1024x512.webp","_updatedAt":"2024-12-18T17:18:30Z"}},"published":"2024-12-18T16:15:00.000Z","authorDetails":[{"displayName":"Laura Joszt, MA","firstName":"Laura","lastName":"Joszt","url":{"current":"laura-joszt","_type":"slug"},"profileImage":{"_type":"mainImage","alt":"Laura Joszt headshot","asset":{"_ref":"image-93ea362164e769dfd84dca31a8b2670a1dd9092b-512x512-jpg","_type":"reference"}},"biography":[{"children":[{"_type":"span","marks":[],"text":"Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®’s parent company, MJH Life Sciences®, since 2011.","_key":"67a67d3764f00"}],"_type":"block","style":"normal","_key":"4a950aea97b3","markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/laura-joszt-05ba7116/","_key":"f77b28536a8d"},{"href":"https://twitter.com/joszt","_key":"c419f18a7ffe","_type":"link"}]},{"children":[{"text":"She has an MA in business and economic reporting from New York University. You can connect with Laura on ","_key":"48d199d8ecd5","_type":"span","marks":[]},{"_type":"span","marks":["f77b28536a8d"],"text":"LinkedIn","_key":"67a67d3764f01"},{"_type":"span","marks":[],"text":" or ","_key":"67a67d3764f02"},{"_type":"span","marks":["c419f18a7ffe"],"text":"Twitter","_key":"67a67d3764f03"},{"_type":"span","marks":[],"text":".","_key":"67a67d3764f04"}],"_type":"block","style":"normal","_key":"b28d8058b3d8","markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/laura-joszt-05ba7116/","_key":"f77b28536a8d","nofollow":true,"blank":true},{"nofollow":true,"blank":true,"_type":"link","href":"https://twitter.com/joszt","_key":"c419f18a7ffe"}]}],"showSocialShare":true},{"biography":[{"children":[{"_type":"span","marks":[],"text":"Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (","_key":"9737335da1ed0"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"b8dda18bb0dc"},{"_type":"span","marks":[],"text":"®). She joined AJMC® in 2013 and is the primary staff editor for ","_key":"f56917041c08"},{"text":"Evidence-Based Oncology, ","_key":"8c710bb1d962","_type":"span","marks":["em"]},{"text":"the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for ","_key":"1b94f48924f3","_type":"span","marks":[]},{"text":"AJMC","_key":"3c5f9805f644","_type":"span","marks":["em"]},{"_type":"span","marks":[],"text":"®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for ","_key":"d533ba55a862"},{"text":"AJMC","_key":"953d8c643cce","_type":"span","marks":["em"]},{"text":" readers. ","_key":"182af2348b04","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"80606b0b2412","markDefs":[]},{"_type":"block","style":"normal","_key":"a03d32973d6e","markDefs":[{"_key":"4f88673cb2c4","nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/marykcaffrey/"}],"children":[{"_type":"span","marks":[],"text":"Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on ","_key":"c2027cf5a357"},{"_key":"9737335da1ed1","_type":"span","marks":["4f88673cb2c4"],"text":"LinkedIn"},{"_type":"span","marks":[],"text":".","_key":"9737335da1ed2"}]}],"showSocialShare":null,"displayName":"Mary Caffrey","firstName":null,"lastName":null,"url":{"current":"mary-caffrey","_type":"slug"},"profileImage":null}],"_id":"e50959e8-10ce-479c-840d-6305809f2085","issueGroup":{"_ref":"b0733662-6367-4a92-b97f-a3f09117b473","_type":"reference"},"title":"SPOTLIGHT: “I Didn’t Go to Med School to Learn How to Save People Money”","url":"spotlight-i-didn-t-go-to-med-school-to-learn-how-to-save-people-money-","factCheckBy":[{"profileImage":{"_type":"mainImage","alt":"Laura Joszt headshot","asset":{"_ref":"image-93ea362164e769dfd84dca31a8b2670a1dd9092b-512x512-jpg","_type":"reference"}},"biography":[{"_type":"block","style":"normal","_key":"4a950aea97b3","markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/laura-joszt-05ba7116/","_key":"f77b28536a8d"},{"_type":"link","href":"https://twitter.com/joszt","_key":"c419f18a7ffe"}],"children":[{"_type":"span","marks":[],"text":"Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®’s parent company, MJH Life Sciences®, since 2011.","_key":"67a67d3764f00"}]},{"_type":"block","style":"normal","_key":"b28d8058b3d8","markDefs":[{"href":"https://www.linkedin.com/in/laura-joszt-05ba7116/","_key":"f77b28536a8d","nofollow":true,"blank":true,"_type":"link"},{"_key":"c419f18a7ffe","nofollow":true,"blank":true,"_type":"link","href":"https://twitter.com/joszt"}],"children":[{"_type":"span","marks":[],"text":"She has an MA in business and economic reporting from New York University. You can connect with Laura on ","_key":"48d199d8ecd5"},{"_type":"span","marks":["f77b28536a8d"],"text":"LinkedIn","_key":"67a67d3764f01"},{"text":" or ","_key":"67a67d3764f02","_type":"span","marks":[]},{"_type":"span","marks":["c419f18a7ffe"],"text":"Twitter","_key":"67a67d3764f03"},{"text":".","_key":"67a67d3764f04","_type":"span","marks":[]}]}],"showSocialShare":true,"displayName":"Laura Joszt, MA","firstName":"Laura","lastName":"Joszt","url":{"current":"laura-joszt","_type":"slug"}},{"url":{"current":"mary-caffrey","_type":"slug"},"profileImage":null,"biography":[{"children":[{"_key":"9737335da1ed0","_type":"span","marks":[],"text":"Mary Caffrey is the Executive Editor for The American Journal of Managed Care® ("},{"_type":"span","marks":["em"],"text":"AJMC","_key":"b8dda18bb0dc"},{"text":"®). She joined AJMC® in 2013 and is the primary staff editor for ","_key":"f56917041c08","_type":"span","marks":[]},{"_type":"span","marks":["em"],"text":"Evidence-Based Oncology, ","_key":"8c710bb1d962"},{"text":"the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for ","_key":"1b94f48924f3","_type":"span","marks":[]},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3c5f9805f644"},{"_type":"span","marks":[],"text":"®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for ","_key":"d533ba55a862"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"953d8c643cce"},{"_key":"182af2348b04","_type":"span","marks":[],"text":" readers. "}],"_type":"block","style":"normal","_key":"80606b0b2412","markDefs":[]},{"style":"normal","_key":"a03d32973d6e","markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/marykcaffrey/","_key":"4f88673cb2c4"}],"children":[{"_type":"span","marks":[],"text":"Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on ","_key":"c2027cf5a357"},{"marks":["4f88673cb2c4"],"text":"LinkedIn","_key":"9737335da1ed1","_type":"span"},{"marks":[],"text":".","_key":"9737335da1ed2","_type":"span"}],"_type":"block"}],"showSocialShare":null,"displayName":"Mary Caffrey","firstName":null,"lastName":null}]},{"summary":null,"url":"spotlight-sarah-hogue-pharmd-on-expanding-the-role-of-oncology-pharmacists","authorDetails":[{"displayName":"Cameron Santoro","firstName":"Cameron","lastName":"Santoro","url":{"_type":"slug","current":"cameron-santoro"},"profileImage":{"asset":{"_ref":"image-6ae51a61642a5ecba7cf4085fe97e68814e3c917-430x430-png","_type":"reference"},"_type":"mainImage","alt":"Cameron Santoro"},"biography":[{"_type":"block","style":"normal","_key":"3da8fced8696","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Cameron Santoro is an associate editor for ","_key":"93662c5c4cfd"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"213c257c1eca"},{"_key":"f546acb0aa91","_type":"span","marks":["superscript"],"text":"®"},{"_type":"span","marks":[],"text":" (","_key":"acd931edd707"},{"_key":"843f7d4e787d","_type":"span","marks":["em"],"text":"AJMC"},{"_type":"span","marks":["superscript"],"text":"®","_key":"7c809e803edb"},{"_type":"span","marks":[],"text":"), AJMC.com, and The Center for Biosimilars","_key":"35b69a01dbbe"},{"_type":"span","marks":["superscript"],"text":"®","_key":"8ddca200bc46"},{"_type":"span","marks":[],"text":".","_key":"ba3cca6122e3"}]}],"showSocialShare":null}],"factCheckBy":[{"url":{"current":"cameron-santoro","_type":"slug"},"profileImage":{"_type":"mainImage","alt":"Cameron Santoro","asset":{"_ref":"image-6ae51a61642a5ecba7cf4085fe97e68814e3c917-430x430-png","_type":"reference"}},"biography":[{"style":"normal","_key":"3da8fced8696","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Cameron Santoro is an associate editor for ","_key":"93662c5c4cfd"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"213c257c1eca"},{"_type":"span","marks":["superscript"],"text":"®","_key":"f546acb0aa91"},{"_type":"span","marks":[],"text":" (","_key":"acd931edd707"},{"_key":"843f7d4e787d","_type":"span","marks":["em"],"text":"AJMC"},{"_type":"span","marks":["superscript"],"text":"®","_key":"7c809e803edb"},{"_type":"span","marks":[],"text":"), AJMC.com, and The Center for Biosimilars","_key":"35b69a01dbbe"},{"text":"®","_key":"8ddca200bc46","_type":"span","marks":["superscript"]},{"_type":"span","marks":[],"text":".","_key":"ba3cca6122e3"}],"_type":"block"}],"showSocialShare":null,"displayName":"Cameron Santoro","firstName":"Cameron","lastName":"Santoro"}],"_id":"566e44be-5a20-4b15-8a06-e36cb8b51fc7","title":"SPOTLIGHT: Sarah Hogue, PharmD, on Expanding the Role of Oncology Pharmacists","published":"2024-12-18T16:11:00.000Z","issueGroup":{"_ref":"b0733662-6367-4a92-b97f-a3f09117b473","_type":"reference"},"thumbnail":{"asset":{"_createdAt":"2024-12-18T19:33:19Z","size":178571,"sha1hash":"79fb2408a93301e41fdf9845653bd0f85247e02f","assetId":"79fb2408a93301e41fdf9845653bd0f85247e02f","metadata":{"dimensions":{"_type":"sanity.imageDimensions","width":1402,"aspectRatio":1,"height":1402},"isOpaque":true,"blurHash":"ePM=?+5Y~NIS,mWrID$*%2WF?DxqxV?FNbxVRQxaxaWDWCoKRkofR,","_type":"sanity.imageMetadata","palette":{"dominant":{"foreground":"#fff","title":"#fff","population":7.29,"background":"#c27813","_type":"sanity.imagePaletteSwatch"},"_type":"sanity.imagePalette","darkMuted":{"background":"#564636","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.41},"muted":{"foreground":"#fff","title":"#fff","population":2.62,"background":"#8a6d5a","_type":"sanity.imagePaletteSwatch"},"lightVibrant":{"background":"#fcc774","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":2.15},"darkVibrant":{"population":7.29,"background":"#c27813","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightMuted":{"title":"#fff","population":5.76,"background":"#d7b9a7","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"vibrant":{"title":"#fff","population":3.96,"background":"#e8c807","_type":"sanity.imagePaletteSwatch","foreground":"#000"}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,/9j/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAAUABQDASIAAhEBAxEB/8QAGgABAAIDAQAAAAAAAAAAAAAAAAMEAQUGCP/EACMQAAEDAwQDAQEAAAAAAAAAAAECAwQABQYREiExEyNBFGH/xAAXAQEBAQEAAAAAAAAAAAAAAAAFBAEC/8QAIBEAAgECBwEAAAAAAAAAAAAAAAECA1EEERITITHBBf/aAAwDAQACEQMRAD8AmyeTHzLIXrJIlrYtcM+3ZxvX8FV8XvKMOyyPbG5jr9olHwJSs6+JfymG2mVactv0SZGUsPr/AEMPuJ1SoD+1pMsiSZ13tUaLGUViYHHHGhwnnvWgZ7SpQgumvBumnLVN9noBazu4NKiQCltCVHUhIBNKGyRQik37GXErAI29/a5O7R247SyyCk7ux3SlZgOflRbs/TmlxVeRm3XmamMEl3dodAVDU0pShtydy/SrH//Z"},"uploadId":"B7ctqdgDqDdcHBKDxYYrFhHh9susWYi0","_type":"sanity.imageAsset","mimeType":"image/jpeg","_id":"image-79fb2408a93301e41fdf9845653bd0f85247e02f-1402x1402-jpg","_updatedAt":"2024-12-18T19:33:19Z","originalFilename":"SHogue Headshot.JPG","extension":"jpg","_rev":"bAl93RvH29PY4NpeOyHPDS","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/79fb2408a93301e41fdf9845653bd0f85247e02f-1402x1402.jpg","path":"images/0vv8moc6/ajmc/79fb2408a93301e41fdf9845653bd0f85247e02f-1402x1402.jpg"},"_type":"mainImage","alt":"Sarah Hogue, PharmD | Image credit: photo provided by Hogue"}},{"issueGroup":{"_ref":"336c2bd9-8d6c-4558-8bd3-24df074cf426","_type":"reference"},"published":"2024-12-17T14:00:00.000Z","authorDetails":[{"lastName":"Marcus","url":{"_type":"slug","current":"roy-g-marcus-md"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Roy G. Marcus, MD","firstName":"Roy"},{"url":{"current":"david-m-miller-mba","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"David M. Miller, MBA","firstName":"David","lastName":"Miller"},{"url":{"current":"brian-h-nathanson-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Brian H. Nathanson, PhD","firstName":"Brian","lastName":"Nathanson"},{"displayName":"Douglas Eckhardt, MBA","firstName":"Douglas","lastName":"Eckhardt","url":{"current":"douglas-eckhardt-mba","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"showSocialShare":null,"displayName":"Steven Henry, PharmD","firstName":"Steven","lastName":"Henry","url":{"current":"steven-henry-pharmd","_type":"slug"},"profileImage":null,"biography":null},{"displayName":"Katherine Kwon, MD","firstName":"Katherine","lastName":"Kwon","url":{"current":"katherine-kwon-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"biography":null,"showSocialShare":null,"displayName":"Rohit Sharma, MD","firstName":"Rohit","lastName":"Sharma","url":{"current":"rohit-sharma-md","_type":"slug"},"profileImage":null},{"firstName":"Nirav","lastName":"Vakharia","url":{"current":"nirav-vakharia-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Nirav Vakharia, MD"}],"_id":"d38be53d-4528-46a4-bccc-0e2417cb289b","summary":"The authors observed a significant increase in optimal starts for dialysis and in peritoneal dialysis rates after implementing a standardized end-stage renal disease transition pathway.","thumbnail":{"_type":"mainImage","alt":"AJMC","asset":{"sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","mimeType":"image/png","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","metadata":{"exif":{"_type":"sanity.imageExifMetadata","PixelXDimension":778,"PixelYDimension":382},"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata","palette":{"darkMuted":{"population":0.71,"background":"#37536a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"muted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.38,"background":"#628cad"},"lightVibrant":{"foreground":"#000","title":"#000","population":0.93,"background":"#cae1f2","_type":"sanity.imagePaletteSwatch"},"darkVibrant":{"title":"#fff","population":0.09,"background":"#044679","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightMuted":{"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26},"vibrant":{"title":"#fff","population":0.52,"background":"#18568d","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"dominant":{"foreground":"#000","title":"#fff","population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch"},"_type":"sanity.imagePalette"},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":778,"aspectRatio":2.0366492146596857,"height":382}},"url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","size":203185,"_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","_updatedAt":"2023-07-11T20:45:56Z","_type":"sanity.imageAsset","_rev":"hiKH9HIKxNVM35TxYdonKh","assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","_createdAt":"2023-07-11T20:45:56Z","originalFilename":"AJMC_logo_NEW.png","extension":"png"}},"url":"a-standardized-care-pathway-increases-optimal-dialysis-starts","factCheckBy":[{"biography":null,"showSocialShare":null,"displayName":"Roy G. Marcus, MD","firstName":"Roy","lastName":"Marcus","url":{"current":"roy-g-marcus-md","_type":"slug"},"profileImage":null},{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"David M. Miller, MBA","firstName":"David","lastName":"Miller","url":{"current":"david-m-miller-mba","_type":"slug"}},{"displayName":"Brian H. Nathanson, PhD","firstName":"Brian","lastName":"Nathanson","url":{"_type":"slug","current":"brian-h-nathanson-phd"},"profileImage":null,"biography":null,"showSocialShare":null},{"displayName":"Douglas Eckhardt, MBA","firstName":"Douglas","lastName":"Eckhardt","url":{"current":"douglas-eckhardt-mba","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"showSocialShare":null,"displayName":"Steven Henry, PharmD","firstName":"Steven","lastName":"Henry","url":{"current":"steven-henry-pharmd","_type":"slug"},"profileImage":null,"biography":null},{"firstName":"Katherine","lastName":"Kwon","url":{"current":"katherine-kwon-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Katherine Kwon, MD"},{"firstName":"Rohit","lastName":"Sharma","url":{"current":"rohit-sharma-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Rohit Sharma, MD"},{"biography":null,"showSocialShare":null,"displayName":"Nirav Vakharia, MD","firstName":"Nirav","lastName":"Vakharia","url":{"current":"nirav-vakharia-md","_type":"slug"},"profileImage":null}],"title":"A Standardized Care Pathway Increases Optimal Dialysis Starts"},{"issueGroup":{"_ref":"336c2bd9-8d6c-4558-8bd3-24df074cf426","_type":"reference"},"published":"2024-12-16T17:00:00.000Z","authorDetails":[{"url":{"current":"jingjing-qian-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Jingjing Qian, PhD","firstName":"Jingjing","lastName":"Qian"}],"_id":"5a821cca-ecbc-492b-b96a-f79fac509885","summary":"Significant uptake of rituximab biosimilars in Medicare and Medicaid occurred within the first 4 years of marketing in the US.","thumbnail":{"_type":"mainImage","alt":"AJMC","asset":{"uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","mimeType":"image/png","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","metadata":{"palette":{"darkVibrant":{"background":"#044679","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.09},"lightMuted":{"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26},"vibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.52,"background":"#18568d"},"dominant":{"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26},"_type":"sanity.imagePalette","darkMuted":{"title":"#fff","population":0.71,"background":"#37536a","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"muted":{"background":"#628cad","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.38},"lightVibrant":{"foreground":"#000","title":"#000","population":0.93,"background":"#cae1f2","_type":"sanity.imagePaletteSwatch"}},"hasAlpha":true,"lqip":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABQAAAAKCAYAAAC0VX7mAAAACXBIWXMAABYlAAAWJQFJUiTwAAABxklEQVQoka2STW/aQBCG+f/qLZdeqkrpoQqpWiIlCk2BhKCEErAxRXGMnQ8wJoAxGMyX7fX6rWbSpqXnWlrN7M7sszPvOAMAaZrif32Z3zCySSKRSIlYJFhtQgTrLVbbCNsohpQSUqYIY8ErigU2YYxNGPGe7hHjFUiHjutj6C0w8ZfQLAeK0UPTtKF2bEwXK8yCNZ+3LAd6d4iOPcbjYIKB63MBO0BvvkSxYaDctHDvuCg0DJzd3OHsRsd+voaG0UP7YYAP+Rren1RxVGnxfjDxMZousN5GL0CCiSRhSLakIFtU0DT7DL9QTVy1HxiQLan4WtPxNlfBm48FHBQVPHtzloIkIvsLmMIP1tzWafUWh+cqCnUD+e+3KCkd1PQnfC5reHd8zRCye58u+IHucMoaU7ukP7EyJHR/PENd76J173CrhyUVuUsN52oH1fYjyk2TK6b1pazhqPKDH9OsPkx7zPfDKH6ZMpVK+tnjGVw/YGjusoVv9TsYvRG6Q48vTOZL1srqu1wZ+aQfDZKGRbJxhdS3SCSESFiL0TRgsZ+ePRaaziiZ8qgbyqP2yCdLMfIpvjPl139RSkRCcPK/sT/7v/3d+E98j+pE3hWucAAAAABJRU5ErkJggg==","dimensions":{"_type":"sanity.imageDimensions","width":778,"aspectRatio":2.0366492146596857,"height":382},"exif":{"_type":"sanity.imageExifMetadata","PixelXDimension":778,"PixelYDimension":382},"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata"},"url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","size":203185,"_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","_updatedAt":"2023-07-11T20:45:56Z","_type":"sanity.imageAsset","_rev":"hiKH9HIKxNVM35TxYdonKh","assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","_createdAt":"2023-07-11T20:45:56Z","originalFilename":"AJMC_logo_NEW.png","extension":"png","sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6"}},"url":"uptake-of-rituximab-biosimilars-in-medicare-and-medicaid-in-2019-2022","factCheckBy":[{"displayName":"Jingjing Qian, PhD","firstName":"Jingjing","lastName":"Qian","url":{"_type":"slug","current":"jingjing-qian-phd"},"profileImage":null,"biography":null,"showSocialShare":null}],"title":"Uptake of Rituximab Biosimilars in Medicare and Medicaid in 2019-2022"},{"thumbnail":{"_type":"mainImage","asset":{"size":203185,"_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","_updatedAt":"2023-07-11T20:45:56Z","_type":"sanity.imageAsset","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","_createdAt":"2023-07-11T20:45:56Z","originalFilename":"AJMC_logo_NEW.png","extension":"png","_rev":"hiKH9HIKxNVM35TxYdonKh","sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","mimeType":"image/png","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","metadata":{"_type":"sanity.imageMetadata","palette":{"muted":{"background":"#628cad","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.38},"lightVibrant":{"background":"#cae1f2","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":0.93},"darkVibrant":{"population":0.09,"background":"#044679","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26,"background":"#9bb7cc"},"vibrant":{"foreground":"#fff","title":"#fff","population":0.52,"background":"#18568d","_type":"sanity.imagePaletteSwatch"},"dominant":{"population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"_type":"sanity.imagePalette","darkMuted":{"title":"#fff","population":0.71,"background":"#37536a","_type":"sanity.imagePaletteSwatch","foreground":"#fff"}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":778,"aspectRatio":2.0366492146596857,"height":382},"exif":{"_type":"sanity.imageExifMetadata","PixelXDimension":778,"PixelYDimension":382},"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj"},"uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT"}},"url":"addressing-stis-through-managed-care-opportunities-in-medicaid-and-beyond","published":"2024-12-16T14:00:00.000Z","issueGroup":{"_ref":"336c2bd9-8d6c-4558-8bd3-24df074cf426","_type":"reference"},"summary":"Medicaid and other managed care organizations could take several key steps to respond to the sexually transmitted infection (STI) epidemic in the US, including congenital syphilis.","authorDetails":[{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Naomi Seiler, JD","firstName":"Naomi","lastName":"Seiler","url":{"current":"naomi-seiler-jd","_type":"slug"}},{"biography":null,"showSocialShare":null,"displayName":"Katie Horton, JD, RN, MPH","firstName":"Katie","lastName":"Horton","url":{"current":"katie-horton-jd-rn-mph","_type":"slug"},"profileImage":null},{"showSocialShare":null,"displayName":"Paige Organick-Lee, MPH","firstName":"Paige","lastName":"Organick-Lee","url":{"current":"paige-organick-lee-mph","_type":"slug"},"profileImage":null,"biography":null},{"firstName":"Mekhi","lastName":"Washington","url":{"current":"mekhi-washington-bs","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Mekhi Washington, BS"},{"displayName":"Taylor Turner, MPH","firstName":"Taylor","lastName":"Turner","url":{"current":"taylor-turner-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"displayName":"William S. Pearson, PhD, MHA","firstName":"William","lastName":"Pearson","url":{"current":"william-s-pearson-phd-mha","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null}],"factCheckBy":[{"biography":null,"showSocialShare":null,"displayName":"Naomi Seiler, JD","firstName":"Naomi","lastName":"Seiler","url":{"current":"naomi-seiler-jd","_type":"slug"},"profileImage":null},{"displayName":"Katie Horton, JD, RN, MPH","firstName":"Katie","lastName":"Horton","url":{"current":"katie-horton-jd-rn-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Paige Organick-Lee, MPH","firstName":"Paige","lastName":"Organick-Lee","url":{"current":"paige-organick-lee-mph","_type":"slug"}},{"displayName":"Mekhi Washington, BS","firstName":"Mekhi","lastName":"Washington","url":{"current":"mekhi-washington-bs","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"showSocialShare":null,"displayName":"Taylor Turner, MPH","firstName":"Taylor","lastName":"Turner","url":{"current":"taylor-turner-mph","_type":"slug"},"profileImage":null,"biography":null},{"displayName":"William S. Pearson, PhD, MHA","firstName":"William","lastName":"Pearson","url":{"current":"william-s-pearson-phd-mha","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null}],"_id":"a4a004f4-c13e-4e82-9b80-c57f6a1b3bfd","title":"Addressing STIs Through Managed Care: Opportunities in Medicaid and Beyond"},{"_id":"1b2f775c-eb1e-4c9d-aab4-b9c0796cb0e2","issueGroup":{"_ref":"5c3d9b93-74e5-4e58-915c-ae8f5885c9b7","_type":"reference"},"title":"Transforming Kidney Care: Policy, Risk Stratification, and Collaborative Models","summary":"Experts at a recent Institute for Value-Based Medicine event emphasized the importance of early intervention, policy innovation, and proactive collaboration to transform the management of kidney disease and optimize patient outcomes. ","url":"transforming-kidney-care-policy-risk-stratification-and-collaborative-models","published":"2024-12-12T18:00:00.000Z","factCheckBy":[{"displayName":"Kyle Munz","firstName":"Kyle","lastName":"Munz","url":{"current":"kyle-munz","_type":"slug"},"profileImage":{"alt":"Kyle Munz","asset":{"_ref":"image-afb5da0a933e7f6f632d76cd52a5bc1c1243fb36-430x430-png","_type":"reference"},"_type":"mainImage"},"biography":null,"showSocialShare":null}],"thumbnail":{"_type":"mainImage","alt":"Park City Utah | Image Credit: © SeanPavonePhoto - stock.adobe.com","asset":{"mimeType":"image/jpeg","path":"images/0vv8moc6/ajmc/d79c993ad4d9e3983bc0d532aad3e304b33becd6-1200x800.jpg","_updatedAt":"2024-12-09T16:14:43Z","uploadId":"HbuqVrHWM61ym51aODEQvln7RdZOo3Y9","size":684667,"_createdAt":"2024-12-09T16:14:43Z","_id":"image-d79c993ad4d9e3983bc0d532aad3e304b33becd6-1200x800-jpg","extension":"jpg","sha1hash":"d79c993ad4d9e3983bc0d532aad3e304b33becd6","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/d79c993ad4d9e3983bc0d532aad3e304b33becd6-1200x800.jpg","metadata":{"hasAlpha":false,"lqip":"data:image/jpeg;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":1200,"aspectRatio":1.5,"height":800},"exif":{"ISO":64,"LensSpecification":[70,200,2.8,2.8],"ExposureBiasValue":0,"MaxApertureValue":2.9708536585365852,"SubSecTimeOriginal":"72","PixelXDimension":1200,"FocalLength":70,"FocalPlaneYResolution":2301.324607329843,"DateTimeOriginal":"2019-09-30T07:53:48.000Z","DateTimeDigitized":"2019-09-30T07:53:48.000Z","SubjectDistanceRange":0,"SceneCaptureType":0,"PixelYDimension":800,"ExposureMode":1,"MeteringMode":5,"GainControl":0,"FocalPlaneXResolution":2301.324607329843,"Contrast":0,"Sharpness":1,"SubSecTimeDigitized":"72","FocalPlaneResolutionUnit":3,"SensingMethod":2,"Saturation":0,"WhiteBalance":1,"SensitivityType":2,"ExposureTime":72,"_type":"sanity.imageExifMetadata","BodySerialNumber":"3009697","FocalLengthIn35mmFormat":70,"RecommendedExposureIndex":64,"ShutterSpeedValue":-6.169924996926103,"ExposureProgram":1,"FNumber":11,"ColorSpace":1,"ApertureValue":6.9188632619439865,"LensModel":"70.0-200.0 mm f/2.8","LightSource":9,"CustomRendered":0},"isOpaque":true,"blurHash":"VbGt,K%NbvogW;-@o~s;xFofxbSiR*s9jvRjNIR*R*bI","_type":"sanity.imageMetadata","palette":{"_type":"sanity.imagePalette","darkMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":6.52,"background":"#55402b"},"muted":{"title":"#fff","population":6.15,"background":"#8c7298","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightVibrant":{"population":5.57,"background":"#db8a8b","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.09,"background":"#531914"},"lightMuted":{"population":1.88,"background":"#baacda","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"vibrant":{"background":"#ce742b","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.86},"dominant":{"foreground":"#fff","title":"#fff","population":6.52,"background":"#55402b","_type":"sanity.imagePaletteSwatch"}}},"_rev":"NpDlOLwo2XgOWDaMKGnmaJ","_type":"sanity.imageAsset","assetId":"d79c993ad4d9e3983bc0d532aad3e304b33becd6","originalFilename":"Park City Utah - SeanPavonePhoto - stock.adobe.com.jpeg"}},"authorDetails":[{"firstName":"Kyle","lastName":"Munz","url":{"current":"kyle-munz","_type":"slug"},"profileImage":{"_type":"mainImage","alt":"Kyle Munz","asset":{"_type":"reference","_ref":"image-afb5da0a933e7f6f632d76cd52a5bc1c1243fb36-430x430-png"}},"biography":null,"showSocialShare":null,"displayName":"Kyle Munz"}]},{"summary":"Recent discussions at an Institute for Value-Based Medicine event highlighted the significant potential of biosimilars in reshaping the health care landscape, despite facing considerable barriers to adoption.","url":"from-approval-to-practice-addressing-the-hurdles-in-biosimilar-integration","published":"2024-12-12T17:00:00.000Z","_id":"f802c956-5821-427f-8529-cd5ac1bf6b46","issueGroup":{"_ref":"5c3d9b93-74e5-4e58-915c-ae8f5885c9b7","_type":"reference"},"title":"From Approval to Practice: Addressing the Hurdles in Biosimilar Integration","thumbnail":{"_type":"mainImage","alt":"Seattle Washington skyline | Image Credit: © espiegle - stock.adobe.com","asset":{"sha1hash":"50d700b88aa9af2c75864177d43c5651d055284b","assetId":"50d700b88aa9af2c75864177d43c5651d055284b","uploadId":"720OvtZqjd5bfGGG0HMUoxl39Z5gnaIE","_rev":"Wk5bXdTaWvRA2U061yIUpH","_id":"image-50d700b88aa9af2c75864177d43c5651d055284b-1200x697-jpg","_type":"sanity.imageAsset","path":"images/0vv8moc6/ajmc/50d700b88aa9af2c75864177d43c5651d055284b-1200x697.jpg","size":691007,"_createdAt":"2024-12-09T16:08:58Z","originalFilename":"Seattle Washington skyline - espiegle - stock.adobe.com.jpeg","extension":"jpg","metadata":{"_type":"sanity.imageMetadata","palette":{"lightVibrant":{"population":0.07,"background":"#8fb9e4","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"darkVibrant":{"population":1.59,"background":"#53590e","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightMuted":{"foreground":"#000","title":"#fff","population":8.22,"background":"#d1c4b3","_type":"sanity.imagePaletteSwatch"},"vibrant":{"title":"#fff","population":4.04,"background":"#1775d9","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"dominant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":8.35,"background":"#565e2e"},"_type":"sanity.imagePalette","darkMuted":{"background":"#565e2e","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":8.35},"muted":{"background":"#92ac4f","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.04}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":1200,"aspectRatio":1.721664275466284,"height":697},"isOpaque":true,"blurHash":"M%DAo?fkWBofWBTOj]j?WWj?IXa~oKayj["},"mimeType":"image/jpeg","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/50d700b88aa9af2c75864177d43c5651d055284b-1200x697.jpg","_updatedAt":"2024-12-09T16:08:58Z"}},"authorDetails":[{"profileImage":{"_type":"mainImage","asset":{"_ref":"image-eca9090f66344b90a493123dfc0035ae7b6b1976-800x800-jpg","_type":"reference"}},"biography":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Skylar is an associate editor for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®, and joined AJMC® in 2020. She is responsible for covering all aspects of the ever-changing global biosimilar industry and produces content that is accessible and informative for all health care stakeholders.","_key":"6fba991875ae0"}],"_type":"block","style":"normal","_key":"f73a10e9267d"},{"style":"normal","_key":"95aad26356ef","markDefs":[{"blank":true,"_type":"link","href":"https://www.linkedin.com/in/skylar-jeremias-0b8879116/","_key":"510f2efa56c7","nofollow":true}],"children":[{"_type":"span","marks":[],"text":"She has a BA in journalism and media studies from Rutgers University. You can connect with Skylar on ","_key":"8bc8c321c24e"},{"_type":"span","marks":["510f2efa56c7"],"text":"LinkedIn","_key":"6fba991875ae1"},{"_type":"span","marks":[],"text":".","_key":"6fba991875ae2"}],"_type":"block"}],"showSocialShare":null,"displayName":"Skylar Jeremias","firstName":null,"lastName":null,"url":{"current":"skylar-jeremias","_type":"slug"}}],"factCheckBy":[{"firstName":null,"lastName":null,"url":{"current":"skylar-jeremias","_type":"slug"},"profileImage":{"_type":"mainImage","asset":{"_ref":"image-eca9090f66344b90a493123dfc0035ae7b6b1976-800x800-jpg","_type":"reference"}},"biography":[{"style":"normal","_key":"f73a10e9267d","markDefs":[],"children":[{"_key":"6fba991875ae0","_type":"span","marks":[],"text":"Skylar is an associate editor for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®, and joined AJMC® in 2020. She is responsible for covering all aspects of the ever-changing global biosimilar industry and produces content that is accessible and informative for all health care stakeholders."}],"_type":"block"},{"_key":"95aad26356ef","markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/skylar-jeremias-0b8879116/","_key":"510f2efa56c7","nofollow":true,"blank":true}],"children":[{"marks":[],"text":"She has a BA in journalism and media studies from Rutgers University. You can connect with Skylar on ","_key":"8bc8c321c24e","_type":"span"},{"_key":"6fba991875ae1","_type":"span","marks":["510f2efa56c7"],"text":"LinkedIn"},{"text":".","_key":"6fba991875ae2","_type":"span","marks":[]}],"_type":"block","style":"normal"}],"showSocialShare":null,"displayName":"Skylar Jeremias"}]},{"summary":"At an Institute for Value-Based Medicine® event held in Aurora, Colorado, experts discussed strategies to improve patient outcomes and manage health care costs in neurological diseases. ","thumbnail":{"_type":"mainImage","alt":"Aurora Colorado aerial | Image Credit: © Jacob - stock.adobe.com","asset":{"_type":"sanity.imageAsset","mimeType":"image/jpeg","_id":"image-e795e86678821e21c6aef5cf087bc961b2661488-1200x799-jpg","originalFilename":"Aurora Colorado aerial - Jacob - stock.adobe.com.jpeg","sha1hash":"e795e86678821e21c6aef5cf087bc961b2661488","path":"images/0vv8moc6/ajmc/e795e86678821e21c6aef5cf087bc961b2661488-1200x799.jpg","size":792084,"_createdAt":"2024-12-09T16:01:02Z","extension":"jpg","uploadId":"hDCo0dHvoUsJtwqc6XFChcP57mr0GYWo","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/e795e86678821e21c6aef5cf087bc961b2661488-1200x799.jpg","assetId":"e795e86678821e21c6aef5cf087bc961b2661488","metadata":{"location":{"alt":1846,"lat":39.63568055555555,"lng":-104.88007777777777,"_type":"geopoint"},"hasAlpha":false,"lqip":"data:image/jpeg;base64,/9j/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAANABQDASIAAhEBAxEB/8QAFwAAAwEAAAAAAAAAAAAAAAAAAAQGBf/EACIQAAIBBAEEAwAAAAAAAAAAAAECAAMEBREhBhIUMUFRYv/EABYBAQEBAAAAAAAAAAAAAAAAAAMAAv/EABwRAAEFAAMAAAAAAAAAAAAAAAEAAgQFIRVRUv/aAAwDAQACEQMRAD8AWt+ocWQKb4s7+uIvd5XC1A2scQR+pBWV1UYM5PK+o75BentlBJ59ydcSmnChFfGcNat0nHVj3pbKoPwX1CStdy9ViCVA40DCMLmZ2scXG8r/2Q==","dimensions":{"aspectRatio":1.5018773466833542,"height":799,"_type":"sanity.imageDimensions","width":1200},"isOpaque":true,"exif":{"MeteringMode":2,"WhiteBalance":0,"ExposureMode":1,"PixelXDimension":1200,"DateTimeOriginal":"2021-10-22T12:38:25.000Z","ColorSpace":1,"SceneCaptureType":0,"ISO":100,"_type":"sanity.imageExifMetadata","FocalLength":10.3,"ExposureBiasValue":0,"Contrast":0,"ExposureTime":0.01,"LensSpecification":[28,28,2.8,11],"ShutterSpeedValue":6.643856143856143,"GainControl":0,"PixelYDimension":799,"ApertureValue":6.9188632619439865,"FNumber":11,"MaxApertureValue":2.9708536585365852,"ExposureProgram":1,"BodySerialNumber":"0K8TFB50024243","DateTimeDigitized":"2021-10-22T12:38:25.000Z","Flash":0,"DigitalZoomRatio":1,"Saturation":0,"FocalLengthIn35mmFormat":28,"Sharpness":0,"LightSource":1},"_type":"sanity.imageMetadata","palette":{"darkVibrant":{"population":0.03,"background":"#054cac","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightMuted":{"title":"#fff","population":0.11,"background":"#ada8bc","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"vibrant":{"background":"#0a71c4","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":3.59},"dominant":{"foreground":"#fff","title":"#fff","population":5.03,"background":"#938a66","_type":"sanity.imagePaletteSwatch"},"_type":"sanity.imagePalette","darkMuted":{"title":"#fff","population":0.95,"background":"#343f53","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"muted":{"foreground":"#fff","title":"#fff","population":5.03,"background":"#938a66","_type":"sanity.imagePaletteSwatch"},"lightVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.11,"background":"#7da9ec"}},"blurHash":"VtBzqmogR*a}aypMofaxa#ayS+j[jZj[ayRkfkj?fPjs"},"_rev":"Wk5bXdTaWvRA2U061yEwr7","_updatedAt":"2024-12-09T16:01:02Z"}},"authorDetails":[{"showSocialShare":null,"displayName":"Pearl Steinzor","firstName":"Pearl ","lastName":"Steinzor","url":{"current":"pearl-steinzor","_type":"slug"},"profileImage":{"_type":"mainImage","alt":"Pearl Steinzor","asset":{"_ref":"image-aaad3972f041cf080c4994a923d62017c74f0ac3-512x512-jpg","_type":"reference"}},"biography":null}],"title":"Navigating the Complexities of Neurological Drug Access","issueGroup":{"_ref":"5c3d9b93-74e5-4e58-915c-ae8f5885c9b7","_type":"reference"},"url":"navigating-the-complexities-of-neurological-drug-access","published":"2024-12-12T16:00:00.000Z","factCheckBy":[{"displayName":"Pearl Steinzor","firstName":"Pearl ","lastName":"Steinzor","url":{"_type":"slug","current":"pearl-steinzor"},"profileImage":{"_type":"mainImage","alt":"Pearl Steinzor","asset":{"_ref":"image-aaad3972f041cf080c4994a923d62017c74f0ac3-512x512-jpg","_type":"reference"}},"biography":null,"showSocialShare":null}],"_id":"07739c7a-2ab2-4136-9387-b461d01ee7d6"},{"_id":"04159ba8-44f9-40b5-b25f-0ae627881e39","title":"Healthy State: Practicing What They Preach in Louisiana","authorDetails":[{"displayName":"Mary K. Caffrey","firstName":null,"lastName":null,"url":{"current":"mary-k-caffrey","_type":"slug"},"profileImage":{"default":false,"_type":"mainImage","alt":"Mary K. Caffrey","asset":{"_ref":"image-ed06a2c91900970a850116ba649d9f9b4a954ca5-430x430-png","_type":"reference"}},"biography":null,"showSocialShare":null}],"factCheckBy":[{"displayName":"Mary K. Caffrey","firstName":null,"lastName":null,"url":{"current":"mary-k-caffrey","_type":"slug"},"profileImage":{"default":false,"_type":"mainImage","alt":"Mary K. Caffrey","asset":{"_ref":"image-ed06a2c91900970a850116ba649d9f9b4a954ca5-430x430-png","_type":"reference"}},"biography":null,"showSocialShare":null}],"issueGroup":{"_type":"reference","_ref":"73c988a3-a73b-49fa-af49-dce7e755e713"},"summary":"An IVBM event cohosted by The American Journal of Managed Care focused on Healthy State, a multiyear, multistakeholder commitment to moving Louisiana ahead in America’s Health Rankings.","thumbnail":{"_type":"mainImage","alt":"New Orleans Bourbon Street | Image Credit: © f11photo - stock.adobe.com","asset":{"description":null,"url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/29b0fbb8f7b48c24276a1a8a300c1168e50e8707-2800x1867.jpg","path":"images/0vv8moc6/ajmc/29b0fbb8f7b48c24276a1a8a300c1168e50e8707-2800x1867.jpg","assetId":"29b0fbb8f7b48c24276a1a8a300c1168e50e8707","originalFilename":"New Orleans Bourbon Street - f11photo - AdobeStock_169182961.jpeg","metadata":{"blurHash":"VLKJoRB?^vPDoi765Ev|$*$x~W-poztRR-%#x]SxNyt7","_type":"sanity.imageMetadata","palette":{"dominant":{"background":"#f6d770","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":6.13},"_type":"sanity.imagePalette","darkMuted":{"background":"#2e3d58","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":2.99},"muted":{"title":"#fff","population":5.22,"background":"#976e64","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightVibrant":{"population":6.13,"background":"#f6d770","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000"},"darkVibrant":{"background":"#935917","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":6.13},"lightMuted":{"foreground":"#000","title":"#fff","population":0.06,"background":"#b6a9cd","_type":"sanity.imagePaletteSwatch"},"vibrant":{"foreground":"#000","title":"#fff","population":5.95,"background":"#efa11f","_type":"sanity.imagePaletteSwatch"}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,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","dimensions":{"height":1867,"_type":"sanity.imageDimensions","width":2800,"aspectRatio":1.4997321906802357},"exif":{"Contrast":0,"DigitalZoomRatio":1,"ExposureProgram":1,"ISO":100,"WhiteBalance":0,"MeteringMode":5,"ExposureBiasValue":0,"FocalPlaneXResolution":2164.4328018223237,"DateTimeDigitized":null,"FocalPlaneResolutionUnit":3,"_type":"sanity.imageExifMetadata","FocalLength":28,"MaxApertureValue":4,"FocalLengthIn35mmFormat":42,"LensModel":"16-35mm F4 G SSM OSS","FNumber":5.6,"SensitivityType":2,"LensSpecification":[16,35,4,4],"Sharpness":0,"ShutterSpeedValue":-1,"LightSource":0,"FocalPlaneYResolution":2164.4328018223237,"DateTimeOriginal":"2016-11-15T06:32:19.000Z","BrightnessValue":-0.89296875,"RecommendedExposureIndex":100,"SceneCaptureType":0,"ColorSpace":1,"PixelXDimension":2800,"ApertureValue":4.970853658536585,"ExposureTime":2,"PixelYDimension":1867,"ExposureMode":1,"CustomRendered":0,"Saturation":2},"isOpaque":true},"altText":null,"mimeType":"image/jpeg","opt":{"media":{"tags":null}},"size":4265557,"_createdAt":"2024-08-28T16:07:24Z","extension":"jpg","_type":"sanity.imageAsset","title":null,"_updatedAt":"2024-08-28T16:07:46Z","uploadId":"kH1bS8OTS7iWFNmOt3qixxFUDmuSmj11","_rev":"LtkInV1jlQdtEIFjVqjDMg","sha1hash":"29b0fbb8f7b48c24276a1a8a300c1168e50e8707","_id":"image-29b0fbb8f7b48c24276a1a8a300c1168e50e8707-2800x1867-jpg"}},"url":"healthy-state-practicing-what-they-preach-in-louisiana","published":"2024-09-16T16:31:55.211Z"},{"summary":"Clinicians, researchers, and payer experts convened in Aurora, Colorado, on August 13, 2024, for discussions on ensuring that the recent advancements in lipid management are making their way to patients.","url":"multifaceted-approach-can-help-patients-benefit-from-the-expanded-lipid-lowering-toolbox","authorDetails":[{"displayName":"Christina Mattina","firstName":"Christina","lastName":"Mattina","url":{"current":"christina-mattina","_type":"slug"},"profileImage":{"alt":"Christina Mattina","asset":{"_ref":"image-6304e08858dcb7b689cd8fa5703c926a96ecdb48-512x492-jpg","_type":"reference"},"_type":"mainImage"},"biography":[{"_key":"9271b97a8f45","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Christina is the associate editorial director of ","_key":"ffac76b64934"},{"text":"The American Journal of Managed Care","_key":"4eac35f29678","_type":"span","marks":["em"]},{"_key":"b16316585120","_type":"span","marks":["superscript"],"text":"®"},{"_type":"span","marks":[],"text":" (","_key":"ed200dc9139a"},{"marks":["em"],"text":"AJMC","_key":"b773bee92455","_type":"span"},{"marks":["superscript"],"text":"®","_key":"1f9bb13b24fa","_type":"span"},{"marks":[],"text":") and ","_key":"b9461d308bc8","_type":"span"},{"_type":"span","marks":["em"],"text":"The American Journal of Accountable Care","_key":"f235dc7df490"},{"_type":"span","marks":["superscript"],"text":"®","_key":"14118ee858d3"},{"_type":"span","marks":[],"text":" (","_key":"a25757970c62"},{"_type":"span","marks":["em"],"text":"AJAC","_key":"6353c3a02e0f"},{"text":"), and joined ","_key":"7f777b20be12","_type":"span","marks":[]},{"_key":"682a0f2ea0d4","_type":"span","marks":["em"],"text":"AJMC"},{"_type":"span","marks":[],"text":" in 2016. She oversees the publication of the print journals, from manuscript submission to publication, and works with the editors in chief and editorial boards to promote the journals.","_key":"8b1f00d70d7f"}],"_type":"block","style":"normal"},{"markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/christinamattina/","_key":"c281c6aba22d"}],"children":[{"_type":"span","marks":[],"text":"She has a BS in public health from Rutgers University. You can connect with Christina on ","_key":"6d8dca7834cc"},{"text":"LinkedIn","_key":"e23534b48658","_type":"span","marks":["c281c6aba22d"]},{"_type":"span","marks":[],"text":".","_key":"83d100c64d0e"}],"_type":"block","style":"normal","_key":"a90d7ab4c801"}],"showSocialShare":null}],"factCheckBy":[{"lastName":"Mattina","url":{"current":"christina-mattina","_type":"slug"},"profileImage":{"_type":"mainImage","alt":"Christina Mattina","asset":{"_ref":"image-6304e08858dcb7b689cd8fa5703c926a96ecdb48-512x492-jpg","_type":"reference"}},"biography":[{"_type":"block","style":"normal","_key":"9271b97a8f45","markDefs":[],"children":[{"_key":"ffac76b64934","_type":"span","marks":[],"text":"Christina is the associate editorial director of "},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"4eac35f29678"},{"_type":"span","marks":["superscript"],"text":"®","_key":"b16316585120"},{"_type":"span","marks":[],"text":" (","_key":"ed200dc9139a"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"b773bee92455"},{"_type":"span","marks":["superscript"],"text":"®","_key":"1f9bb13b24fa"},{"_type":"span","marks":[],"text":") and ","_key":"b9461d308bc8"},{"_type":"span","marks":["em"],"text":"The American Journal of Accountable Care","_key":"f235dc7df490"},{"_type":"span","marks":["superscript"],"text":"®","_key":"14118ee858d3"},{"_type":"span","marks":[],"text":" (","_key":"a25757970c62"},{"_type":"span","marks":["em"],"text":"AJAC","_key":"6353c3a02e0f"},{"text":"), and joined ","_key":"7f777b20be12","_type":"span","marks":[]},{"_key":"682a0f2ea0d4","_type":"span","marks":["em"],"text":"AJMC"},{"_key":"8b1f00d70d7f","_type":"span","marks":[],"text":" in 2016. She oversees the publication of the print journals, from manuscript submission to publication, and works with the editors in chief and editorial boards to promote the journals."}]},{"style":"normal","_key":"a90d7ab4c801","markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/christinamattina/","_key":"c281c6aba22d","nofollow":true,"blank":true}],"children":[{"_type":"span","marks":[],"text":"She has a BS in public health from Rutgers University. You can connect with Christina on ","_key":"6d8dca7834cc"},{"_key":"e23534b48658","_type":"span","marks":["c281c6aba22d"],"text":"LinkedIn"},{"_type":"span","marks":[],"text":".","_key":"83d100c64d0e"}],"_type":"block"}],"showSocialShare":null,"displayName":"Christina Mattina","firstName":"Christina"}],"published":"2024-09-16T16:31:18.436Z","_id":"2a95bae0-0c9f-4bc1-8e7d-3602ac803646","issueGroup":{"_ref":"73c988a3-a73b-49fa-af49-dce7e755e713","_type":"reference"},"title":"Institute for Value-Based Medicine®: Multifaceted Approach Can Help Patients Benefit From the Expanded Lipid-Lowering Toolbox","thumbnail":{"_type":"mainImage","alt":"Denver Colorado | Image Credit: © f11photo - stock.adobe.com","asset":{"extension":"jpg","metadata":{"palette":{"darkMuted":{"background":"#4f4e2c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":6.64},"muted":{"title":"#fff","population":4.67,"background":"#50659b","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":0.31,"background":"#e9cf8d"},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.56,"background":"#544d07"},"lightMuted":{"background":"#a2a7c8","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":2.17},"vibrant":{"foreground":"#fff","title":"#fff","population":1.42,"background":"#ca762d","_type":"sanity.imagePaletteSwatch"},"dominant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":6.64,"background":"#4f4e2c"},"_type":"sanity.imagePalette"},"hasAlpha":false,"lqip":"data:image/jpeg;base64,/9j/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAAMABQDASIAAhEBAxEB/8QAGAAAAgMAAAAAAAAAAAAAAAAAAAcCBAX/xAAfEAACAgICAwEAAAAAAAAAAAABAgADBBEGEiExYQX/xAAWAQEBAQAAAAAAAAAAAAAAAAACAwT/xAAdEQABBAIDAAAAAAAAAAAAAAADAAECEQQxBRJB/9oADAMBAAIRAxEAPwCeBhfnUkd7arNe+reptUZ/HVcV2voiKx8m2mtTWQCfgly3NtZEdhWWHgHqJI3InaVstA4C6aTkqyOIJWvfKRSRvREImxc7gMx8n5CBs83qLxhel//Z","dimensions":{"aspectRatio":1.7142857142857142,"height":700,"_type":"sanity.imageDimensions","width":1200},"exif":{"PixelYDimension":700,"_type":"sanity.imageExifMetadata","DateTimeDigitized":"2014-09-12T07:37:33.000Z","ColorSpace":1,"PixelXDimension":1200},"isOpaque":true,"blurHash":"MjHx1~IoS$S4oL%QRijZWrbH9vocWAoffP","_type":"sanity.imageMetadata"},"uploadId":"H7WTao1JKvhWv1JBicLCJENbGPV6jpQH","_type":"sanity.imageAsset","_rev":"WVB52uR738qojYGNKmrerb","_updatedAt":"2024-09-13T18:14:54Z","_createdAt":"2024-09-13T18:14:54Z","_id":"image-c2b2ded664a1fbdc0483dd96d0b7deae84831a7b-1200x700-jpg","mimeType":"image/jpeg","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/c2b2ded664a1fbdc0483dd96d0b7deae84831a7b-1200x700.jpg","size":584915,"assetId":"c2b2ded664a1fbdc0483dd96d0b7deae84831a7b","sha1hash":"c2b2ded664a1fbdc0483dd96d0b7deae84831a7b","path":"images/0vv8moc6/ajmc/c2b2ded664a1fbdc0483dd96d0b7deae84831a7b-1200x700.jpg","originalFilename":"Denver Colorado - f11photo - stock.adobe.com.jpeg"}}},{"url":"telehealth-insights-from-an-integrated-care-system","authorDetails":[{"displayName":"Rebecca Flournoy, MPH","firstName":"Rebecca","lastName":"Flournoy","url":{"current":"rebecca-flournoy-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"lastName":"Shah","url":{"current":"reema-shah-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Reema Shah, MPH","firstName":"Reema"},{"displayName":"Elizabeth Moisan, MS","firstName":"Elizabeth","lastName":"Moisan","url":{"current":"elizabeth-moisan-ms","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Cecilia Oregón, MPP, MPH","firstName":"Cecilia","lastName":"Oregón","url":{"current":"cecilia-oreg-n-mpp-mph","_type":"slug"}}],"factCheckBy":[{"lastName":"Flournoy","url":{"current":"rebecca-flournoy-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Rebecca Flournoy, MPH","firstName":"Rebecca"},{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Reema Shah, MPH","firstName":"Reema","lastName":"Shah","url":{"current":"reema-shah-mph","_type":"slug"}},{"lastName":"Moisan","url":{"_type":"slug","current":"elizabeth-moisan-ms"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Elizabeth Moisan, MS","firstName":"Elizabeth"},{"firstName":"Cecilia","lastName":"Oregón","url":{"current":"cecilia-oreg-n-mpp-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Cecilia Oregón, MPP, MPH"}],"summary":"Experiences from a large, integrated, value-based health system suggest that telehealth can be an effective care delivery approach. Public policies can improve telehealth access and care.","issueGroup":{"_ref":"73c988a3-a73b-49fa-af49-dce7e755e713","_type":"reference"},"title":"Telehealth Insights From an Integrated Care System","thumbnail":{"_type":"mainImage","alt":"telemedicine | Image Credit: © rh2010 - stock.adobe.com","asset":{"extension":"jpg","metadata":{"isOpaque":true,"blurHash":"VEDl=,D%4n?c-;_N%M-pD%xvM{-;_3DiWBt7xax]t7M{","_type":"sanity.imageMetadata","palette":{"darkVibrant":{"population":6.07,"background":"#493a1a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightMuted":{"population":6.95,"background":"#bbbcbe","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"vibrant":{"background":"#ba825c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.01},"dominant":{"foreground":"#000","title":"#fff","population":6.95,"background":"#bbbcbe","_type":"sanity.imagePaletteSwatch"},"_type":"sanity.imagePalette","darkMuted":{"background":"#61553c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":6.82},"muted":{"population":0,"background":"#b4745c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightVibrant":{"title":"#000","population":0.05,"background":"#e7d1c6","_type":"sanity.imagePaletteSwatch","foreground":"#000"}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":7360,"aspectRatio":1.498371335504886,"height":4912}},"url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/aa55cba013e542363db5e3021a7d049b005c0d44-7360x4912.jpg","path":"images/0vv8moc6/ajmc/aa55cba013e542363db5e3021a7d049b005c0d44-7360x4912.jpg","mimeType":"image/jpeg","size":10640408,"_type":"sanity.imageAsset","assetId":"aa55cba013e542363db5e3021a7d049b005c0d44","_createdAt":"2023-12-05T16:28:07Z","_id":"image-aa55cba013e542363db5e3021a7d049b005c0d44-7360x4912-jpg","_updatedAt":"2023-12-05T16:28:07Z","uploadId":"ueKegQc9OLg07IP1riXXhgBAywYfiVMU","_rev":"yLkPQ1Yunv4gUqVh5QBQaa","sha1hash":"aa55cba013e542363db5e3021a7d049b005c0d44","originalFilename":"telemedicine - rh2010.jpeg"}},"published":"2024-09-16T16:29:41.215Z","_id":"336a74f6-937d-40c6-a94c-b14c26f025f6"},{"factCheckBy":[{"displayName":"Giuliana Grossi","firstName":"Giuliana","lastName":"Grossi","url":{"current":"giuliana-grossi","_type":"slug"},"profileImage":{"_type":"mainImage","alt":"Giuliana Grossi","asset":{"_ref":"image-5dc1da24786c43a7f87e4ea0a7ae3880e6cee39f-430x430-png","_type":"reference"}},"biography":null,"showSocialShare":null}],"title":"Cardiometabolic Interventions Focus on Accessibility, Evidence-Based Medicine","summary":"At an Institute for Value-Based Medicine® (IVBM) event cohosted by The American Journal of Managed Care® and Sutter Health, experts illuminated the current state of cardiometabolic health care and offered a glimpse into the future.","published":"2024-06-14T13:00:00.000Z","authorDetails":[{"biography":null,"showSocialShare":null,"displayName":"Giuliana Grossi","firstName":"Giuliana","lastName":"Grossi","url":{"current":"giuliana-grossi","_type":"slug"},"profileImage":{"alt":"Giuliana Grossi","asset":{"_ref":"image-5dc1da24786c43a7f87e4ea0a7ae3880e6cee39f-430x430-png","_type":"reference"},"_type":"mainImage"}}],"_id":"1472df1f-ab77-4b68-8ced-12ff81256022","issueGroup":{"_ref":"c6747bef-322f-4aa5-bf20-1af9d678cde0","_type":"reference"},"thumbnail":{"_type":"mainImage","alt":"San Francisco's Golden Gate Bridge | Image Credit: © phitha - stock.adobe.com","asset":{"sha1hash":"1f3095024fd984fa3a60b43c4cf33663635bcaf7","_id":"image-1f3095024fd984fa3a60b43c4cf33663635bcaf7-1200x800-jpg","metadata":{"_type":"sanity.imageMetadata","palette":{"dominant":{"foreground":"#000","title":"#fff","population":8.5,"background":"#9099c0","_type":"sanity.imagePaletteSwatch"},"_type":"sanity.imagePalette","darkMuted":{"background":"#2e3250","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":7.93},"muted":{"background":"#9c5c58","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.47},"lightVibrant":{"background":"#fbe182","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":4.62},"darkVibrant":{"foreground":"#fff","title":"#fff","population":3.69,"background":"#6f2c2a","_type":"sanity.imagePaletteSwatch"},"lightMuted":{"population":8.5,"background":"#9099c0","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"vibrant":{"population":7.2,"background":"#f2a973","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,/9j/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAANABQDASIAAhEBAxEB/8QAFwAAAwEAAAAAAAAAAAAAAAAAAAQGAv/EACQQAAIBAwMDBQAAAAAAAAAAAAECAwAEBQYREgchMRMyYYKx/8QAFgEBAQEAAAAAAAAAAAAAAAAAAgME/8QAHREAAQQCAwAAAAAAAAAAAAAAAQACBREDEiFBkf/aAAwDAQACEQMRAD8ApV1bi0YGO9mif9pDKdR4IZYIg0dyjNxZnGxHzU9YY7HX0aSzWacmG/Zj2p59G4i7MJ9AxhW3IU+6i6FwgbVa1Nk3PdqaTU2uMRLIWkVOXjxRWJNGYYOdrcj7UVYRGCuL9QMjlB6X/9k=","dimensions":{"_type":"sanity.imageDimensions","width":1200,"aspectRatio":1.5,"height":800},"exif":{"FocalLengthIn35mmFormat":220,"DateTimeDigitized":"2016-06-04T04:25:41.000Z","ColorSpace":1,"MeteringMode":5,"Sharpness":0,"ExposureTime":3.2,"ExposureMode":0,"LensModel":"FE 70-300mm F4.5-5.6 G OSS","ShutterSpeedValue":-1.6780719083366258,"FocalLength":220,"Contrast":0,"LensSpecification":[70,300,4.5,5.6],"PixelYDimension":800,"BrightnessValue":-0.44765625,"FocalPlaneResolutionUnit":3,"LightSource":14,"ApertureValue":6.9188632619439865,"PixelXDimension":1200,"DateTimeOriginal":"2016-06-04T04:25:41.000Z","CustomRendered":0,"Saturation":0,"DigitalZoomRatio":1,"_type":"sanity.imageExifMetadata","ExposureProgram":3,"FNumber":11,"FocalPlaneYResolution":2164.4328018223237,"FocalPlaneXResolution":2164.4328018223237,"WhiteBalance":1,"SensitivityType":2,"RecommendedExposureIndex":200,"SceneCaptureType":0,"MaxApertureValue":4.970853658536585,"ISO":200,"ExposureBiasValue":0},"isOpaque":true,"blurHash":"VuJ@2qs:WCjYbb}%soahbIjs-:R*WBoJW:I.W=WEoLj["},"uploadId":"O5nnIZFuz4knEBd9QmteN8nCCmR8xh2K","size":416089,"assetId":"1f3095024fd984fa3a60b43c4cf33663635bcaf7","extension":"jpg","_createdAt":"2024-06-07T15:30:01Z","_updatedAt":"2024-06-07T15:30:01Z","originalFilename":"San Francisco Golden Gate Bridge - phitha - stock.adobe.com.jpeg","path":"images/0vv8moc6/ajmc/1f3095024fd984fa3a60b43c4cf33663635bcaf7-1200x800.jpg","_type":"sanity.imageAsset","mimeType":"image/jpeg","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/1f3095024fd984fa3a60b43c4cf33663635bcaf7-1200x800.jpg","_rev":"SWZtARO2mf3vRstToueLld"}},"url":"cardiometabolic-interventions-focus-on-accessibility-evidence-based-medicine"},{"thumbnail":{"asset":{"metadata":{"lqip":"data:image/jpeg;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":1200,"aspectRatio":1.5,"height":800},"exif":{"FocalLengthIn35mmFormat":27,"PixelXDimension":1200,"Saturation":1,"DateTimeDigitized":"2016-07-24T00:00:00.000Z","SubjectDistanceRange":0,"WhiteBalance":1,"FNumber":20,"ExposureBiasValue":0.33,"_type":"sanity.imageExifMetadata","ApertureValue":8.643856143856144,"MaxApertureValue":2.9708536585365852,"BrightnessValue":5.84,"FocalPlaneResolutionUnit":3,"ColorSpace":1,"SensitivityType":1,"LensMake":"FUJIFILM","MeteringMode":5,"ShutterSpeedValue":3.584962502403692,"DateTimeOriginal":"2016-07-24T18:28:07.000Z","LensSpecification":[18,55,2.8,4],"SensingMethod":2,"CustomRendered":0,"PixelYDimension":800,"FocalPlaneXResolution":2083.4231274638632,"FocalLength":18,"ExposureProgram":3,"LensSerialNumber":"48A03748","ExposureMode":0,"ISO":500,"SceneCaptureType":0,"ExposureTime":0.08333333333333333,"Sharpness":0,"FocalPlaneYResolution":2083.4231274638632,"LightSource":11,"LensModel":"XF18-55mmF2.8-4 R LM OIS"},"isOpaque":true,"blurHash":"VwHx:8$xRit5WA_4$~jEaej[T1oMWEa}axENR-f6bIWC","_type":"sanity.imageMetadata","palette":{"lightVibrant":{"title":"#000","population":2.52,"background":"#efc989","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"darkVibrant":{"title":"#fff","population":0,"background":"#043484","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightMuted":{"title":"#fff","population":2.56,"background":"#8897be","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"vibrant":{"background":"#0d90d3","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":5.13},"dominant":{"title":"#fff","population":6.22,"background":"#677397","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"_type":"sanity.imagePalette","darkMuted":{"background":"#30384f","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":2.79},"muted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":6.22,"background":"#677397"}},"hasAlpha":false},"path":"images/0vv8moc6/ajmc/264df279db594adda69bc3737a08c6773f27a6ef-1200x800.jpg","_createdAt":"2024-06-07T15:42:37Z","originalFilename":"Cleveland Ohio - Ai - stock.adobe.com.jpeg","extension":"jpg","_type":"sanity.imageAsset","mimeType":"image/jpeg","sha1hash":"264df279db594adda69bc3737a08c6773f27a6ef","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/264df279db594adda69bc3737a08c6773f27a6ef-1200x800.jpg","assetId":"264df279db594adda69bc3737a08c6773f27a6ef","uploadId":"gcL2RcGUNOwVnVWGsh0ao9mQiEvDHrKK","_rev":"FTf7O3KU2GxuMy4tElpSB4","size":501001,"_id":"image-264df279db594adda69bc3737a08c6773f27a6ef-1200x800-jpg","_updatedAt":"2024-06-07T15:42:37Z"},"_type":"mainImage","alt":"Cleveland Ohio | Image Credit: © Ai - stock.adobe.com.jpeg"},"url":"experts-highlight-how-glp-1s-have-revolutionized-management-of-t2d-and-obesity","authorDetails":[{"url":{"current":"laura-joszt","_type":"slug"},"profileImage":{"_type":"mainImage","alt":"Laura Joszt headshot","asset":{"_ref":"image-93ea362164e769dfd84dca31a8b2670a1dd9092b-512x512-jpg","_type":"reference"}},"biography":[{"children":[{"_type":"span","marks":[],"text":"Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®’s parent company, MJH Life Sciences®, since 2011.","_key":"67a67d3764f00"}],"_type":"block","style":"normal","_key":"4a950aea97b3","markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/laura-joszt-05ba7116/","_key":"f77b28536a8d"},{"href":"https://twitter.com/joszt","_key":"c419f18a7ffe","_type":"link"}]},{"markDefs":[{"_key":"f77b28536a8d","nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/laura-joszt-05ba7116/"},{"nofollow":true,"blank":true,"_type":"link","href":"https://twitter.com/joszt","_key":"c419f18a7ffe"}],"children":[{"text":"She has an MA in business and economic reporting from New York University. You can connect with Laura on ","_key":"48d199d8ecd5","_type":"span","marks":[]},{"_type":"span","marks":["f77b28536a8d"],"text":"LinkedIn","_key":"67a67d3764f01"},{"_type":"span","marks":[],"text":" or ","_key":"67a67d3764f02"},{"_type":"span","marks":["c419f18a7ffe"],"text":"Twitter","_key":"67a67d3764f03"},{"_type":"span","marks":[],"text":".","_key":"67a67d3764f04"}],"_type":"block","style":"normal","_key":"b28d8058b3d8"}],"showSocialShare":true,"displayName":"Laura Joszt, MA","firstName":"Laura","lastName":"Joszt"}],"factCheckBy":[{"lastName":"Joszt","url":{"current":"laura-joszt","_type":"slug"},"profileImage":{"_type":"mainImage","alt":"Laura Joszt headshot","asset":{"_ref":"image-93ea362164e769dfd84dca31a8b2670a1dd9092b-512x512-jpg","_type":"reference"}},"biography":[{"style":"normal","_key":"4a950aea97b3","markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/laura-joszt-05ba7116/","_key":"f77b28536a8d"},{"_type":"link","href":"https://twitter.com/joszt","_key":"c419f18a7ffe"}],"children":[{"_type":"span","marks":[],"text":"Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®’s parent company, MJH Life Sciences®, since 2011.","_key":"67a67d3764f00"}],"_type":"block"},{"markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/laura-joszt-05ba7116/","_key":"f77b28536a8d"},{"nofollow":true,"blank":true,"_type":"link","href":"https://twitter.com/joszt","_key":"c419f18a7ffe"}],"children":[{"_type":"span","marks":[],"text":"She has an MA in business and economic reporting from New York University. You can connect with Laura on ","_key":"48d199d8ecd5"},{"_type":"span","marks":["f77b28536a8d"],"text":"LinkedIn","_key":"67a67d3764f01"},{"text":" or ","_key":"67a67d3764f02","_type":"span","marks":[]},{"_type":"span","marks":["c419f18a7ffe"],"text":"Twitter","_key":"67a67d3764f03"},{"text":".","_key":"67a67d3764f04","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"b28d8058b3d8"}],"showSocialShare":true,"displayName":"Laura Joszt, MA","firstName":"Laura"}],"published":"2024-06-13T19:00:00.000Z","_id":"4d553701-915f-4873-8b9f-4f53893d6561","issueGroup":{"_ref":"c6747bef-322f-4aa5-bf20-1af9d678cde0","_type":"reference"},"title":"Experts Highlight How GLP-1s Have Revolutionized Management of T2D and Obesity ","summary":"The number of Americans with type 2 diabetes and/or obesity is rising, and the entry of therapies such as glucagon-like peptide-1 (GLP-1) receptor agonists has been revolutionary."},{"authorDetails":[{"showSocialShare":null,"displayName":"Dennis R. Holmes, MD","firstName":"Dennis","lastName":"Holmes","url":{"current":"dennis-r-holmes-md","_type":"slug"},"profileImage":null,"biography":null},{"url":{"current":"steven-d-evans-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Steven D. Evans, MD","firstName":"Steven","lastName":"Evans"},{"url":{"current":"warren-fisher-do","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Warren Fisher, DO","firstName":"Warren","lastName":"Fisher"},{"showSocialShare":null,"displayName":"Darren Wheeler, MD","firstName":"Darren","lastName":"Wheeler","url":{"current":"darren-wheeler-md","_type":"slug"},"profileImage":null,"biography":null},{"firstName":"Riya","lastName":"Pulicharam","url":{"_type":"slug","current":"riya-pulicharam-md-cpi"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Riya Pulicharam, MD, CPI"}],"factCheckBy":[{"displayName":"Dennis R. Holmes, MD","firstName":"Dennis","lastName":"Holmes","url":{"_type":"slug","current":"dennis-r-holmes-md"},"profileImage":null,"biography":null,"showSocialShare":null},{"biography":null,"showSocialShare":null,"displayName":"Steven D. Evans, MD","firstName":"Steven","lastName":"Evans","url":{"current":"steven-d-evans-md","_type":"slug"},"profileImage":null},{"showSocialShare":null,"displayName":"Warren Fisher, DO","firstName":"Warren","lastName":"Fisher","url":{"current":"warren-fisher-do","_type":"slug"},"profileImage":null,"biography":null},{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Darren Wheeler, MD","firstName":"Darren","lastName":"Wheeler","url":{"current":"darren-wheeler-md","_type":"slug"}},{"displayName":"Riya Pulicharam, MD, CPI","firstName":"Riya","lastName":"Pulicharam","url":{"_type":"slug","current":"riya-pulicharam-md-cpi"},"profileImage":null,"biography":null,"showSocialShare":null}],"_id":"e881417a-9e64-48ca-9b72-7daafa2dd9c4","issueGroup":{"_ref":"c6747bef-322f-4aa5-bf20-1af9d678cde0","_type":"reference"},"thumbnail":{"_type":"mainImage","alt":"Medical technology and digital health network concept | Image Credit: © ipopba - stock.adobe.com","asset":{"_updatedAt":"2023-09-25T20:33:46Z","extension":"jpg","metadata":{"isOpaque":true,"blurHash":"VKJ01o~pIBTJo#K6MxxuRjs:R6xuNGxuRORi-;IUSexb","_type":"sanity.imageMetadata","palette":{"_type":"sanity.imagePalette","darkMuted":{"background":"#655176","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.14},"muted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":7.54,"background":"#629eb9"},"lightVibrant":{"foreground":"#000","title":"#000","population":3.38,"background":"#badff5","_type":"sanity.imagePaletteSwatch"},"darkVibrant":{"background":"#205a7b","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":8.47},"lightMuted":{"title":"#fff","population":4.58,"background":"#a4c2d3","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"vibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.22,"background":"#2bc4d6"},"dominant":{"background":"#205a7b","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":8.47}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":1280,"aspectRatio":1.6,"height":800}},"uploadId":"hTRTLrPbL2uAPSQkjvmAG41W4tGru8UX","mimeType":"image/jpeg","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/1e602bba35858bd62230432132517d1d42061e3d-1280x800.jpg","_rev":"pEhoUqandJkxjPidorVwRV","_type":"sanity.imageAsset","path":"images/0vv8moc6/ajmc/1e602bba35858bd62230432132517d1d42061e3d-1280x800.jpg","size":323017,"assetId":"1e602bba35858bd62230432132517d1d42061e3d","_id":"image-1e602bba35858bd62230432132517d1d42061e3d-1280x800-jpg","sha1hash":"1e602bba35858bd62230432132517d1d42061e3d","_createdAt":"2023-09-25T20:33:46Z","originalFilename":"Medicine doctor hold icon health and electronic medical record on interface. Digital healthcare and network connection on hologram virtual screen, insurance. medical technology and network concept - ipopba - stock.adobe.com.jpeg"}},"published":"2024-06-13T13:00:00.000Z","title":"Reducing Delays in Breast Cancer Care Using an Innovative Digital Health Platform","summary":"The use of a novel digital health platform achieved a 55% reduction in time to treatment among women with a new diagnosis of breast cancer.","url":"reducing-delays-in-breast-cancer-care-using-an-innovative-digital-health-platform"}],"isLiveSite":true,"host":"www.ajmc.com","settings":{"title":"AJMC","networkID":"4688","adUnit":"ajmc.com","liveDomain":"www.ajmc.com","publicationName":"AJMC","logo":"/ajmc_logo_inverted.png","white_logo":"/ajmc_logo_inverted.png","logoHeight":"50px","enableEdgeCache":true,"sMaxAge":300,"staleWhileRevalidate":359,"clinicalTopicTopLatestNews":true,"megaMenuTaxName":"topic","megaMenuChildren":true,"sharingImageUrl":"https://s3.amazonaws.com/mjhlifesciences.com/sitelogos/AJMC_1200x637.png","twitterHandle":"@AJMC_Journal","publicationMapping":"publications","useNewSubNavMegaMenu":true,"redesignDetail":true,"redesignSAP":true,"useNewFooter":true,"newFooterLogos":[{"img":"/CHA_Logo.png","alt":"CH Logo","mobileWidth":"158px","mobileHeight":"42px","link":"/topic/center-on-health-equity-and-access","target":"_self"},{"img":"/CB.png","alt":"Center for Biosimilars Logo","mobileWidth":"170px","mobileHeight":"42px","link":"https://www.centerforbiosimilars.com/","target":"_blank"}],"useV3Components":true,"useAuthorRedesign":true,"navigationOptions":{"version":"2","variant":"4","customSpecialtyText":"Speciality Area"},"gateEnabled":"modal"},"homepage_creative_layout":{"creativeLayout":null}},"targeting":{"content_placement":["compendium/biosimilars"],"document_url":["compendium/biosimilars"],"document_group":[],"rootDocumentGroup":[],"hostname":"www.ajmc.com"},"statusCode":200,"data":{"page":{"relatedMegaMenu":null,"pages":null,"identifier":null,"parent":null,"labelRequired":false,"styling":{"contentControl":{"_type":"contentControl","showPublished":true,"readMore":true,"showAuthor":true,"showSummary":true},"imageControl":{"showImage":true,"thumbnailRadius":{"topRight":"0rem","bottomLeft":"0rem","bottomRight":"0rem","topLeft":"0rem"},"_type":"imageControl"},"divider":{"_type":"divider","dividerSize":1},"titleOptions":{"_type":"titleOptions","titleSize":"1rem"},"useDefaultLayout":true,"border":{"borderType":"lines","borderRadius":{"bottomLeft":"0rem","bottomRight":"0rem","topLeft":"0rem","topRight":"0rem"},"_type":"border","borderSize":0}},"fixIdentifier":null,"label":null,"searchConfig":{"baseUrl":"/view/"},"excludeFromSitemap":false,"creativeLayoutDetail":null,"docGroup":null,"taxonomy":{"_rev":"oruil6rlosjyltJbhrNMGF","_type":"taxonomy","name":"Compendium","_updatedAt":"2024-04-09T09:14:18Z","isMainTopic":true,"_createdAt":"2020-03-30T18:16:46Z","_id":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","identifier":"compendium","pixelTrackingCode":null},"hasSubCategory":false,"archived":false,"linkedPage":null,"gateCode":null,"pageSliders":null,"orderDesc":null,"creativeLayoutLatestNews":null,"url":{"_type":"slug","current":"/compendium"},"content":null,"contentCategory":null,"useV3":true,"theme":"default","intro":null,"contentCategories":null,"filters":null,"franchise":null,"cmeConfig":null,"pageType":"Clinical Topic","externalLinks":null,"filterRequired":false,"title":"Compendium","isDsoGated":null,"videoPlayerConfig":null,"disableEpisode":null,"creativeLayout":null,"articleDetailConfig":{"brightcovePlayerID":"pbDmfQhRw","drupalleadBaseURL":"https://drupalleads.mjh.group/injectablewebform/output/","issueMapping":"/publications","enableSegmentRecommend":true,"brightcoveAccountID":"10203567001","disqusShortName":"www-ajmc-com","downloadCitation":true,"shareOptions":{"hidePinterest":false,"shareSubject":"Check out this article!","twitterHandle":"AJMC","siteName":"ajmc","hideFacebook":false,"SocialIconSize":32,"twitterSiteName":"@AJMC_Journal"}},"featureContent":null},"pageData":{"totalCount":566,"pageSize":30,"pageNumber":1,"data":[{"factCheckAuthors":null,"title":"The Future of Pharmacy: Trends, Threats, Transformations","url":"the-future-of-pharmacy-trends-threats-transformations","updatedOn":null,"contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"authors":[{"displayName":"Cameron Santoro","url":"cameron-santoro"}],"_id":"b5216764-05fa-4158-8775-2ebec0a4ca98","thumbnail":{"alt":"Pharmaceutical industry. | Image Credit: Africa Studio - stock.adobe.com","caption":"The pharmaceutical landscape enters 2025 with a mix of challenges and opportunities while promising to be pivotal as it shapes the future of drug access and affordability for patients across the nation. | Image Credit: Africa Studio - stock.adobe.com","asset":{"_type":"reference","_ref":"image-4d2b1e0a5fb7993e065301c6d238736aeb12075e-5760x3840-jpg"},"_type":"mainImage"},"summary":"The pharmaceutical landscape enters 2025 with a mix of challenges and opportunities, with the potential to shape the future of drug access and affordability for patients across the nation. ","published":"2025-01-10T12:00:00.000Z"},{"title":"Top 5 Biosimilar Articles of 2024","url":"top-5-biosimilar-articles-of-2024","thumbnail":{"asset":{"_ref":"image-0fa217cda72fba54cc623e6430e8ea59cecb406a-3187x1625-png","_type":"reference"},"_type":"mainImage","alt":"The top 5 biosimilar articles touch on the growing biosimilar landscape, including recent FDA approvals, patent disputes, cost-saving potential, and challenges in market entry.","caption":"The top 5 biosimilar articles touch on the growing biosimilar landscape, including recent FDA approvals, patent disputes, cost-saving potential, and challenges in market entry."},"contentCategory":{"_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh"},"factCheckAuthors":null,"_id":"1616831c-6316-4dcb-a8d5-2b7527c79ed1","summary":"The top 5 biosimilar articles touch on the growing biosimilar landscape, including recent FDA approvals, patent disputes, cost-saving potential, and challenges in market entry.","published":"2024-12-28T12:00:00.000Z","updatedOn":null,"authors":[{"displayName":"Cameron Santoro","url":"cameron-santoro"}]},{"_id":"54e84f07-56e9-4743-b862-aa803084d27d","url":"5-key-drug-approvals-and-crls-in-2024","published":"2024-12-27T13:20:00.000Z","authors":[{"displayName":"Laura Joszt, MA","url":"laura-joszt"}],"title":"5 Key Drug Approvals and CRLs in 2024","thumbnail":{"_type":"mainImage","alt":"Paper with FDA approved on top of a magnifying glass and a keyboard | Image Credit: Pawel - stock.adobe.com","asset":{"_ref":"image-b0002ea79080e3493345e3c993b00be4690f0087-4279x2706-jpg","_type":"reference"}},"summary":"In 2024, multiple drugs received complete response letters (CRLs), sometimes unrelated to the safety and efficacy of the drug, but patients with schizophrenia gained the first new treatment with a new mechanism of action in decades.","updatedOn":null,"contentCategory":{"_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z"},"factCheckAuthors":null},{"authors":[{"displayName":"Cameron Santoro","url":"cameron-santoro"}],"factCheckAuthors":null,"url":"fda-approves-seventh-ustekinumab-biosimilar-to-reference-stelara","summary":"The FDA granted approval to Steqeyma (ustekinumab-stba) for inflammatory conditions, making it the seventh biosimilar to reference Stelara after a year of multiple ustekinumab biosimilar approvals.","contentCategory":{"_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2"},"published":"2024-12-20T17:39:00.000Z","updatedOn":null,"_id":"93b03420-da7e-4db0-b339-9c6cf70d6c8a","title":"FDA Approves Seventh Ustekinumab Biosimilar to Reference Stelara","thumbnail":{"caption":"The FDA granted approval to Steqeyma (ustekinumab-stba) for inflammatory conditions, making it the seventh biosimilar to reference Stelara after a year of multiple ustekinumab biosimilar approvals. | Image Credit: Surendra - stock.adobe.com\n","asset":{"_ref":"image-ca845f7e6dfc35ab2f006b74744bb6c3a34fff11-5500x4093-jpg","_type":"reference"},"_type":"mainImage","alt":"FDA approval with stamp. | Image Credit: Surendra - stock.adobe.com"}},{"url":"uptake-of-rituximab-biosimilars-in-medicare-and-medicaid-in-2019-2022","thumbnail":{"_type":"mainImage","alt":"AJMC","asset":{"_ref":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","_type":"reference"}},"factCheckAuthors":null,"published":"2024-12-16T17:00:00.000Z","updatedOn":null,"contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"authors":[{"displayName":"Jingjing Qian, PhD","url":"jingjing-qian-phd"}],"_id":"5a821cca-ecbc-492b-b96a-f79fac509885","title":"Uptake of Rituximab Biosimilars in Medicare and Medicaid in 2019-2022","summary":"Significant uptake of rituximab biosimilars in Medicare and Medicaid occurred within the first 4 years of marketing in the US."},{"thumbnail":{"_type":"mainImage","alt":"Seattle Washington skyline | Image Credit: © espiegle - stock.adobe.com","asset":{"_ref":"image-50d700b88aa9af2c75864177d43c5651d055284b-1200x697-jpg","_type":"reference"}},"published":"2024-12-12T17:00:00.000Z","updatedOn":null,"factCheckAuthors":null,"_id":"f802c956-5821-427f-8529-cd5ac1bf6b46","title":"From Approval to Practice: Addressing the Hurdles in Biosimilar Integration","url":"from-approval-to-practice-addressing-the-hurdles-in-biosimilar-integration","summary":"Recent discussions at an Institute for Value-Based Medicine event highlighted the significant potential of biosimilars in reshaping the health care landscape, despite facing considerable barriers to adoption.","contentCategory":{"_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z"},"authors":[{"displayName":"Skylar Jeremias","url":"skylar-jeremias"}]},{"summary":"Panelists proposed policy solutions to ensure long-term sustainability of infused biosimilars amid current challenges, including average sales price erosion and reimbursement issues.","contentCategory":{"_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2"},"authors":[{"displayName":"Cameron Santoro","url":"cameron-santoro"}],"factCheckAuthors":null,"_id":"1fe9c275-331f-496d-a003-96846cfea914","url":"policy-proposals-aim-to-stimulate-the-long-term-sustainability-of-infused-biosimilars","thumbnail":{"_type":"mainImage","alt":"Health Policy. | Image Credit: Mohamad Zaki - stock.adobe.com","caption":"Panelists proposed policy solutions to ensure long-term sustainability of infusedbiosimilars amid current challenges, including average sales price (ASP) erosion and reimbursement issues. | Image Credit: Mohamad Zaki - stock.adobe.com","asset":{"_ref":"image-7cad58a0175282b6a9e2f0292dc22ac8b8dc9d40-3600x2401-jpg","_type":"reference"}},"title":"Policy Proposals Aim to Stimulate the Long-Term Sustainability of Infused Biosimilars","published":"2024-12-04T21:00:00.000Z","updatedOn":null},{"_id":"db9e097d-c43c-4401-862d-84bf5357376a","thumbnail":{"_type":"mainImage","alt":"FDA approval. | Image Credit: syahrir - stock.adobe.com","caption":"The approval of Yesintek (ustekinumab-kfce), the sixth biosimilar to reference Stelara, will be used to treat patients with various immunology conditions, including psoriatic arthritis and inflammatory bowel disease. | Image Credit: syahrir - stock.adobe.com","asset":{"_ref":"image-2f366a4ab7421a6a697b539c22b8aedf46713899-6000x4000-jpg","_type":"reference"}},"updatedOn":null,"contentCategory":{"_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh"},"authors":[{"displayName":"Skylar Jeremias","url":"skylar-jeremias"}],"factCheckAuthors":null,"title":"FDA Approves Sixth Ustekinumab Biosimilar, Yesintek","url":"fda-approves-sixth-ustekinumab-biosimilar-yesintek","summary":"The approval of Yesintek (ustekinumab-kfce), the sixth biosimilar to reference Stelara, will be used to treat patients with various immunology conditions, including psoriatic arthritis and inflammatory bowel disease.","published":"2024-12-02T16:42:16.672Z"},{"_id":"7bb46815-bb41-4520-b61a-732a9a197112","url":"addressing-patent-hurdles-payer-barriers-and-interchangeability","updatedOn":null,"contentCategory":{"_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles"},"title":"Addressing Patent Hurdles, Payer Barriers, and Interchangeability","thumbnail":{"asset":{"_ref":"image-acfa79aea9d4d9915415c5b57644f564014a966a-6760x4171-jpg","_type":"reference"},"_type":"mainImage","alt":"Patient access to medication. | Image Credit: Supatman - stock.adobe.com","caption":"Global Biosimilars Week discussed issues in biosimilar adoption and called for reforms to streamline processes, foster competition, and increase biosimilar access for patients. | Image Credit: Supatman - stock.adobe.com\n"},"summary":"Global Biosimilars Week discussed issues in biosimilar adoption and called for reforms to streamline processes, foster competition, and increase biosimilar access for patients.","published":"2024-11-22T19:48:00.000Z","authors":[{"displayName":"Cameron Santoro","url":"cameron-santoro"}],"factCheckAuthors":null},{"title":"Financial Incentives Drive Biosimilar Adoption in Japan","thumbnail":{"_type":"mainImage","alt":"Health care expenses. | Image Credit: izzuan - stock.adobe.com","caption":"Financial incentives provided to hospitals in Japan led to a significant increase in biosimilar oncology drug prescriptions. | Image Credit: izzuan - stock.adobe.com","asset":{"_type":"reference","_ref":"image-dfa1025ae10a86f9ce44cdc2182c02e7a8c82f5d-4924x3288-jpg"}},"contentCategory":{"name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory"},"factCheckAuthors":null,"_id":"0db2a193-6e27-4094-b983-74c772bff77a","url":"financial-incentives-drive-biosimilar-adoption-in-japan","summary":"Financial incentives provided to hospitals in Japan led to a significant increase in biosimilar oncology drug prescriptions.","published":"2024-11-20T15:00:00.000Z","updatedOn":null,"authors":[{"displayName":"Cameron Santoro","url":"cameron-santoro"}]},{"_id":"e94e9e75-15ca-4204-9bda-5ea95b153626","thumbnail":{"_type":"mainImage","alt":"FDA logo and website | Image credit: Postmodern Studio - stock.adobe.com","asset":{"_ref":"image-ebfb40d061db8cb94776018fe5f4c50f7871539b-5293x3529-jpg","_type":"reference"}},"published":"2024-11-06T17:14:55.772Z","updatedOn":null,"authors":[{"displayName":"Skylar Jeremias","url":"skylar-jeremias"}],"title":"FDA Q\u0026A: Addressing Biosimilar Safety, AI in Drug Development, and Supply Chain Challenges","url":"fda-q-a-addressing-biosimilar-safety-ai-in-drug-development-and-supply-chain-challenges","summary":"In a Q\u0026A, an FDA spokesperson discusses efforts to reduce misinformation about biosimilars through education, the agency’s collaboration with global regulators to streamline development, and its work to address drug shortages while emphasizing safety, efficacy, and public trust.","contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"factCheckAuthors":null},{"_id":"97158d05-1837-44f4-a42d-2f3b8c9566fc","title":"Biosimilar Aflibercept P041 as Effective, Safe as Originator in nAMD","url":"biosimilar-aflibercept-p041-as-effective-safe-as-originator-in-namd","contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"factCheckAuthors":null,"thumbnail":{"_type":"mainImage","alt":"Retinal condition | Image Credit: Yakobchuk Olena - stock.adobe.com","caption":"Biosimilar aflibercept (P041) demonstrated comparable safety and efficacy to the originator aflibercept (Eylea) in treating patients with retinal conditions like neovascular age-related macular degeneration (nAMD). | Image Credit: Yakobchuk Olena - stock.adobe.com","asset":{"_ref":"image-d2cd5de30ba7677ccd28c41ab29de29b346bdf3c-7689x5128-jpg","_type":"reference"}},"summary":"Biosimilar aflibercept (P041) demonstrated comparable safety and efficacy to the originator aflibercept (Eylea) in treating patients with retinal conditions like neovascular age-related macular degeneration (nAMD).","published":"2024-10-30T14:00:00.000Z","updatedOn":null,"authors":[{"displayName":"Cameron Santoro","url":"cameron-santoro"}]},{"_id":"d2968b0a-f1d6-4311-a6db-d90b0182e7f0","title":"Exploring the Complexities of Biosimilars and Interchangeability","summary":"A panel of industry experts discussed the complexities of biosimilars and interchangeability, emphasizing the challenges in adoption, the need for regulatory and legislative solutions, and the importance of education to combat misinformation.","published":"2024-10-30T13:27:00.000Z","updatedOn":null,"contentCategory":{"name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory"},"authors":[{"displayName":"Skylar Jeremias","url":"skylar-jeremias"}],"factCheckAuthors":null,"url":"exploring-the-complexities-of-biosimilars-and-interchangeability","thumbnail":{"asset":{"_ref":"image-0d5a24832621e6f9d53f32a6423b928fb5b1679b-6011x3452-jpg","_type":"reference"},"_type":"mainImage","alt":"health policy chart | Image credit: JOURNEY STUDIO7 - stock.adobe.com"}},{"url":"biosimilars-expand-access-and-reduce-costs-in-oncology-immunology","title":"Biosimilars Expand Access and Reduce Costs in Oncology, Immunology","thumbnail":{"asset":{"_ref":"image-7fc5480ec7e34a8f5b00fd8c0b3f673a38015d46-5184x3456-jpg","_type":"reference"},"_type":"mainImage","alt":"Cost of health care | Image Credit: Scott Hales - stock.adobe.com","caption":"Biosimilars offer significant cost-saving potential while expanding patient access, particularly in oncology and immunology. | Image Credit: Scott Hales - stock.adobe.com"},"summary":"Biosimilars offer significant cost-saving potential while expanding patient access, particularly in oncology and immunology.","published":"2024-10-28T16:00:00.000Z","updatedOn":null,"contentCategory":{"_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh"},"authors":[{"displayName":"Cameron Santoro","url":"cameron-santoro"}],"_id":"20888327-d470-467b-8ca8-54d49dcc9c45","factCheckAuthors":null},{"thumbnail":{"_type":"mainImage","alt":"Market share increase | Image Credit: Kiattisak - stock.adobe.com","caption":"Adalimumab biosimilar market shares have steadily increased, but challenges remain due to pricing strategies and limited government support, according to the Samsung Bioepis report. | Image Credit: Kiattisak - stock.adobe.com","asset":{"_ref":"image-c0595641740ddb95dbc346b73a0a63639345e1ea-7008x4672-jpg","_type":"reference"}},"summary":"Adalimumab biosimilar market shares have steadily increased, but challenges remain due to pricing strategies and limited government support, according to the Samsung Bioepis report.","published":"2024-10-15T20:35:00.000Z","updatedOn":null,"authors":[{"displayName":"Cameron Santoro","url":"cameron-santoro"}],"_id":"6a32debd-239d-45f1-a906-812ca144f467","title":"Samsung Bioepis Reports 2024 Biosimilar Market Growth Trends","url":"samsung-bioepis-reports-2024-biosimilar-market-growth-trends","factCheckAuthors":null,"contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"}},{"title":"FDA Approves Imuldosa, a Fifth Biosimilar to Stelara","url":"fda-approves-imuldosa-a-fifth-biosimilar-to-stelara","thumbnail":{"_type":"mainImage","alt":"FDA approve graphic on screen over a doctor | Image credit: wladimir1804 - stock.adobe.com","asset":{"_ref":"image-140642b191f4ee4e4895ffeda9ce6e76c770dfe2-1200x700-jpg","_type":"reference"}},"authors":[{"displayName":"Skylar Jeremias","url":"skylar-jeremias"}],"factCheckAuthors":null,"_id":"7c97b3a5-ee44-495b-a9ed-04d6428ca255","summary":"Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.","published":"2024-10-11T20:35:16.297Z","updatedOn":null,"contentCategory":{"name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory"}},{"title":"Blue Shield of California Lowers Humira Biosimilar Costs, Challenges PBM Pricing","summary":"Blue Shield of California will offer an adalimumab biosimilar at a price that is 75% less than the reference product Humira for the monthly dose.","published":"2024-10-07T17:47:08.052Z","contentCategory":{"name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory"},"authors":[{"displayName":"Cameron Santoro","url":"cameron-santoro"}],"_id":"49cba82c-0dbf-4c0d-9da7-ce6fcfb58468","url":"blue-shield-of-california-lowers-humira-biosimilar-costs-challenges-pbm-pricing","thumbnail":{"asset":{"_ref":"image-21c4db2b1f658d537c0a022c79b65c35f7d39b8e-3888x2592-jpg","_type":"reference"},"_type":"mainImage","alt":"Cost reduction in health care. | Image Credit: wladimir1804 - stock.adobe.com","caption":"Blue Shield of California will offer an adalimumab biosimilar at a price that is 75% less than the reference product Humira for the monthly dose. | Image Credit: wladimir1804 - stock.adobe.com"},"updatedOn":null,"factCheckAuthors":null},{"updatedOn":null,"contentCategory":{"name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory"},"authors":[{"displayName":"Laura Joszt, MA","url":"laura-joszt"}],"factCheckAuthors":null,"_id":"7cb69552-82c1-4ef6-9145-850ea6cac17f","url":"fourth-ustekinumab-biosimilar-otulfi-approved-in-us","thumbnail":{"_type":"mainImage","alt":"Blue FDA approved stamp | Image credit: cartoon-stock - adobe.com","asset":{"_type":"reference","_ref":"image-60acf610ed5d8534057fb31e98f029c28409bcc1-1200x738-jpg"}},"summary":"Otulfi from Formycon and Fresenius Kabi was approved simultaneously in the US and the European Union. In the US, it will launch in February 2025.","published":"2024-10-02T13:01:24.510Z","title":"Fourth Ustekinumab Biosimilar, Otulfi, Approved in US"},{"factCheckAuthors":null,"_id":"198999ce-6848-4d37-9a0b-b4c4fcec90b5","thumbnail":{"_type":"mainImage","alt":"Follitropin alfa | Image Credit: cristianstorto - stock.adobe.com","caption":"A French study found that follitropin alfa, a biosimilar fertility drug, is more cost-effective compared with its originator, leading to potential savings for both patients and the health care system. | Image Credit: cristianstorto - stock.adobe.com","asset":{"_ref":"image-8dde0bb2ca949518399ff30fcdce451a7f607d87-4993x3317-jpg","_type":"reference"}},"published":"2024-09-30T21:04:53.650Z","authors":[{"displayName":"Cameron Santoro","url":"cameron-santoro"}],"contentCategory":{"_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z"},"title":"Biosimilar Follitropin Alfa Offers Fertility Savings in France","url":"biosimilar-follitropin-alfa-offers-fertility-savings-in-france","summary":"A French study found that follitropin alfa, a biosimilar fertility drug, is more cost-effective compared with its originator, leading to potential savings for both patients and the health care system. ","updatedOn":null},{"published":"2024-09-27T19:01:15.551Z","updatedOn":null,"factCheckAuthors":null,"_id":"f3626855-fc19-4d1c-b8a2-4bf1bdd751d4","thumbnail":{"_type":"mainImage","alt":"Cost savings | Image credit: joyfotoliakid - stock.adobe.com","caption":"Cost savings | Image credit: joyfotoliakid - stock.adobe.com","asset":{"_ref":"image-4d51334652648b7d20b479e8ff9a35a3962ea6df-4896x3264-jpg","_type":"reference"}},"summary":"Out-of-pocket costs for biosimilars and generics are still high for patients despite these drugs leading to estimated savings of $445 billion in 2023.","contentCategory":{"_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles"},"authors":[{"displayName":"Julia Bonavitacola","url":"julia-bonavitacola"}],"title":"Report Highlights Biosimilars Savings, but High Out-of-Pocket Costs for Patients","url":"report-highlights-biosimilars-savings-but-high-out-of-pocket-costs-for-patients"},{"_id":"7cf0d7db-8c76-4cf1-8fe2-8cfc271cce2e","url":"drug-survival-of-biosimilars-originator-tnf-inhibitors-similar","thumbnail":{"alt":"Rows of identical clear vials | Image credit: nordroden - stock.adobe.com","asset":{"_ref":"image-17e1a80a0af08634c1c58ed128411771f0bb71f1-1280x807-jpg","_type":"reference"},"_type":"mainImage"},"updatedOn":null,"contentCategory":{"_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2"},"title":"Drug Survival of Biosimilars, Originator TNF Inhibitors Similar","summary":"The rates of discontinuation due to inefficacy or adverse events for biosimilars and originators of etanercept and adalimumab were similar, according to an analysis of a prospective registry.","published":"2024-09-04T19:26:06.172Z","authors":[{"displayName":"Laura Joszt, MA","url":"laura-joszt"}],"factCheckAuthors":null},{"updatedOn":null,"contentCategory":{"name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory"},"authors":[{"displayName":"Skylar Jeremias","url":"skylar-jeremias"}],"url":"biosimilar-updates-celltrion-costco-partnership-amgen-sues-samsung-bioepis-denosumab-results","summary":"Celltrion's adalimumab-aaty biosimilar is now accessible for all Costco members, while Amgen sues Samsung Bioepis over the latter’s denosumab biosimilar candidate, and GlycoNex progresses its denosumab biosimilar SPD8 to phase 3 trials.","thumbnail":{"alt":"White piggy bank next to a stethoscope with health icons above it | Image credit: Kiattisak - stock.adobe.com","asset":{"_ref":"image-1b666f2bfe935d0536114ee5e312d8f5c043a68c-1280x756-jpg","_type":"reference"},"_type":"mainImage"},"published":"2024-08-25T14:15:00.000Z","factCheckAuthors":null,"_id":"40e7c3ca-c17b-44e7-bab3-3b9189fa5051","title":"Biosimilar Updates: Celltrion, Costco Partnership; Amgen Sues Samsung Bioepis; Denosumab Results"},{"_id":"be81c52c-91fb-487a-a9cb-941a523ed955","title":"Biosimilar Uptake Lags in US Despite Potential Cost Savings","thumbnail":{"_type":"mainImage","alt":"Interest rates control inflation | Image Credit: Thongdee - stock.adobe.com","caption":"Delayed biosimilar uptake in the US is driven by payer, provider, and patient barriers, but targeted interventions can help boost utilization and savings. | Image Credit: Thongdee - stock.adobe.com","asset":{"_ref":"image-4b5dea1abd963d1413ab85a5ad21a6b7ca30e788-4853x2720-jpg","_type":"reference"}},"published":"2024-08-16T13:39:00.000Z","updatedOn":null,"contentCategory":{"_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh"},"url":"biosimilar-uptake-lags-in-us-despite-potential-cost-savings","summary":"Delayed biosimilar uptake in the US is driven by payer, provider, and patient barriers, but targeted interventions can help boost utilization and savings.","authors":[{"displayName":"Cameron Santoro","url":"cameron-santoro"}],"factCheckAuthors":null},{"_id":"9f701edc-8110-46bc-94fe-36ced306d029","thumbnail":{"alt":"Kathy Oubre, MS | Image: LinkedIn","caption":"Kathy Oubre, MS | Image: LinkedIn","asset":{"_ref":"image-bac9119d52d062950c417fc4c28b4780940ac404-225x225-jpg","_type":"reference"},"_type":"mainImage"},"contentCategory":{"_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh"},"factCheckAuthors":null,"title":"Biosimilars and Employers: Strategies for Success","url":"biosimilars-and-employers-strategies-for-success","summary":"This article first appeared on The Center for Biosimilars®.","published":"2024-08-16T10:08:00.000Z","updatedOn":null,"authors":[{"displayName":"Kathy Oubre, MS","url":"kathy-oubre-ms"}]},{"title":"FDA Approves Biosimilar Enzeevu for Eye Conditions","url":"fda-approves-biosimilar-enzeevu-for-eye-conditions","thumbnail":{"alt":"eye and tech | Image credit: eevl - stock.adobe.com","asset":{"_ref":"image-01db92ab6c03e1018494ce00a2848e9bd662af7d-1200x629-jpg","_type":"reference"},"_type":"mainImage"},"published":"2024-08-13T14:32:32.404Z","updatedOn":null,"contentCategory":{"_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2"},"authors":[{"displayName":"Skylar Jeremias","url":"skylar-jeremias"}],"_id":"ed7ddcd9-0217-42ee-adc4-481e5e4771a2","summary":"The FDA approved Sandoz’ Enzeevu, the fourth aflibercept biosimilar to be approved for Americans with age-related macular degeneration and other retinal eye diseases.","factCheckAuthors":null},{"url":"first-aflibercept-biosimilars-approved-in-us","thumbnail":{"alt":"Close of up of an older woman's eye | Image credit: Syda Productions - stock.adobe.com","asset":{"_ref":"image-7edc257aff3f99bf7ce8baf67cd930524592e5ee-1280x813-jpg","_type":"reference"},"_type":"mainImage"},"summary":"The FDA approved the first 2 biosimilars referencing aflibercept (Eylea). However, patent litigation has left it unclear when the biosimilars will come to market.","published":"2024-05-20T21:05:55.699Z","authors":[{"displayName":"Skylar Jeremias","url":"skylar-jeremias"}],"factCheckAuthors":null,"_id":"942bbc18-245e-49e4-9c8c-2ee46b7c46ab","title":"First Aflibercept Biosimilars Approved in US","updatedOn":null,"contentCategory":{"_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2"}},{"title":"Budget Impact Analysis of Biosimilar Natalizumab in the US","summary":"Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.","updatedOn":null,"contentCategory":{"_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles"},"authors":[{"displayName":"Edward Li, PharmD, MPH","url":"edward-li-pharmd-mph"},{"displayName":"Adrian Goh, MEc","url":"adrian-goh-mec"},{"displayName":"Soni Gupta, MEc","url":"soni-gupta-mec"},{"displayName":"Marion Schauf, Dipl-Kff","url":"marion-schauf-dipl-kff"},{"displayName":"Anna Chen, PharmD, MS","url":"anna-chen-pharmd-ms"},{"displayName":"Daniel M. Hartung, PharmD, MPH","url":"daniel-m-hartung-pharmd-mph"}],"factCheckAuthors":null,"_id":"39fd89a2-e5fa-424e-bac7-07fc0c48522b","url":"budget-impact-analysis-of-biosimilar-natalizumab-in-the-us","thumbnail":{"_type":"mainImage","alt":"AJMC","asset":{"_ref":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","_type":"reference"}},"published":"2024-05-17T13:00:00.000Z"},{"_id":"7309e85c-cc1d-47c4-ba35-38ec18d75207","contentCategory":{"_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh"},"factCheckAuthors":null,"authors":[{"displayName":"Kimberly Rath, PharmD","url":"kimberly-rath-pharmd"}],"title":"Radiographic Progression Low for High-Risk Patients With axSpA on Both Secukinumab and an Adalimumab Biosimilar","url":"radiographic-progression-low-for-high-risk-patients-with-axspa-on-both-secukinumab-and-an-adalimumab-biosimilar","thumbnail":{"asset":{"_ref":"image-fafb1b7e7ca04361c98cf0f8b2f5890932aba302-5616x3744-jpg","_type":"reference"},"_type":"mainImage","alt":"Woman sitting on bed with back pain illustrated by a highlighted spine | Image credit: WavebreakMediaMicro - stock.adobe.com"},"summary":"Patients with radiographic axial spondyloarthritis (ax-SpA) and a high risk of radiographic progression had similar low progression on both secukinumab and an adalimumab biosimilar.","published":"2024-04-12T13:17:57.631Z","updatedOn":null},{"factCheckAuthors":null,"title":"FDA Approves First 2 Denosumab Biosimilars","url":"fda-approves-first-2-denosumab-biosimilars","updatedOn":null,"published":"2024-03-05T21:17:01.344Z","contentCategory":{"_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh"},"authors":[{"displayName":"Laura Joszt, MA","url":"laura-joszt"}],"_id":"97acdb47-9eca-4477-9b5d-2295bb160472","thumbnail":{"asset":{"_ref":"image-bf365d9c6f891c03e1fc1d99398a075dea15607e-3508x2480-jpg","_type":"reference"},"_type":"mainImage","alt":"FDA approval stamp in red | Image credit: chrisdorney - stock.adobe.com"},"summary":"Wyost and Jubbonti were approved as interchangeable biosimilars for Xgeva and Prolia; however, there is no launch date yet pending litigation with the maker of the reference products."},{"published":"2024-01-14T13:55:00.000Z","updatedOn":null,"contentCategory":{"_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles"},"_id":"4a5edec5-757b-4bd1-a04d-69a9eedc1ba0","title":"Navigating the Biosimilar Frontier: Opportunities and Challenges in 2024 ","url":"navigating-the-biosimilar-frontier-opportunities-and-challenges-in-2024","summary":"Biosimilars offer substantial promise for a new era of accessibility and affordability for patients and the broader health care industry, but better understanding of these products from payers and providers is necessary for biosimilars to reach their full potential in the US.","thumbnail":{"_type":"mainImage","alt":"Doctor stacking wooden blocks with health care icons | image credit: REDPIXEL - stock.adobe.com","asset":{"_ref":"image-8f2665e13dc96affc156be2470971e666473ce82-1280x792-jpg","_type":"reference"}},"authors":[{"displayName":"Jayne Hornung","url":"jayne-hornung"}],"factCheckAuthors":null}],"targeting":{"content_placement":["compendium/biosimilars"],"document_url":["compendium/biosimilars"],"document_group":[],"rootDocumentGroup":[],"hostname":"www.ajmc.com"},"currentTopic":{"summary":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"The ","_key":"d9a7c16be264"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"5aab8321660a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"84efcc202b1e"},{"marks":[],"text":" Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.","_key":"2454ce1e8332","_type":"span"}],"_type":"block","style":"normal","_key":"21a8926c2669"}],"url":"biosimilars","cmeType":"per","parent":{"_id":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","name":"Compendium","url":"compendium","parent":null},"thumbnail":null,"name":"Biosimilars","perKeywordMapping":["Pharmacy","Health Equity Diversity \u0026 Inclusion"],"ptceKeywordMapping":null,"pixelTrackingCode":null,"_id":"compendium_biosimilars"},"filterData":[],"relatedTopics":null,"podcastsData":[{"taxonomyMapping":[{"_key":"26a4f9365353","_ref":"compendium_biosimilars","_type":"reference"},{"_key":"276f2dadba66","_ref":"d39ec421-0b9c-48cf-874a-1003391b925f","_type":"reference"},{"_ref":"a3fc756d-9cf3-4cbf-9174-96d1490f19d2","_type":"reference","_key":"a54e96fe58ee"}],"_rev":"QAlhr0nVrF3vg56Xb5GiLh","url":{"current":"how-health-care-institutions-can-leverage-biosimilars-to-generate-savings","_type":"slug"},"contentCategory":{"_updatedAt":"2021-08-12T18:05:19Z","_createdAt":"2020-04-03T20:07:37Z","_rev":"DuxacMYwkIxWPw8NDZCeiZ","_type":"contentCategory","name":"Podcasts","disableAds":false,"_id":"367becaf-13c4-4502-9c8c-939f4f480898"},"seoTag":["biosimilars","pharmacoeconomics","biosimilar savings"],"summary":"On this episode of Managed Care Cast, Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and the Winship Cancer Institute, explains the evolution of biosimilar pharmacoeconomics and the different strategies that health care institutions can implement to reap the benefits of biosimilar savings.","_updatedAt":"2022-08-17T17:12:08Z","_createdAt":"2022-08-17T15:24:47Z","ExcludeFromPubMedXML":false,"link":"/view/how-health-care-institutions-can-leverage-biosimilars-to-generate-savings","_type":"article","internalTag":["biosimilars","pharmacoeconomics","biosimilar savings"],"documentGroupMapping":[],"thumbnail":{"_type":"mainImage","alt":"managed care cast banner","asset":{"_ref":"image-4a316e64089806bda54f9d53f783fa1d7a93a6b5-1280x720-jpg","_type":"reference"}},"is_visible":true,"_id":"fb10e244-b992-49d9-bc10-19825ab303d5","updatedOn":null,"documentGroup":null,"title":"How Health Care Institutions Can Leverage Biosimilars to Generate Savings","body":[{"markDefs":[{"href":"https://www.ajmc.com/compendium/biosimilars","_key":"75168f80ec8d","nofollow":true,"_type":"link"}],"children":[{"_type":"span","marks":[],"text":"As more and more ","_key":"e01a5e46342a0"},{"marks":["75168f80ec8d"],"text":"biosimilars","_key":"16daa6e39da9","_type":"span"},{"marks":[],"text":" enter different markets around the globe, payers and practices will need to consistently evaluate the economics of covering biosimilars and take a stance on whether to support their adoption.","_key":"ee93a097423e","_type":"span"}],"_type":"block","style":"normal","_key":"aadf26ece9ac"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Both payers and practices can play a big role in encouraging biosimilar adoption, and health care institutions that have already begun pushing for more biosimilar use, such as Emory Healthcare, have seen substantial savings.","_key":"2f38b78531c30"}],"_type":"block","style":"normal","_key":"b029ac6927f3"},{"_key":"2d4408d7dd59","markDefs":[{"_type":"link","href":"https://www.centerforbiosimilars.com/","_key":"b58f3682f37a","nofollow":true,"blank":true}],"children":[{"_type":"span","marks":[],"text":"On this episode of Managed Care Cast, we speak with Ryan Haumschild, PharmD, MS, MBA, the director of pharmacy services at Emory Healthcare and the Winship Cancer Institute. Haumschild is also an Advisory Board member for The American Journal of Managed Care® and its sister site, ","_key":"c5b93821e3450"},{"_type":"span","marks":["b58f3682f37a"],"text":"The Center for Biosimilars","_key":"65181f34c0e0"},{"_type":"span","marks":[],"text":"®. The interview took place at the The Institute of Value-Based Medicine® (IVBM), hosted by Emory Healthcare, on July 18 in Atlanta, Georgia. Haumschild was chair of the event and gave a presentation on the current pharmacoeconomics of biosimilars and his predictions for how the market will develop in the future.","_key":"7e508ea7d848"}],"_type":"block","style":"normal"},{"_type":"block","style":"normal","_key":"538d8086d6bb","markDefs":[],"children":[{"_type":"span","marks":[],"text":"The episode discussed how the pharmacoeconomics of biosimilars have evolved and different strategies that health care institutions can implement to reap the benefits of biosimilar savings.","_key":"88b7b433cf2e0"}]},{"children":[{"_type":"span","marks":[],"text":"We also talked about how stakeholders can collaborate to promote biosimilars and how technology can be used to assist this mission.","_key":"afffe069cbf20"}],"_type":"block","style":"normal","_key":"40611c6b0f8c","markDefs":[]},{"_type":"block","style":"normal","_key":"21e23a5713aa","markDefs":[{"_type":"link","href":"https://www.ajmc.com/ivbm","_key":"1e0ef662e5f4","nofollow":true}],"children":[{"_type":"span","marks":[],"text":"To learn more about IVBM events, ","_key":"eab14512ac4f"},{"_type":"span","marks":["1e0ef662e5f4"],"text":"click here","_key":"69bc89b5dc19"},{"text":".","_key":"0ca5f6626a8d","_type":"span","marks":[]}]},{"_type":"iframe","_key":"8713f5447149","needSegmentSupport":true,"url":"https://w.soundcloud.com/player/?url=https%3A//api.soundcloud.com/tracks/1325846122\u0026color=%23ff5500\u0026auto_play=false\u0026hide_related=false\u0026show_comments=true\u0026show_user=true\u0026show_reposts=false\u0026show_teaser=true\u0026visual=true\""},{"style":"normal","_key":"9af383b0a9b2","markDefs":[],"children":[{"_key":"3a8b859d7a24","_type":"span","marks":[],"text":"Listen to the interview above or through one of these podcast services:"}],"_type":"block"},{"children":[{"_type":"span","marks":["9c8c6ae96c1b"],"text":"iTunes","_key":"54e2f7db794d"},{"marks":[],"text":"\n","_key":"d967a8d68ebe","_type":"span"},{"_type":"span","marks":["296402f952c8"],"text":"TuneIn","_key":"6a0ed8ecb360"},{"text":"\n","_key":"6c5caa226df6","_type":"span","marks":[]},{"text":"Stitcher","_key":"95d67abbaea0","_type":"span","marks":["b107f4bca379"]},{"_type":"span","marks":[],"text":"\n","_key":"51d92a6e8b12"},{"_type":"span","marks":["251c883162d1"],"text":"Spotify","_key":"46b918b2df53"}],"_type":"block","style":"normal","_key":"385a3cfda436","markDefs":[{"href":"https://podcasts.apple.com/us/podcast/managed-care-cast/id1177540313","_key":"9c8c6ae96c1b","nofollow":true,"blank":true,"_type":"link"},{"_key":"296402f952c8","nofollow":true,"blank":true,"_type":"link","href":"https://tunein.com/podcasts/Health--Wellness-Podcasts/Managed-Care-Cast-p937637/"},{"_type":"link","href":"https://www.stitcher.com/podcast/managed-care-cast","_key":"b107f4bca379","nofollow":true,"blank":true},{"href":"https://open.spotify.com/show/7JQZGTuflqnkt8wjfX238y","_key":"251c883162d1","nofollow":true,"blank":true,"_type":"link"}]}],"authorMapping":[{"_ref":"author_23eb58ee573d6006f4342daadc88b50b","_type":"reference","_key":"35020105025b"}],"published":"2022-08-17T17:00:34.242Z"},{"documentGroup":null,"thumbnail":{"_type":"mainImage","alt":"Managed Care Cast","asset":{"_type":"reference","_ref":"image-4a316e64089806bda54f9d53f783fa1d7a93a6b5-1280x720-jpg"}},"taxonomyMapping":[{"_ref":"a3fc756d-9cf3-4cbf-9174-96d1490f19d2","_type":"reference","_key":"4cd3efda705b"},{"_ref":"39be7351-bd4c-4e98-82b3-0d675ae4671b","_type":"reference","_key":"ecfa449321e0"},{"_ref":"compendium_biosimilars","_type":"reference","_key":"f21265d538f4"}],"contentCategory":{"_type":"contentCategory","name":"Podcasts","disableAds":false,"_id":"367becaf-13c4-4502-9c8c-939f4f480898","_updatedAt":"2021-08-12T18:05:19Z","_createdAt":"2020-04-03T20:07:37Z","_rev":"DuxacMYwkIxWPw8NDZCeiZ"},"_id":"f2572d33-7f10-4458-b6b8-beba21dee422","_rev":"EvpR3UzU3veoB0FakctY7N","link":"/view/biosimilar-whisky-this-expert-says-it-s-doable-no-aging-required","updatedOn":null,"is_visible":true,"_updatedAt":"2022-06-14T20:58:27Z","seoTag":["biosimiliar","whisky"],"ExcludeFromPubMedXML":false,"published":"2022-06-14T21:15:38.027Z","title":"Biosimilar Whisky? This Expert Says It’s Doable, No Aging Required","internalTag":["biosimilar","whisky"],"_createdAt":"2022-06-14T19:22:32Z","url":{"current":"biosimilar-whisky-this-expert-says-it-s-doable-no-aging-required","_type":"slug"},"_type":"article","summary":"On this episode of Managed Care Cast, we’re highlighting a hobby from a biosimilar expert who says he can make whisky more accessible and affordable through—you guessed it—his own biosimilar whisky.","body":[{"style":"normal","_key":"c32c278d6d15","markDefs":[{"_type":"link","href":"https://www.medicalworldnews.com/","_key":"03dcf82b77f0","nofollow":true,"blank":true}],"children":[{"_type":"span","marks":[],"text":"On the After Hours section of ","_key":"aac427834d510"},{"_type":"span","marks":["03dcf82b77f0"],"text":"Medical World News","_key":"052d29ee4085"},{"marks":[],"text":", we like to show you what scientists, researchers, health care providers, and others are doing in their spare time to relax and recharge. On this episode of Managed Care Cast, we’re highlighting a hobby from a biosimilar expert who says he can make whisky more accessible and affordable through—you guessed it—his own biosimilar whisky.","_key":"c22217177315","_type":"span"}],"_type":"block"},{"markDefs":[{"nofollow":true,"_type":"link","href":"https://www.centerforbiosimilars.com/","_key":"2007c77651b6"}],"children":[{"text":"Sarfaraz K. Niazi, PhD, is an adjunct professor of biopharmaceutical sciences at the University of Illinois and the University of Houston, and a member of the advisory board of ","_key":"6c4c9b27d9db0","_type":"span","marks":[]},{"_type":"span","marks":["2007c77651b6"],"text":"The Center for Biosimilars","_key":"b71d8252b146"},{"_type":"span","marks":["superscript"],"text":"®","_key":"559d8b3df5a2"},{"_type":"span","marks":[],"text":", a sister site to AJMC.com, the website of ","_key":"b771ff958bbf"},{"text":"The American Journal of Managed Care","_key":"7002b489a354","_type":"span","marks":["em"]},{"_type":"span","marks":["superscript"],"text":"®","_key":"354b09ba4c83"},{"marks":[],"text":".","_key":"4de6457ff17b","_type":"span"}],"_type":"block","style":"normal","_key":"0d5cf5e73999"},{"_type":"block","style":"normal","_key":"7cb760d9c248","markDefs":[{"_key":"834917bd50f8","nofollow":true,"blank":true,"_type":"link","href":"https://www.medicalworldnews.com/view/after-hours-biosimilar-whisky"}],"children":[{"_type":"span","marks":[],"text":"On a ","_key":"dc6d9c3186ac"},{"marks":["834917bd50f8"],"text":"recent episode of After Hours","_key":"4c32b44341c0","_type":"span"},{"_type":"span","marks":[],"text":", he spoke with Matthew Gavidia, an associate editor at AJMC.com, about his unusual whiskey-making hobby, the history of the traditional process, and how he distills his own biosimilar version.","_key":"00de4c135bd0"}]},{"children":[{"_type":"span","marks":[],"text":"","_key":"886d681a1a54"}],"_type":"block","style":"normal","_key":"544bd94c7f30","markDefs":[]},{"_type":"iframe","_key":"a1ac06ad2696","url":"https://w.soundcloud.com/player/?url=https%3A//api.soundcloud.com/tracks/1287437206%3Fsecret_token%3Ds-JZ7c5RXDKYe\u0026color=%23ff5500\u0026auto_play=false\u0026hide_related=false\u0026show_comments=true\u0026show_user=true\u0026show_reposts=false\u0026show_teaser=true\u0026visual=true"},{"children":[{"_type":"span","marks":[],"text":"\nListen to an excerpt of the interview above or through one of these podcast services:","_key":"c3ffe27435f8"}],"_type":"block","style":"normal","_key":"f032ee4edb78","markDefs":[]},{"markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://podcasts.apple.com/us/podcast/managed-care-cast/id1177540313","_key":"05babff26b1d"},{"nofollow":true,"blank":true,"_type":"link","href":"https://tunein.com/podcasts/Health--Wellness-Podcasts/Managed-Care-Cast-p937637/","_key":"a83c700399d0"},{"blank":true,"_type":"link","href":"https://www.stitcher.com/podcast/managed-care-cast","_key":"5d25f47d6d7b","nofollow":true},{"href":"https://open.spotify.com/show/7JQZGTuflqnkt8wjfX238y","_key":"fcc79015fac2","nofollow":true,"blank":true,"_type":"link"}],"children":[{"_type":"span","marks":["05babff26b1d"],"text":"iTunes","_key":"d9334fc67caf"},{"_type":"span","marks":[],"text":"\n","_key":"b667ea19d12f"},{"_type":"span","marks":["a83c700399d0"],"text":"TuneIn","_key":"b294a6fe90cd"},{"_key":"8e2da6d8be8f","_type":"span","marks":[],"text":"\n"},{"_key":"473e80edfbe1","_type":"span","marks":["5d25f47d6d7b"],"text":"Stitcher"},{"_type":"span","marks":[],"text":"\n","_key":"a2aa0296f8c4"},{"_type":"span","marks":["fcc79015fac2"],"text":"Spotify","_key":"09acb2d51e12"}],"_type":"block","style":"normal","_key":"54a20355b2fe"},{"_type":"block","style":"normal","_key":"ea23953db096","markDefs":[],"children":[{"_type":"span","marks":[],"text":"\n","_key":"59c80578104e"}]},{"_key":"01b130ee3373","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"0c9d1e6b10d5"}],"_type":"block","style":"normal"},{"_key":"50b76bc18807","markDefs":[],"children":[{"_key":"b1480a1f5e180","_type":"span","marks":[],"text":""}],"_type":"block","style":"normal"}]},{"url":{"current":"exploring-2022-trends-in-health-and-hospital-drug-spending-with-vizient","_type":"slug"},"_createdAt":"2021-08-10T17:00:55Z","thumbnail":{"_type":"mainImage","asset":{"_ref":"image-be0b7b58876ac810caae8ed95b44a57df5c930dd-800x400-jpg","_type":"reference"}},"title":" Exploring 2022 Trends in Health and Hospital Drug Spending With Vizient","internalTag":["vizient","covid-19","drug spending","biosimilars","insulin"],"_rev":"DuxacMYwkIxWPw8NDUQkXb","_updatedAt":"2021-08-10T20:01:34Z","body":[{"_key":"ba58a1d3e4b8","markDefs":[],"children":[{"text":"What’s ahead for hospitals and health systems in projected drug spending for 2022?","_key":"a62ac0dfce93","_type":"span","marks":[]}],"_type":"block","style":"normal"},{"children":[{"_type":"span","marks":[],"text":"Vizient recently released its ","_key":"14c37c9a93e40"},{"_type":"span","marks":["b7beda9a108b"],"text":"Summer 2021 Pharmacy Market Outlook","_key":"1fb5733b2015"},{"_type":"span","marks":[],"text":", which looks at what purchasers can expect next year. The report, which delves into its members’ purchasing patterns, predicts a 3.1% increase in pharmaceutical spending next year, with oncology drugs accounting for about 25% of the increase. The report also discusses increasing competition from ","_key":"4202dfe4db1f"},{"marks":["cccd11894c18"],"text":"biosimilars","_key":"91ae20018f16","_type":"span"},{"_type":"span","marks":[],"text":", including the recent approval of insulin glargine as an interchangeable biosimilar for the treatment of ","_key":"63fe0eecc73e"},{"_type":"span","marks":["a84671dae1f0"],"text":"diabetes","_key":"9821ce03d7df"},{"marks":[],"text":"; the practice of white bagging; and other issues. ","_key":"d143d25a7d15","_type":"span"}],"_type":"block","style":"normal","_key":"4d21711f96bd","markDefs":[{"_type":"link","href":"https://www.ajmc.com/compendium/biosimilars","_key":"cccd11894c18"},{"_type":"link","href":"https://www.ajmc.com/compendium/diabetes","_key":"a84671dae1f0"},{"href":"https://info.vizientinc.com/pharmacy-market-outlook?src=DPFpublic","_key":"b7beda9a108b","blank":true,"_type":"link"}]},{"style":"normal","_key":"80918d11a189","markDefs":[],"children":[{"text":"On this episode of Managed Care Cast, we speak with Steven Lucio, PharmD, BCPS, senior principal, Pharmacy Solutions, about the report, which also discusses the continued impact of COVID-19 on health care.","_key":"a9beca22545a0","_type":"span","marks":[]}],"_type":"block"},{"_type":"block","style":"normal","_key":"e54655346dbf","markDefs":[],"children":[{"_key":"594ed11a59c9","_type":"span","marks":[],"text":""}]},{"_type":"iframe","_key":"d360864ff787","url":"https://w.soundcloud.com/player/?url=https%3A//api.soundcloud.com/tracks/1103671801%3Fsecret_token%3Ds-BUfCH7fvDWJ\u0026color=%23ff5500\u0026auto_play=false\u0026hide_related=false\u0026show_comments=true\u0026show_user=true\u0026show_reposts=false\u0026show_teaser=true\u0026visual=true"},{"style":"normal","_key":"e6dfbdd3308b","markDefs":[],"children":[{"_key":"915b9e52c1fd","_type":"span","marks":[],"text":"Listen above or through one of these podcast services:"}],"_type":"block"},{"_key":"5e75a4a0523a","markDefs":[{"blank":true,"_type":"link","href":"https://podcasts.apple.com/us/podcast/managed-care-cast/id1177540313","_key":"07706b7c79de"},{"blank":true,"_type":"link","href":"https://tunein.com/podcasts/Health--Wellness-Podcasts/Managed-Care-Cast-p937637/","_key":"dcf31b090896"},{"blank":true,"_type":"link","href":"https://www.stitcher.com/podcast/managed-care-cast","_key":"77d6c8aa9713"},{"_key":"ec8714ea51cc","blank":true,"_type":"link","href":"https://open.spotify.com/show/7JQZGTuflqnkt8wjfX238y"}],"children":[{"marks":["07706b7c79de"],"text":"iTunes","_key":"f27212dd5290","_type":"span"},{"_key":"9bb0d736a730","_type":"span","marks":[],"text":"\n"},{"_key":"7ffb7a0d3e42","_type":"span","marks":["dcf31b090896"],"text":"TuneIn"},{"text":"\n","_key":"854744027859","_type":"span","marks":[]},{"_type":"span","marks":["77d6c8aa9713"],"text":"Stitcher","_key":"4327de17ffee"},{"_key":"2a8921c6589f","_type":"span","marks":[],"text":"\n"},{"text":"Spotify","_key":"f507c39f9598","_type":"span","marks":["ec8714ea51cc"]}],"_type":"block","style":"normal"}],"link":"/view/exploring-2022-trends-in-health-and-hospital-drug-spending-with-vizient","contentCategory":{"disableAds":false,"_id":"367becaf-13c4-4502-9c8c-939f4f480898","_updatedAt":"2021-08-12T18:05:19Z","_createdAt":"2020-04-03T20:07:37Z","_rev":"DuxacMYwkIxWPw8NDZCeiZ","_type":"contentCategory","name":"Podcasts"},"summary":"Vizient recently released its Summer 2021 Pharmacy Market Outlook, which projects pharmaceutical spending for 2022 based on an analysis of its members' data. On this episode of Managed Care Cast, we talk about some of the findings.","_id":"e58065ae-3a2f-41f4-bf58-beb11ed73fb1","updatedOn":null,"documentGroup":null,"_type":"article","published":"2021-08-10T20:00:00.000Z","is_visible":true,"seoTag":["covid-19","vizient","drug spending","biosimilars","insulin","oncology","pharmacy","hospital pharmacy"],"taxonomyMapping":[{"_ref":"compendium_biosimilars","_type":"reference","_key":"8e5643118460"},{"_ref":"c299e541-89d0-456b-8b2a-4cb16235097b","_type":"reference","_key":"56d73f08b3aa"},{"_ref":"topic_healthcare-cost","_type":"reference","_key":"096e6526256c"},{"_key":"f140f5f23c38","_ref":"topic_healthcare-delivery","_type":"reference"},{"_ref":"e6d00060-6fac-4bf6-9b44-4be71a23cb38","_type":"reference","_key":"21c049b4997f"},{"_type":"reference","_key":"3cd85801f376","_ref":"39be7351-bd4c-4e98-82b3-0d675ae4671b"},{"_key":"bf1978c73a9e","_ref":"5aa8e7d5-8a2d-44dd-99fc-fc43f03e2bed","_type":"reference"},{"_key":"ea6ab886e968","_ref":"a3fc756d-9cf3-4cbf-9174-96d1490f19d2","_type":"reference"}]},{"published":"2019-07-17T00:02:00.000Z","password":"","_createdAt":"2020-04-07T16:03:48Z","_type":"article","passwordLock":false,"is_visible":true,"thumbnail":{"_type":"mainImage","asset":{"_ref":"image-ab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167-jpg","_type":"reference"}},"link":"/view/biosimilars-are-being-approved-but-not-reaching-the-market","url":{"current":"biosimilars-are-being-approved-but-not-reaching-the-market","_type":"slug"},"seoTag":["biosimilars","fda","drug costs"],"internalTag":["biosimilars","fda","drug costs"],"updatedOn":null,"documentGroup":null,"contentCategory":{"_createdAt":"2020-04-03T20:07:37Z","_rev":"DuxacMYwkIxWPw8NDZCeiZ","_type":"contentCategory","name":"Podcasts","disableAds":false,"_id":"367becaf-13c4-4502-9c8c-939f4f480898","_updatedAt":"2021-08-12T18:05:19Z"},"_updatedAt":"2020-07-30T17:50:13Z","summary":"Just halfway through the year, 2019 has been busy for biosimilars, with new guidance and approvals but also the loss of a big advocate of biosimilars from the FDA.","body":[{"style":"normal","_key":"3ZTK85cq","markDefs":[],"children":[{"_type":"span","text":"Just halfway through the year, 2019 has been busy for biosimilars, with new guidance and approvals but also the loss of a big advocate of biosimilars from the FDA. In this episode of Managed Care Cast, Kelly Davio, senior editor of The Center for Biosimilars","_key":"xtE83I3a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"wCxdjfQ2"},{"_type":"span","text":", a sister site of ","_key":"4CE7673U"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"ZkA5nsJa"},{"_type":"span","marks":["superscript"],"text":"®","_key":"pBN8XOF2"},{"_type":"span","text":", discusses new approvals; what the loss of Scott Gottlieb, MD, as FDA commissioner means; the reality of pay-for-delay deals; and more.","_key":"Jd1gDHcr"}],"_type":"block"},{"_type":"block","style":"normal","_key":"dJciglu4","markDefs":[],"children":[]},{"_type":"block","style":"normal","_key":"ecFyYUVN","markDefs":[{"blank":true,"_type":"link","href":"https://www.centerforbiosimilars.com/news/amgen-and-allergan-launch-mvasi-and-kanjinti-the-first-anticancer-biosimilars-in-the-united-states","_key":"aprhWaAQwn"}],"children":[{"text":"Editor's note: since this conversation was recorded, 2 additional biosimilars, both anticancer agents, have launched in the United States. ","_key":"FYipUcZX","_type":"span","marks":["em"]},{"_key":"oRwZ9akt","_type":"span","marks":["aprhWaAQwn","em"],"text":"Learn more here"},{"_key":"Z348r8uZ","_type":"span","marks":["em"],"text":"."}]},{"_key":"l8nb3szh","markDefs":[],"children":[],"_type":"block","style":"normal"},{"_type":"iframe","_key":"yAKfFbvB","url":"https://w.soundcloud.com/player/?url=https%3A//api.soundcloud.com/tracks/652085135%3Fsecret_token%3Ds-wxaI5\u0026color=%23ff5500\u0026auto_play=false\u0026hide_related=false\u0026show_comments=true\u0026show_user=true\u0026show_reposts=false\u0026show_teaser=true"},{"markDefs":[],"children":[],"_type":"block","style":"normal","_key":"nssMmzsE"},{"children":[],"_type":"block","style":"normal","_key":"QmDCuOla","markDefs":[]},{"markDefs":[{"_type":"link","href":"http://apple.co/2eYWTss?rel=0","_key":"fXDR_sDM_q","blank":true}],"children":[{"_type":"span","marks":["fXDR_sDM_q"],"text":"iTunes","_key":"BVDYxA9k"}],"_type":"block","style":"normal","_key":"0XpZz2Zh"},{"children":[{"marks":["orNypAeFwt"],"text":"TuneIn","_key":"z0OScDVV","_type":"span"}],"_type":"block","style":"normal","_key":"0gnMixmt","markDefs":[{"blank":true,"_type":"link","href":"http://bit.ly/2gv7iwj?rel=0","_key":"orNypAeFwt"}]},{"markDefs":[{"_type":"link","href":"http://bit.ly/2gCqtFg?rel=0","_key":"aA7IXTNCl0","blank":true}],"children":[{"_type":"span","marks":["aA7IXTNCl0"],"text":"Stitcher","_key":"TsnQg6X5"}],"_type":"block","style":"normal","_key":"0P8kHUB0"},{"_type":"block","style":"normal","_key":"jDWsk6or","markDefs":[{"blank":true,"_type":"link","href":"https://open.spotify.com/show/7JQZGTuflqnkt8wjfX238y?rel=0","_key":"BHsB3yl6X1"}],"children":[{"_type":"span","marks":["BHsB3yl6X1"],"text":"Spotify","_key":"OJMrv1pk"}]},{"_key":"FIZbk25c","markDefs":[],"children":[],"_type":"block","style":"normal"},{"style":"normal","_key":"iBbULYoC","markDefs":[{"blank":true,"_type":"link","href":"https://www.centerforbiosimilars.com/","_key":"KtbGRCgDxQ"}],"children":[{"_type":"span","text":"Learn more about biosimilars at ","_key":"JZ6NyJUG"},{"_type":"span","marks":["KtbGRCgDxQ"],"text":"centerforbiosimilars.com","_key":"e6ir1zVq"},{"_type":"span","text":".","_key":"FQejOThM"}],"_type":"block"},{"markDefs":[],"children":[{"_type":"span","text":"Listen above or through one of these podcast services:","_key":"1CvaKYxU"}],"_type":"block","style":"normal","_key":"aAU6lqPf"}],"title":"Biosimilars Are Being Approved but Not Reaching the Market","authorMapping":[],"taxonomyMapping":[{"_ref":"a3fc756d-9cf3-4cbf-9174-96d1490f19d2","_type":"reference","_key":"DCtw4gaC"},{"_ref":"compendium_biosimilars","_type":"reference","_key":"gRGsvwK6"}],"_rev":"GQ2iWOdzjKwgYpKUFW3zgz","_id":"cme_article_40399"},{"_id":"cme_article_38339","seoTag":["biosimilars","healthcare cost","drug pricing","scott gottlieb","biosimilar action plan"],"updatedOn":null,"_rev":"UwoPTp0rpTY11EWI0U5d4y","summary":"Last year was a big year for biosimilars in the United States, with the number of FDA-approved biosimilars nearly doubling and major policy and regulatory developments taking place.","thumbnail":{"_type":"mainImage","asset":{"_type":"reference","_ref":"image-ab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167-jpg"}},"authorMapping":[],"url":{"current":"progress-in-the-us-with-biosimilars-but-opportunities-remain","_type":"slug"},"contentCategory":{"_id":"367becaf-13c4-4502-9c8c-939f4f480898","_updatedAt":"2021-08-12T18:05:19Z","_createdAt":"2020-04-03T20:07:37Z","_rev":"DuxacMYwkIxWPw8NDZCeiZ","_type":"contentCategory","name":"Podcasts","disableAds":false},"_updatedAt":"2020-07-30T17:50:12Z","is_visible":true,"published":"2019-01-09T00:03:00.000Z","passwordLock":false,"password":"","_createdAt":"2020-04-07T16:03:48Z","_type":"article","link":"/view/progress-in-the-us-with-biosimilars-but-opportunities-remain","documentGroup":null,"taxonomyMapping":[{"_key":"ntDJ14Iu","_ref":"a3fc756d-9cf3-4cbf-9174-96d1490f19d2","_type":"reference"},{"_key":"9G7PSH1r","_ref":"compendium_biosimilars","_type":"reference"}],"internalTag":["biosimilars","healthcare cost","drug pricing","scott gottlieb","biosimilar action plan"],"body":[{"children":[{"_key":"vnAdk3OU","_type":"span","text":"Last year was a big year for biosimilars in the United States, with the number of FDA-approved biosimilars nearly doubling and major policy and regulatory developments taking place in 2018. Kelly Davio, senior editor of "},{"_type":"span","marks":["em"],"text":"AJMC","_key":"Nlh1tWte"},{"_type":"span","marks":["superscript"],"text":"®","_key":"AOMBHpq6"},{"_type":"span","text":"'s The Center for Biosimilars","_key":"t5976ST6"},{"_type":"span","marks":["superscript"],"text":"®","_key":"i41s5tSh"},{"_type":"span","text":", highlights recent progress, how the US market compares with Europe, and what remains to be seen.","_key":"psCzQjP9"}],"_type":"block","style":"normal","_key":"1zl6EeLR","markDefs":[]},{"_type":"block","style":"normal","_key":"0OscqBbR","markDefs":[],"children":[]},{"markDefs":[],"children":[{"_type":"span","text":"You may need to log in to the website to access this podcast.","_key":"8XXMCsNr"}],"_type":"block","style":"normal","_key":"eweEtGCl"},{"url":"https://w.soundcloud.com/player/?url=https%3A//api.soundcloud.com/tracks/555978360%3Fsecret_token%3Ds-Eb1oS\u0026color=%23ff5500\u0026auto_play=false\u0026hide_related=false\u0026show_comments=true\u0026show_user=true\u0026show_reposts=false\u0026show_teaser=true\u0026rel=0","_type":"iframe","_key":"YRCD1pKE"},{"markDefs":[],"children":[],"_type":"block","style":"normal","_key":"973bQsrf"},{"markDefs":[],"children":[],"_type":"block","style":"normal","_key":"AUlGWR4e"},{"_key":"N9L8AAq7","markDefs":[{"blank":true,"_type":"link","href":"https://itunes.apple.com/us/podcast/managed-care-cast/id1177540313?mt=2\u0026ign-mpt=uo%3D4\u0026rel=0","_key":"1MCnWzYOY"}],"children":[{"text":"iTunes","_key":"Nzu8vdwC","_type":"span","marks":["1MCnWzYOY"]}],"_type":"block","style":"normal"},{"_type":"block","style":"normal","_key":"vdrUR4sM","markDefs":[{"blank":true,"_type":"link","href":"https://tunein.com/podcasts/Health--Wellness-Podcasts/Managed-Care-Cast-p937637/?rel=0","_key":"7pdzcwN608"}],"children":[{"_type":"span","marks":["7pdzcwN608"],"text":"TuneIn","_key":"DqhseuKR"}]},{"markDefs":[{"blank":true,"_type":"link","href":"https://www.stitcher.com/podcast/managed-care-cast?rel=0","_key":"hUZP9foy7t"}],"children":[{"text":"Stitcher","_key":"22QgLyAW","_type":"span","marks":["hUZP9foy7t"]}],"_type":"block","style":"normal","_key":"ZXQbXfze"},{"markDefs":[],"children":[{"_type":"span","text":"Listen above or through one of these podcast services:","_key":"7J9xljJw"}],"_type":"block","style":"normal","_key":"1A1mNoyy"},{"style":"normal","_key":"hQrG5pi5","markDefs":[{"_key":"y2_MkSOwlf","blank":true,"_type":"link","href":"https://www.centerforbiosimilars.com/?rel=0"}],"children":[{"text":"The Center for Biosimilars","_key":"KWjxPPHG","_type":"span","marks":["y2_MkSOwlf"]},{"marks":["superscript","y2_MkSOwlf"],"text":"®","_key":"JfaEHXeV","_type":"span"}],"_type":"block"},{"_key":"cBNHaz3Q","markDefs":[{"blank":true,"_type":"link","href":"https://www.centerforbiosimilars.com/?rel=0","_key":"bO-4W9jSv-"}],"children":[{"_type":"span","marks":["bO-4W9jSv-"],"text":"Stakeholders Weigh In on the Key Biosimilar Developments of 2018","_key":"79DO857t"}],"_type":"block","style":"normal"},{"_type":"block","style":"normal","_key":"3i0E8Opn","markDefs":[{"blank":true,"_type":"link","href":"https://www.centerforbiosimilars.com/?rel=0","_key":"X8USQG_-iV"}],"children":[{"marks":["X8USQG_-iV"],"text":"Coherus Confirms That It Has Launched Its Pegfilgrastim Biosimilar, Udenyca","_key":"BqqvxXhC","_type":"span"}]},{"markDefs":[{"blank":true,"_type":"link","href":"https://www.centerforbiosimilars.com/?rel=0","_key":"YvwpiCQDM9"}],"children":[{"_type":"span","marks":["YvwpiCQDM9"],"text":"FDA Releases Biosimilar Action Plan","_key":"XAHIbrfu"}],"_type":"block","style":"normal","_key":"zXcRzukc"},{"style":"normal","_key":"C3Ostr7a","markDefs":[{"blank":true,"_type":"link","href":"https://www.centerforbiosimilars.com/?rel=0","_key":"8tbznUNz3Y"}],"children":[{"marks":["8tbznUNz3Y"],"text":"Pfizer Launches Epoetin Alfa Biosimilar, Retacrit, at 33.5% Discount to Reference Epogen","_key":"8geEfQP2","_type":"span"}],"_type":"block"},{"children":[{"_type":"span","marks":["LnLG5vEVNy"],"text":"Pfizer Becomes Latest to Settle With AbbVie Over Humira","_key":"9RU7HZxO"}],"_type":"block","style":"normal","_key":"yZqPcNdX","markDefs":[{"blank":true,"_type":"link","href":"https://www.centerforbiosimilars.com/?rel=0","_key":"LnLG5vEVNy"}]},{"markDefs":[],"children":[{"_type":"span","text":"Read more about the stories in this podcast:","_key":"g5kkWpmh"}],"_type":"block","style":"normal","_key":"DhQb6U5Z"}],"title":"Progress in the US With Biosimilars, but Opportunities Remain"},{"audioUrl":"https://s3.us-east-1.amazonaws.com/ai-generated-audios/www.ajmc.com/cme_article_37546_1736274946929.a238adab-46a6-41bd-be52-7c0ba1acf8c8.mp3","articleType":"News","authorMapping":[],"seoTag":["apm","health policy","health insurance","oncology","specialty pharmacy","biosimilars"],"taxonomyMapping":[{"_type":"reference","_key":"sldPiQvs","_ref":"a3fc756d-9cf3-4cbf-9174-96d1490f19d2"},{"_ref":"compendium_apm","_type":"reference","_key":"Fi4u8fG1"},{"_ref":"compendium_oncology","_type":"reference","_key":"G3kgwBUW"},{"_type":"reference","_key":"Ozj6lLpV","_ref":"compendium_biosimilars"}],"title":"Podcast: This Week in Managed Care—States Gain Power to Alter ACA Offerings and Other Health News","thumbnail":{"_type":"mainImage","asset":{"_type":"reference","_ref":"image-ab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167-jpg"}},"_id":"cme_article_37546","internalTag":["apm","health policy","health insurance","oncology","specialty pharmacy","biosimilars"],"_rev":"6qtEO0uNThoN127hQcm1Wh","summary":"Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.","updatedOn":null,"url":{"current":"podcast-this-week-in-managed-caremdashstates-gain-power-to-alter-aca-offerings-and-other-health-news","_type":"slug"},"is_visible":true,"passwordLock":false,"documentGroup":null,"published":"2018-10-27T17:58:00.000Z","link":"/view/podcast-this-week-in-managed-caremdashstates-gain-power-to-alter-aca-offerings-and-other-health-news","_type":"article","contentCategory":{"_type":"contentCategory","name":"Podcasts","disableAds":false,"_id":"367becaf-13c4-4502-9c8c-939f4f480898","_updatedAt":"2021-08-12T18:05:19Z","_createdAt":"2020-04-03T20:07:37Z","_rev":"DuxacMYwkIxWPw8NDZCeiZ"},"_createdAt":"2020-04-07T16:03:47Z","body":[{"_key":"fmKHJYfG","markDefs":[],"children":[{"_type":"span","text":"Every week, ","_key":"EFH3ww8K"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"0mxelaoR"},{"_type":"span","marks":["superscript"],"text":"®","_key":"Mk370qi2"},{"_key":"HIoRl3YN","_type":"span","text":" recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast."}],"_type":"block","style":"normal"},{"_type":"block","style":"normal","_key":"Qjna04FX","markDefs":[],"children":[{"_key":"a3301b47e03e","_type":"span","text":""}]},{"_key":"z9YhZIlG","markDefs":[],"children":[{"_type":"span","text":"This week, the top managed care news included the Trump administration giving governors the power to overhaul section 1332 waivers under the Affordable Care Act (ACA); CMS disclosed a breach in the portal that agents and brokers use to assist consumers signing up for health coverage under the ACA; about one-third of all US healthcare payments in 2017 were tied to alternative payment models.","_key":"TYE36rps"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"_type":"span","text":"","_key":"2561c67ccedf"}],"_type":"block","style":"normal","_key":"IYG6WbtD"},{"children":[{"_type":"span","text":"You may need to log in to the website to access this podcast.","_key":"Bacslg81"}],"_type":"block","style":"normal","_key":"3nx05yYn","markDefs":[]},{"markDefs":[],"children":[{"_type":"span","text":"","_key":"a0abef8b1e56"}],"_type":"block","style":"normal","_key":"JkdPzPUu"},{"_type":"iframe","_key":"151SZM2z","url":"https://w.soundcloud.com/player/?url=https%3A//api.soundcloud.com/tracks/520692768\u0026color=%23ff5500\u0026auto_play=false\u0026hide_related=false\u0026show_comments=true\u0026show_user=true\u0026show_reposts=false\u0026show_teaser=true"},{"markDefs":[],"children":[{"_type":"span","text":"","_key":"f27aad525b95"}],"_type":"block","style":"normal","_key":"fBIGUO8o"},{"markDefs":[],"children":[{"_type":"span","text":"","_key":"501d541eefa2"}],"_type":"block","style":"normal","_key":"HaQhrwG4"},{"children":[{"_type":"span","text":"iTunes: ","_key":"XlsPimuF"},{"marks":["OOKXU5cgU7j"],"text":"http://apple.co/2eYWTss","_key":"xKK7obOG","_type":"span"}],"_type":"block","style":"normal","_key":"f67EqL80","markDefs":[{"blank":true,"_type":"link","href":"http://apple.co/2eYWTss","_key":"OOKXU5cgU7j"}]},{"style":"normal","_key":"JDvL0emj","markDefs":[{"blank":true,"_type":"link","href":"http://bit.ly/2gv7iwj","_key":"EcoLIzjc_UZ"}],"children":[{"_type":"span","text":"TuneIn: ","_key":"KQOCC3HZ"},{"_type":"span","marks":["EcoLIzjc_UZ"],"text":"http://bit.ly/2gv7iwj","_key":"LtXj2csw"}],"_type":"block"},{"_key":"KpVGTvOI","markDefs":[{"blank":true,"_type":"link","href":"http://bit.ly/2gCqtFg","_key":"47t6fijqLp7"}],"children":[{"_type":"span","text":"Stitcher: ","_key":"kP5Ovh7L"},{"text":"http://bit.ly/2gCqtFg","_key":"fkPe2zQU","_type":"span","marks":["47t6fijqLp7"]}],"_type":"block","style":"normal"},{"style":"normal","_key":"uEtPDnGV","markDefs":[],"children":[{"_key":"LmgbHUlu","_type":"span","text":"Listen above or through one of these podcast services:"}],"_type":"block"},{"markDefs":[{"blank":true,"_type":"link","href":"https://www.ajmc.com/newsroom/trump-administration-gives-states-more-power-to-alter-aca-exchange-offerings","_key":"URcu_a-kJ7h"}],"children":[{"marks":["URcu_a-kJ7h"],"text":"Trump Administration Gives States More Power to Alter ACA Exchange Offerings","_key":"nagyslN7","_type":"span"}],"_type":"block","style":"normal","_key":"cMJIKUyV"},{"markDefs":[{"_key":"AQDywbhEbg3","blank":true,"_type":"link","href":"https://www.ajmc.com/focus-of-the-week/cms-reports-data-breach-in-aca-agent-and-broker-portal"}],"children":[{"marks":["AQDywbhEbg3"],"text":"CMS Reports Data Breach in ACA Agent and Broker Portal","_key":"uRfbbUmP","_type":"span"}],"_type":"block","style":"normal","_key":"jX3bb4ZJ"},{"style":"normal","_key":"geisoEPz","markDefs":[{"blank":true,"_type":"link","href":"https://www.ajmc.com/newsroom/cms-cuts-budget-for-aca-marketing-to-10-million-for-2019-plan-year","_key":"sYXSCFF-rtX"}],"children":[{"_key":"3eMAExPm","_type":"span","marks":["sYXSCFF-rtX"],"text":"CMS Cuts Budget for ACA Marketing to $10 Million for 2019 Plan Year"}],"_type":"block"},{"_type":"block","style":"normal","_key":"9XZ1CnhB","markDefs":[{"blank":true,"_type":"link","href":"https://www.ajmc.com/newsroom/payments-are-increasingly-tied-to-value-but-more-riskbased-models-needed","_key":"TplzztISWlA"}],"children":[{"_type":"span","marks":["TplzztISWlA"],"text":"Payments Are Increasingly Tied to Value, but More Risk-Based Models Needed","_key":"SuYfYxUr"}]},{"_type":"block","style":"normal","_key":"Wey7esiF","markDefs":[{"blank":true,"_type":"link","href":"https://www.ajmc.com/conferences/amcpnexus2018/drug-market-to-see-more-competition-launch-of-biosimilars-in-2019","_key":"-7PxD9lxRFt"}],"children":[{"_type":"span","marks":["-7PxD9lxRFt"],"text":"Drug Market to See More Competition, Launch of Biosimilars in 2019","_key":"Glt6Phkd"}]},{"style":"normal","_key":"l4Xu7bYc","markDefs":[{"blank":true,"_type":"link","href":"https://www.ajmc.com/conference/amcp-nexus","_key":"w_3LctCw6ZD"}],"children":[{"marks":["w_3LctCw6ZD"],"text":"The Academy of Managed Care Pharmacy Nexus 2018","_key":"oFtjvGqr","_type":"span"}],"_type":"block"},{"_key":"pa5uZG1A","markDefs":[{"blank":true,"_type":"link","href":"https://www.ajmc.com/conference/psych-congress","_key":"BjvARpoRuB2"}],"children":[{"marks":["BjvARpoRuB2"],"text":"Psych Congress 2018","_key":"sxFH12OF","_type":"span"}],"_type":"block","style":"normal"},{"style":"normal","_key":"QhCAzNMn","markDefs":[{"blank":true,"_type":"link","href":"https://www.ajmc.com/interviews/dr-barbara-mcaneny-discusses-the-effect-of-ocms-second-performance-period-results","_key":"JymDrad7OLB"}],"children":[{"_type":"span","marks":["JymDrad7OLB"],"text":"Dr Barbara McAneny Discusses the Effect of OCM's Second Performance Period Results","_key":"5gdooLnq"}],"_type":"block"},{"markDefs":[{"blank":true,"_type":"link","href":"https://www.ajmc.com/conference/pcoc","_key":"ZvCx9sz03Ku"}],"children":[{"_type":"span","marks":["ZvCx9sz03Ku"],"text":"Patient-Centered Oncology","_key":"kfirfMMc"},{"text":"®","_key":"BN6w1OSC","_type":"span","marks":["superscript","ZvCx9sz03Ku"]}],"_type":"block","style":"normal","_key":"LO2uiHpg"},{"markDefs":[],"children":[{"_type":"span","text":"Read more about the stories in this podcast:","_key":"6x98EULz"}],"_type":"block","style":"normal","_key":"cGdARWhK"}],"password":"","_updatedAt":"2025-01-07T18:35:47Z"},{"documentGroup":null,"taxonomyMapping":[{"_type":"reference","_key":"jvFrOW27","_ref":"a3fc756d-9cf3-4cbf-9174-96d1490f19d2"},{"_type":"reference","_key":"Ff5j3K9h","_ref":"compendium_oncology"},{"_ref":"compendium_hematology","_type":"reference","_key":"Upq24pkA"},{"_ref":"topic_technology","_type":"reference","_key":"MC6srRcK"},{"_ref":"compendium_biosimilars","_type":"reference","_key":"SiPZrioW"}],"contentCategory":{"_updatedAt":"2021-08-12T18:05:19Z","_createdAt":"2020-04-03T20:07:37Z","_rev":"DuxacMYwkIxWPw8NDZCeiZ","_type":"contentCategory","name":"Podcasts","disableAds":false,"_id":"367becaf-13c4-4502-9c8c-939f4f480898"},"_type":"article","is_visible":true,"body":[{"_type":"block","style":"normal","_key":"tz8MHdi3","markDefs":[],"children":[{"_type":"span","text":"Every week, ","_key":"u8ZNYoOF"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"glgTOKTL"},{"_type":"span","marks":["superscript"],"text":"®","_key":"rgvi1ocB"},{"_type":"span","text":" recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.","_key":"PYQOLvX3"}]},{"markDefs":[],"children":[],"_type":"block","style":"normal","_key":"pIytm05G"},{"style":"normal","_key":"hsxKwVAx","markDefs":[],"children":[{"_key":"9Suix3Mn","_type":"span","text":"This week, the top managed care stories included Cigna's deal to buy Express Scripts; Seema Verma, Alex Azar, and Scott Gottlieb, MD, made the rounds at health conferences; an analysis finds FDA's accelerated approval pathway has been a success with hematology and oncology drugs."}],"_type":"block"},{"markDefs":[],"children":[],"_type":"block","style":"normal","_key":"2o0YcJQN"},{"_key":"pwh1mtGj","url":"https://w.soundcloud.com/player/?url=https%3A//api.soundcloud.com/tracks/411277704\u0026color=%23ff5500\u0026auto_play=false\u0026hide_related=false\u0026show_comments=true\u0026show_user=true\u0026show_reposts=false\u0026show_teaser=true","_type":"iframe"},{"children":[],"_type":"block","style":"normal","_key":"2iRfksCJ","markDefs":[]},{"markDefs":[],"children":[],"_type":"block","style":"normal","_key":"Pn5FOJNd"},{"_type":"block","style":"normal","_key":"CNADPLCk","markDefs":[],"children":[{"_type":"span","text":"Listen above or through one of these podcast services:","_key":"Hq7odhUM"}]},{"_type":"block","style":"normal","_key":"HuI7GITN","markDefs":[{"blank":true,"_type":"link","href":"http://apple.co/2eYWTss","_key":"UaY5iToaQd"}],"children":[{"text":"iTunes: ","_key":"tu3eompw","_type":"span"},{"_type":"span","marks":["UaY5iToaQd"],"text":"http://apple.co/2eYWTss","_key":"D7z18SKq"}]},{"children":[{"_type":"span","text":"TuneIn: ","_key":"NxxDRxTW"},{"_type":"span","marks":["nWY_mEkAOz"],"text":"http://bit.ly/2gv7iwj","_key":"a6hhFBv3"}],"_type":"block","style":"normal","_key":"cTfqSZUF","markDefs":[{"blank":true,"_type":"link","href":"http://bit.ly/2gv7iwj","_key":"nWY_mEkAOz"}]},{"_key":"KTgRDmlp","markDefs":[{"blank":true,"_type":"link","href":"http://bit.ly/2gCqtFg","_key":"IBasAeNlRY"}],"children":[{"text":"Stitcher: ","_key":"CVTWNJWU","_type":"span"},{"text":"http://bit.ly/2gCqtFg","_key":"FSDX71me","_type":"span","marks":["IBasAeNlRY"]}],"_type":"block","style":"normal"},{"_key":"OTYhgDDS","markDefs":[],"children":[],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"text":"Read more about the stories in this podcast:","_key":"rjET9zFL","_type":"span"}],"_type":"block","style":"normal","_key":"VW17Le6f"},{"children":[{"_type":"span","marks":["4RYhaR5FSa"],"text":"Healthcare Mergers Continue With Deal for Cigna to Acquire Express Scripts","_key":"fhM13LKq"}],"_type":"block","style":"normal","_key":"AndGc98m","markDefs":[{"_key":"4RYhaR5FSa","blank":true,"_type":"link","href":"http://www.ajmc.com/newsroom/cigna-to-acquire-express-scripts-in-67-billion-deal"}]},{"markDefs":[{"_key":"mEmKyjjNY1","blank":true,"_type":"link","href":"http://www.ajmc.com/newsroom/what-were-reading-verma-on-health-data-more-medicaid-work-requirements-nj-individual-mandate"}],"children":[{"_type":"span","marks":["mEmKyjjNY1"],"text":"What We're Reading: Verma on Health Data; More Medicaid Work Requirements; NJ Individual Mandate","_key":"rD8ioh54"}],"_type":"block","style":"normal","_key":"mmiDfdZn"},{"style":"normal","_key":"9OD7YsrR","markDefs":[{"blank":true,"_type":"link","href":"http://www.ajmc.com/newsroom/azar-tells-insurance-industry-patients-must-be-in-charge-of-their-own-data","_key":"7V4N7I245jE"}],"children":[{"_type":"span","marks":["7V4N7I245jE"],"text":"Azar Tells Insurance Industry Patients Must Be in Charge of Their Own Data","_key":"V7D17m95"}],"_type":"block"},{"_key":"FJmouVo4","markDefs":[{"blank":true,"_type":"link","href":"http://www.ajmc.com/newsroom/fdas-gottlieb-blames-rebates-reimbursement-issues-for-holding-back-biosimilar-market","_key":"jC3KjznHGZy"}],"children":[{"text":"FDA's Gottlieb Blames Rebates, Reimbursement Issues for Holding Back Biosimilar Market","_key":"BiU6bHWt","_type":"span","marks":["jC3KjznHGZy"]}],"_type":"block","style":"normal"},{"style":"normal","_key":"VAzLAwyd","markDefs":[{"_type":"link","href":"http://www.ajmc.com/newsroom/what-were-reading-azar-to-announce-healthcare-actions-opposition-to-cms-opioid-limits-diabetes-disagreement","_key":"8-M02tKcW1g","blank":true}],"children":[{"_type":"span","marks":["8-M02tKcW1g"],"text":"What We're Reading: Azar to Announce Healthcare Actions; Opposition to CMS Opioid Limits; Diabetes Disagreement","_key":"xNMWDYnl"}],"_type":"block"},{"children":[{"_key":"Ngx6oY6n","_type":"span","marks":["RYBzRi3vnmr"],"text":"Expedited Approval Is Successful for Cancer Therapies, FDA Says"}],"_type":"block","style":"normal","_key":"e6jGavIn","markDefs":[{"blank":true,"_type":"link","href":"http://www.ajmc.com/focus-of-the-week/expedited-approval-is-successful-for-cancer-therapies-fda-says","_key":"RYBzRi3vnmr"}]},{"style":"normal","_key":"560SfJ04","markDefs":[{"blank":true,"_type":"link","href":"http://www.ajmc.com/managed-care-cast/the-shift-from-episodic-to-continuous-care-wearable-technology-and-telemedicine-in-cardiology","_key":"nuHlgi-1Uh7"}],"children":[{"marks":["nuHlgi-1Uh7"],"text":"The Shift From Episodic to Continuous Care: Wearable Technology and Telemedicine in Cardiology","_key":"oZONr5uJ","_type":"span"}],"_type":"block"},{"markDefs":[{"_type":"link","href":"http://www.ajmc.com/conferences/acc-2018","_key":"H0tgis_TrV-","blank":true}],"children":[{"text":"American College of Cardiology’s 67th Annual Scientific Session \u0026 Expo","_key":"aFuXmxrA","_type":"span","marks":["H0tgis_TrV-"]}],"_type":"block","style":"normal","_key":"y5ruFfPb"}],"thumbnail":{"_type":"mainImage","asset":{"_ref":"image-ab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167-jpg","_type":"reference"}},"_createdAt":"2020-04-07T16:03:47Z","seoTag":["oncology","hematology","health policy","health data","interoperability","health IT","HIT","biosimilars"],"_id":"cme_article_35108","internalTag":["oncology","hematology","health policy","health data","interoperability","health IT","HIT","biosimilars"],"passwordLock":false,"url":{"_type":"slug","current":"podcast-this-week-in-managed-caremdashverma-on-health-data-and-other-health-news"},"authorMapping":[],"published":"2018-03-10T19:00:00.000Z","password":"","title":"Podcast: This Week in Managed Care\u0026mdash;Verma on Health Data and Other Health News","_rev":"GQ2iWOdzjKwgYpKUFW3yvN","_updatedAt":"2020-07-30T17:50:11Z","summary":"Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.","link":"/view/podcast-this-week-in-managed-caremdashverma-on-health-data-and-other-health-news","updatedOn":null},{"title":"The State of Biosimilars in the United States: The Center for Biosimilars® Peer Exchange","_updatedAt":"2020-07-30T17:50:11Z","taxonomyMapping":[{"_key":"4HCGDdwj","_ref":"a3fc756d-9cf3-4cbf-9174-96d1490f19d2","_type":"reference"},{"_ref":"compendium_biosimilars","_type":"reference","_key":"6pI3K82m"}],"url":{"current":"the-state-of-biosimilars-in-the-united-states-center-for-biosimilars-peer-exchange","_type":"slug"},"thumbnail":{"_type":"mainImage","asset":{"_ref":"image-ab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167-jpg","_type":"reference"}},"updatedOn":null,"internalTag":["biosimilars","reimbursement","health policy","litigation"],"_type":"article","_id":"cme_article_34662","published":"2018-01-24T00:44:00.000Z","body":[{"_key":"dgZNU3l0","markDefs":[],"children":[{"text":"The introduction of biosimilars to the US market has led to an unprecedented amount of uncertainty as stakeholders try to understand the implications of their arrival. The Center for Biosimilars","_key":"HDG1KfuI","_type":"span"},{"marks":["superscript"],"text":"®","_key":"dFcKkcXj","_type":"span"},{"_type":"span","text":", a sister site of ","_key":"HuXFOkVl"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"qvUidpYR"},{"text":"®","_key":"OkAZ7vYB","_type":"span","marks":["superscript"]},{"_type":"span","text":", serves as an online resource that brings together the worlds of clinical, business, regulatory, policy, and economic outcomes of biosimilars.","_key":"WuzuXfOa"}],"_type":"block","style":"normal"},{"style":"normal","_key":"DTsS3DNk","markDefs":[],"children":[],"_type":"block"},{"_type":"block","style":"normal","_key":"ciwIW1fD","markDefs":[],"children":[{"_type":"span","text":"The introduction of biosimilars to the United States provides great promise, as they are expected to bring down the price of medications, but also challenges. Biosimilars face stringent regulatory requirements, continued education of patients and physicians, and ongoing litigation issues.","_key":"JcjV1YfQ"}]},{"children":[],"_type":"block","style":"normal","_key":"kQ5X4YOH","markDefs":[]},{"_key":"GdyKqcj8","markDefs":[{"blank":true,"_type":"link","href":"http://www.centerforbiosimilars.com/","_key":"B8Zvikuzn1"}],"children":[{"_type":"span","text":"In the following Peer Exchange discussion from The Center for Biosimilars","_key":"DFWZYJIr"},{"_type":"span","marks":["superscript"],"text":"®","_key":"78YoFTYp"},{"text":", held in September 2017, industry experts discuss regulation, policy, and litigation issues in the world of biosimilars. For more insight into the world of biosimilar therapies, visit ","_key":"UUoRBSOr","_type":"span"},{"_type":"span","marks":["B8Zvikuzn1"],"text":"centerforbiosimilars.com","_key":"yvw5RtJW"},{"_type":"span","text":".","_key":"E61XBi80"}],"_type":"block","style":"normal"},{"style":"normal","_key":"QSI2EOZt","markDefs":[],"children":[],"_type":"block"},{"_type":"iframe","_key":"ayAGtejf","url":"https://w.soundcloud.com/player/?url=https%3A//api.soundcloud.com/tracks/388046051\u0026color=%23ff5500\u0026auto_play=false\u0026hide_related=false\u0026show_comments=true\u0026show_user=true\u0026show_reposts=false\u0026show_teaser=true"},{"children":[],"_type":"block","style":"normal","_key":"JzQRlcJz","markDefs":[]},{"markDefs":[],"children":[],"_type":"block","style":"normal","_key":"91pXaSVI"},{"style":"normal","_key":"baBkckho","markDefs":[],"children":[{"_type":"span","text":"Listen below or through one of these podcast services:","_key":"0ULM9PCu"}],"_type":"block"},{"children":[{"_type":"span","text":"iTunes: ","_key":"EUxtObhy"},{"_type":"span","marks":["xS77ejPK_D"],"text":"http://apple.co/2eYWTss","_key":"KVNoBpxI"}],"_type":"block","style":"normal","_key":"o82g6UQz","markDefs":[{"blank":true,"_type":"link","href":"https://itunes.apple.com/us/podcast/managed-care-cast/id1177540313?mt=2\u0026ign-mpt=uo%3D4","_key":"xS77ejPK_D"}]},{"children":[{"_type":"span","text":"TuneIn: ","_key":"AAojH7XD"},{"_type":"span","marks":["DkO24eAD1w"],"text":"http://bit.ly/2gv7iwj","_key":"xztr3tDD"}],"_type":"block","style":"normal","_key":"Bma3Tvwi","markDefs":[{"blank":true,"_type":"link","href":"https://tunein.com/radio/Managed-Care-Cast-p937637/","_key":"DkO24eAD1w"}]},{"_type":"block","style":"normal","_key":"fUt4CrtP","markDefs":[{"href":"https://www.stitcher.com/podcast/managed-care-cast","_key":"NAN3AM0-Bc","blank":true,"_type":"link"}],"children":[{"_key":"dL1CeBPY","_type":"span","text":"Stitcher: "},{"_key":"elLRdTaX","_type":"span","marks":["NAN3AM0-Bc"],"text":"http://bit.ly/2gCqtFg"}]},{"markDefs":[],"children":[],"_type":"block","style":"normal","_key":"Ws4OEdbh"},{"markDefs":[],"children":[{"_type":"span","text":" ","_key":"9yW004gr"}],"_type":"block","style":"normal","_key":"fD1fcjqK"}],"password":"","seoTag":["biosimilars","reimbursement","health policy","litigation"],"_rev":"GQ2iWOdzjKwgYpKUFW3yvN","link":"/view/the-state-of-biosimilars-in-the-united-states-center-for-biosimilars-peer-exchange","authorMapping":[],"summary":"The introduction of biosimilars to the US market has led to an unprecedented amount of uncertainty as stakeholders try to understand the implications of their arrival. In the following Peer Exchange discussion from The Center for Biosimilars®, held in September 2017, industry experts discuss regulation, policy, and litigation issues in the world of biosimilars.","passwordLock":false,"is_visible":true,"contentCategory":{"disableAds":false,"_id":"367becaf-13c4-4502-9c8c-939f4f480898","_updatedAt":"2021-08-12T18:05:19Z","_createdAt":"2020-04-03T20:07:37Z","_rev":"DuxacMYwkIxWPw8NDZCeiZ","_type":"contentCategory","name":"Podcasts"},"_createdAt":"2020-04-07T16:03:47Z","documentGroup":null},{"internalTag":["reimbursement","payment models","biosimilars","Medicare","diabetes"],"authorMapping":[],"passwordLock":false,"_updatedAt":"2020-07-30T17:50:11Z","taxonomyMapping":[{"_key":"Xzwl8Uwl","_ref":"a3fc756d-9cf3-4cbf-9174-96d1490f19d2","_type":"reference"},{"_type":"reference","_key":"J62SgNfa","_ref":"compendium_biosimilars"},{"_ref":"topic_insurance","_type":"reference","_key":"HuWOV9mw"},{"_ref":"compendium_diabetes","_type":"reference","_key":"BUjWapUV"}],"updatedOn":null,"thumbnail":{"_type":"mainImage","asset":{"_ref":"image-ab90dc5c18fd1eee5d25bf9f23b7e60c5589bc7e-300x167-jpg","_type":"reference"}},"title":"Podcast: This Week in Managed Care\u0026mdash;New Voluntary Payment Model and Other Health News","published":"2018-01-13T19:00:00.000Z","contentCategory":{"_createdAt":"2020-04-03T20:07:37Z","_rev":"DuxacMYwkIxWPw8NDZCeiZ","_type":"contentCategory","name":"Podcasts","disableAds":false,"_id":"367becaf-13c4-4502-9c8c-939f4f480898","_updatedAt":"2021-08-12T18:05:19Z"},"_id":"cme_article_34578","is_visible":true,"_type":"article","url":{"current":"podcast-this-week-in-managed-caremdashnew-voluntary-payment-model-and-other-health-news","_type":"slug"},"documentGroup":null,"body":[{"children":[{"_type":"span","text":"Every week, ","_key":"Nr9CSZo6"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"wUji4c53"},{"_type":"span","marks":["superscript"],"text":"®","_key":"Mrj8T0DP"},{"_type":"span","text":" recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.","_key":"zQv0KgE8"}],"_type":"block","style":"normal","_key":"3zUAcVa0","markDefs":[]},{"style":"normal","_key":"Ms5NEtOh","markDefs":[],"children":[],"_type":"block"},{"style":"normal","_key":"ftWAY8v3","markDefs":[],"children":[{"_type":"span","text":"This week, the top managed care stories included CMS unveiling a new voluntary bundled payment model; coverage from the JP Morgan Healthcare Conference, including immunotherapy's impact on HIV treatment and biosimilars; and news that 2 key diabetes devices will be covered by Medicare.","_key":"KO1b27Ww"}],"_type":"block"},{"style":"normal","_key":"wcs8udYo","markDefs":[],"children":[],"_type":"block"},{"children":[{"_type":"span","text":"Listen below or through one of these podcast services:","_key":"tHqJRo7X"}],"_type":"block","style":"normal","_key":"KorrbN5y","markDefs":[]},{"markDefs":[{"_key":"C1J6g4HdtLq","blank":true,"_type":"link","href":"http://apple.co/2eYWTss"}],"children":[{"_type":"span","text":"iTunes: ","_key":"O5ZyrIdB"},{"marks":["C1J6g4HdtLq"],"text":"http://apple.co/2eYWTss","_key":"u8VPTrrW","_type":"span"}],"_type":"block","style":"normal","_key":"zcFuGFPh"},{"_type":"block","style":"normal","_key":"tZj6uKkj","markDefs":[{"blank":true,"_type":"link","href":"http://bit.ly/2gv7iwj","_key":"qSyF8dvw8qt"}],"children":[{"_type":"span","text":"TuneIn: ","_key":"8dZrYall"},{"text":"http://bit.ly/2gv7iwj","_key":"ycAQvWg7","_type":"span","marks":["qSyF8dvw8qt"]}]},{"style":"normal","_key":"4Dkyz1Hh","markDefs":[{"_key":"riUuEiKm7uj","blank":true,"_type":"link","href":"http://bit.ly/2gCqtFg"}],"children":[{"_type":"span","text":"Stitcher: ","_key":"oXYfQGdJ"},{"_key":"9zAxYstq","_type":"span","marks":["riUuEiKm7uj"],"text":"http://bit.ly/2gCqtFg"}],"_type":"block"},{"markDefs":[],"children":[],"_type":"block","style":"normal","_key":"2DatFvw1"},{"_type":"iframe","_key":"48nm9CXR","url":"https://w.soundcloud.com/player/?url=https%3A//api.soundcloud.com/tracks/382727876\u0026color=%23ff5500\u0026auto_play=false\u0026hide_related=false\u0026show_comments=true\u0026show_user=true\u0026show_reposts=false\u0026show_teaser=true"},{"_type":"block","style":"normal","_key":"ziCOnvMW","markDefs":[],"children":[]},{"markDefs":[],"children":[],"_type":"block","style":"normal","_key":"kWM4eNYt"},{"_key":"5CKIsuHs","markDefs":[],"children":[{"text":"Read more about the stories in this podcast:","_key":"c1vKav25","_type":"span"}],"_type":"block","style":"normal"},{"style":"normal","_key":"Hbc2qvDz","markDefs":[{"_type":"link","href":"http://www.ajmc.com/newsroom/cms-tells-states-how-to-require-work-for-medicaid","_key":"_1ZTcn232pr","blank":true}],"children":[{"_type":"span","marks":["_1ZTcn232pr"],"text":"CMS Tells States How to Require Work for Medicaid","_key":"ieDQ4JEM"}],"_type":"block"},{"style":"normal","_key":"5yCeEjjA","markDefs":[{"_type":"link","href":"http://www.ajmc.com/newsroom/kentucky-first-state-approved-for-medicaid-work-requirements","_key":"w_aOSmY6kxd","blank":true}],"children":[{"_type":"span","marks":["w_aOSmY6kxd"],"text":"Kentucky First State Approved for Medicaid Work Requirements","_key":"JMidz6dB"}],"_type":"block"},{"_type":"block","style":"normal","_key":"6TS8Gmpz","markDefs":[{"blank":true,"_type":"link","href":"http://www.ajmc.com/newsroom/medpac-votes-a-resounding-no-to-mips-recommends-voluntary-value-program","_key":"pKgmI6ZF8tv"}],"children":[{"_type":"span","marks":["pKgmI6ZF8tv"],"text":"MedPAC Votes a Resounding \"No\" to MIPS, Recommends Voluntary Value Program","_key":"OvZU6ahd"}]},{"children":[{"text":"CMS Unveils New Voluntary Bundled Payment Model","_key":"95t3EDXb","_type":"span","marks":["zdj2tonEYic"]}],"_type":"block","style":"normal","_key":"LttKISqa","markDefs":[{"blank":true,"_type":"link","href":"http://www.ajmc.com/newsroom/cms-unveils-new-voluntary-bundled-payment-model","_key":"zdj2tonEYic"}]},{"_type":"block","style":"normal","_key":"qQYry57u","markDefs":[{"blank":true,"_type":"link","href":"http://www.ajmc.com/newsroom/5-things-from-the-36th-annual-jp-morgan-healthcare-conference","_key":"Vcs9JJXohVl"}],"children":[{"_type":"span","marks":["Vcs9JJXohVl"],"text":"5 Things From the 36th Annual JP Morgan Healthcare Conference","_key":"fdiooYQw"}]},{"_key":"3ju6HHdo","markDefs":[{"blank":true,"_type":"link","href":"http://www.ajmc.com/newsroom/dexcom-works-to-bring-cgm-to-the-medicare-population-and-more","_key":"GDuiuy-9qF6"}],"children":[{"_type":"span","marks":["GDuiuy-9qF6"],"text":"Dexcom Works to Bring CGM to the Medicare Population, and More","_key":"dxnZfKRQ"}],"_type":"block","style":"normal"},{"_type":"block","style":"normal","_key":"9NYJZ6tP","markDefs":[{"blank":true,"_type":"link","href":"http://www.ajmc.com/newsroom/abbotts-freestyle-libre-cgm-gains-medicare-coverage","_key":"bc4gS9NDLrM"}],"children":[{"_key":"w0uPxrmQ","_type":"span","marks":["bc4gS9NDLrM"],"text":"Abbott's Freestyle Libre CGM Gains Medicare Coverage"}]},{"children":[{"_type":"span","marks":["alZjXzks9lG"],"text":"Study Shows the Impact Synchronization Programs Have on Medication Adherence","_key":"AvtzaiOF"}],"_type":"block","style":"normal","_key":"SL0omsYS","markDefs":[{"blank":true,"_type":"link","href":"http://www.ajmc.com/newsroom/study-shows-the-impact-synchronization-programs-have-on-medication-adherence","_key":"alZjXzks9lG"}]}],"_rev":"XYcAcmtx9uUuoc2rVSNEHU","password":"","seoTag":["reimbursement","payment models","biosimilars","Medicare","diabetes"],"summary":"Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.","_createdAt":"2020-04-07T16:03:47Z","link":"/view/podcast-this-week-in-managed-caremdashnew-voluntary-payment-model-and-other-health-news"}],"videoSeriesData":[{"is_visible":true,"_rev":"Gmi5Xhy5pv5SCH9X7nMmEK","body":[{"children":[{"_type":"span","marks":[],"text":"","_key":"5507773e64e1"}],"_type":"block","style":"normal","_key":"ce097808c573","markDefs":[]},{"_type":"video","videoID":"6278919381001","source":"brightcove","_key":"af618a288400"},{"markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Kathy Oubre, MS","_key":"9fb3be7ae8050"},{"_type":"span","marks":[],"text":": We evaluate new approvals and possible switches to our internal formulary a few weeks before the start of a quarter. The stakeholders involve all of the HCPs [health care providers] and the business office, including someone from the financial team, the authorization team, as well as myself.","_key":"9fb3be7ae8051"}],"_type":"block","style":"normal","_key":"cc5287191d4d"},{"_key":"651c35102193","markDefs":[],"children":[{"text":"","_key":"f878a557d8530","_type":"span","marks":[]}],"_type":"block","style":"normal"},{"children":[{"_key":"c5328a00fa9d0","_type":"span","marks":[],"text":"The information around the biosimilar pipeline does come from a lot of reading and a great partnership with our GPO [group purchasing organization]. It’s in conversations with our pharmaceutical partners, those biosimilar pharmaceutical partners and educating us around their offerings and what they do have coming down the pipeline. This can be really fun when you have particular patients who do have potential financial insecurities around particular products and being able to afford the therapies and knowing that pretty soon you might have some answers for them and ways to help increase their access to care and alleviate their financial burden. At the end of the day, that’s why we all get out of bed in the morning, to provide the best care possible for our patients. Anything that we can do as health care providers, from the science around it, and also helping to relieve that financial burden, those are 2 huge wins in patient care."}],"_type":"block","style":"normal","_key":"2601ae768cec","markDefs":[]},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"c30a6c02dead0"}],"_type":"block","style":"normal","_key":"74368152d301"},{"markDefs":[],"children":[{"text":"In an ideal world, our organization would have 1 drug per indication on our formulary. However, these decisions are really more dictated by the payers and their formularies. We stock 2 to 3 products per reference product. How do we distinguish which biosimilar products we prefer in our organization? That’s not an easy answer. As an organization, determining which and where each product sits on our practice formulary is a marriage between the payer formulary, the drug acquisition cost, and payer reimbursement.","_key":"fad61a7c9ed30","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"394680d1ce1e"},{"children":[{"_type":"span","marks":[],"text":"Our providers have been eagerly watching the biosimilar space and the market for a few years prior to the launch of any biosimilar in the oncology space. They’re pretty familiar and comfortable around the science, the approval process, and the way they all became available. We do continue to watch the idea of interchangeability, which will be a huge win in the oncology space when we achieve interchangeable status, but until then it hasn’t been a large concern within our organization. If and when it is, on the provider and even the patient perspective, or from a nursing perspective, we have developed educational tools for all of those segments of our population, and we continue to update them as new science and new findings come into the market.","_key":"a5b19ad969af0"}],"_type":"block","style":"normal","_key":"1480e78dfcd8","markDefs":[]},{"markDefs":[],"children":[{"_key":"a20bd06f8c010","_type":"span","marks":[],"text":"Payers and PBMs [pharmacy benefit managers] have the most significant impact on our biosimilar choices at Pontchartrain [Cancer Center]. PBMs and private payers vary in their approach to biosimilars. Although some PBMs and payers include biosimilars on their formularies without real aggressive management, some will only approve the originator product. Others will create preferred coverage for 1 or more biosimilars. The rub becomes when different payers approve different biosimilars on their formularies."}],"_type":"block","style":"normal","_key":"1450a50a9c98"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"As an organization, years ago we made the decision to not do any type of off-label medicine. One of the ways that we ensure that is the treatment plans are not built within the EMR [electronic medical record] if they’re not within that labeled indication. If a provider goes to look for that particular treatment plan for an off-label indication around the biosimilars, they won’t find it. There are some hard stops within workflows in our organization so that if something were to be developed and go to the nursing team or the authorization team, and it’s for an off-label indication, it does flag with those people because they do keep some flag material, some hand-written lists to the right of their desk that talk about biosimilars by payer and indication. They will then go back to that prescribing provider and educate them to pick an approved biosimilar or a different product.","_key":"e907a96c70f90"}],"_type":"block","style":"normal","_key":"df8ecb59d751"},{"style":"normal","_key":"41050a6b614e","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"796feab2fd8c"}],"_type":"block"},{"_key":"821f2d41bfc3","markDefs":[],"children":[{"text":"This transcript has been edited for clarity.","_key":"44cf07a48dd5","_type":"span","marks":["strong","em"]}],"_type":"block","style":"normal"}],"taxonomyMapping":[{"_id":"54959cfc-9805-4ede-bc8f-7ecfcd2530c6","_updatedAt":"2022-01-19T10:12:39Z","identifier":"insights","_createdAt":"2020-03-30T19:15:55Z","sortOrder":2,"_rev":"Pqv14IIDiWFMzK5solyWKi","_type":"taxonomy","name":"Insights"},{"_id":"999720cf-b3b3-4d42-935d-beb17775844e","_updatedAt":"2022-01-06T09:02:13Z","identifier":"video-series","_createdAt":"2020-10-14T04:51:21Z","_rev":"ChnBnF2xw1R5u2UJBDlozJ","_type":"taxonomy","name":"Video Series"},{"name":"Clinical","_updatedAt":"2022-02-18T12:13:55Z","identifier":"clinical","parent":{"_type":"reference","_ref":"15012229-f713-4f0a-8f82-7667530bb382"},"_rev":"HexDiduX8d6Nqnq1ECriVF","_type":"taxonomy","_id":"topic_clinical","summary":[{"_key":"dd8ad578cd0b","markDefs":[],"children":[{"_key":"e80c79954e08","_type":"span","marks":[],"text":"The "},{"_type":"span","marks":["em"],"text":"AJMC","_key":"a8e0f75c5d05"},{"_type":"span","marks":["superscript"],"text":"®","_key":"f7d4dddf7edd"},{"_type":"span","marks":[],"text":" clinical page includes all the published content across AJMC.com, ","_key":"0f03d46e3b3a"},{"marks":["em"],"text":"The American Journal of Managed Care","_key":"cc409f2da7da","_type":"span"},{"_type":"span","marks":["superscript"],"text":"®","_key":"2babb3e59bb3"},{"_type":"span","marks":[],"text":" and ","_key":"d86a5bb12052"},{"text":"Evidence-Based Oncology","_key":"40b2eaba6c17","_type":"span","marks":["em"]},{"text":"™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.","_key":"b59bef533cdf","_type":"span","marks":[]}],"_type":"block","style":"normal"}],"_createdAt":"2020-05-04T23:46:13Z"},{"identifier":"biosimilars","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"cmeType":"per","_createdAt":"2020-04-14T15:02:13Z","name":"Biosimilars","_id":"compendium_biosimilars","summary":[{"_key":"21a8926c2669","markDefs":[],"children":[{"_type":"span","marks":[],"text":"The ","_key":"d9a7c16be264"},{"text":"AJMC","_key":"5aab8321660a","_type":"span","marks":["em"]},{"_type":"span","marks":["superscript"],"text":"®","_key":"84efcc202b1e"},{"_key":"2454ce1e8332","_type":"span","marks":[],"text":" Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates."}],"_type":"block","style":"normal"}],"perKeywordMapping":["Pharmacy","Health Equity Diversity \u0026 Inclusion"],"_rev":"rs7eCk0lrr8LMiZP9GDaQL","_type":"taxonomy","_updatedAt":"2023-11-03T18:20:52Z"}],"_type":"article","summary":"Kathy Oubre, MS, closes this Insights program by evaluating her organization’s biosimilars program and formularies, including third party preference on the use of specific biosimilars and whether biosimilars can be used outside of their indications.","link":"/view/evaluating-biosimilar-programs-and-formularies","documentGroup":{"_ref":"d537a5b9-b33e-485d-aa7f-6f9c16e0f599","_type":"reference"},"seoTag":["Biosimilars","formulary"," evaluation"," payers"," patient access"," financial burden"," preference"," payer","payer reimbursement"," drug acquisition cost"," interchangeability"," providers"," education"," tools"," coverage "],"_createdAt":"2021-11-16T17:37:25Z","title":"Evaluating Biosimilar Programs and Formularies","internalTag":["Biosimilars"],"_id":"44e85545-02cc-4739-92f0-ea67fc317d8a","_updatedAt":"2021-11-29T14:47:09Z","published":"2021-11-16T17:38:00.000Z","thumbnail":{"asset":{"_rev":"zYFJ6fTR7QCWPh1X1BRgu9","mimeType":"image/png","originalFilename":"Oubre_HS.png","extension":"png","metadata":{"_type":"sanity.imageMetadata","palette":{"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":1.09,"background":"#082983"},"lightMuted":{"background":"#b4bcc6","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":2.08},"vibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":3.61,"background":"#3681e2"},"dominant":{"population":3.61,"background":"#3681e2","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"_type":"sanity.imagePalette","darkMuted":{"foreground":"#fff","title":"#fff","population":2.06,"background":"#4d2f30","_type":"sanity.imagePaletteSwatch"},"muted":{"foreground":"#fff","title":"#fff","population":0.88,"background":"#a96055","_type":"sanity.imagePaletteSwatch"},"lightVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.33,"background":"#d5ae9f"}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"aspectRatio":1.7777777777777777,"height":1080,"_type":"sanity.imageDimensions","width":1920},"isOpaque":false,"blurHash":"MTIFDMxs0pM{D,4po~IVR-Rj_NWGn1tRxp"},"_type":"sanity.imageAsset","path":"images/0vv8moc6/ajmc/5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png","_createdAt":"2021-11-02T21:06:16Z","sha1hash":"5877f3599b18f1db82bacba5d328e3e743fec483","size":1177244,"assetId":"5877f3599b18f1db82bacba5d328e3e743fec483","_id":"image-5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080-png","uploadId":"vG5pYzlgenu2glXC7mBtsYgj4nivwlhg","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png","_updatedAt":"2021-11-02T21:06:16Z"}},"url":{"current":"evaluating-biosimilar-programs-and-formularies","_type":"slug"},"contentCategory":{"_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76"},"updatedOn":null,"authorMapping":null,"factCheckAuthorMapping":null},{"_rev":"5191BVBESQS1doGi7SpXfG","_createdAt":"2021-11-16T17:32:27Z","_updatedAt":"2021-11-29T14:46:09Z","published":"2021-11-16T17:33:00.000Z","url":{"current":"integrating-biosimilars-for-hcps-into-electronic-health-records-and-in-clinical-pathways-care-plans","_type":"slug"},"updatedOn":null,"authorMapping":null,"_id":"cf6bb9d5-6619-440a-a0f9-e7c671cb4444","title":"Integrating Biosimilars for HCPs, into Electronic Health Records, and in Clinical Pathways/Care Plans","_type":"article","documentGroup":{"_ref":"d537a5b9-b33e-485d-aa7f-6f9c16e0f599","_type":"reference"},"is_visible":true,"factCheckAuthorMapping":null,"internalTag":["Biosimilars"],"seoTag":["Biosimilars","health care providers"," awareness"," health care providers"," HCPs"," electronic health record"," EHR"," IT"," order sets"," substitutions"," EMR"," electronic medical record"," treatment plans"," nurses"," clinical pathways"," care plans"," computerized physician entry"," providers"," utilization"],"taxonomyMapping":[{"sortOrder":2,"_rev":"Pqv14IIDiWFMzK5solyWKi","_type":"taxonomy","name":"Insights","_id":"54959cfc-9805-4ede-bc8f-7ecfcd2530c6","_updatedAt":"2022-01-19T10:12:39Z","identifier":"insights","_createdAt":"2020-03-30T19:15:55Z"},{"_updatedAt":"2022-01-06T09:02:13Z","identifier":"video-series","_createdAt":"2020-10-14T04:51:21Z","_rev":"ChnBnF2xw1R5u2UJBDlozJ","_type":"taxonomy","name":"Video Series","_id":"999720cf-b3b3-4d42-935d-beb17775844e"},{"_type":"taxonomy","_id":"topic_clinical","summary":[{"markDefs":[],"children":[{"_key":"e80c79954e08","_type":"span","marks":[],"text":"The "},{"_type":"span","marks":["em"],"text":"AJMC","_key":"a8e0f75c5d05"},{"_type":"span","marks":["superscript"],"text":"®","_key":"f7d4dddf7edd"},{"_type":"span","marks":[],"text":" clinical page includes all the published content across AJMC.com, ","_key":"0f03d46e3b3a"},{"marks":["em"],"text":"The American Journal of Managed Care","_key":"cc409f2da7da","_type":"span"},{"_type":"span","marks":["superscript"],"text":"®","_key":"2babb3e59bb3"},{"_type":"span","marks":[],"text":" and ","_key":"d86a5bb12052"},{"text":"Evidence-Based Oncology","_key":"40b2eaba6c17","_type":"span","marks":["em"]},{"text":"™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.","_key":"b59bef533cdf","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"dd8ad578cd0b"}],"_createdAt":"2020-05-04T23:46:13Z","_rev":"HexDiduX8d6Nqnq1ECriVF","_updatedAt":"2022-02-18T12:13:55Z","identifier":"clinical","parent":{"_type":"reference","_ref":"15012229-f713-4f0a-8f82-7667530bb382"},"name":"Clinical"},{"cmeType":"per","_createdAt":"2020-04-14T15:02:13Z","name":"Biosimilars","_id":"compendium_biosimilars","identifier":"biosimilars","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"_rev":"rs7eCk0lrr8LMiZP9GDaQL","_type":"taxonomy","_updatedAt":"2023-11-03T18:20:52Z","summary":[{"_type":"block","style":"normal","_key":"21a8926c2669","markDefs":[],"children":[{"_type":"span","marks":[],"text":"The ","_key":"d9a7c16be264"},{"text":"AJMC","_key":"5aab8321660a","_type":"span","marks":["em"]},{"_type":"span","marks":["superscript"],"text":"®","_key":"84efcc202b1e"},{"_key":"2454ce1e8332","_type":"span","marks":[],"text":" Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates."}]}],"perKeywordMapping":["Pharmacy","Health Equity Diversity \u0026 Inclusion"]}],"link":"/view/integrating-biosimilars-for-hcps-into-electronic-health-records-and-in-clinical-pathways-care-plans","body":[{"children":[{"_type":"span","marks":[],"text":"","_key":"ce7f696947d1"}],"_type":"block","style":"normal","_key":"e7ae5525ec01","markDefs":[]},{"_key":"d5ef27b66381","_type":"video","videoID":"6279773517001","source":"brightcove"},{"_key":"4787ae165fd7","markDefs":[],"children":[{"text":"Ryan Haumschild, PharmD, MS, MBA","_key":"4487752461bf0","_type":"span","marks":["strong"]},{"_type":"span","marks":[],"text":": We didn’t use any incentives or require people to utilize them. We thought that if we had people understand the background of biosimilars and the benefits to the patient, the organization, and the health care system, that would help drive the narrative. That was really helpful for us in being successful. We have strong medical leaders too who understand the benefits and were able to help with some of those just-in-time conversations. That helped people understand the concept of biosimilars, be comfortable with utilizing them both in curative and noncurative intent and helping drive value to the patient.","_key":"4487752461bf1"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Kathy Oubre, MS","_key":"74ff3243b2ef0"},{"marks":[],"text":": We had started talking about biosimilars a few years ago when we knew the science was coming onto the market. By nature of our patients, and some come from rural areas and perhaps have trouble affording their medications, we’ve been watching the biosimilar market closely because we very strongly believe as an organization that it would result in increased access to care. There wasn’t a lot of education or persuading needed to get the practitioners excited about biosimilars. There wasn’t a need to incentivize any of them. As far as it being a requirement within our providers, that wasn’t needed because it was more of an opportunity for our health care providers to continue to live out our mission statement, which is to provide the best care possible to our patients while helping to reduce their financial burden.","_key":"74ff3243b2ef1","_type":"span"}],"_type":"block","style":"normal","_key":"418d6d1eea4e"},{"_key":"0b41c3fe55b1","markDefs":[],"children":[{"_key":"219b3aa9a4870","_type":"span","marks":[],"text":""}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Ryan Haumschild, PharmD, MS, MBA","_key":"56107cedbe680"},{"_type":"span","marks":[],"text":": There were some IT [information technology] and electronic health record challenges that we experienced from the get-go, and it was no fault of our IT team. It had to do with the amount of work that was involved for adding these products. We initially started adding a product as we approved it through formulary 1 by 1 to each order set. As you can imagine with some of these biosimilars, you’re touching greater than 100 different order sets to include a new medication. Every time a biosimilar came to market, it wasn’t feasible to keep tagging each one of these order sets to include the new product. We became a bit smarter instead of working harder, and our way was creating a unique adaptive strategy of building out biosimilars. That can be preferring a certain biosimilar and then having a subsequent biosimilar there in the order set, therefore you’re reducing the number of biosimilars that you have, or you build out a biosimilar more in a generic name. To use an example like trastuzumab, you build out trastuzumab, then you create an internal preference of which product you want to utilize in terms of biosimilar. You can substitute that specific product for trastuzumab when you go to dispense. Again, that must be blessed by a pharmacy and therapeutics–approved policy. But that allows the organization to be operationally effective, utilize the medications the provider wants without having this massive IT burden that causes a delay in giving these medications on formulary for the patient. That allows us to adopt medications more in real time, based on the payer requirements that we were having difficulty keeping up with.","_key":"56107cedbe681"}],"_type":"block","style":"normal","_key":"b31f6bb306f7"},{"_key":"36ef0d2e9f27","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Kathy Oubre, MS","_key":"9803e5e4fd640"},{"_type":"span","marks":[],"text":": As you can imagine, within our EMR [electronic medical record], every time you have a new product, you have to build a new treatment plan with your EMR. When the biosimilars came to market, that did mean a new treatment plan for every individual biosimilar that came to market. There are 19 to 21 approved products that require a treatment plan per indication per product. That number can grow quite quickly, and that does become a cumbersome process for the nurses devising those treatment plans.","_key":"9803e5e4fd641"}],"_type":"block","style":"normal"},{"_key":"1dfc1134a2b8","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"3c42835389470"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"text":"We didn’t see the need to implement any new software because our EMR vendor anticipated this problem and the burden behind it. To help alleviate some of those burdens around biosimilars, there is a beta site with our EMR vendor for biosimilar integration. In this pilot, our EMR will now have a drop-down box for all of the drugs per drug class, per indication, and it will cross reference the drugs with the patient’s payer formulary. As I mentioned, it is in a beta site, and we’ve been “beta-ing” this project now for about 3 weeks and we’re working out the bugs. Our EMR vendor is extremely receptive and has been a great partner during this process. I applaud them for looking at this because as biosimilars continue to come into the market, if you look at the pipeline, we’re looking at another 20 to 30 in the next 2 to 3 years. It’s going to be important to have some automated processes and workflows around biosimilars.","_key":"9b4334c5b78e0","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"221338071b78"},{"style":"normal","_key":"951877d1dcdd","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Ryan Haumschild, PharmD, MS, MBA","_key":"ad09ebc37f8c0"},{"_type":"span","marks":[],"text":": Clinical pathways are one of the latest strategies and recommendations to create consistent quality care for patients across all spectrums of their care. Within pathways people utilize order sets, especially if they have computerized physician order entry. That’s a great way to make sure that you have the prehydration, the premedications, the treatment medications, and the monitoring all in one succinct plan that can be blessed by a greater group, like a disease state working group or tumor board. So that way, when a provider goes to order it, they know that the great discussion and consolidated plan has already been built out in the EMR. They can review it, then initiate it for a patient. Yes, within those care plans, it’s so important to build in biosimilars because that allows the provider to not have to think, “How do I order this biosimilar or that generic trastuzumab name that I’ve heard Ryan talk about?” When we can build it in there that means it’ll automatically get ordered when they initiate that plan, and it’ll follow that standard work. Then if a payer wants a different biosimilar or something needs to be substituted, that can all occur within the EMR and it helps drive utilization, but most importantly, appropriate utilization that was intended by the physician.","_key":"ad09ebc37f8c1"}],"_type":"block"},{"children":[{"_type":"span","marks":["strong"],"text":"Kathy Oubre, MS","_key":"5492198603bc0"},{"_type":"span","marks":[],"text":": We don’t use clinical pathways. We do have them, but we prefer to use more of a clinical decision support tool, which is what we are doing in a separate pilot project with our EMR vendor. We have treatment plans built for each approved product per indication on an individual payer formulary.","_key":"5492198603bc1"}],"_type":"block","style":"normal","_key":"6041a914f2ce","markDefs":[]},{"_key":"67fbdcfdc1ac","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"e3a90a740bee"}],"_type":"block","style":"normal"},{"_type":"block","style":"normal","_key":"e970a4a81b93","markDefs":[],"children":[{"marks":["strong","em"],"text":"This transcript has been edited for clarity.","_key":"cd7703c75d84","_type":"span"}]}],"contentCategory":{"_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z"},"summary":"Two experts explain if they had to create any incentives for health care providers to prescribe biosimilars, whether they encountered challenges with their electronic health records, and if their biosimilar programs impacted their clinical pathway/care plans.","thumbnail":{"asset":{"_updatedAt":"2021-10-26T18:27:51Z","mimeType":"image/jpeg","_rev":"yPN4n5TcElVjh0RH5xNX8U","_type":"sanity.imageAsset","path":"images/0vv8moc6/ajmc/117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg","size":444731,"originalFilename":"MicrosoftTeams-image.png","uploadId":"1QgtxdQLTQ5lCgCxvDnsUJDPlSOnJLB6","_id":"image-117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080-jpg","metadata":{"dimensions":{"_type":"sanity.imageDimensions","width":1920,"aspectRatio":1.7777777777777777,"height":1080},"isOpaque":true,"blurHash":"MPGle$t55IWAIE00tTNKNHRQ~qWZwEt8xs","_type":"sanity.imageMetadata","palette":{"dominant":{"background":"#2b78de","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":4.38},"_type":"sanity.imagePalette","darkMuted":{"background":"#342920","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":1.78},"muted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":2.34,"background":"#967e68"},"lightVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.86,"background":"#a6c0d6"},"darkVibrant":{"background":"#04207e","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":1.48},"lightMuted":{"foreground":"#000","title":"#fff","population":0.07,"background":"#88b1c0","_type":"sanity.imagePaletteSwatch"},"vibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":4.38,"background":"#2b78de"}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,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"},"sha1hash":"117ab7594e690a311c7eec0c65d4487c98258b47","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg","assetId":"117ab7594e690a311c7eec0c65d4487c98258b47","_createdAt":"2021-10-26T18:27:51Z","extension":"jpg"}}},{"title":"Tracking Usage and Monitoring the Impact of Biosimilars","taxonomyMapping":[{"_type":"taxonomy","name":"Insights","_id":"54959cfc-9805-4ede-bc8f-7ecfcd2530c6","_updatedAt":"2022-01-19T10:12:39Z","identifier":"insights","_createdAt":"2020-03-30T19:15:55Z","sortOrder":2,"_rev":"Pqv14IIDiWFMzK5solyWKi"},{"_updatedAt":"2022-01-06T09:02:13Z","identifier":"video-series","_createdAt":"2020-10-14T04:51:21Z","_rev":"ChnBnF2xw1R5u2UJBDlozJ","_type":"taxonomy","name":"Video Series","_id":"999720cf-b3b3-4d42-935d-beb17775844e"},{"parent":{"_type":"reference","_ref":"15012229-f713-4f0a-8f82-7667530bb382"},"name":"Clinical","_updatedAt":"2022-02-18T12:13:55Z","identifier":"clinical","_createdAt":"2020-05-04T23:46:13Z","_rev":"HexDiduX8d6Nqnq1ECriVF","_type":"taxonomy","_id":"topic_clinical","summary":[{"style":"normal","_key":"dd8ad578cd0b","markDefs":[],"children":[{"_key":"e80c79954e08","_type":"span","marks":[],"text":"The "},{"_type":"span","marks":["em"],"text":"AJMC","_key":"a8e0f75c5d05"},{"_type":"span","marks":["superscript"],"text":"®","_key":"f7d4dddf7edd"},{"_type":"span","marks":[],"text":" clinical page includes all the published content across AJMC.com, ","_key":"0f03d46e3b3a"},{"marks":["em"],"text":"The American Journal of Managed Care","_key":"cc409f2da7da","_type":"span"},{"_type":"span","marks":["superscript"],"text":"®","_key":"2babb3e59bb3"},{"_type":"span","marks":[],"text":" and ","_key":"d86a5bb12052"},{"text":"Evidence-Based Oncology","_key":"40b2eaba6c17","_type":"span","marks":["em"]},{"text":"™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.","_key":"b59bef533cdf","_type":"span","marks":[]}],"_type":"block"}]},{"_id":"compendium_biosimilars","identifier":"biosimilars","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"cmeType":"per","_createdAt":"2020-04-14T15:02:13Z","name":"Biosimilars","summary":[{"style":"normal","_key":"21a8926c2669","markDefs":[],"children":[{"_type":"span","marks":[],"text":"The ","_key":"d9a7c16be264"},{"text":"AJMC","_key":"5aab8321660a","_type":"span","marks":["em"]},{"_type":"span","marks":["superscript"],"text":"®","_key":"84efcc202b1e"},{"_key":"2454ce1e8332","_type":"span","marks":[],"text":" Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates."}],"_type":"block"}],"perKeywordMapping":["Pharmacy","Health Equity Diversity \u0026 Inclusion"],"_rev":"rs7eCk0lrr8LMiZP9GDaQL","_type":"taxonomy","_updatedAt":"2023-11-03T18:20:52Z"}],"_id":"9f5c1215-ea3b-4bb4-8e66-74b8ec29f5ea","seoTag":["Biosimilars","tracking usage"," dispense report"," consistent utilization"," buy-in"," EMR"," electronic medical record"," adherence"," cost of care"," out-of-pocket expenses"," financial toxicity"," payers"," denials"," precertification"," drug acquisition costs"," access to care"],"body":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"a888e78a803a"}],"_type":"block","style":"normal","_key":"125b2444166e"},{"_type":"video","videoID":"6278919214001","source":"brightcove","_key":"3360f79674f0"},{"_type":"block","style":"normal","_key":"028ce11796f2","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Ryan Haumschild, PharmD, MS, MBA:","_key":"22a2c7f3a0b50"},{"_type":"span","marks":[],"text":" We always try to look at our dispense reports, and that’s across every medication. We want to make sure we’re utilizing medications consistently for all our patients, and we do that mainly because we want to make sure if there are any abnormalities that we’re able to pick up on them. Also, when we move forward with a formulary approval and build them into our order sets, we want to make sure that utilization is consistent and predictable. That way, we can staff accordingly, generate pars, and make sure any contracts or any type of purchasing volumes that we’re looking at are consistent across the board. With biosimilars, do we track usage of biosimilars? We do track usage of biosimilars to make sure that we’re providing consistent care and we have enough drug on hand. We believe our providers have the buy-in for biosimilars, so that’s not an issue for us. They’re the ones who wanted to use biosimilars and implement them. We track for operational excellence, but otherwise we don’t create a report card provider. That’s not something that we do because we feel like we have good buy-in from the greater group.","_key":"22a2c7f3a0b51"}]},{"children":[{"marks":[],"text":"","_key":"69d3d79f475e0","_type":"span"}],"_type":"block","style":"normal","_key":"4bcd8e9bdb34","markDefs":[]},{"children":[{"_type":"span","marks":["strong"],"text":"Kathy Oubre, MS: ","_key":"50037aa1d30a0"},{"_key":"50037aa1d30a1","_type":"span","marks":[],"text":"We do track by provider and as an organization. Currently, we run biweekly reports out of our EMRs [electronic medical records] to identify patients as a whole and individually and prescribe a provider for each biosimilar and innovator product. This allows us to monitor our biosimilar adherence. We’re at around 95%. It allows us to identify and track anomalies, such as human error, on the practice side at the prescribing or authorization level. It allows us to track usage of individual biosimilars and innovators by payer and by product. And last, we measure this when reviewing the impact biosimilars have had on our overall drug spend and how that biosimilar usage has increased patient access and driven down cost to the patient as a whole."}],"_type":"block","style":"normal","_key":"c8b5170079b1","markDefs":[]},{"_key":"b112f8030e3e","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"6ceaa343ca860"}],"_type":"block","style":"normal"},{"style":"normal","_key":"0f91363ae7b9","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Ryan Haumschild, PharmD, MS, MBA:","_key":"e32395068d270"},{"_type":"span","marks":[],"text":" You have to look at outcome measures because you want to have some measure of success for any type of strategy. One of the main reasons you want to adopt biosimilars is to reduce cost of care, reduce the number of denials, reduce the number of denials on a patient, and reduce their out-of-patient expenses if possible. We know that financial toxicity is such a barrier in cancer care. We did evaluate some of these measures of success because a lot of the payers are requiring biosimilars. When we were starting to utilize the reference product, we would get a denial from the payer. We’d have to switch to the biosimilar and then hope we have a successful precertification that would allow that patient to be treated and that we would end up getting paid for that claim.","_key":"e32395068d271"}],"_type":"block"},{"markDefs":[],"children":[{"_key":"cd7b6e6b45ca0","_type":"span","marks":[],"text":""}],"_type":"block","style":"normal","_key":"67b1ec307ca1"},{"style":"normal","_key":"e7a29d75eca8","markDefs":[],"children":[{"_type":"span","marks":[],"text":"When we weren’t adopting biosimilars we had more denials. That means the insurance company asked us to use the biosimilar, and we didn’t have enough time to switch it out or have the biosimilar on formulary. Then that patient would have to figure out what to do. By implementing biosimilars and reducing that denial rate, it improved our operational excellence and reduced that out-of-pocket expense for patients. At the same time, when it reduces your total cost of care, you’re helping meet those organizational goals. That’s what you need to be focused right now, when we have so many high-cost therapies: how to reduce that cost to care and how to track that reduction and expense for an organization. Those are the measures of success that we try to focus in on when we consider biosimilars.","_key":"6c94c446192c0"}],"_type":"block"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"72a01b0c0ed40"}],"_type":"block","style":"normal","_key":"9ff40d28d2be"},{"_key":"09a057e7e9b0","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Kathy Oubre, MS:","_key":"8cabcf59da830"},{"_type":"span","marks":[],"text":" We know which patients are receiving which product. We look at those biweekly to see if we’re seeing an increased toxicity at any level as a result of a particular product, whether they’re coming in for more hydration or more phone calls to the practice. We monitor this biosimilar conversion in reviewing our drug acquisition costs vs our reimbursement, then we closely monitor the number of patients on any particular drug. Conversely, we’ve seen a large increase in access to care within our organization as a result of these biosimilars, and that decreased out of pocket for our patients.","_key":"8cabcf59da831"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"5272951372ff"}],"_type":"block","style":"normal","_key":"d7ba22eee0b0"},{"style":"normal","_key":"ad15b8874a20","markDefs":[],"children":[{"marks":["strong","em"],"text":"This transcript has been edited for clarity.","_key":"63c9d2a0f0c6","_type":"span"}],"_type":"block"}],"_updatedAt":"2021-11-19T15:16:51Z","_type":"article","url":{"current":"tracking-usage-and-monitoring-the-impact-of-biosimilars","_type":"slug"},"thumbnail":{"asset":{"uploadId":"vG5pYzlgenu2glXC7mBtsYgj4nivwlhg","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png","_updatedAt":"2021-11-02T21:06:16Z","_rev":"zYFJ6fTR7QCWPh1X1BRgu9","mimeType":"image/png","originalFilename":"Oubre_HS.png","extension":"png","metadata":{"lqip":"data:image/png;base64,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","dimensions":{"aspectRatio":1.7777777777777777,"height":1080,"_type":"sanity.imageDimensions","width":1920},"isOpaque":false,"blurHash":"MTIFDMxs0pM{D,4po~IVR-Rj_NWGn1tRxp","_type":"sanity.imageMetadata","palette":{"vibrant":{"background":"#3681e2","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":3.61},"dominant":{"population":3.61,"background":"#3681e2","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"_type":"sanity.imagePalette","darkMuted":{"background":"#4d2f30","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":2.06},"muted":{"background":"#a96055","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.88},"lightVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.33,"background":"#d5ae9f"},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":1.09,"background":"#082983"},"lightMuted":{"population":2.08,"background":"#b4bcc6","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"}},"hasAlpha":true},"_type":"sanity.imageAsset","path":"images/0vv8moc6/ajmc/5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png","_createdAt":"2021-11-02T21:06:16Z","sha1hash":"5877f3599b18f1db82bacba5d328e3e743fec483","size":1177244,"assetId":"5877f3599b18f1db82bacba5d328e3e743fec483","_id":"image-5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080-png"}},"published":"2021-11-09T17:09:00.000Z","link":"/view/tracking-usage-and-monitoring-the-impact-of-biosimilars","internalTag":["Biosimilars"],"contentCategory":{"_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z"},"documentGroup":{"_ref":"d537a5b9-b33e-485d-aa7f-6f9c16e0f599","_type":"reference"},"_createdAt":"2021-11-09T17:08:04Z","authorMapping":null,"_rev":"uNtBwCwtqRwQLOCysROHWg","is_visible":true,"updatedOn":null,"factCheckAuthorMapping":null,"summary":"Ryan Haumschild, PharmD, MS, MBA, and Kathy Oubre, MS, discuss tracking their use of biosimilar by their providers and outcome measures they utilize to monitor biosimilars."},{"_id":"df7f7713-5858-475d-a751-a0e0b37977dc","thumbnail":{"asset":{"extension":"jpg","sha1hash":"117ab7594e690a311c7eec0c65d4487c98258b47","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg","assetId":"117ab7594e690a311c7eec0c65d4487c98258b47","_createdAt":"2021-10-26T18:27:51Z","mimeType":"image/jpeg","_updatedAt":"2021-10-26T18:27:51Z","uploadId":"1QgtxdQLTQ5lCgCxvDnsUJDPlSOnJLB6","_rev":"yPN4n5TcElVjh0RH5xNX8U","_type":"sanity.imageAsset","path":"images/0vv8moc6/ajmc/117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg","size":444731,"originalFilename":"MicrosoftTeams-image.png","metadata":{"palette":{"darkVibrant":{"population":1.48,"background":"#04207e","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightMuted":{"foreground":"#000","title":"#fff","population":0.07,"background":"#88b1c0","_type":"sanity.imagePaletteSwatch"},"vibrant":{"background":"#2b78de","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":4.38},"dominant":{"background":"#2b78de","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":4.38},"_type":"sanity.imagePalette","darkMuted":{"background":"#342920","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":1.78},"muted":{"background":"#967e68","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":2.34},"lightVibrant":{"background":"#a6c0d6","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.86}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":1920,"aspectRatio":1.7777777777777777,"height":1080},"isOpaque":true,"blurHash":"MPGle$t55IWAIE00tTNKNHRQ~qWZwEt8xs","_type":"sanity.imageMetadata"},"_id":"image-117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080-jpg"}},"internalTag":["Biosimilars"],"is_visible":true,"link":"/view/protocols-and-laws-for-transitioning-to-biosimilars","factCheckAuthorMapping":null,"published":"2021-11-09T17:04:00.000Z","taxonomyMapping":[{"sortOrder":2,"_rev":"Pqv14IIDiWFMzK5solyWKi","_type":"taxonomy","name":"Insights","_id":"54959cfc-9805-4ede-bc8f-7ecfcd2530c6","_updatedAt":"2022-01-19T10:12:39Z","identifier":"insights","_createdAt":"2020-03-30T19:15:55Z"},{"name":"Video Series","_id":"999720cf-b3b3-4d42-935d-beb17775844e","_updatedAt":"2022-01-06T09:02:13Z","identifier":"video-series","_createdAt":"2020-10-14T04:51:21Z","_rev":"ChnBnF2xw1R5u2UJBDlozJ","_type":"taxonomy"},{"summary":[{"_type":"block","style":"normal","_key":"dd8ad578cd0b","markDefs":[],"children":[{"_key":"e80c79954e08","_type":"span","marks":[],"text":"The "},{"_type":"span","marks":["em"],"text":"AJMC","_key":"a8e0f75c5d05"},{"_type":"span","marks":["superscript"],"text":"®","_key":"f7d4dddf7edd"},{"_type":"span","marks":[],"text":" clinical page includes all the published content across AJMC.com, ","_key":"0f03d46e3b3a"},{"marks":["em"],"text":"The American Journal of Managed Care","_key":"cc409f2da7da","_type":"span"},{"_type":"span","marks":["superscript"],"text":"®","_key":"2babb3e59bb3"},{"_type":"span","marks":[],"text":" and ","_key":"d86a5bb12052"},{"text":"Evidence-Based Oncology","_key":"40b2eaba6c17","_type":"span","marks":["em"]},{"text":"™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.","_key":"b59bef533cdf","_type":"span","marks":[]}]}],"_createdAt":"2020-05-04T23:46:13Z","_rev":"HexDiduX8d6Nqnq1ECriVF","_type":"taxonomy","_id":"topic_clinical","identifier":"clinical","parent":{"_type":"reference","_ref":"15012229-f713-4f0a-8f82-7667530bb382"},"name":"Clinical","_updatedAt":"2022-02-18T12:13:55Z"},{"identifier":"biosimilars","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"cmeType":"per","_createdAt":"2020-04-14T15:02:13Z","name":"Biosimilars","_id":"compendium_biosimilars","summary":[{"_key":"21a8926c2669","markDefs":[],"children":[{"_type":"span","marks":[],"text":"The ","_key":"d9a7c16be264"},{"text":"AJMC","_key":"5aab8321660a","_type":"span","marks":["em"]},{"_type":"span","marks":["superscript"],"text":"®","_key":"84efcc202b1e"},{"_key":"2454ce1e8332","_type":"span","marks":[],"text":" Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates."}],"_type":"block","style":"normal"}],"perKeywordMapping":["Pharmacy","Health Equity Diversity \u0026 Inclusion"],"_rev":"rs7eCk0lrr8LMiZP9GDaQL","_type":"taxonomy","_updatedAt":"2023-11-03T18:20:52Z"}],"url":{"current":"protocols-and-laws-for-transitioning-to-biosimilars","_type":"slug"},"documentGroup":{"_type":"reference","_ref":"d537a5b9-b33e-485d-aa7f-6f9c16e0f599"},"updatedOn":null,"_type":"article","_rev":"uNtBwCwtqRwQLOCysLmAUo","seoTag":["Biosimilars","local substitution laws"," state substitution laws"," shared decision-making"," payers"," providers"," quality","patient-family advocates"," P\u0026T committee"," pharmacy"," Board of Pharmacy"," rules and regulations"," treatment plans"," adherence"],"title":"Protocols and Laws for Transitioning to Biosimilars","_updatedAt":"2021-11-17T20:03:39Z","summary":"Ryan Haumschild, PharmD, MS, MBA, and Kathy Oubre, MS, recall what protocols and laws their organizations needed to abide by when transitioning to their biosimilars programs.","contentCategory":{"_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76"},"_createdAt":"2021-11-09T17:03:07Z","authorMapping":null,"body":[{"_key":"67be8f626c67","markDefs":[],"children":[{"_key":"f208f0863a6e","_type":"span","marks":[],"text":""}],"_type":"block","style":"normal"},{"_type":"video","videoID":"6278919085001","source":"brightcove","_key":"fe645dfa4c84"},{"markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Ryan Haumschild, PharmD, MS, MBA","_key":"4f49effe37b70"},{"_type":"span","marks":[],"text":": When you go to implement biosimilars, it’s important to make sure that you’re bringing through your strategy, and you have all of the decisions made through a shared decision-making framework. That means that you want to make sure nursing is involved, the providers are involved, quality is involved, everyone has insight into and transparency regarding why we’re trying to implement biosimilars, and the benefits of them. As we create transitions, we want input from everyone, patient family advocates, etc, to make sure we’re always doing the right thing. As we went to drive forward with biosimilar implementation, we continued to bring the biosimilars initially through our P\u0026T [pharmacy and therapeutics] committee and created a monograph. Over time, our physicians and the greater P\u0026T committee said, “We get the concept of biosimilars. Once they’re approved by the FDA to highly similar products, you don’t need to bring them forward, because we recognize more biosimilars are going to come to market. Let’s approve the concept of biosimilars and have some standard work in the way we look at biosimilars, but after that’s complete, let’s defer to pharmacy to choose the best product that provides the best pricing to our organization and our patients. That way we can reduce carrying costs and create more real time implementation.” That’s also important because we had payers that were already requiring biosimilars. If we don’t become efficient in the way that we onboarded these biosimilars to formulary, we may end up getting a lot of denials, which creates frustration for the patient, our providers, and the organization. Getting that P\u0026T approval and that P\u0026T policy approval on biosimilars allows us to be a lot more operationally efficient. When it comes to switches, you want to consult your local board of pharmacy rules and regulations. We want to make sure that we’re complying with any of those regulatory considerations. We made sure we did our homework within our P\u0026T-approved policy, and within our provider approval for making those substitutions that actually complied with local board of pharmacy regulations and allowed us to be successful with our strategy and utilizing biosimilars. In addition to that, we also had payer mandates that were requiring it, and we were having to tag our physicians anyway to have them switch it out. By creating this policy and procedure, it met our regulatory requirements, it met our shared decision-making requirement, and it met the needs for that just-in-time treatment plan that benefitted the patient.","_key":"4f49effe37b71"}],"_type":"block","style":"normal","_key":"e87b14a1a293"},{"markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Kathy Oubre, MS","_key":"3659444013df0"},{"marks":[],"text":": The protocols that we used to drive this transition were to build new treatment plans for all of those biosimilars, update any existing treatment plans, and then use detailed workflows around the steps for authorization, administration, and adherence. The next step is to develop reports internally, and within our EMR [electronic medical records], to monitor all of those moving parts. Last, for switches, the way biosimilars are designated requires both physician-approval and patient-reconsent for therapy for interchange to occur. From a state and regulatory perspective, we have not seen that be a large barrier within our transition.","_key":"3659444013df1","_type":"span"}],"_type":"block","style":"normal","_key":"91dd33d31d5f"},{"children":[{"_type":"span","marks":[],"text":"","_key":"ff1a683158f9"}],"_type":"block","style":"normal","_key":"fdd00090b94e","markDefs":[]},{"style":"normal","_key":"ea9925125f8d","markDefs":[],"children":[{"_type":"span","marks":["strong","em"],"text":"This transcript has been edited for clarity.","_key":"70936d10b8b0"}],"_type":"block"}]},{"_createdAt":"2021-11-02T21:12:55Z","summary":"Two experts examine how the biosimilar programs at their organization were created and the initial goals they had in mind.","is_visible":true,"contentCategory":{"_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos"},"_rev":"Yi2bn4k8OtohOHqwyRKN3r","taxonomyMapping":[{"_type":"taxonomy","name":"Insights","_id":"54959cfc-9805-4ede-bc8f-7ecfcd2530c6","_updatedAt":"2022-01-19T10:12:39Z","identifier":"insights","_createdAt":"2020-03-30T19:15:55Z","sortOrder":2,"_rev":"Pqv14IIDiWFMzK5solyWKi"},{"name":"Video Series","_id":"999720cf-b3b3-4d42-935d-beb17775844e","_updatedAt":"2022-01-06T09:02:13Z","identifier":"video-series","_createdAt":"2020-10-14T04:51:21Z","_rev":"ChnBnF2xw1R5u2UJBDlozJ","_type":"taxonomy"},{"summary":[{"markDefs":[],"children":[{"_key":"e80c79954e08","_type":"span","marks":[],"text":"The "},{"_type":"span","marks":["em"],"text":"AJMC","_key":"a8e0f75c5d05"},{"_type":"span","marks":["superscript"],"text":"®","_key":"f7d4dddf7edd"},{"_type":"span","marks":[],"text":" clinical page includes all the published content across AJMC.com, ","_key":"0f03d46e3b3a"},{"marks":["em"],"text":"The American Journal of Managed Care","_key":"cc409f2da7da","_type":"span"},{"_type":"span","marks":["superscript"],"text":"®","_key":"2babb3e59bb3"},{"_type":"span","marks":[],"text":" and ","_key":"d86a5bb12052"},{"text":"Evidence-Based Oncology","_key":"40b2eaba6c17","_type":"span","marks":["em"]},{"text":"™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.","_key":"b59bef533cdf","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"dd8ad578cd0b"}],"_createdAt":"2020-05-04T23:46:13Z","_rev":"HexDiduX8d6Nqnq1ECriVF","_type":"taxonomy","_id":"topic_clinical","identifier":"clinical","parent":{"_type":"reference","_ref":"15012229-f713-4f0a-8f82-7667530bb382"},"name":"Clinical","_updatedAt":"2022-02-18T12:13:55Z"},{"identifier":"biosimilars","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"cmeType":"per","_createdAt":"2020-04-14T15:02:13Z","name":"Biosimilars","_id":"compendium_biosimilars","summary":[{"children":[{"_type":"span","marks":[],"text":"The ","_key":"d9a7c16be264"},{"text":"AJMC","_key":"5aab8321660a","_type":"span","marks":["em"]},{"_type":"span","marks":["superscript"],"text":"®","_key":"84efcc202b1e"},{"_key":"2454ce1e8332","_type":"span","marks":[],"text":" Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates."}],"_type":"block","style":"normal","_key":"21a8926c2669","markDefs":[]}],"perKeywordMapping":["Pharmacy","Health Equity Diversity \u0026 Inclusion"],"_rev":"rs7eCk0lrr8LMiZP9GDaQL","_type":"taxonomy","_updatedAt":"2023-11-03T18:20:52Z"}],"authorMapping":null,"url":{"current":"transitioning-to-a-biosimilar-program","_type":"slug"},"internalTag":["Biosimilars"],"thumbnail":{"asset":{"sha1hash":"5877f3599b18f1db82bacba5d328e3e743fec483","size":1177244,"assetId":"5877f3599b18f1db82bacba5d328e3e743fec483","_id":"image-5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080-png","uploadId":"vG5pYzlgenu2glXC7mBtsYgj4nivwlhg","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png","_updatedAt":"2021-11-02T21:06:16Z","_rev":"zYFJ6fTR7QCWPh1X1BRgu9","mimeType":"image/png","originalFilename":"Oubre_HS.png","_createdAt":"2021-11-02T21:06:16Z","extension":"png","metadata":{"dimensions":{"aspectRatio":1.7777777777777777,"height":1080,"_type":"sanity.imageDimensions","width":1920},"isOpaque":false,"blurHash":"MTIFDMxs0pM{D,4po~IVR-Rj_NWGn1tRxp","_type":"sanity.imageMetadata","palette":{"dominant":{"population":3.61,"background":"#3681e2","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"_type":"sanity.imagePalette","darkMuted":{"population":2.06,"background":"#4d2f30","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"muted":{"background":"#a96055","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.88},"lightVibrant":{"foreground":"#000","title":"#fff","population":0.33,"background":"#d5ae9f","_type":"sanity.imagePaletteSwatch"},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":1.09,"background":"#082983"},"lightMuted":{"background":"#b4bcc6","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":2.08},"vibrant":{"background":"#3681e2","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":3.61}},"hasAlpha":true,"lqip":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABQAAAALCAYAAAB/Ca1DAAAACXBIWXMAAAPoAAAD6AG1e1JrAAADOUlEQVQokXXMXUxTBxwF8Ps44xYf5pPLQgwBscTSoRIZk0+3waix4FdclI8orXxUmUwZWKQdCDqEoJW0hVqYgICyohhQi7RC8MJkbGWAgiJrEAibIFIpNdx7/8fUPexpJ/k9nJzkMBuOtNF7h2/R52k3SF5k5tX6dq7AaOHOmjq5IlMnV2js4Ao93WjhNPp27oy2lVNdbOESTlXyvjtyaLVfKj7wUdIqvx+I2ai4Rx5+h1sp9mQzVd/sEX4becr/MfYXPzIxzQ8+meC7bSzfeec+38sO8L2/2vkHNpa3Wlm+3GAWgnZp6KNNJ/FhgIbWbC0lxj/dRh4bU9ooPtdMbV0DND07RY7pSZqZnaKnQ3a6azRQS0kxWZsayN7TRfZuK7EWCxlMNyk8wUBrQyuwNsJE62IbBEacyUJ8nIX/UQvicsy4bXuEqekJDA724xHbhY7mJlRnZ+HnY6moyc9DQ4UWNyp1qNMbUFxah7Dka/hE2gyvfe3km2wVGMmJfhJn9pFIfodiT9RTU6uFhga6qaXeSPqSIirPyabS5ENUmyGn8rSjpFIoSKXMoGJVPqkKqihC0Uw+CfchSusj8Xe/C4xYyUKksMJ7fx0ik8pQVl6BKxc0yDwQj28jQ7EvJBiJ27Yg75sopO2IgCwkFHuipTguT8cptQ4x2RaSZNmxOXeMtuaNC8ynsmqsi67Ax8FnII5SQnEkA6m7ZZBKJNjuI0Kgly+CvXywOyAQX4ok2OQdAIk4DLK4RKRkX0ZMXo/nCEHqSQrSTAqMb9RpeId+j/XB6fgsXA5ZvBwH4hKwV5oIaWwKtkcmISz8EHZJ5YiRKvBFdApCdiqxMykfB3NrEVfYS18VjeLr4mcUfW5cYNQ/XUVuYRVyCiqhPm/ChUu10Ooboa9pg77eBm1NJ7TVHdDVP4C+sQu6xm7orveg8pc+VN2yo8w8Qj82DuPs9cd06fY4Mc+eOzA0PIo/h55gdOw5HJMzmJmdw9/zTrxccP3ntQtzr5cxt7iM+UX3e7OvlvDY8Q89HHagf/QFTcy8IsbtduON0wmn0wmXawkrKysAEf4/nu3fXRB4vFly0cv5BcwvLNKy+y29AytMWXYOrM3AAAAAAElFTkSuQmCC"},"_type":"sanity.imageAsset","path":"images/0vv8moc6/ajmc/5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png"}},"title":"Transitioning to a Biosimilar Program","published":"2021-11-02T21:14:00.000Z","link":"/view/transitioning-to-a-biosimilar-program","updatedOn":null,"factCheckAuthorMapping":null,"_updatedAt":"2021-11-16T17:40:23Z","_id":"1b11ddbd-ade5-4d1e-84f1-121d8e0e921d","body":[{"style":"normal","_key":"ad305fd6ff2d","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"f5b8929c84c4"}],"_type":"block"},{"source":"brightcove","_key":"64a314b7a57c","_type":"video","videoID":"6278920330001"},{"children":[{"text":"Ryan Haumschild, PharmD, MS, MBA:","_key":"17649b3775ff0","_type":"span","marks":["strong"]},{"marks":[],"text":" Gaining buy-in for biosimilars involves multiple stakeholders. We appreciate the relationship we have with our physician partners and advanced practice practitioners who had to be involved. Our physician medical leadership had to be involved because we value their input, and we like to make decisions through a shared decision-making process. We wanted to bring in their take. What are their observations around biosimilars? Have they been familiar with them through research? Do they understand the concepts? Do they understand the science and the manufacturing process and feel comfortable with the FDA-approval process? Some may be comfortable. Some may be familiar with the idea. Maybe they’re even familiar with some of the data available from Europe. Others might be a little more hesitant. That’s OK if they’re hesitant because that’s an opportunity for us both to look into the data more and answer some of the questions that come up.","_key":"17649b3775ff1","_type":"span"}],"_type":"block","style":"normal","_key":"8995dc3f2ddb","markDefs":[]},{"children":[{"_type":"span","marks":[],"text":"","_key":"0b41707413720"}],"_type":"block","style":"normal","_key":"866af72848a2","markDefs":[]},{"style":"normal","_key":"077fcce16e2d","markDefs":[],"children":[{"_type":"span","marks":[],"text":"As we take on biosimilars, we get stakeholders involved but there’s also a strategy. That strategy involves [asking], what type of patients do you initially start utilizing biosimilars in? Do you utilize it in those patients who are going to start on medication for the first time, or do you consider switching patients midcycle for those who have been stable on the reference product? Many organizations, depending on how aggressive they are or familiar with biosimilars, have taken a different route. We like to start with new-start patients. That’s where the providers felt comfortable. We felt comfortable that we could go ahead and get precertifications for the product and oversee those patients and monitor them. That was helpful because it allowed us to grow comfortable with the data and transition as more biosimilars came to market. We eventually felt comfortable switching patients, not only patients on new starts but switching patients who are stable on the reference product to the biosimilar. That’s a natural transition that works well through that shared decision-making model.","_key":"9f4def5f16180"}],"_type":"block"},{"_key":"161af359c9ec","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"6509e4b3fcbb0"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Kathy Oubre, MS:","_key":"1c6b43d120b30"},{"_type":"span","marks":[],"text":" The first thing we did as an organization was to explain the why to everyone. As with many new programs or changes that we make within our organization, we’ve found that the most seamless transitions occur when everyone is involved. We started with the physicians and our nurse practitioners to ensure that they were comfortable with the science, the clinical trials, and the FDA-approval process. Next, we met with the nurses and because nurses spend the most time with our oncology patients in that infusion room. They often form very strong relationships, and the nurses take those relationships very personally.","_key":"1c6b43d120b31"}],"_type":"block","style":"normal","_key":"8f8b3b1481f7"},{"markDefs":[],"children":[{"text":"","_key":"32b5a0b283050","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"bb94b6412330"},{"children":[{"_type":"span","marks":[],"text":"We spend a lot of time with them talking about the biosimilar education and the science behind it, and we also included that potential cost savings that it would provide for their patients. Often we hear about the financial struggles of our patients, and we hear about it from the nurses. We felt it was important to include that financial piece in our discussion with them. Last, we met with the financial team and the authorization teams so they understand why we would be asking them to redo patients’ treatment plans a week after the original treatment plan had been completed but now a new biosimilar came to market. We used all these meetings as an opportunity to stress the importance of accuracy of authorizing and administering the correct and approved biosimilar or innovator product to the correct patient to help minimize error and risk to practice.","_key":"650cfb1f25730"}],"_type":"block","style":"normal","_key":"6698d7e28ad1","markDefs":[]},{"style":"normal","_key":"816e89c492ef","markDefs":[],"children":[{"_type":"span","marks":[],"text":"When we were doing those original sets of meetings with the providers, that decision was made then to move everyone as a whole, so everyone that was on current treatment were included in that decision making process. We made those decisions with all our new treatments moving forward.","_key":"a5bdd1cc113e0"}],"_type":"block"},{"markDefs":[],"children":[{"text":"","_key":"d1d770c330890","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"47316e8bf31a"},{"_type":"block","style":"normal","_key":"a8f21a93d1dd","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Ryan Haumschild, PharmD, MS, MBA:","_key":"764047f83ec20"},{"_type":"span","marks":[],"text":" The initial goals of implementing biosimilars are that we want to maintain patient safety, provide a clinical efficacious treatment, and provide the best care. That’s our true north for us when we’re making these decisions. When we look at these initial goals, we also wanted to comply with the payer mandates. We wanted to feel comfortable with the clinical data and in using these medications. We’re using biosimilars only because payers are making us. We know payers were forcing a lot of people across the country. We wanted to feel comfortable because we thought it was the right thing to do for patients who could potentially reduce their co-pays and reduce total cost of care, which is important in our health care system as drug prices continue to rise. We wanted to get more data around biosimilars so that we feel comfortable with the outcomes they gave us. As more biosimilars come to market for additional reference products, we had some real-world evidence.","_key":"764047f83ec21"}]},{"_type":"block","style":"normal","_key":"cd16ee3e1746","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"7517564120a40"}]},{"children":[{"_type":"span","marks":[],"text":"Some of the successes we’ve seen are that we felt comfortable with the data, and we saw good outcomes with our patients. Patients felt comfortable moving to a biosimilar, and they started to understand the topic. One of the challenges was matching up our reimbursement with biosimilars. That’s something that’s always going to be a bit of a challenge. When you’re trying to maximize your margin and make sure you’re doing a good job and staying operationally excellent, sometimes biosimilars can help, but sometimes they can’t. We’re trying to track some of those financial outcomes with something that was a little more challenging at the beginning, especially because it could be payer specific in terms of what was being approved. Another challenge, as we transition with biosimilars, was that specific physicians had concerns around immunogenicity or individual patients didn’t want to be switched off the reference product. We dealt with those in 1-off situations. If the patient felt strongly enough, we try to appeal for the reference product because ultimately we want to do best by the patient and what makes them feel most comfortable.","_key":"cf50d4b3b9d20"}],"_type":"block","style":"normal","_key":"3a874d71acb1","markDefs":[]},{"_type":"block","style":"normal","_key":"6b0abb5fd6da","markDefs":[],"children":[{"text":"","_key":"cd78830e7f000","_type":"span","marks":[]}]},{"markDefs":[],"children":[{"_key":"814f6c8fb0470","_type":"span","marks":[],"text":"Over time we’ve been able to get more familiar and feel more confident in utilizing biosimilars across the board, but those were some of the initial challenges we ran into as we wrapped up our program."}],"_type":"block","style":"normal","_key":"ba74e2aab99a"},{"_key":"eab86bf6c107","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"61726b0980690"}],"_type":"block","style":"normal"},{"children":[{"marks":["strong"],"text":"Kathy Oubre, MS:","_key":"925b2e219d730","_type":"span"},{"_key":"925b2e219d731","_type":"span","marks":[],"text":" As an organization, our goal for biosimilars was to do our part in bringing down drug cost as a nation and an organization and support the biosimilar market because we, as an organization, feel that biosimilars are going to play a very pivotal role in helping drive down health care costs. Most important, our primary goal was to increase access to care for many of our patients by offering a high-quality, less costly alternative to the originator product, which is quality without compromise. The challenges around implementing and maintaining those are keeping track of all the biosimilars on market, how the payer formularies change, and ensuring that our authorization team, financial team, and nursing team are giving approved products to the correct patients. Holistically, this has been a huge win for our organization and our patients. In our first month, we saw a 23% decrease in out-of-pocket costs for our patients, which is a lower cost to a health care system."}],"_type":"block","style":"normal","_key":"03b034b8afca","markDefs":[]},{"markDefs":[],"children":[{"marks":[],"text":"","_key":"936e387923f6","_type":"span"}],"_type":"block","style":"normal","_key":"024b3f5b0241"},{"children":[{"_type":"span","marks":["strong","em"],"text":"This transcript has been edited for clarity.","_key":"26b17c1c2e14"}],"_type":"block","style":"normal","_key":"22e34312ba1e","markDefs":[]}],"seoTag":["Biosimilars","stakeholders"," shared decision-making"," research data"," patient strategy"," physicians"," pharmacists"," nurses"," cost"," financial team"," authorization team"," accuracy"," safety"," efficacy"," payer mandates"," immunogenicity"," patient needs"," patient access"],"documentGroup":{"_ref":"d537a5b9-b33e-485d-aa7f-6f9c16e0f599","_type":"reference"},"_type":"article"},{"_updatedAt":"2021-11-16T17:38:39Z","published":"2021-11-02T21:07:00.000Z","body":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"068de848c743"}],"_type":"block","style":"normal","_key":"c9b7cda815a4"},{"_type":"video","videoID":"6278919317001","source":"brightcove","_key":"09480d7df455"},{"_key":"d84bd108402f","markDefs":[],"children":[{"_key":"ab641ed5d9e0","_type":"span","marks":["strong"],"text":"Ryan Haumschild, PharmD, MS, MBA:"},{"_type":"span","marks":[],"text":" The uptake of biosimilars is something we’ve been working on over the past few years. As biosimilars came to market initially, a lot of people were hesitant, and rightfully so. What does a biosimilar mean? What does it mean when it’s highly similar to the reference product, and how do we utilize these medications? Many of us were forced to use biosimilars in the supportive care side when we think of medications like pegfilgrastim. Those initially came to market and soon after, the last couple of years we’ve had a lot of pegfilgrastim biosimilars for supportive care measures, and we’ve had to adopt it. Because not only did we want to decrease cost of care, but payers started mandating it. As health care facilities, to comply with payer mandates we had to get familiar with these medications and utilize them.","_key":"339d63cf11ae"}],"_type":"block","style":"normal"},{"_type":"block","style":"normal","_key":"16e769d70e99","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"603e853e61700"}]},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"That’s 1 area where biosimilars started to gain understanding—within health care providers, within the pharmacy team members—of what benefits biosimilars bring to the table. After we had biosimilars, we got comfortable with them in the supportive care arena. All of a sudden, we started to see newer biosimilars come forward in the therapeutic area, in the treatment space. This is something that gained a bit of hesitancy at first, just as it did when biosimilars were brought through supportive care, because we’re treating patients who might be curative in therapy or metastatic with a biosimilar, not the reference product.","_key":"f85d1ba0117e0"}],"_type":"block","style":"normal","_key":"8f4e399576fd"},{"_type":"block","style":"normal","_key":"a3317949b5c2","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"8c7bf9e90cb60"}]},{"markDefs":[],"children":[{"text":"What we did was leverage the great data that we saw in Europe. Europe has been using biosimilars since 2008. We’re able to see what their real-world evidence looked like. We’re able to translate that in our health care system. We still have some challenges with people concerned about immunogenicity: how do we create uptake, how do we add these medications to formulary, do we consider them equivalent. Those are decisions that we’ve methodically thought through and come up with plans for. Those were the initial challenges that came up. Successes are: We’ve been able to provide medications with good clinical efficacy at a reduced cost of care, which has been helpful. We’ve been able to comply with some of our payers, meeting value-based goals and reducing the cost. Last, we’ve been able to reduce co-pays for some patients by bringing them a more cost-effective therapy and utilize it for their treatment. Those are some of the barriers and successes we’ve seen with biosimilars coming to market.","_key":"d5a58ba98f1c0","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"47cef112ab73"},{"_key":"89cb7d9cdb02","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"4a545226e7c90"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"_key":"94f0b1a10a190","_type":"span","marks":["strong"],"text":"Kathy Oubre, MS:"},{"_type":"span","marks":[],"text":" Our biggest success with biosimilars has been increased access to care for our patients. Biosimilars allow us to offer these potentially life-saving medications at a lower out-of-pocket cost to our patients. The estimated cost savings per dose for our patients has been $500 to $1400 for some of the more expensive therapeutic products. These types of cost savings have been more crucial during the pandemic as disparities in care have come to the forefront of our lives as health care providers.","_key":"94f0b1a10a191"}],"_type":"block","style":"normal","_key":"33a51ab1d3b7"},{"_type":"block","style":"normal","_key":"e6791c6c2195","markDefs":[],"children":[{"marks":[],"text":"","_key":"734acc82c8dc0","_type":"span"}]},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"As many people continue to be faced with job and financial insecurities as a result of the pandemic, we’re going to see that problem moving forward. The cost savings of biosimilars has helped many people continue to afford their treatments. Some challenges that we see at Pontchartrain Cancer [Center] have been more operational in nature because of the requirement to stop multiple biosimilars and perhaps the originator because of variation in payer formulary. This has led though to an increased risk from an operational perspective if a nonauthorized biosimilar is administered to the wrong patient. If this happens, there’s a good chance the practice won’t receive payment from the payer.","_key":"c29230a307a50"}],"_type":"block","style":"normal","_key":"3821e5052590"},{"markDefs":[],"children":[{"_key":"0efcd3e602c40","_type":"span","marks":[],"text":""}],"_type":"block","style":"normal","_key":"fc95a6dd3d37"},{"markDefs":[],"children":[{"text":"We haven’t seen a big difference in our success or challenges around supportive care or therapeutic biosimilars from an operational perspective. However, in looking at our patient population as a whole, we’ve seen a lot more success due to an increase in access to care around the therapeutic agents because there are more of them. That does consequently lead to more of an increased risk in ensuring that the correct patient receives the approved drug.","_key":"4bc3f05087a70","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"381807758e91"},{"style":"normal","_key":"450f41258385","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"fd55bb3381e10"}],"_type":"block"},{"_key":"bb7bf58d846b","markDefs":[],"children":[{"marks":["strong"],"text":"Ryan Haumschild, PharmD, MS, MBA:","_key":"1293b9a0fc750","_type":"span"},{"_type":"span","marks":[],"text":" What was the catalyst for us to implement biosimilars? It was multiple factors, but first it was the payers. Payers started seeing that they could provide a therapeutic medication, approve it, and have equivalent efficacy because it’s highly similar. It’s the biosimilar. We had to start looking at them. We also were starting to look at how to reduce cost of care for our patients and our organization. That was the start of how we explore biosimilars further, especially now that we know they’re highly similar to the reference product and should give an equivalent clinical response.","_key":"1293b9a0fc751"}],"_type":"block","style":"normal"},{"children":[{"marks":[],"text":"","_key":"340bee9731bf0","_type":"span"}],"_type":"block","style":"normal","_key":"28f0a8558c4d","markDefs":[]},{"style":"normal","_key":"fe99ab2d303e","markDefs":[],"children":[{"_type":"span","marks":[],"text":"That process started with creating a survey across organization, understanding what were the barriers. What were the concerns from our provides? Was it immunogenicity? Was it enough data in the curative intent patient population? What were some of the barriers from finance from our EMR [electronic medical record] in terms of how we build these out quicker? Once you grapple with those topics and understand your biggest barriers—or what I consider the biggest areas of opportunity to learn more about biosimilars—you start to see the benefits of biosimilars. You answer some of the questions people have. It creates better transition for biosimilars into an organization, ultimately utilizing them within patients while reducing total cost to care.","_key":"7f5f9119279a0"}],"_type":"block"},{"style":"normal","_key":"edd7fe2495c9","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"29b0cbb5283f0"}],"_type":"block"},{"_key":"890756109b91","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Kathy Oubre, MS:","_key":"4f6c9207a2810"},{"_type":"span","marks":[],"text":" Our transition to biosimilars happened a week and a half after the first biosimilar hit the market. Given that there are multiple biosimilars and the innovator to choose from, we felt that it was important to have fairly specific and detailed workflows around implementing biosimilars to minimize operational errors. First, our nursing director reviewed and continues to review all new orders and substitutes the biosimilar from the originator. They’re cross-referencing this with the list of approved biosimilars or reference products by each payer. Unless that payer insists on an originator or a biosimilar not in our EMR—we have our internal formulary to manage that with. We also run weekly reports out of our EMR to identify all existing patients who are eligible to switch to a biosimilar based on indication and payer. Next, follow that consultation with the physician. The pharmacist substitutes the biosimilar, and patients are then educated and reconsented for the biosimilar. After that, those new orders go to our financial and authorization teams to get the new product authorized and update the patient’s out of pocket.","_key":"4f6c9207a2811"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"53039ab14dea"}],"_type":"block","style":"normal","_key":"1f9865cec832"},{"children":[{"_type":"span","marks":["strong","em"],"text":"This transcript has been edited for clarity.","_key":"968bb73fce40"}],"_type":"block","style":"normal","_key":"958ebf87e8a5","markDefs":[]}],"documentGroup":{"_ref":"d537a5b9-b33e-485d-aa7f-6f9c16e0f599","_type":"reference"},"is_visible":true,"taxonomyMapping":[{"_rev":"Pqv14IIDiWFMzK5solyWKi","_type":"taxonomy","name":"Insights","_id":"54959cfc-9805-4ede-bc8f-7ecfcd2530c6","_updatedAt":"2022-01-19T10:12:39Z","identifier":"insights","_createdAt":"2020-03-30T19:15:55Z","sortOrder":2},{"_createdAt":"2020-10-14T04:51:21Z","_rev":"ChnBnF2xw1R5u2UJBDlozJ","_type":"taxonomy","name":"Video Series","_id":"999720cf-b3b3-4d42-935d-beb17775844e","_updatedAt":"2022-01-06T09:02:13Z","identifier":"video-series"},{"identifier":"clinical","parent":{"_type":"reference","_ref":"15012229-f713-4f0a-8f82-7667530bb382"},"name":"Clinical","_updatedAt":"2022-02-18T12:13:55Z","summary":[{"markDefs":[],"children":[{"_key":"e80c79954e08","_type":"span","marks":[],"text":"The "},{"_type":"span","marks":["em"],"text":"AJMC","_key":"a8e0f75c5d05"},{"_type":"span","marks":["superscript"],"text":"®","_key":"f7d4dddf7edd"},{"_type":"span","marks":[],"text":" clinical page includes all the published content across AJMC.com, ","_key":"0f03d46e3b3a"},{"marks":["em"],"text":"The American Journal of Managed Care","_key":"cc409f2da7da","_type":"span"},{"_type":"span","marks":["superscript"],"text":"®","_key":"2babb3e59bb3"},{"_type":"span","marks":[],"text":" and ","_key":"d86a5bb12052"},{"text":"Evidence-Based Oncology","_key":"40b2eaba6c17","_type":"span","marks":["em"]},{"text":"™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.","_key":"b59bef533cdf","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"dd8ad578cd0b"}],"_createdAt":"2020-05-04T23:46:13Z","_rev":"HexDiduX8d6Nqnq1ECriVF","_type":"taxonomy","_id":"topic_clinical"},{"_updatedAt":"2023-11-03T18:20:52Z","summary":[{"children":[{"_type":"span","marks":[],"text":"The ","_key":"d9a7c16be264"},{"text":"AJMC","_key":"5aab8321660a","_type":"span","marks":["em"]},{"_type":"span","marks":["superscript"],"text":"®","_key":"84efcc202b1e"},{"_key":"2454ce1e8332","_type":"span","marks":[],"text":" Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates."}],"_type":"block","style":"normal","_key":"21a8926c2669","markDefs":[]}],"perKeywordMapping":["Pharmacy","Health Equity Diversity \u0026 Inclusion"],"_rev":"rs7eCk0lrr8LMiZP9GDaQL","_type":"taxonomy","name":"Biosimilars","_id":"compendium_biosimilars","identifier":"biosimilars","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"cmeType":"per","_createdAt":"2020-04-14T15:02:13Z"}],"internalTag":["Biosimilars"],"_rev":"jFlyVyB0S45zgvAzVyLiC1","_type":"article","link":"/view/increased-use-of-biosimilars","factCheckAuthorMapping":null,"thumbnail":{"asset":{"extension":"png","metadata":{"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"aspectRatio":1.7777777777777777,"height":1080,"_type":"sanity.imageDimensions","width":1920},"isOpaque":false,"blurHash":"MTIFDMxs0pM{D,4po~IVR-Rj_NWGn1tRxp","_type":"sanity.imageMetadata","palette":{"darkMuted":{"background":"#4d2f30","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":2.06},"muted":{"background":"#a96055","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.88},"lightVibrant":{"population":0.33,"background":"#d5ae9f","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":1.09,"background":"#082983"},"lightMuted":{"background":"#b4bcc6","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":2.08},"vibrant":{"background":"#3681e2","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":3.61},"dominant":{"population":3.61,"background":"#3681e2","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"_type":"sanity.imagePalette"}},"_type":"sanity.imageAsset","path":"images/0vv8moc6/ajmc/5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png","_createdAt":"2021-11-02T21:06:16Z","sha1hash":"5877f3599b18f1db82bacba5d328e3e743fec483","size":1177244,"assetId":"5877f3599b18f1db82bacba5d328e3e743fec483","_id":"image-5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080-png","uploadId":"vG5pYzlgenu2glXC7mBtsYgj4nivwlhg","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5877f3599b18f1db82bacba5d328e3e743fec483-1920x1080.png","_updatedAt":"2021-11-02T21:06:16Z","_rev":"zYFJ6fTR7QCWPh1X1BRgu9","mimeType":"image/png","originalFilename":"Oubre_HS.png"}},"title":"Increased Use of Biosimilars","seoTag":["Biosimilars","supportive care"," therapeutic"," efficacy"," payers"," providers"," co-pay"," pegfilgrastim"," immunogenicity"," access"," out-of-pocket costs"," barriers"," concerns"," EMR"," electronic medical record"," patient education"],"contentCategory":{"_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76"},"_id":"d0c623fa-bc82-4c0b-98c2-7ded75914ee2","updatedOn":null,"authorMapping":null,"url":{"_type":"slug","current":"increased-use-of-biosimilars"},"_createdAt":"2021-11-02T21:06:30Z","summary":"Ryan Haumschild, PharmD, MS, MBA, and Kathy Oubre, MS, discuss the increased use of biosimilars, including successes and challenges and the process of transitioning to biosimilars at their organizations."},{"is_visible":true,"_rev":"jC0WRQg8Xm6XMDuB6WQlqx","internalTag":["Biosimilars"],"documentGroup":{"_type":"reference","_ref":"d537a5b9-b33e-485d-aa7f-6f9c16e0f599"},"url":{"current":"optimizing-transitions-to-biosimilars","_type":"slug"},"_id":"68cd7bf6-95bd-4ba9-9c59-23b910745c17","authorMapping":null,"_type":"article","published":"2021-10-26T18:29:00.000Z","contentCategory":{"_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z"},"taxonomyMapping":[{"_updatedAt":"2022-01-19T10:12:39Z","identifier":"insights","_createdAt":"2020-03-30T19:15:55Z","sortOrder":2,"_rev":"Pqv14IIDiWFMzK5solyWKi","_type":"taxonomy","name":"Insights","_id":"54959cfc-9805-4ede-bc8f-7ecfcd2530c6"},{"identifier":"video-series","_createdAt":"2020-10-14T04:51:21Z","_rev":"ChnBnF2xw1R5u2UJBDlozJ","_type":"taxonomy","name":"Video Series","_id":"999720cf-b3b3-4d42-935d-beb17775844e","_updatedAt":"2022-01-06T09:02:13Z"},{"_createdAt":"2020-05-04T23:46:13Z","_rev":"HexDiduX8d6Nqnq1ECriVF","_type":"taxonomy","_id":"topic_clinical","summary":[{"children":[{"_key":"e80c79954e08","_type":"span","marks":[],"text":"The "},{"_type":"span","marks":["em"],"text":"AJMC","_key":"a8e0f75c5d05"},{"_type":"span","marks":["superscript"],"text":"®","_key":"f7d4dddf7edd"},{"_type":"span","marks":[],"text":" clinical page includes all the published content across AJMC.com, ","_key":"0f03d46e3b3a"},{"marks":["em"],"text":"The American Journal of Managed Care","_key":"cc409f2da7da","_type":"span"},{"_type":"span","marks":["superscript"],"text":"®","_key":"2babb3e59bb3"},{"_type":"span","marks":[],"text":" and ","_key":"d86a5bb12052"},{"text":"Evidence-Based Oncology","_key":"40b2eaba6c17","_type":"span","marks":["em"]},{"text":"™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.","_key":"b59bef533cdf","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"dd8ad578cd0b","markDefs":[]}],"parent":{"_type":"reference","_ref":"15012229-f713-4f0a-8f82-7667530bb382"},"name":"Clinical","_updatedAt":"2022-02-18T12:13:55Z","identifier":"clinical"},{"_id":"compendium_biosimilars","identifier":"biosimilars","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"cmeType":"per","_createdAt":"2020-04-14T15:02:13Z","name":"Biosimilars","summary":[{"style":"normal","_key":"21a8926c2669","markDefs":[],"children":[{"_type":"span","marks":[],"text":"The ","_key":"d9a7c16be264"},{"text":"AJMC","_key":"5aab8321660a","_type":"span","marks":["em"]},{"_type":"span","marks":["superscript"],"text":"®","_key":"84efcc202b1e"},{"_key":"2454ce1e8332","_type":"span","marks":[],"text":" Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates."}],"_type":"block"}],"perKeywordMapping":["Pharmacy","Health Equity Diversity \u0026 Inclusion"],"_rev":"rs7eCk0lrr8LMiZP9GDaQL","_type":"taxonomy","_updatedAt":"2023-11-03T18:20:52Z"}],"factCheckAuthorMapping":null,"thumbnail":{"asset":{"mimeType":"image/jpeg","_updatedAt":"2021-10-26T18:27:51Z","uploadId":"1QgtxdQLTQ5lCgCxvDnsUJDPlSOnJLB6","_rev":"yPN4n5TcElVjh0RH5xNX8U","_type":"sanity.imageAsset","path":"images/0vv8moc6/ajmc/117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg","size":444731,"originalFilename":"MicrosoftTeams-image.png","metadata":{"lqip":"data:image/jpeg;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":1920,"aspectRatio":1.7777777777777777,"height":1080},"isOpaque":true,"blurHash":"MPGle$t55IWAIE00tTNKNHRQ~qWZwEt8xs","_type":"sanity.imageMetadata","palette":{"vibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":4.38,"background":"#2b78de"},"dominant":{"background":"#2b78de","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":4.38},"_type":"sanity.imagePalette","darkMuted":{"background":"#342920","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":1.78},"muted":{"title":"#fff","population":2.34,"background":"#967e68","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightVibrant":{"foreground":"#000","title":"#fff","population":1.86,"background":"#a6c0d6","_type":"sanity.imagePaletteSwatch"},"darkVibrant":{"population":1.48,"background":"#04207e","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightMuted":{"title":"#fff","population":0.07,"background":"#88b1c0","_type":"sanity.imagePaletteSwatch","foreground":"#000"}},"hasAlpha":false},"_id":"image-117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080-jpg","extension":"jpg","sha1hash":"117ab7594e690a311c7eec0c65d4487c98258b47","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg","assetId":"117ab7594e690a311c7eec0c65d4487c98258b47","_createdAt":"2021-10-26T18:27:51Z"}},"seoTag":["Biosimilars","financial toxicity"," immunogenicity"," candidates for biosimilars"," reference product"," medication switch"," biosimilars transition"," electronic medical record"," EMR"," electronic health record"," EHR","switching data"," disease state"," provider buy-in"," patient education"," reducing cost of care"],"_createdAt":"2021-10-26T16:22:56Z","_updatedAt":"2021-11-09T21:12:52Z","updatedOn":null,"summary":"Ryan Haumschild, PharmD, MS, MBA, discusses optimizing the transition to biosimilars, covering from what patients to look for as candidates to the process of switching a patient from a brand to a biosimilar to the importance of patient education.","body":[{"_key":"fd7c1a06e896","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"656855b507fd"}],"_type":"block","style":"normal"},{"_type":"video","videoID":"6278024763001","source":"brightcove","_key":"143d11b77ceb"},{"style":"normal","_key":"ef5bcc8c725e","markDefs":[],"children":[{"text":"Ryan Haumschild, PharmD, MS, MBA","_key":"39b59e162109","_type":"span","marks":["strong"]},{"marks":[],"text":": I believe in the science of biosimilars. I’ve done a lot of research and looked into the FDA, and seen data around great patient outcomes with biosimilars, especially in Europe, and now here in the United States. There have been a lot of data published. Biosimilars are great candidates for all patients. I wouldn’t want to treat 1 patient population one way, and 1 patient population another way. But if we’re looking at who’s going to be the strongest candidate for biosimilars, I would focus on patients who are dealing with financial toxicity, where they have coinsurance, and there’s of out-of-pocket expense. If we can give them a product almost like a generic, that reduces the expense of the drug, that could reduce their coinsurance and allow them to afford it, that’s a great thing. For patients who are new to starting therapy, it might be a great option for them. Some patients who I would consider in terms of switching to a biosimilar from a reference product, I would say, especially patients where there isn’t concern about immunogenicity, patients who may be starting a new cycle of therapy. You can consider patients who are stable on therapy, we’ve seen really good results, but again, it’s going to come down to how stable has that patient been. Did the patient just become stable on the reference product, and maybe the timing isn’t perfect to switch them to a biosimilar? Or someone who’s been able for a while on the reference product, and all clinical indications say that they’re going to do well if they switch to the biosimilar. That’s how I’d stratify patient populations, but overall, biosimilars are great options for all patients regardless of status.","_key":"d5ba938778f2","_type":"span"}],"_type":"block"},{"_key":"67cd648ee0b0","markDefs":[],"children":[{"_type":"span","marks":[],"text":"This is going to be a tough situation that we’re going to be challenged with. With all the biosimilars coming to market, is every patient the perfect candidate to switch from a reference product to a biosimilar? It depends, as we know there are patient-specific factors. If someone hasn’t been doing well on the reference product and is still trying to get established on that product, maybe it’s not the best time to switch into a biosimilar. If their reference product has some type of citrate-free additive that gives it less burning at injection site, which causes a lot of pain for the patient. Or if the patient just switched from the reference product to another reference product that’s citrate-free, that may not be the best time to switch them. There are a lot of clinical considerations, and there’s not a one-size-fits-all approach, but the majority of patients will do well transitioning to the biosimilar, but there’s some that won’t and that’s OK. We can keep them on the reference product as long as the team feels it’s appropriate and the patient’s responding well.","_key":"3deb19ce4a82"}],"_type":"block","style":"normal"},{"_type":"block","style":"normal","_key":"8323acdf4b61","markDefs":[],"children":[{"_type":"span","marks":[],"text":"We’re always looking at patients who have the potential to reduce their out-of-pocket cost. We always look at patients who have the potential to have their medication therapy optimized. That’s our responsibility as a health care provider to make sure we’re doing that due diligence for the patient. A lot of patients can be identified as candidates to transition to biosimilars, and it’s going to be safe and effective for them. Particularly we may look for patients with high out-of-pocket expenses, patients who have had difficulty covering their coinsurance. For the most part, patients who are starting on therapies where there are strong data in terms of switching from the biosimilar to the reference, and the reference to the biosimilar. There are also data internally around biosimilar use as part of starting a new treatment regimen. Those would be patients we’d always look at for starting a new therapy, and that would be driven more from that order set perspective because we always want to do what’s best for all of our patients and not single out any unique patient. We would do it from a disease state, get the provider buy in, and start patients on biosimilars. If we were going to do a one-off scenario, I would look for patient out of pocket expense, and make sure if we’re going to switch a patient in their specific therapeutic area that there is a good amount of switching data available that we could reference to ensure that they would have a good medical outcome.","_key":"c4224ffd0e15"}]},{"style":"normal","_key":"bf0ae41e9554","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Patient education is a huge part of the process when you’re transitioning patients to a biosimilar, not just new start patients, but more importantly, patients you’re transitioning from a brand or reference product to a biosimilar. Rightfully so they may be hesitant. They may be wondering why they’re changing their therapies. And you never want a patient just to show up, sit in a chair and look up at their medication and go, “I’m receiving a different type of medication than I normally receive. Why is that happening to me?” No. 1, it’s being really proactive and making sure that patients understand biosimilars. It’s easier with new start patients because it’s the first time they’re receiving therapy. We can educate them in the clinic that they’re going to be starting a biosimilar, and that they’ll continue that for their treatment scale. For patients who are on a branded product, who are relatively stable, you want to make sure you carve out time for them to provide them education around biosimilars, the importance of reducing total cost of care, how these molecules are highly similar to the reference product, and that they’re treating provider feels comfortable with them transitioning from the brand to the biosimilar.","_key":"de15d75849da"}],"_type":"block"},{"_type":"block","style":"normal","_key":"8a00de9aaace","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Lastly, you want to leave them with education. You want them to be able to think about the decision, understand what we’re going to do, and transition them and give them some lead time. If they have enough concerns and want to opt out from transitioning to a biosimilar, you’re able to have that conversation with the patient and give them time to digest all the information. When you do it that way, and you’re proactive in your approach, patients tend to understand better and have time to process the information. Usually, they’re going to be a lot more onboard and understand the value of biosimilars than if you just start them on a biosimilar without going through that proper education sequence.","_key":"cc995ea56076"}]},{"_type":"block","style":"normal","_key":"373fe871e43e","markDefs":[],"children":[{"marks":[],"text":"","_key":"951a9207ebec","_type":"span"}]},{"style":"normal","_key":"b8585db45d21","markDefs":[],"children":[{"_type":"span","marks":["strong","em"],"text":"This transcript has been edited for clarity.","_key":"08792f5149d4"}],"_type":"block"}],"title":"Optimizing Transitions to Biosimilars","link":"/view/optimizing-transitions-to-biosimilars"},{"thumbnail":{"asset":{"extension":"jpg","sha1hash":"117ab7594e690a311c7eec0c65d4487c98258b47","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg","assetId":"117ab7594e690a311c7eec0c65d4487c98258b47","_createdAt":"2021-10-26T18:27:51Z","mimeType":"image/jpeg","_updatedAt":"2021-10-26T18:27:51Z","originalFilename":"MicrosoftTeams-image.png","uploadId":"1QgtxdQLTQ5lCgCxvDnsUJDPlSOnJLB6","_rev":"yPN4n5TcElVjh0RH5xNX8U","_type":"sanity.imageAsset","path":"images/0vv8moc6/ajmc/117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080.jpg","size":444731,"metadata":{"isOpaque":true,"blurHash":"MPGle$t55IWAIE00tTNKNHRQ~qWZwEt8xs","_type":"sanity.imageMetadata","palette":{"darkVibrant":{"background":"#04207e","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":1.48},"lightMuted":{"title":"#fff","population":0.07,"background":"#88b1c0","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"vibrant":{"title":"#fff","population":4.38,"background":"#2b78de","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"dominant":{"title":"#fff","population":4.38,"background":"#2b78de","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"_type":"sanity.imagePalette","darkMuted":{"background":"#342920","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":1.78},"muted":{"population":2.34,"background":"#967e68","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightVibrant":{"population":1.86,"background":"#a6c0d6","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":1920,"aspectRatio":1.7777777777777777,"height":1080}},"_id":"image-117ab7594e690a311c7eec0c65d4487c98258b47-1920x1080-jpg"}},"seoTag":["Biosimilars","inventory"," carrying cost"," treatment plans"," reference product"," order sets"," interchangeable product"," stratification"," payers"," streamline"," providers"," utilization"," research"," stakeholders"," payers"," financing"," patient education"," buy-in"," shared decision-making"],"documentGroup":{"_ref":"d537a5b9-b33e-485d-aa7f-6f9c16e0f599","_type":"reference"},"published":"2021-10-26T18:29:00.000Z","summary":"Ryan Haumschild, PharmD, MS, MBA, continues focusing on transition optimization, explaining how to efficiently create your inventory, how his use of biosimilars will change in the future, and offering advice to those looking to transition to biosimilars.","_createdAt":"2021-10-26T16:56:45Z","body":[{"_type":"block","style":"normal","_key":"2fdf0ca065c8","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"1620dcf718ee"}]},{"videoID":"6278025355001","source":"brightcove","_key":"e5091272bb4f","_type":"video"},{"children":[{"_key":"eb870fb84433","_type":"span","marks":["strong"],"text":"Ryan Haumschild, PharmD, MS, MBA"},{"_key":"f491d8d84150","_type":"span","marks":[],"text":": Managing inventory, both biosimilar and reference products, is an important part of the job for any pharmacy director. You want to make sure that you always have a drug on hand for your patients, that you’re storing it appropriately, and that you have enough that even if there’s a natural disaster, or if there’s a disruption in the supply chain, you can continue to treat patients. If you’re carrying the reference product and multiple biosimilars, eventually your carrying costs are going to rise. When your carrying costs rise, that means you’re tying up cash and cash equivalents, and days cash on hand that could otherwise be utilized by the organization. We try to look into our treatment plans, look at the amount of treatment plans that utilize the biosimilar, ones that utilize the reference product, and use historical dispense history to determine what’s going to be about 3 to 4 days of inventory on hand. How do we make sure we have enough drugs in all different areas? We try to approve formulary agents as stocked or nonstocked, but with the reference product and the biosimilar, we try to stock both. We’ll stock different quantities for the reference and biosimilars based on our purchase history and the products we have built out within the order sets. That allows us to be operationally effective, but at the same time, reduce our inventory and carrying costs and allow the organization to have that cash and cash equivalents to be used in another area."}],"_type":"block","style":"normal","_key":"ffc61846db6e","markDefs":[]},{"children":[{"_type":"span","marks":[],"text":"When we look at biosimilars in the future, if you would’ve asked me a few months ago, I’d say I’d love to have our first interchangeable product on the market. We know that just got approved. That’s an exciting time. Interchangeability allows the pharmacy to switch out that product without any type of approval, but we have a P\u0026T [pharmacy and therapeutics committee] approval in most places. That’s not as big of an issue. But one of the things that should be a focus is, you’re starting to see many biosimilars come to market, but there’s stratification in the way that each payer prefers biosimilars. So, me at an organization, I don’t want to stock maybe 8 biosimilars for every 1 reference product, so I’m going to try to streamline the biosimilar that I want to keep on hand. I’m doing my due diligence in taking care of organizational resources appropriately. But what the difficult piece is, once I streamline to 1 or 2 agents, if I have 5 different payers and all 5 payers are preferring 5 different biosimilars because they’ve contracted toward 1 specific product, that makes it difficult for me as the health care provider. Now I’ve got to increase my inventory and the number of products across all our different centers to make sure we have enough drugs on hand for the patient. It would be great to create more parity of approval from payers for biosimilars. Organizations, if they’re utilizing a biosimilar, they could have a choice in which biosimilar they stocked, and it would create better approvals in the precertification department and create fewer delays when it comes time for patient care, if the payer comes in with a last-minute denial and preferencing a product that we don’t stock.","_key":"74e14a4d6a670"}],"_type":"block","style":"normal","_key":"def6e7f30e7c","markDefs":[]},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"My advice for any type of other provider that wants to start a similar program and utilize biosimilars is first do your homework. Do a baseline survey of all your key stakeholders to make sure you understand what are the barriers to biosimilar implementation. I don’t think you can truly be successful in doing this on your own. You need partnership. That’s one of our core values, partnership. You need partnership with the medical team, nursing, finance, managed care, and your local payers to be able to pull this off. Across the different spectrums of those different stakeholders, it’s really important to understand where the biggest concerns lie, so you can do work and educate, work through them, make people feel comfortable with the concepts and the utilization of biosimilars. And not until you get that buy-in will you ultimately be successful. Take the time to plan ahead, get key partnership and buy-in, and start to make decisions through a shared decision-making framework. That’s going to be the way that sticks, and you’re going to need that stickiness and those policies that are approved through oncology P\u0026T to be successful as more biosimilars come to market. There’s more stringency on drug spending and ultimately more payer restrictions coming down the pipeline.","_key":"ac8c9eecc3ea0"}],"_type":"block","style":"normal","_key":"0d5088311803"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"53f54293d930"}],"_type":"block","style":"normal","_key":"5da65c59fc6c"},{"markDefs":[],"children":[{"text":"This transcript has been edited for clarity.","_key":"2046cf0b2d20","_type":"span","marks":["strong","em"]}],"_type":"block","style":"normal","_key":"5a98592a04f0"}],"link":"/view/optimizing-transitions-to-biosimilars-continued","factCheckAuthorMapping":null,"taxonomyMapping":[{"sortOrder":2,"_rev":"Pqv14IIDiWFMzK5solyWKi","_type":"taxonomy","name":"Insights","_id":"54959cfc-9805-4ede-bc8f-7ecfcd2530c6","_updatedAt":"2022-01-19T10:12:39Z","identifier":"insights","_createdAt":"2020-03-30T19:15:55Z"},{"identifier":"video-series","_createdAt":"2020-10-14T04:51:21Z","_rev":"ChnBnF2xw1R5u2UJBDlozJ","_type":"taxonomy","name":"Video Series","_id":"999720cf-b3b3-4d42-935d-beb17775844e","_updatedAt":"2022-01-06T09:02:13Z"},{"_type":"taxonomy","_id":"topic_clinical","summary":[{"children":[{"_key":"e80c79954e08","_type":"span","marks":[],"text":"The "},{"_type":"span","marks":["em"],"text":"AJMC","_key":"a8e0f75c5d05"},{"_type":"span","marks":["superscript"],"text":"®","_key":"f7d4dddf7edd"},{"_type":"span","marks":[],"text":" clinical page includes all the published content across AJMC.com, ","_key":"0f03d46e3b3a"},{"marks":["em"],"text":"The American Journal of Managed Care","_key":"cc409f2da7da","_type":"span"},{"_type":"span","marks":["superscript"],"text":"®","_key":"2babb3e59bb3"},{"_type":"span","marks":[],"text":" and ","_key":"d86a5bb12052"},{"text":"Evidence-Based Oncology","_key":"40b2eaba6c17","_type":"span","marks":["em"]},{"text":"™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.","_key":"b59bef533cdf","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"dd8ad578cd0b","markDefs":[]}],"_createdAt":"2020-05-04T23:46:13Z","_rev":"HexDiduX8d6Nqnq1ECriVF","_updatedAt":"2022-02-18T12:13:55Z","identifier":"clinical","parent":{"_type":"reference","_ref":"15012229-f713-4f0a-8f82-7667530bb382"},"name":"Clinical"},{"summary":[{"_type":"block","style":"normal","_key":"21a8926c2669","markDefs":[],"children":[{"_type":"span","marks":[],"text":"The ","_key":"d9a7c16be264"},{"text":"AJMC","_key":"5aab8321660a","_type":"span","marks":["em"]},{"_type":"span","marks":["superscript"],"text":"®","_key":"84efcc202b1e"},{"_key":"2454ce1e8332","_type":"span","marks":[],"text":" Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates."}]}],"perKeywordMapping":["Pharmacy","Health Equity Diversity \u0026 Inclusion"],"_rev":"rs7eCk0lrr8LMiZP9GDaQL","_type":"taxonomy","_updatedAt":"2023-11-03T18:20:52Z","_id":"compendium_biosimilars","identifier":"biosimilars","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"cmeType":"per","_createdAt":"2020-04-14T15:02:13Z","name":"Biosimilars"}],"_updatedAt":"2021-11-09T21:14:32Z","url":{"current":"optimizing-transitions-to-biosimilars-continued","_type":"slug"},"is_visible":true,"_rev":"I5v7ktwtjrwhVb5i9Hyp8O","authorMapping":null,"_type":"article","internalTag":["Biosimilars"],"_id":"a9f08d66-3774-4d20-beb8-fd074c83447f","contentCategory":{"_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76"},"title":"Optimizing Transitions to Biosimilars Continued","updatedOn":null}],"videoNonSeriesData":[{"documentGroupMapping":[{"_ref":"9096b048-eb8c-4d59-bd01-a5e9276f3386","_type":"reference","_key":"f0ed4e28b2f3"}],"taxonomyMapping":[{"_id":"999720cf-b3b3-4d42-935d-beb17775844e","_updatedAt":"2022-01-06T09:02:13Z","identifier":"video-series","_createdAt":"2020-10-14T04:51:21Z","_rev":"ChnBnF2xw1R5u2UJBDlozJ","_type":"taxonomy","name":"Video Series"},{"identifier":"clinical","parent":{"_ref":"15012229-f713-4f0a-8f82-7667530bb382","_type":"reference"},"_createdAt":"2020-05-04T23:46:13Z","_rev":"HexDiduX8d6Nqnq1ECriVF","_type":"taxonomy","name":"Clinical","_id":"topic_clinical","summary":[{"_type":"block","style":"normal","_key":"dd8ad578cd0b","markDefs":[],"children":[{"_type":"span","marks":[],"text":"The ","_key":"e80c79954e08"},{"_key":"a8e0f75c5d05","_type":"span","marks":["em"],"text":"AJMC"},{"_type":"span","marks":["superscript"],"text":"®","_key":"f7d4dddf7edd"},{"_type":"span","marks":[],"text":" clinical page includes all the published content across AJMC.com, ","_key":"0f03d46e3b3a"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"cc409f2da7da"},{"_key":"2babb3e59bb3","_type":"span","marks":["superscript"],"text":"®"},{"marks":[],"text":" and ","_key":"d86a5bb12052","_type":"span"},{"_type":"span","marks":["em"],"text":"Evidence-Based Oncology","_key":"40b2eaba6c17"},{"marks":[],"text":"™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.","_key":"b59bef533cdf","_type":"span"}]}],"_updatedAt":"2022-02-18T12:13:55Z"},{"identifier":"insights","_createdAt":"2020-03-30T19:15:55Z","sortOrder":2,"_rev":"Pqv14IIDiWFMzK5solyWKi","_type":"taxonomy","name":"Insights","_id":"54959cfc-9805-4ede-bc8f-7ecfcd2530c6","_updatedAt":"2022-01-19T10:12:39Z"},{"_rev":"rs7eCk0lrr8LMiZP9GDaQL","_type":"taxonomy","_id":"compendium_biosimilars","summary":[{"children":[{"_type":"span","marks":[],"text":"The ","_key":"d9a7c16be264"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"5aab8321660a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"84efcc202b1e"},{"_type":"span","marks":[],"text":" Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.","_key":"2454ce1e8332"}],"_type":"block","style":"normal","_key":"21a8926c2669","markDefs":[]}],"perKeywordMapping":["Pharmacy","Health Equity Diversity \u0026 Inclusion"],"cmeType":"per","_createdAt":"2020-04-14T15:02:13Z","identifier":"biosimilars","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"name":"Biosimilars","_updatedAt":"2023-11-03T18:20:52Z"}],"contentCategory":{"_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos"},"body":[{"source":"brightcove","_key":"58be5ffb11f2","videoObject":{"videoDuration":"AJMC5M22S","videoDescription":"Panelists discuss how employers optimize biosimilar uptake through strategic formulary design, financial incentives, and provider education, enabling health care systems to achieve substantial cost savings while maintaining high-quality patient care.","_type":"videoDetails","videoTitle":"Best Practices for Employers to Maximize Uptake of Biosimilars","thumbnail":{"_type":"image","asset":{"_ref":"image-7e8db2a7450136a10fd1d2663574e5a9c7826d7d-1920x1080-png","_type":"reference"}}},"_type":"video","videoID":"6368382635112","disableAutoPlayVideo":false},{"markDefs":[],"children":[{"marks":["em","strong"],"text":"Video content above is prompted by the following:","_key":"24bc4f9d79fd","_type":"span"}],"_type":"block","style":"normal","_key":"0aea363da3be"},{"listItem":"bullet","markDefs":[],"children":[{"_type":"span","marks":[],"text":"What are best practices for employers working with pharmacy benefit managers and health plans to ensure maximal uptake and cost savings of biosimilars?","_key":"b4be9e9c2376"}],"level":1,"_type":"block","style":"normal","_key":"4e2db97a2683"},{"level":1,"_type":"block","style":"normal","_key":"c91b1b39ca61","listItem":"bullet","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Please share how you were able to achieve this in practice.","_key":"f228d8369945"}]}],"showSocialShare":true,"thumbnail":{"asset":{"uploadId":"pekDpCvQy8zEcNOZLneqAd5vGD4p4ANQ","_rev":"IEEE3cZRDuaTRQNV5ejPXf","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/7e8db2a7450136a10fd1d2663574e5a9c7826d7d-1920x1080.png","mimeType":"image/png","path":"images/0vv8moc6/ajmc/7e8db2a7450136a10fd1d2663574e5a9c7826d7d-1920x1080.png","_createdAt":"2025-02-10T15:18:29Z","_type":"sanity.imageAsset","sha1hash":"7e8db2a7450136a10fd1d2663574e5a9c7826d7d","size":1072129,"assetId":"7e8db2a7450136a10fd1d2663574e5a9c7826d7d","_updatedAt":"2025-02-10T15:18:29Z","originalFilename":"Marketing Image (5).png","extension":"png","metadata":{"blurHash":"MYG+tOs,ozRjW?00W@t7RjWq_No#RPt7WA","_type":"sanity.imageMetadata","palette":{"lightVibrant":{"background":"#91b9da","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.74},"darkVibrant":{"background":"#071c5a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":4.69},"lightMuted":{"title":"#fff","population":1.85,"background":"#c3caad","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"vibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":5.93,"background":"#3d7fdf"},"dominant":{"background":"#3d485a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":6.67},"_type":"sanity.imagePalette","darkMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":6.67,"background":"#3d485a"},"muted":{"background":"#a4646c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":1920,"aspectRatio":1.7777777777777777,"height":1080},"isOpaque":true},"_id":"image-7e8db2a7450136a10fd1d2663574e5a9c7826d7d-1920x1080-png"}},"_rev":"luhKIQIwHW4vFhtorqDvSO","documentGroup":{"_type":"reference","_ref":"9096b048-eb8c-4d59-bd01-a5e9276f3386"},"factCheckAuthorMapping":null,"title":"Best Practices for Employers to Maximize Uptake of Biosimilars","seoTag":["Biosimilars","biologics","healthcare cost-reduction","pharmaceutical-innovation","treatment-algorithms","patient-care","molecular-equivalence","therapeutic-substitution","pharmacoeconomics","clinical-pathways","clinical-pathways","regulatory-compliance","healthcare-economics","precision-medicine","therapeutic-optimization","pharmaceutical-market","drug-development"],"source":null,"articleType":"Opinion","_type":"article","_updatedAt":"2025-02-10T17:02:01Z","url":{"current":"best-practices-for-employers-to-maximize-uptake-of-biosimilars","_type":"slug"},"link":"/view/best-practices-for-employers-to-maximize-uptake-of-biosimilars","updatedOn":null,"authorMapping":[{"url":{"current":"ryan-haumschild-pharmd-ms-mba-cpel","_type":"slug"},"firstName":"Ryan","_createdAt":"2024-08-02T15:09:20Z","_rev":"ELFKWX5zlCikAqlfg38IU3","_id":"c3086c92-aac8-4cfd-8790-ab82f09e5bc9","lastName":"Haumschild","displayName":"Ryan Haumschild, PharmD, MS, MBA, CPEL","_type":"author","_updatedAt":"2024-08-02T15:09:20Z"},{"authorType":"expert","_createdAt":"2025-02-10T15:00:51Z","_rev":"luhKIQIwHW4vFhtorpzYPi","_type":"author","_id":"02ab53f7-a763-40e3-98e2-7b416a29add8","_updatedAt":"2025-02-10T15:01:13Z","lastName":"Butrus","displayName":"Casey Butrus, PharmD","url":{"current":"casey-butrus-pharmd","_type":"slug"},"firstName":"Casey "}],"summary":"Panelists discuss how employers optimize biosimilar uptake through strategic formulary design, financial incentives, and provider education, enabling health care systems to achieve substantial cost savings while maintaining high-quality patient care.","is_visible":true,"ExcludeFromPubMedXML":false,"_createdAt":"2025-02-10T15:20:57Z","_id":"36b658dd-b6f9-465b-baba-18e3b2b0587c","published":"2025-02-10T17:02:57.253Z"},{"link":"/view/the-economic-impact-of-biosimilars","source":null,"url":{"current":"the-economic-impact-of-biosimilars","_type":"slug"},"summary":"Panelists discuss how biosimilars have significantly reduced health care costs in the US, with health care systems experiencing significant savings across various therapeutic areas. These cost reductions improve treatment affordability and patient access, with potential cumulative savings in 2025. ","_createdAt":"2025-02-10T14:59:43Z","showSocialShare":true,"documentGroup":{"_ref":"9096b048-eb8c-4d59-bd01-a5e9276f3386","_type":"reference"},"ExcludeFromPubMedXML":false,"_type":"article","updatedOn":null,"body":[{"videoObject":{"_type":"videoDetails","videoTitle":"The Economic Impact of Biosimilars","thumbnail":{"_type":"image","asset":{"_type":"reference","_ref":"image-7e8db2a7450136a10fd1d2663574e5a9c7826d7d-1920x1080-png"}},"videoDuration":"AJMC4M37S","videoDescription":"Panelists discuss how biosimilars have significantly reduced health care costs in the US, with health care systems experiencing significant savings across various therapeutic areas. These cost reductions improve treatment affordability and patient access, with potential cumulative savings in 2025. "},"_type":"video","videoID":"6368382549112","disableAutoPlayVideo":false,"source":"brightcove","_key":"58be5ffb11f2"},{"_key":"0aea363da3be","markDefs":[],"children":[{"_type":"span","marks":["em","strong"],"text":"Video content above is prompted by the following:","_key":"24bc4f9d79fd"}],"_type":"block","style":"normal"},{"level":1,"_type":"block","style":"normal","_key":"b87a28ea3edc","listItem":"bullet","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Biosimilars have been shown to reduce costs to the US health system overall. What kind of savings are you seeing in your health system since fully implementing biosimilars?","_key":"2b21924fe970"}]}],"_id":"efdb1e12-e4e8-421d-afa4-5089ec44b71a","_updatedAt":"2025-02-10T17:00:04Z","seoTag":["Biosimilars","biologics","healthcare cost-reduction","pharmaceutical-innovation","treatment-algorithms","patient-care","molecular-equivalence","therapeutic-substitution","pharmacoeconomics","clinical-pathways","clinical-pathways","regulatory-compliance","healthcare-economics","precision-medicine","therapeutic-optimization","pharmaceutical-market","drug-development"],"title":"The Economic Impact of Biosimilars","contentCategory":{"_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos"},"is_visible":true,"thumbnail":{"asset":{"uploadId":"pekDpCvQy8zEcNOZLneqAd5vGD4p4ANQ","_rev":"IEEE3cZRDuaTRQNV5ejPXf","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/7e8db2a7450136a10fd1d2663574e5a9c7826d7d-1920x1080.png","mimeType":"image/png","path":"images/0vv8moc6/ajmc/7e8db2a7450136a10fd1d2663574e5a9c7826d7d-1920x1080.png","_createdAt":"2025-02-10T15:18:29Z","_updatedAt":"2025-02-10T15:18:29Z","originalFilename":"Marketing Image (5).png","_type":"sanity.imageAsset","sha1hash":"7e8db2a7450136a10fd1d2663574e5a9c7826d7d","size":1072129,"assetId":"7e8db2a7450136a10fd1d2663574e5a9c7826d7d","extension":"png","metadata":{"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":1920,"aspectRatio":1.7777777777777777,"height":1080},"isOpaque":true,"blurHash":"MYG+tOs,ozRjW?00W@t7RjWq_No#RPt7WA","_type":"sanity.imageMetadata","palette":{"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":4.69,"background":"#071c5a"},"lightMuted":{"title":"#fff","population":1.85,"background":"#c3caad","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"vibrant":{"population":5.93,"background":"#3d7fdf","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"dominant":{"background":"#3d485a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":6.67},"_type":"sanity.imagePalette","darkMuted":{"title":"#fff","population":6.67,"background":"#3d485a","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"muted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0,"background":"#a4646c"},"lightVibrant":{"population":0.74,"background":"#91b9da","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"}},"hasAlpha":true},"_id":"image-7e8db2a7450136a10fd1d2663574e5a9c7826d7d-1920x1080-png"}},"taxonomyMapping":[{"_updatedAt":"2022-01-06T09:02:13Z","identifier":"video-series","_createdAt":"2020-10-14T04:51:21Z","_rev":"ChnBnF2xw1R5u2UJBDlozJ","_type":"taxonomy","name":"Video Series","_id":"999720cf-b3b3-4d42-935d-beb17775844e"},{"summary":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"The ","_key":"e80c79954e08"},{"_key":"a8e0f75c5d05","_type":"span","marks":["em"],"text":"AJMC"},{"_type":"span","marks":["superscript"],"text":"®","_key":"f7d4dddf7edd"},{"_type":"span","marks":[],"text":" clinical page includes all the published content across AJMC.com, ","_key":"0f03d46e3b3a"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"cc409f2da7da"},{"_key":"2babb3e59bb3","_type":"span","marks":["superscript"],"text":"®"},{"marks":[],"text":" and ","_key":"d86a5bb12052","_type":"span"},{"_type":"span","marks":["em"],"text":"Evidence-Based Oncology","_key":"40b2eaba6c17"},{"marks":[],"text":"™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.","_key":"b59bef533cdf","_type":"span"}],"_type":"block","style":"normal","_key":"dd8ad578cd0b"}],"identifier":"clinical","parent":{"_ref":"15012229-f713-4f0a-8f82-7667530bb382","_type":"reference"},"_createdAt":"2020-05-04T23:46:13Z","_rev":"HexDiduX8d6Nqnq1ECriVF","_type":"taxonomy","name":"Clinical","_id":"topic_clinical","_updatedAt":"2022-02-18T12:13:55Z"},{"identifier":"insights","_createdAt":"2020-03-30T19:15:55Z","sortOrder":2,"_rev":"Pqv14IIDiWFMzK5solyWKi","_type":"taxonomy","name":"Insights","_id":"54959cfc-9805-4ede-bc8f-7ecfcd2530c6","_updatedAt":"2022-01-19T10:12:39Z"},{"summary":[{"_key":"21a8926c2669","markDefs":[],"children":[{"_type":"span","marks":[],"text":"The ","_key":"d9a7c16be264"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"5aab8321660a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"84efcc202b1e"},{"_type":"span","marks":[],"text":" Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.","_key":"2454ce1e8332"}],"_type":"block","style":"normal"}],"perKeywordMapping":["Pharmacy","Health Equity Diversity \u0026 Inclusion"],"cmeType":"per","_createdAt":"2020-04-14T15:02:13Z","_rev":"rs7eCk0lrr8LMiZP9GDaQL","_type":"taxonomy","_id":"compendium_biosimilars","identifier":"biosimilars","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"name":"Biosimilars","_updatedAt":"2023-11-03T18:20:52Z"}],"factCheckAuthorMapping":null,"articleType":"Opinion","documentGroupMapping":[{"_ref":"9096b048-eb8c-4d59-bd01-a5e9276f3386","_type":"reference","_key":"f0ed4e28b2f3"}],"authorMapping":[{"_createdAt":"2024-08-02T15:09:20Z","_rev":"ELFKWX5zlCikAqlfg38IU3","_id":"c3086c92-aac8-4cfd-8790-ab82f09e5bc9","url":{"current":"ryan-haumschild-pharmd-ms-mba-cpel","_type":"slug"},"firstName":"Ryan","displayName":"Ryan Haumschild, PharmD, MS, MBA, CPEL","_type":"author","_updatedAt":"2024-08-02T15:09:20Z","lastName":"Haumschild"},{"_createdAt":"2025-02-10T15:00:51Z","_rev":"luhKIQIwHW4vFhtorpzYPi","_type":"author","_id":"02ab53f7-a763-40e3-98e2-7b416a29add8","_updatedAt":"2025-02-10T15:01:13Z","lastName":"Butrus","authorType":"expert","url":{"current":"casey-butrus-pharmd","_type":"slug"},"firstName":"Casey ","displayName":"Casey Butrus, PharmD"}],"_rev":"luhKIQIwHW4vFhtorqDSd8","published":"2025-02-10T17:00:57.253Z"},{"taxonomyMapping":[{"_createdAt":"2020-03-30T19:16:54Z","sortOrder":3,"_rev":"xqhc4WIQcOa1P2rns6bqkh","_type":"taxonomy","name":"Interviews","_id":"2d909731-8acf-4e3d-8962-d59b0da85320","_updatedAt":"2023-10-30T17:48:32Z","identifier":"interviews"},{"_type":"taxonomy","_id":"compendium_biosimilars","summary":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"The ","_key":"d9a7c16be264"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"5aab8321660a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"84efcc202b1e"},{"_type":"span","marks":[],"text":" Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.","_key":"2454ce1e8332"}],"_type":"block","style":"normal","_key":"21a8926c2669"}],"perKeywordMapping":["Pharmacy","Health Equity Diversity \u0026 Inclusion"],"cmeType":"per","_createdAt":"2020-04-14T15:02:13Z","_rev":"rs7eCk0lrr8LMiZP9GDaQL","identifier":"biosimilars","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"name":"Biosimilars","_updatedAt":"2023-11-03T18:20:52Z"},{"_updatedAt":"2022-11-29T18:34:38Z","identifier":"healthcare-cost","parent":{"_ref":"15012229-f713-4f0a-8f82-7667530bb382","_type":"reference"},"_createdAt":"2020-05-04T23:46:13Z","_rev":"52vAUxG62nnEnK65ZDnwlC","_type":"taxonomy","name":"Health Care Cost","_id":"topic_healthcare-cost"},{"name":"Payers","_id":"d58c9cdc-7922-468a-8ec2-654846edc983","_updatedAt":"2020-04-14T19:37:02Z","identifier":"payers","parent":{"_ref":"5aa8e7d5-8a2d-44dd-99fc-fc43f03e2bed","_type":"reference"},"_createdAt":"2020-04-14T19:37:02Z","_rev":"Wa44PLk8JzTa4XEWdp4v2C","_type":"taxonomy"}],"seoTag":["biosimilars","cost","payer","formulary"],"thumbnail":{"asset":{"assetId":"f28ae1dc3219faac65fe94e1cf673b17d8bcd3a8","originalFilename":"James Chambers Nexus 2024.png","extension":"png","_rev":"KLVqzQL7KTVccOrMxrBgDe","sha1hash":"f28ae1dc3219faac65fe94e1cf673b17d8bcd3a8","size":976614,"_createdAt":"2024-10-16T20:49:14Z","_updatedAt":"2024-10-16T20:49:14Z","uploadId":"rrGIVh4VrDYX3AX7ObeJA6mPB3rfNjCN","_type":"sanity.imageAsset","path":"images/0vv8moc6/ajmc/f28ae1dc3219faac65fe94e1cf673b17d8bcd3a8-1280x719.png","metadata":{"palette":{"lightMuted":{"population":2.84,"background":"#a5b4d2","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"vibrant":{"background":"#444c94","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0},"dominant":{"background":"#918470","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":3.38},"_type":"sanity.imagePalette","darkMuted":{"background":"#523f37","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.82},"muted":{"background":"#918470","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":3.38},"lightVibrant":{"population":1.86,"background":"#c3d2e3","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000"},"darkVibrant":{"background":"#292e5a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":1280,"aspectRatio":1.7802503477051461,"height":719},"isOpaque":true,"blurHash":"MmLEKNxZR*-=M{~p%NWA%Mof-;kCRjt6ax","_type":"sanity.imageMetadata"},"mimeType":"image/png","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/f28ae1dc3219faac65fe94e1cf673b17d8bcd3a8-1280x719.png","_id":"image-f28ae1dc3219faac65fe94e1cf673b17d8bcd3a8-1280x719-png"}},"_id":"f6e1a3de-abb1-44d8-be63-29c75cfac926","contentCategory":{"_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z"},"_createdAt":"2024-11-01T19:24:06Z","title":"Biosimilars Are Getting a Foothold and Becoming Preferred, Says Dr James Chambers","link":"/view/biosimilars-are-getting-a-foothold-and-becoming-preferred-says-dr-james-chambers","is_visible":true,"published":"2024-11-13T15:00:00.000Z","body":[{"source":"brightcove","_key":"b27c8494cc48","videoObject":{"thumbnail":{"_type":"image","asset":{"_ref":"image-f28ae1dc3219faac65fe94e1cf673b17d8bcd3a8-1280x719-png","_type":"reference"}},"videoDuration":"PT1M59S","videoDescription":"Over time, biosimilars are gaining traction in the US and becoming preferred products, explained James D. Chambers, PhD, of Tufts Medical Center.","_type":"videoDetails","videoTitle":"Biosimilars Are Getting a Foothold and Becoming Preferred, Says Dr James Chambers"},"_type":"video","videoID":"6364091745112","disableAutoPlayVideo":false},{"children":[{"text":"Early in a biosimilar’s life cycle, it can be challenging to gain a foothold, but over time biosimilars are gaining traction and becoming preferred products, said James D. Chambers, PhD, professor, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center.","_key":"f39085bdef060","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"d6a9388a547f","markDefs":[]},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"5740c085a4640"}],"_type":"block","style":"normal","_key":"4ce67719a14f"},{"markDefs":[],"children":[{"_type":"span","marks":["em"],"text":"This transcript has been lightly edited for clarity.","_key":"a4e31df46edf0"}],"_type":"block","style":"normal","_key":"349e1c2fa8bf"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"ce3373d83bc10"}],"_type":"block","style":"normal","_key":"acddb6034f0d"},{"markDefs":[],"children":[{"_type":"span","marks":["strong","underline"],"text":"Transcript","_key":"5fc80629a6830"}],"_type":"block","style":"normal","_key":"2df2d11aa907"},{"_type":"block","style":"normal","_key":"aba9ed6f1e6c","markDefs":[],"children":[{"marks":["strong"],"text":"Considering safety and efficacy is the same, but the cost is cheaper, why wouldn't a payer prefer a biosimilar over the originator product on formulary?","_key":"48314cff523e0","_type":"span"}]},{"children":[{"_type":"span","marks":[],"text":"I think, historically, there's been some reticence about biosimilars and, are they truly equivalent? ","_key":"577c14de7e860"},{"_key":"577c14de7e861","_type":"span","marks":["50b43464b503"],"text":"We talked about interchangeability"},{"_type":"span","marks":[],"text":" and so on. I don't think that is the same concern now as it once was. I don't think that really is a factor. I think that what you maybe getting towards here are some of the rebate rules and some of the negotiations, and what's the net price and the rebate? Who gets the benefit from the magnitude of the rebate? And so on. And the incentive to put a higher list price so that you can offer larger discount and so on, obfuscates things, confuses things, and I think that that could be a challenge.","_key":"577c14de7e862"}],"_type":"block","style":"normal","_key":"917ce1b83e16","markDefs":[{"_key":"50b43464b503","blank":true,"_type":"link","href":"http://ajmc.com/view/removing-need-for-switching-studies-could-change-payer-perspectives-of-biosimilars"}]},{"_type":"block","style":"normal","_key":"81270b1b991b","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"3e57da29be650"}]},{"_type":"block","style":"normal","_key":"50d2be4bd00a","markDefs":[],"children":[{"text":"My research certainly suggests, though, that even given that the biosimilars have increasingly become preferred amongst payers. While that may be a hurdle at the beginning and be very obstructive at the beginning of a drug's life cycle, over time, it does seem as if the biosimilars are gaining traction and getting the foothold in the market and often becoming the preferred product in some cases.","_key":"bd87952536400","_type":"span","marks":[]}]},{"_key":"9a420e5e6afb","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"269dc7f0f7710"}],"_type":"block","style":"normal"},{"style":"normal","_key":"44903066b554","markDefs":[],"children":[{"_type":"span","marks":[],"text":"While in some ways you could argue that the system is against the new biosimilar entry, over time, it is gaining traction, it is getting a foothold. It is hard to understand those complicated rules, exactly where the money goes, and the system is opaque, and it's hard to figure out. But from a good news perspective, our data does show that over time, biosimilars are becoming more successful and gaining market share, so that is a good thing.","_key":"108534e229280"}],"_type":"block"}],"url":{"current":"biosimilars-are-getting-a-foothold-and-becoming-preferred-says-dr-james-chambers","_type":"slug"},"_rev":"Z7vrbBY6HLdSiYKgHAsoaB","documentGroupMapping":[{"_type":"reference","_key":"ec29c387a921","_ref":"conference_amcp-nexus"}],"summary":"Over time, biosimilars are gaining traction in the US and becoming preferred products, explained James D. Chambers, PhD, of Tufts Medical Center.","source":null,"_type":"article","articleType":"Commentary","_updatedAt":"2024-11-01T20:49:34Z","authorMapping":[{"url":{"current":"laura-joszt","_type":"slug"},"email":"ljoszt@mjhlifesciences.com","lastName":"Joszt","_rev":"9TKueq5ejdLplzrUGbD1nt","profileImage":{"_type":"mainImage","alt":"Laura Joszt headshot","asset":{"_ref":"image-93ea362164e769dfd84dca31a8b2670a1dd9092b-512x512-jpg","_type":"reference"}},"_updatedAt":"2022-08-30T13:17:14Z","linkedIn":"https://www.linkedin.com/in/laura-joszt-05ba7116/","twitter":"https://twitter.com/joszt","state":"New Jersey","firstName":"Laura","_createdAt":"2020-05-05T10:50:00Z","_id":"author_92a2fea3320665be4c3d03e7f1766110","showSocialShare":true,"displayName":"Laura Joszt, MA","_type":"author","biography":[{"_type":"block","style":"normal","_key":"4a950aea97b3","markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/laura-joszt-05ba7116/","_key":"f77b28536a8d"},{"_type":"link","href":"https://twitter.com/joszt","_key":"c419f18a7ffe"}],"children":[{"_type":"span","marks":[],"text":"Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®’s parent company, MJH Life Sciences®, since 2011.","_key":"67a67d3764f00"}]},{"style":"normal","_key":"b28d8058b3d8","markDefs":[{"blank":true,"_type":"link","href":"https://www.linkedin.com/in/laura-joszt-05ba7116/","_key":"f77b28536a8d","nofollow":true},{"_key":"c419f18a7ffe","nofollow":true,"blank":true,"_type":"link","href":"https://twitter.com/joszt"}],"children":[{"_type":"span","marks":[],"text":"She has an MA in business and economic reporting from New York University. You can connect with Laura on ","_key":"48d199d8ecd5"},{"_type":"span","marks":["f77b28536a8d"],"text":"LinkedIn","_key":"67a67d3764f01"},{"_type":"span","marks":[],"text":" or ","_key":"67a67d3764f02"},{"_key":"67a67d3764f03","_type":"span","marks":["c419f18a7ffe"],"text":"Twitter"},{"_type":"span","marks":[],"text":".","_key":"67a67d3764f04"}],"_type":"block"}]}],"ExcludeFromPubMedXML":false,"updatedOn":null,"factCheckAuthorMapping":null},{"_updatedAt":"2024-11-01T20:07:40Z","ExcludeFromPubMedXML":false,"_createdAt":"2024-11-01T19:10:54Z","articleType":"Commentary","title":"Removing Need for Switching Studies Could Change Payer Perspectives of Biosimilars","seoTag":["biosimilars","interchangeability"],"url":{"current":"removing-need-for-switching-studies-could-change-payer-perspectives-of-biosimilars","_type":"slug"},"contentCategory":{"_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z"},"source":null,"updatedOn":null,"body":[{"videoObject":{"_type":"videoDetails","videoTitle":"Removing Need for Switching Studies Could Change Payer Perspectives of Biosimilars","thumbnail":{"_type":"image","asset":{"_ref":"image-f28ae1dc3219faac65fe94e1cf673b17d8bcd3a8-1280x719-png","_type":"reference"}},"videoDuration":"PT3M06S","videoDescription":"The US could start catching up to Europe on biosimilars if the FDA removed the need for switching studies to be granted interchangeability."},"_type":"video","videoID":"6363311308112","disableAutoPlayVideo":false,"source":"brightcove","_key":"359c011157c5"},{"_type":"block","style":"normal","_key":"d1f24fc7b5ad","markDefs":[],"children":[{"text":"The FDA’s draft guidance to remove the requirement for switching studies to gain the interchangeability designation could change payer perspectives and bring the US more in line with Europe, explained James D. Chambers, PhD, professor, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center.","_key":"a71a0c5c9eeb0","_type":"span","marks":[]}]},{"markDefs":[],"children":[{"text":"","_key":"521fad7a02890","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"684806c244de"},{"_type":"block","style":"normal","_key":"9c0ac6886f33","markDefs":[],"children":[{"_type":"span","marks":["em"],"text":"This transcript has been lightly edited for clarity.","_key":"b2408f69341e0"}]},{"style":"normal","_key":"15599a894769","markDefs":[],"children":[{"text":"","_key":"c9faf9fd4e170","_type":"span","marks":[]}],"_type":"block"},{"style":"normal","_key":"3388e63f1e7a","markDefs":[],"children":[{"_type":"span","marks":["strong","underline"],"text":"Transcript","_key":"9be5da6ee1030"}],"_type":"block"},{"children":[{"_type":"span","marks":["strong"],"text":"The FDA has published draft guidance to remove the requirement for switching studies for biosimilar interchangeability. What is the current challenge with conducting switching studies and how will getting rid of the requirement benefit patients?","_key":"784810c222910"}],"_type":"block","style":"normal","_key":"ae5374623322","markDefs":[]},{"_key":"efbb96131082","markDefs":[],"children":[{"_type":"span","marks":[],"text":"In Europe, we've seen much more success with biosimilars, and I think this is part of it. This is analogous, I think, to generic substitution, which is long-standing policy here in the US that a pharmacy can—as long as it's not explicitly told not to do so by the prescribing physician—it can substitute a generic for the prescribed brand. That's important for these biologics. I work at Tufts Medical Center. Tufts Medical Center would like to stock certain drugs and has an incentive to have certain biosimilars on hand and not others. But then, if the insurance companies determine access, then the patient might require others. It does simplify things, in general, because it provides the providers and hospitals greater flexibility of what they stock and how they use these drugs.","_key":"6785019efaf30"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"_key":"eec965cda7df0","_type":"span","marks":[],"text":""}],"_type":"block","style":"normal","_key":"7a4fba9e5908"},{"_key":"3f6e959050e3","markDefs":[],"children":[{"_type":"span","marks":[],"text":"It would change things, I think, from the payer perspective, because with these step therapy protocols and payers requiring the patient to be treated with drug A before drug B or originator before biosimilar or vice versa, that would become less important moving forward, because of this change. It might also change negotiations between product manufacturers and insurance companies, because the large rebates offered are often done to secure preferred status for their product, and if the insurance company can't offer preferred status, then it might impact the magnitude of the rebate offered, which is not what we're looking for.","_key":"ed304e3021b40"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"5da92ab343070"}],"_type":"block","style":"normal","_key":"799783927d95"},{"children":[{"marks":[],"text":"So, I think, I think it's unclear. I mean, certainly the US has been lagging Europe in terms of biosimilars for a while now. In theory that should speed things up. But given the complexity of coverage policies and so on, I guess we'll have to see.","_key":"8ea66116147e0","_type":"span"}],"_type":"block","style":"normal","_key":"20a939e6ac07","markDefs":[]},{"children":[{"_type":"span","marks":[],"text":"","_key":"8648c255730f0"}],"_type":"block","style":"normal","_key":"34c64e1b6599","markDefs":[]},{"_type":"block","style":"normal","_key":"555c92085eab","markDefs":[],"children":[{"marks":[],"text":"You see with some of these Humira biosimilars, it’s really expensive to bring a biosimilar to the market. It’s not like a generic. You’re not following a recipe and it’s exactly the same. It is what it is. Biosimilars are a biologic, they’re very costly to produce, and there’s a risk that if insurance companies don’t cover the drug, then the company is going to fail and there’s a real fear, I think, for biosimilar innovators to develop a drug. I think the interchangeability laws would reassure them that their drug might have more of a fighting chance up against the big manufacturers that can negotiate large rebates and a basket of goods, and so on, in their negotiations.","_key":"1db8f222bbf60","_type":"span"}]}],"_id":"bd2325ad-f7be-4f0a-bad7-6d6712b34833","_rev":"W27rc60TaCa3Usex9hgD0d","authorMapping":[{"profileImage":{"_type":"mainImage","alt":"Laura Joszt headshot","asset":{"_ref":"image-93ea362164e769dfd84dca31a8b2670a1dd9092b-512x512-jpg","_type":"reference"}},"lastName":"Joszt","_rev":"9TKueq5ejdLplzrUGbD1nt","state":"New Jersey","_updatedAt":"2022-08-30T13:17:14Z","linkedIn":"https://www.linkedin.com/in/laura-joszt-05ba7116/","twitter":"https://twitter.com/joszt","biography":[{"style":"normal","_key":"4a950aea97b3","markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/laura-joszt-05ba7116/","_key":"f77b28536a8d"},{"_type":"link","href":"https://twitter.com/joszt","_key":"c419f18a7ffe"}],"children":[{"_type":"span","marks":[],"text":"Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®’s parent company, MJH Life Sciences®, since 2011.","_key":"67a67d3764f00"}],"_type":"block"},{"markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/laura-joszt-05ba7116/","_key":"f77b28536a8d"},{"blank":true,"_type":"link","href":"https://twitter.com/joszt","_key":"c419f18a7ffe","nofollow":true}],"children":[{"_type":"span","marks":[],"text":"She has an MA in business and economic reporting from New York University. You can connect with Laura on ","_key":"48d199d8ecd5"},{"_type":"span","marks":["f77b28536a8d"],"text":"LinkedIn","_key":"67a67d3764f01"},{"_type":"span","marks":[],"text":" or ","_key":"67a67d3764f02"},{"_key":"67a67d3764f03","_type":"span","marks":["c419f18a7ffe"],"text":"Twitter"},{"_type":"span","marks":[],"text":".","_key":"67a67d3764f04"}],"_type":"block","style":"normal","_key":"b28d8058b3d8"}],"firstName":"Laura","_createdAt":"2020-05-05T10:50:00Z","_id":"author_92a2fea3320665be4c3d03e7f1766110","showSocialShare":true,"displayName":"Laura Joszt, MA","_type":"author","url":{"current":"laura-joszt","_type":"slug"},"email":"ljoszt@mjhlifesciences.com"},{"_rev":"GeM6ny2T6Y1Qp0cm9jBdHm","_type":"author","_id":"author_b4f6302b3eb9b204ccca339a2949bf3c","_updatedAt":"2020-07-30T14:44:25Z","url":{"current":"peter-wehrwein","_type":"slug"},"displayName":"Peter Wehrwein","_createdAt":"2020-05-05T10:50:09Z"}],"thumbnail":{"asset":{"metadata":{"isOpaque":true,"blurHash":"MmLEKNxZR*-=M{~p%NWA%Mof-;kCRjt6ax","_type":"sanity.imageMetadata","palette":{"lightVibrant":{"population":1.86,"background":"#c3d2e3","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000"},"darkVibrant":{"background":"#292e5a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0},"lightMuted":{"title":"#fff","population":2.84,"background":"#a5b4d2","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"vibrant":{"background":"#444c94","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0},"dominant":{"population":3.38,"background":"#918470","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"_type":"sanity.imagePalette","darkMuted":{"background":"#523f37","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.82},"muted":{"background":"#918470","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":3.38}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":1280,"aspectRatio":1.7802503477051461,"height":719}},"mimeType":"image/png","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/f28ae1dc3219faac65fe94e1cf673b17d8bcd3a8-1280x719.png","_id":"image-f28ae1dc3219faac65fe94e1cf673b17d8bcd3a8-1280x719-png","assetId":"f28ae1dc3219faac65fe94e1cf673b17d8bcd3a8","originalFilename":"James Chambers Nexus 2024.png","_createdAt":"2024-10-16T20:49:14Z","_updatedAt":"2024-10-16T20:49:14Z","extension":"png","_rev":"KLVqzQL7KTVccOrMxrBgDe","sha1hash":"f28ae1dc3219faac65fe94e1cf673b17d8bcd3a8","size":976614,"uploadId":"rrGIVh4VrDYX3AX7ObeJA6mPB3rfNjCN","_type":"sanity.imageAsset","path":"images/0vv8moc6/ajmc/f28ae1dc3219faac65fe94e1cf673b17d8bcd3a8-1280x719.png"}},"published":"2024-11-05T14:00:00.000Z","link":"/view/removing-need-for-switching-studies-could-change-payer-perspectives-of-biosimilars","factCheckAuthorMapping":null,"is_visible":true,"taxonomyMapping":[{"_rev":"xqhc4WIQcOa1P2rns6bqkh","_type":"taxonomy","name":"Interviews","_id":"2d909731-8acf-4e3d-8962-d59b0da85320","_updatedAt":"2023-10-30T17:48:32Z","identifier":"interviews","_createdAt":"2020-03-30T19:16:54Z","sortOrder":3},{"identifier":"biosimilars","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"name":"Biosimilars","_updatedAt":"2023-11-03T18:20:52Z","summary":[{"style":"normal","_key":"21a8926c2669","markDefs":[],"children":[{"_type":"span","marks":[],"text":"The ","_key":"d9a7c16be264"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"5aab8321660a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"84efcc202b1e"},{"_type":"span","marks":[],"text":" Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.","_key":"2454ce1e8332"}],"_type":"block"}],"perKeywordMapping":["Pharmacy","Health Equity Diversity \u0026 Inclusion"],"cmeType":"per","_createdAt":"2020-04-14T15:02:13Z","_rev":"rs7eCk0lrr8LMiZP9GDaQL","_type":"taxonomy","_id":"compendium_biosimilars"},{"name":"Payers","_id":"d58c9cdc-7922-468a-8ec2-654846edc983","_updatedAt":"2020-04-14T19:37:02Z","identifier":"payers","parent":{"_ref":"5aa8e7d5-8a2d-44dd-99fc-fc43f03e2bed","_type":"reference"},"_createdAt":"2020-04-14T19:37:02Z","_rev":"Wa44PLk8JzTa4XEWdp4v2C","_type":"taxonomy"},{"name":"Health Care Cost","_id":"topic_healthcare-cost","_updatedAt":"2022-11-29T18:34:38Z","identifier":"healthcare-cost","parent":{"_ref":"15012229-f713-4f0a-8f82-7667530bb382","_type":"reference"},"_createdAt":"2020-05-04T23:46:13Z","_rev":"52vAUxG62nnEnK65ZDnwlC","_type":"taxonomy"}],"documentGroupMapping":[{"_ref":"conference_amcp-nexus","_type":"reference","_key":"bd505312e700"}],"summary":"The US could start catching up to Europe on biosimilars if the FDA removed the need for switching studies to be granted interchangeability.","_type":"article"},{"_id":"a1a37075-936c-4f09-95ca-3a0d6852bf51","articleType":"Commentary","_updatedAt":"2024-09-27T20:28:12Z","link":"/view/role-of-the-pharmacist-in-the-care-team-to-contain-costs-in-oncology","published":"2024-09-28T14:30:00.000Z","taxonomyMapping":[{"_rev":"xqhc4WIQcOa1P2rns6bqkh","_type":"taxonomy","name":"Interviews","_id":"2d909731-8acf-4e3d-8962-d59b0da85320","_updatedAt":"2023-10-30T17:48:32Z","identifier":"interviews","_createdAt":"2020-03-30T19:16:54Z","sortOrder":3},{"_id":"385b1a25-0f07-45fd-906a-410c8acbd92e","_updatedAt":"2023-12-19T21:06:11Z","identifier":"interviews","parent":{"_ref":"d39ec421-0b9c-48cf-874a-1003391b925f","_type":"reference"},"_createdAt":"2020-04-23T19:37:55Z","_rev":"NuKmNEJEtqI7CGtQXk1JuD","_type":"taxonomy","name":"Interviews"},{"identifier":"biosimilars","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"name":"Biosimilars","_updatedAt":"2023-11-03T18:20:52Z","summary":[{"children":[{"_type":"span","marks":[],"text":"The ","_key":"d9a7c16be264"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"5aab8321660a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"84efcc202b1e"},{"_type":"span","marks":[],"text":" Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.","_key":"2454ce1e8332"}],"_type":"block","style":"normal","_key":"21a8926c2669","markDefs":[]}],"perKeywordMapping":["Pharmacy","Health Equity Diversity \u0026 Inclusion"],"cmeType":"per","_createdAt":"2020-04-14T15:02:13Z","_rev":"rs7eCk0lrr8LMiZP9GDaQL","_type":"taxonomy","_id":"compendium_biosimilars"},{"_type":"taxonomy","name":"Health Care Cost","_id":"topic_healthcare-cost","_updatedAt":"2022-11-29T18:34:38Z","identifier":"healthcare-cost","parent":{"_ref":"15012229-f713-4f0a-8f82-7667530bb382","_type":"reference"},"_createdAt":"2020-05-04T23:46:13Z","_rev":"52vAUxG62nnEnK65ZDnwlC"}],"ExcludeFromPubMedXML":false,"_createdAt":"2024-09-27T19:30:56Z","documentGroupMapping":[{"_ref":"7ea0814d-a596-4897-aa0c-92d2f5b473fc","_type":"reference","_key":"84a657ed40d9"},{"_key":"b96153b7a0c1","_ref":"3b34ebd7-d5ae-4f77-913d-2860ae97e8ec","_type":"reference"}],"thumbnail":{"asset":{"originalFilename":"Kirollos Hanna-09-2024.png","assetId":"f698018f94ae99ba6f548f81a15462f47765951b","_createdAt":"2024-09-27T19:33:41Z","_rev":"5KaBU1lgRFcqRTy3hpEukR","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/f698018f94ae99ba6f548f81a15462f47765951b-1280x720.png","size":1105542,"_id":"image-f698018f94ae99ba6f548f81a15462f47765951b-1280x720-png","_updatedAt":"2024-09-27T19:33:41Z","_type":"sanity.imageAsset","sha1hash":"f698018f94ae99ba6f548f81a15462f47765951b","uploadId":"LAfTKRO54zVHcSswzTxzAseCVhS6g4Ju","mimeType":"image/png","path":"images/0vv8moc6/ajmc/f698018f94ae99ba6f548f81a15462f47765951b-1280x720.png","extension":"png","metadata":{"palette":{"dominant":{"population":9.89,"background":"#cfbb9b","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"_type":"sanity.imagePalette","darkMuted":{"background":"#383342","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":2.57},"muted":{"foreground":"#fff","title":"#fff","population":0.2,"background":"#5c608a","_type":"sanity.imagePaletteSwatch"},"lightVibrant":{"title":"#000","population":1.37,"background":"#f2c5a2","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.07,"background":"#c37110"},"lightMuted":{"background":"#cfbb9b","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":9.89},"vibrant":{"population":8.12,"background":"#e79d10","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"aspectRatio":1.7777777777777777,"height":720,"_type":"sanity.imageDimensions","width":1280},"isOpaque":true,"blurHash":"MPM?xR^H@q$zTM}}=Y5ts.jcR;Ek=sNHs*","_type":"sanity.imageMetadata"}}},"summary":"The pharmacist is a critical member of the care team to help manage patients on treatment and contain costs of cancer care, said Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, director of pharmacy, Minnesota Oncology.","title":"Role of the Pharmacist in the Care Team to Contain Costs in Oncology","is_visible":true,"_rev":"eXPlK0dEAMoQjxaMF7a6zU","seoTag":["biosimilars","oncology","pharmacist"],"source":null,"authorMapping":[{"linkedIn":"https://www.linkedin.com/in/laura-joszt-05ba7116/","twitter":"https://twitter.com/joszt","state":"New Jersey","_updatedAt":"2022-08-30T13:17:14Z","displayName":"Laura Joszt, MA","_type":"author","biography":[{"children":[{"_type":"span","marks":[],"text":"Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®’s parent company, MJH Life Sciences®, since 2011.","_key":"67a67d3764f00"}],"_type":"block","style":"normal","_key":"4a950aea97b3","markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/laura-joszt-05ba7116/","_key":"f77b28536a8d"},{"_type":"link","href":"https://twitter.com/joszt","_key":"c419f18a7ffe"}]},{"markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/laura-joszt-05ba7116/","_key":"f77b28536a8d"},{"_key":"c419f18a7ffe","nofollow":true,"blank":true,"_type":"link","href":"https://twitter.com/joszt"}],"children":[{"_type":"span","marks":[],"text":"She has an MA in business and economic reporting from New York University. You can connect with Laura on ","_key":"48d199d8ecd5"},{"_type":"span","marks":["f77b28536a8d"],"text":"LinkedIn","_key":"67a67d3764f01"},{"_type":"span","marks":[],"text":" or ","_key":"67a67d3764f02"},{"_key":"67a67d3764f03","_type":"span","marks":["c419f18a7ffe"],"text":"Twitter"},{"_type":"span","marks":[],"text":".","_key":"67a67d3764f04"}],"_type":"block","style":"normal","_key":"b28d8058b3d8"}],"firstName":"Laura","_createdAt":"2020-05-05T10:50:00Z","_id":"author_92a2fea3320665be4c3d03e7f1766110","showSocialShare":true,"url":{"current":"laura-joszt","_type":"slug"},"email":"ljoszt@mjhlifesciences.com","lastName":"Joszt","_rev":"9TKueq5ejdLplzrUGbD1nt","profileImage":{"_type":"mainImage","alt":"Laura Joszt headshot","asset":{"_ref":"image-93ea362164e769dfd84dca31a8b2670a1dd9092b-512x512-jpg","_type":"reference"}}}],"contentCategory":{"_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z"},"body":[{"_type":"video","videoID":"6362519617112","disableAutoPlayVideo":false,"source":"brightcove","_key":"c4220b895756","videoObject":{"videoDescription":"The pharmacist is a critical member of the care team to help manage patients on treatment and contain costs of cancer care.","_type":"videoDetails","videoTitle":"Role of the Pharmacist in the Care Team to Contain Costs in Oncology","thumbnail":{"_type":"image","asset":{"_ref":"image-f698018f94ae99ba6f548f81a15462f47765951b-1280x720-png","_type":"reference"}},"videoDuration":"PT4M21S"}},{"_type":"block","style":"normal","_key":"c2f0c3b27869","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Including a pharmacist placed among the care team of patients with cancer is crucial, because the pharmacist can provide support, ensure guideline-concordant care, and educate patients, explained Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, director of pharmacy, Minnesota Oncology, and assistant professor of pharmacy, Mayo Clinic School of Medicine.","_key":"49da0ccddb640"}]},{"_key":"5c88a52a8ff6","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"83343809975c0"}],"_type":"block","style":"normal"},{"children":[{"_type":"span","marks":[],"text":"Hanna chaired an Institute for Value-Based Medicine","_key":"caa04d9676b40"},{"marks":["superscript"],"text":"®","_key":"5e4a5cb8901a","_type":"span"},{"_type":"span","marks":[],"text":" (IVBM) meeting with Minnesota Oncology and ","_key":"ac99eb8aada4"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"caa04d9676b41"},{"_type":"span","marks":["superscript"],"text":"®","_key":"caa04d9676b42"},{"_type":"span","marks":[],"text":" on September 10 in Minneapolis, Minnesota.","_key":"3ec028d7da63"}],"_type":"block","style":"normal","_key":"5d6215fe108a","markDefs":[]},{"_key":"887cfbb75bde","markDefs":[],"children":[{"_key":"b7cdb240d5060","_type":"span","marks":[],"text":""}],"_type":"block","style":"normal"},{"_type":"block","style":"normal","_key":"340bf4f1a4ec","markDefs":[],"children":[{"_key":"2f6c05c93a570","_type":"span","marks":["em"],"text":"This transcript has been lightly edited for clarity."}]},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"6f0dd749e78b0"}],"_type":"block","style":"normal","_key":"b084d0af6dba"},{"_type":"block","style":"normal","_key":"2f4ea0db259c","markDefs":[],"children":[{"_type":"span","marks":["strong","underline"],"text":"Transcript","_key":"7b65065561000"}]},{"style":"normal","_key":"6a1dc5c98fc8","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"As cancer therapies become more complex, how does the pharmacist’s role evolve in patient care?","_key":"e05143b2593c0"}],"_type":"block"},{"_type":"block","style":"normal","_key":"d18007b59682","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Pharmacists play a critical role in the cancer care armamentarium, whether that is as a reactive role or a proactive role. It is inevitable that you have to somehow place a pharmacist among the care team. There are multiple ways that pharmacists can help in terms of cost containment and providing value. You look at biosimilar adoption and biosimilar integration and various other things. We got out of this IVBM program that we had that many of our pharmacists help support our bispecific antibody program, whether that is remote monitoring of patients or clinical interventions when patients need it.","_key":"f1e3301337760"}]},{"children":[{"_type":"span","marks":[],"text":"","_key":"65cb4d640bb10"}],"_type":"block","style":"normal","_key":"3a7f2226ec40","markDefs":[]},{"style":"normal","_key":"535da35671d9","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Our pharmacists are doing clinical reviews on every brand new regimen that's selected for our patients to ensure that we're providing guideline-concordant care, not only within our pathway but also National Comprehensive Cancer Network and the best clinical practice. They can catch things like laboratory parameters that may be needed, particular monitoring that may be needed, and obviously pharmacists play a critical role in education of patients. There are multiple things that I think pharmacy has been able to demonstrate as a value or return on investment. I would say that within the care team, it's extremely important to ensure that a pharmacist is placed among the care team.","_key":"9ca8985b03870"}],"_type":"block"},{"children":[{"text":"","_key":"9fcbcb42c15c0","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"29dcfe9ff432","markDefs":[]},{"markDefs":[],"children":[{"marks":["strong"],"text":"How are pharmacists and doctors working together to manage costs in cancer care?","_key":"356ff1adc61f0","_type":"span"}],"_type":"block","style":"normal","_key":"10e221b3d6d8"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"I think there are multiple opportunities where our providers, our prescribers, and the pharmacy team really come together to really help control the cost of care. Number one, when we look at that partnership through an organizational lens, we know both of these stakeholders play a critical role on your P\u0026T committees, your pharmacy and therapeutic committees. Through our P\u0026Ts, we're evaluating clinical trials, we're evaluating drug portfolios, we're evaluating group purchasing organization contracts to really help us place and navigate oncology, which is always complex, always changing. We utilize our pharmacy team as well as our providers to come together and serve on a committee to help us place certain therapeutics on pathways, to help us prefer certain biosimilars. And there are a lot of opportunities I think within that space as we try to help control cost.","_key":"595a67450e150"}],"_type":"block","style":"normal","_key":"6ca4372463be"},{"_type":"block","style":"normal","_key":"70f43f99f89a","markDefs":[],"children":[{"_key":"f5d787ef14cb0","_type":"span","marks":[],"text":""}]},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Now the other aspect of it is now in actual clinical practice, our providers are seeing patients and they're prescribing. Our pharmacy teams play a reactive role based on orders that come through or regimens that are adopted or selected for patients, and our pharmacists ensure that the P\u0026T decisions, that the formulary decisions, that the pathway decisions are actually in effect, and they will reach out and work side by side with our providers to recommend potential changes or alternates based on what the system has in place.","_key":"e0ffe6b47e290"}],"_type":"block","style":"normal","_key":"6778e38865c9"},{"_type":"block","style":"normal","_key":"2a562925f4d9","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"8cbaca9c959b0"}]},{"_type":"block","style":"normal","_key":"3b963c6341d8","markDefs":[],"children":[{"_key":"87a7359235200","_type":"span","marks":[],"text":"The other side of it, too, to help manage cost—pharmacists can help avoid and prevent cost as it relates to just really oncology altogether. Oral chemotherapy monitoring programs: pharmacists calling patients, checking on adherence and compliance, responding to lab results. All of that is proactive so that your patient doesn't accidentally take the medication incorrectly. Maybe the patient needs some type of supportive care that through a collaborative practice the pharmacist can prescribe. All of these things also free up the physician time."}]},{"_type":"block","style":"normal","_key":"853a5ec6803d","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"076b9260a3ba0"}]},{"_key":"f1ed63fb4e10","markDefs":[],"children":[{"_type":"span","marks":[],"text":"There’s a lot of opportunity, I think, across the spectrum and it's never a one-size-fits-all model. Every practice will find ways to integrate their pharmacist in terms of strategies to help control and contain cost.","_key":"dd7106e688150"}],"_type":"block","style":"normal"}],"updatedOn":null,"factCheckAuthorMapping":null,"url":{"current":"role-of-the-pharmacist-in-the-care-team-to-contain-costs-in-oncology","_type":"slug"},"_type":"article"},{"thumbnail":{"asset":{"_rev":"PwtudI1Atq8Z7xHPGzT50i","mimeType":"image/png","assetId":"70743c5a831ed6464c87b7ead422566b0dc3e8ec","uploadId":"77ibnVj1ybPZnSbNuNQWAyW1GKjZ6wak","_type":"sanity.imageAsset","sha1hash":"70743c5a831ed6464c87b7ead422566b0dc3e8ec","_id":"image-70743c5a831ed6464c87b7ead422566b0dc3e8ec-1920x1080-png","_updatedAt":"2024-06-28T11:49:14Z","originalFilename":"MarketingWS (30).png","extension":"png","metadata":{"blurHash":"MTH_0@t601jZx^2xWV9FR*^*}@azM{oLR+","_type":"sanity.imageMetadata","palette":{"lightMuted":{"foreground":"#000","title":"#fff","population":0.01,"background":"#b4acc4","_type":"sanity.imagePaletteSwatch"},"vibrant":{"background":"#c43443","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.1},"dominant":{"foreground":"#fff","title":"#fff","population":8.05,"background":"#043b6c","_type":"sanity.imagePaletteSwatch"},"_type":"sanity.imagePalette","darkMuted":{"population":2.98,"background":"#404752","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"muted":{"background":"#ae8267","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":2.77},"lightVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":4.21,"background":"#f6ad87"},"darkVibrant":{"background":"#043b6c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":8.05}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"width":1920,"aspectRatio":1.7777777777777777,"height":1080,"_type":"sanity.imageDimensions"},"isOpaque":true},"url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/70743c5a831ed6464c87b7ead422566b0dc3e8ec-1920x1080.png","path":"images/0vv8moc6/ajmc/70743c5a831ed6464c87b7ead422566b0dc3e8ec-1920x1080.png","size":2796588,"_createdAt":"2024-06-28T11:49:14Z"}},"title":"Private Label Biosimilars","source":null,"link":"/view/private-label-biosimilars","seoTag":["biosimilars","private label biosimilars","biosimilar therapies","biosimilar therapy","private label"],"is_visible":true,"documentGroup":{"_ref":"ad7906e5-a3e9-4050-9211-cc2890f3cb23","_type":"reference"},"showSocialShare":true,"summary":"The expert panel discusses the greater potential for private label biosimilars.","ExcludeFromPubMedXML":false,"_id":"ce788e7c-dd52-414e-adfd-5d1e8966a1fc","updatedOn":null,"factCheckAuthorMapping":null,"published":"2024-07-23T15:20:48.312Z","body":[{"_key":"4b655b7a28f8","videoObject":{"_type":"videoDetails","videoTitle":"Private Label Biosimilars","thumbnail":{"asset":{"_ref":"image-70743c5a831ed6464c87b7ead422566b0dc3e8ec-1920x1080-png","_type":"reference"},"_type":"image"},"videoDuration":"PT5M20S","videoDescription":"The expert panel discusses the greater potential for private label biosimilars."},"_type":"video","videoID":"6358325373112","disableAutoPlayVideo":false,"source":"brightcove"},{"_key":"3e5d278ee19f","markDefs":[],"children":[{"text":"","_key":"b60def07fa71","_type":"span","marks":[]}],"_type":"block","style":"normal"},{"children":[{"_type":"span","marks":["strong","em"],"text":"Video content above is prompted by the following questions:","_key":"954436f263e1"}],"_type":"block","style":"normal","_key":"9064f6cd2c7e","markDefs":[]},{"_type":"block","style":"normal","_key":"c6f63c92a3d0","listItem":"bullet","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Some healthcare companies are investigating the potential for private label biosimilars, including products like adalimumab. What is the value of offering a private label biosimilar to patients? What are some of the challenges that may arise?","_key":"bf25e963a95d0"}],"level":1}],"documentGroupMapping":[{"_ref":"ad7906e5-a3e9-4050-9211-cc2890f3cb23","_type":"reference","_key":"707c7c05bf7e"}],"contentCategory":{"_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z"},"_type":"article","_updatedAt":"2024-07-23T15:54:16Z","_createdAt":"2024-07-23T15:20:37Z","authorMapping":[{"url":{"current":"sophia-humphreys-pharmd-mha-bcbbs","_type":"slug"},"firstName":"Sophia","lastName":"Humphreys","_createdAt":"2023-08-16T19:35:54Z","_rev":"EMm72SZbLZTRULqDxCLn6d","displayName":"Sophia Humphreys, PharmD, MHA, BCBBS","_type":"author","_id":"70ef06cd-c5fd-4885-b40a-1dd2b04ae72a","_updatedAt":"2023-08-16T19:35:54Z"},{"_updatedAt":"2024-07-23T15:21:37Z","url":{"current":"chad-cannon-pharmd-bcccp","_type":"slug"},"_createdAt":"2024-07-23T15:21:37Z","_rev":"hS25uTmEvsaaDM5BOqBco1","_id":"2298a208-82a8-4197-8bee-2864d09e5eb3","_type":"author","firstName":"Chad","lastName":"Cannon","displayName":"Chad Cannon, PharmD, BCCCP"},{"_type":"author","url":{"current":"eric-tichy-pharmd-mba-bcps-fccp-fast","_type":"slug"},"firstName":"Eric","lastName":"Tichy","displayName":"Eric Tichy, PharmD, MBA, BCPS, FCCP, FAST","_createdAt":"2024-07-23T15:22:08Z","_rev":"AGf4LvcO2r7q1La1cjZhBt","_id":"73393f14-d8f8-47d3-bcc9-c081fff445c6","_updatedAt":"2024-07-23T15:22:08Z"},{"lastName":"Peppers","displayName":"Susan Peppers, RPh","_rev":"mQnYCYbyJQ5d5tNwMCyOtk","_type":"author","firstName":"Susan","_createdAt":"2024-07-23T15:22:41Z","_id":"f2bb9c28-1028-435b-a726-851a48a7d50d","_updatedAt":"2024-07-23T15:22:41Z","url":{"current":"susan-peppers-rph","_type":"slug"}}],"taxonomyMapping":[{"identifier":"biosimilars","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"name":"Biosimilars","_updatedAt":"2023-11-03T18:20:52Z","summary":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"The ","_key":"d9a7c16be264"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"5aab8321660a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"84efcc202b1e"},{"_type":"span","marks":[],"text":" Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.","_key":"2454ce1e8332"}],"_type":"block","style":"normal","_key":"21a8926c2669"}],"perKeywordMapping":["Pharmacy","Health Equity Diversity \u0026 Inclusion"],"cmeType":"per","_createdAt":"2020-04-14T15:02:13Z","_rev":"rs7eCk0lrr8LMiZP9GDaQL","_type":"taxonomy","_id":"compendium_biosimilars"},{"_rev":"XH8IynABFFUkUnvZmkb21z","name":"Peer Exchange","summary":[{"style":"normal","_key":"b0f5dba695a8","markDefs":[],"children":[{"_type":"span","marks":["em"],"text":"AJMC","_key":"8f85c4bb6762"},{"marks":[],"text":"® ","_key":"10038819bd05","_type":"span"},{"text":"Peer Exchange","_key":"721da0888c89","_type":"span","marks":["em"]},{"_type":"span","marks":[],"text":"® peer-to-peer panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's managed care professionals.","_key":"37d23a56a63e"}],"_type":"block"}],"identifier":"peer-exchange","sortOrder":1,"_updatedAt":"2022-01-19T10:37:00Z","_createdAt":"2020-03-30T20:08:04Z","_type":"taxonomy","_id":"02c6c999-e6fe-4275-98ca-ceef28f91e14"}],"_rev":"mQnYCYbyJQ5d5tNwMD11d4","url":{"current":"private-label-biosimilars","_type":"slug"},"articleType":"Opinion"},{"ExcludeFromPubMedXML":false,"documentGroupMapping":[{"_key":"c4c64a326e1c","_ref":"conference_amcp-nexus","_type":"reference"}],"published":"2023-11-19T14:00:00.000Z","_createdAt":"2023-11-16T21:30:35Z","summary":"Kimberly Maxfield, PhD, of the FDA discussed actions been taken by the FDA since President Biden's reauthorization of the Biosimilar User Fee Act (BsUFA) III last year, as well as what they plan to achieve through 2027. \n","thumbnail":{"asset":{"uploadId":"feImgu4WgDO2jRnOFQ66Uafp55P53TPp","_type":"sanity.imageAsset","mimeType":"image/png","_createdAt":"2023-10-20T20:38:03Z","sha1hash":"4cf6cb481888a7102b78a253bb317a345b32d0d3","path":"images/0vv8moc6/ajmc/4cf6cb481888a7102b78a253bb317a345b32d0d3-2880x1603.png","extension":"png","metadata":{"blurHash":"MmHg4Gu5XUZ#o~~qZ~n$V@oz#*ayj[XTjE","_type":"sanity.imageMetadata","palette":{"_type":"sanity.imagePalette","darkMuted":{"foreground":"#fff","title":"#fff","population":0.03,"background":"#304c57","_type":"sanity.imagePaletteSwatch"},"muted":{"population":5.86,"background":"#857c82","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.02,"background":"#6dc8fc"},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.52,"background":"#1e5879"},"lightMuted":{"background":"#9dbbcc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.04},"vibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.05,"background":"#3c9cc4"},"dominant":{"background":"#857c82","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":5.86}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"height":1603,"_type":"sanity.imageDimensions","width":2880,"aspectRatio":1.7966313162819714},"isOpaque":true},"_rev":"DEP8fOtEq5CxLu2TFZuIzG","assetId":"4cf6cb481888a7102b78a253bb317a345b32d0d3","_id":"image-4cf6cb481888a7102b78a253bb317a345b32d0d3-2880x1603-png","originalFilename":"Screen Shot 2023-10-20 at 4.36.04 PM.png","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/4cf6cb481888a7102b78a253bb317a345b32d0d3-2880x1603.png","size":5310091,"_updatedAt":"2023-10-20T20:38:03Z"}},"_type":"article","body":[{"style":"normal","_key":"71e7161d4cb8","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"c72ba17a0bff"}],"_type":"block"},{"videoObject":{"thumbnail":{"_type":"image","asset":{"_ref":"image-4cf6cb481888a7102b78a253bb317a345b32d0d3-2880x1603-png","_type":"reference"}},"videoDuration":"PT2M27S","videoDescription":"dr kimberly maxfield, fda, bsufa iii, biosimilar user fee act","_type":"videoDetails","videoTitle":"Dr Kimberly Maxfield Discusses FDA Actions Since BsUFA III Reauthorization"},"_type":"video","caption":"Kimberly Maxfield, PhD, of the FDA","videoID":"6341319918112","disableAutoPlayVideo":false,"source":"brightcove","_key":"131606535a34"},{"_type":"block","style":"normal","_key":"77c3a6c3a4ba","markDefs":[{"blank":false,"_type":"link","href":"https://www.centerforbiosimilars.com/view/biden-authorizes-update-to-the-biosimilar-user-fee-act-through-2027","_key":"14bd65ccaa97","nofollow":false}],"children":[{"text":"Kimberly Maxfield, PhD, of the FDA discussed what actions have been taken by the FDA, and what they plan to achieve over the next 4 years, since President Biden reauthorized the Biosimilar User Fee Act (BsUFA) III ","_key":"b546a4dd2136","_type":"span","marks":[]},{"text":"last year","_key":"97ce3dbd9de6","_type":"span","marks":["14bd65ccaa97"]},{"marks":[],"text":" through 2027. She also explained the BsUFA III demonstration projects and their impact on the biosimilar industry.","_key":"0ac78be5ebba","_type":"span"}]},{"_type":"block","style":"normal","_key":"0fc75f11ffd3","markDefs":[{"nofollow":false,"blank":false,"_type":"link","href":"https://www.ajmc.com/compendium/biosimilars","_key":"b7daac17ce40"},{"nofollow":false,"blank":false,"_type":"link","href":"https://www.ajmc.com/conference/amcp-nexus","_key":"195667fe294f"}],"children":[{"marks":[],"text":"\nAt the FDA, Maxfield currently serves as the scientific lead on the BsUFA III regulatory research pilot program in the Office of Therapeutic Biologics and Biosimilars (OTBB). Also, at ","_key":"5c7b728a9f570","_type":"span"},{"_type":"span","marks":["195667fe294f"],"text":"AMCP Nexus","_key":"f9267ca8b621"},{"_type":"span","marks":[],"text":" on October 17, she further discussed ","_key":"3f64f4ad2228"},{"_type":"span","marks":["b7daac17ce40"],"text":"biosimilars","_key":"0a2b3a9d5d79"},{"text":" during the session, \"Biosimilar Operational Readiness: Marketplace Trends and Regulatory Considerations.\"","_key":"1261c8c1c3dd","_type":"span","marks":[]}]},{"_key":"b00cd594ec03","markDefs":[],"children":[{"marks":[],"text":"","_key":"24256902fded","_type":"span"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"_type":"span","marks":["strong","underline"],"text":"Transcript","_key":"5352235ad236"}],"_type":"block","style":"normal","_key":"10ed2d7ba381"},{"_key":"1be9fd0c339e","markDefs":[],"children":[{"_key":"31ff6fa535c3","_type":"span","marks":[],"text":""}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"marks":["strong"],"text":"Since President Biden reauthorized BsUFA III last year through 2027, what actions has the FDA taken with this funding so far? What does it plan to achieve over the next 4 years?","_key":"77bb0c3950d7","_type":"span"}],"_type":"block","style":"normal","_key":"6e46e88bed69"},{"children":[{"_type":"span","marks":[],"text":"","_key":"7759a4a7680a0"}],"_type":"block","style":"normal","_key":"176e1c120599","markDefs":[]},{"_type":"block","style":"normal","_key":"241fcd18234f","markDefs":[{"href":"https://www.fda.gov/media/152279/download","_key":"03c66f1cb4ad","nofollow":true,"blank":true,"_type":"link"}],"children":[{"text":"BsUFA III included a lot of different enhancement areas, and that's all outlined in the ","_key":"acad1e5e25e8","_type":"span","marks":[]},{"_type":"span","marks":["03c66f1cb4ad"],"text":"commitment letter","_key":"16f8b0e5700b"},{"text":", which is public online. Some of the things that we've done thus far is there's been additional meeting types that biosimilar developers can request that are related to how much data you have when you submit the request. Additionally, for BIA [Biosimilar Initial Advisory] meetings, those previously had requirements for analytical data and now no longer has those requirements. ","_key":"c9700c5dac4b","_type":"span","marks":[]}]},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"c222e1f26c3c"}],"_type":"block","style":"normal","_key":"744a4a342a0f"},{"markDefs":[],"children":[{"_key":"a2f9e4e3e562","_type":"span","marks":[],"text":"Additionally, we have met some of the requirements involving the reg sci program [the regulatory science pilot program], which I know we'll talk about a little bit later. The other commitment that we've achieved so far is the labeling guidance, so a new labeling guide is labeling for biosimilar products has come out at the end of August, and that was a commitment; the major highlight there would be the interchangeability statement is now no longer a part of the labeling."}],"_type":"block","style":"normal","_key":"b6a85ef4e787"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"bded8ead842d"}],"_type":"block","style":"normal","_key":"401d03acc161"},{"_key":"5fa26d79b2f5","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"What do the BsUFA III demonstration projects entail? What impact will they ultimately have on the biosimilar industry?","_key":"d041d6e9edb8"}],"_type":"block","style":"normal"},{"style":"normal","_key":"4727bab2e6c3","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"b89e6bca18570"}],"_type":"block"},{"_key":"f9eca24c4aaa","markDefs":[],"children":[{"_type":"span","marks":[],"text":"The demonstration projects are part of the regulatory science pilot program commitment. So, the commitment was for the FDA to explore areas and fund support areas that will enhance the regulatory decision making and scientific recommendations in regards to biosimilar development and interchangeable development. ","_key":"591932bee5c0"}],"_type":"block","style":"normal"},{"_type":"block","style":"normal","_key":"5b2dfc20e46f","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"39036961c54b"}]},{"markDefs":[],"children":[{"_key":"d0db2e23f246","_type":"span","marks":[],"text":"As part of that letter, as part of that commitment, there are 2 aims or demonstration projects. The first is advancing the development of interchangeable products, and the second is increasing the efficiency of biosimilar development. Those were our starting point for the reg sci program where we have now since defined regulatory impacts and research priorities to inform our efforts to move that forward."}],"_type":"block","style":"normal","_key":"2eb56acea5b5"}],"updatedOn":null,"source":null,"seoTag":["fda","bsufa iii","Biosimilar User Fee Act","dr kimberly maxfield"],"url":{"_type":"slug","current":"dr-kimberly-maxfield-discusses-fda-actions-since-bsufa-iii-reauthorization"},"contentCategory":{"_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z"},"factCheckAuthorMapping":null,"_rev":"5WzuELUF8U9PqF2lijSVM8","_updatedAt":"2023-11-17T18:24:17Z","taxonomyMapping":[{"identifier":"conference","_createdAt":"2020-03-30T19:06:53Z","_rev":"Zzg2CQjl4x3UedGJkY3tyu","_type":"taxonomy","name":"Conference","_id":"1862ee25-8e65-4dbe-8fd3-d4c11642b211","_updatedAt":"2022-07-31T01:47:04Z"},{"_type":"taxonomy","name":"Interviews","_id":"2d909731-8acf-4e3d-8962-d59b0da85320","_updatedAt":"2023-10-30T17:48:32Z","identifier":"interviews","_createdAt":"2020-03-30T19:16:54Z","sortOrder":3,"_rev":"xqhc4WIQcOa1P2rns6bqkh"},{"identifier":"policy","parent":{"_ref":"15012229-f713-4f0a-8f82-7667530bb382","_type":"reference"},"_createdAt":"2020-05-04T23:46:13Z","_rev":"GQ2iWOdzjKwgYpKUFVt5oL","_type":"taxonomy","name":"Policy","_id":"topic_policy","_updatedAt":"2020-07-30T14:47:46Z"},{"_createdAt":"2020-04-14T15:02:13Z","_rev":"rs7eCk0lrr8LMiZP9GDaQL","_type":"taxonomy","_id":"compendium_biosimilars","summary":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"The ","_key":"d9a7c16be264"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"5aab8321660a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"84efcc202b1e"},{"_type":"span","marks":[],"text":" Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.","_key":"2454ce1e8332"}],"_type":"block","style":"normal","_key":"21a8926c2669"}],"perKeywordMapping":["Pharmacy","Health Equity Diversity \u0026 Inclusion"],"cmeType":"per","_updatedAt":"2023-11-03T18:20:52Z","identifier":"biosimilars","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"name":"Biosimilars"}],"articleType":"Commentary","internalTag":["dr kimberly maxfield","fda","bsufa iii","Biosimilar User Fee Act"],"title":"Dr Kimberly Maxfield Discusses FDA Actions Since BsUFA III Reauthorization","_id":"208d77cd-c8ae-4858-b931-c982288c3def","link":"/view/dr-kimberly-maxfield-discusses-fda-actions-since-bsufa-iii-reauthorization","is_visible":true,"authorMapping":[{"firstName":"Brooke","_rev":"A9UM2QVfJg2GpKiBNGLBGh","biography":[{"children":[{"_type":"span","marks":[],"text":"Brooke is an associate editor for ","_key":"8d68730a8da0"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"730c46c984c9"},{"_type":"span","marks":[],"text":"® (","_key":"0b218fbaa571"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"b1b5b3d9cff0"},{"_type":"span","marks":[],"text":"®). She joined ","_key":"7de919198f04"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"f31a60d737e2"},{"_type":"span","marks":[],"text":" in 2023, where she produces written content covering multiple disease states.","_key":"df11193684f8"}],"_type":"block","style":"normal","_key":"936ecf4b7f0c","markDefs":[]},{"_key":"9af540ce04de","markDefs":[],"children":[{"_key":"5731fbb8e0ae","_type":"span","marks":[],"text":""}],"_type":"block","style":"normal"},{"style":"normal","_key":"98aee68dab9d","markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/brooke-mccormick-1a254b1b6/","_key":"80a1c1a9d7cd"}],"children":[{"_type":"span","marks":[],"text":"She has a BA in journalism from Seton Hall University. You can connect with Brooke on ","_key":"bb68b5e8ee83"},{"text":"LinkedIn","_key":"4bb222fe2840","_type":"span","marks":["80a1c1a9d7cd"]},{"_type":"span","marks":[],"text":".","_key":"c87621477700"}],"_type":"block"}],"profileImage":{"alt":"Brooke McCormick","asset":{"_ref":"image-1fe4e81696463cdd9c1d6b62a2e47c2228d7df99-430x430-png","_type":"reference"},"_type":"mainImage"},"_updatedAt":"2025-01-08T16:42:13Z","lastName":"McCormick","authorType":"author","displayName":"Brooke McCormick","_createdAt":"2023-06-21T17:59:19Z","_type":"author","_id":"00af9d05-a2c4-4451-a6d1-0e28b08cbb65","url":{"current":"brooke-mccormick","_type":"slug"}}]},{"authorMapping":[{"lastName":"Bonavitacola","_createdAt":"2022-02-23T21:42:42Z","_rev":"sgy4yN0CjmArmRDnE2Khrz","biography":[{"markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/julia-bonavitacola-b5aa63171/","_key":"d45285824c6f"}],"children":[{"_key":"8a55e07516550","_type":"span","marks":[],"text":"Julia is an associate editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2022. She produces written and video content covering multiple disease states, and assists in the screening process for manuscripts submitted to AJMC®."}],"_type":"block","style":"normal","_key":"106fd454900b"},{"children":[{"text":"She has a BA in English language and literature from Rutgers University. You can connect with Julia on ","_key":"c2ef3167786d","_type":"span","marks":[]},{"_type":"span","marks":["d45285824c6f"],"text":"LinkedIn","_key":"8a55e07516551"},{"_key":"8a55e07516552","_type":"span","marks":[],"text":"."}],"_type":"block","style":"normal","_key":"769839c11518","markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/julia-bonavitacola-b5aa63171/","_key":"d45285824c6f","nofollow":true,"blank":true}]}],"_updatedAt":"2024-05-20T19:27:55Z","firstName":"Julia","displayName":"Julia Bonavitacola","_type":"author","_id":"15b1de57-6a71-4655-ba17-eeaa1c733634","profileImage":{"_type":"mainImage","alt":"Julia Bonavitacola","asset":{"_type":"reference","_ref":"image-fa6d7df41e3dda6f2ed66b65f3313ff5869748c2-430x430-png"}},"url":{"current":"julia-bonavitacola","_type":"slug"}}],"ExcludeFromPubMedXML":false,"updatedOn":null,"thumbnail":{"asset":{"extension":"jpg","_rev":"rs7eCk0lrr8LMiZP9BtO4q","mimeType":"image/jpeg","_type":"sanity.imageAsset","size":87559,"_id":"image-b0d5d3aac945a97b5115f78767fa29ef92b0ae9d-1280x720-jpg","_updatedAt":"2023-11-02T16:50:52Z","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/b0d5d3aac945a97b5115f78767fa29ef92b0ae9d-1280x720.jpg","path":"images/0vv8moc6/ajmc/b0d5d3aac945a97b5115f78767fa29ef92b0ae9d-1280x720.jpg","originalFilename":"Humphreys Thumbnail.jpg","metadata":{"isOpaque":true,"blurHash":"MFCs5F_3AB?b~Wx[%f%gbbNG4:M|xHM{IU","_type":"sanity.imageMetadata","palette":{"dominant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":6.85,"background":"#55462e"},"_type":"sanity.imagePalette","darkMuted":{"background":"#55462e","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":6.85},"muted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0,"background":"#ac5454"},"lightVibrant":{"foreground":"#000","title":"#000","population":0.18,"background":"#e4bec2","_type":"sanity.imagePaletteSwatch"},"darkVibrant":{"title":"#fff","population":1.04,"background":"#422504","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightMuted":{"foreground":"#000","title":"#fff","population":0.06,"background":"#d6b4bc","_type":"sanity.imagePaletteSwatch"},"vibrant":{"background":"#ac4c6c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.01}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":1280,"aspectRatio":1.7777777777777777,"height":720}},"uploadId":"4WyNMUrfgPHBHWXFyFB8rjjzw3K8l2XA","sha1hash":"b0d5d3aac945a97b5115f78767fa29ef92b0ae9d","assetId":"b0d5d3aac945a97b5115f78767fa29ef92b0ae9d","_createdAt":"2023-11-02T16:50:52Z"}},"seoTag":["biosimilars","formulary management","IVBM","biologics"],"summary":"Sophia Humphreys, PharmD, MHA, BCBBS, discussed how biosimilars can play a role in formulary management as well as the main takeaways of her presentations at the Newport Beach Institute for Value-Based Care conference.","taxonomyMapping":[{"parent":{"_ref":"d39ec421-0b9c-48cf-874a-1003391b925f","_type":"reference"},"_createdAt":"2020-04-23T19:37:55Z","_rev":"NuKmNEJEtqI7CGtQXk1JuD","_type":"taxonomy","name":"Interviews","_id":"385b1a25-0f07-45fd-906a-410c8acbd92e","_updatedAt":"2023-12-19T21:06:11Z","identifier":"interviews"},{"_createdAt":"2020-04-23T19:36:16Z","_rev":"UoosHf5LKj69ImzsXs4QZt","_type":"taxonomy","name":"IVBM","_id":"d39ec421-0b9c-48cf-874a-1003391b925f","_updatedAt":"2022-02-18T12:08:18Z","identifier":"ivbm"},{"identifier":"biosimilars","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"name":"Biosimilars","_updatedAt":"2023-11-03T18:20:52Z","_rev":"rs7eCk0lrr8LMiZP9GDaQL","_type":"taxonomy","_id":"compendium_biosimilars","summary":[{"_type":"block","style":"normal","_key":"21a8926c2669","markDefs":[],"children":[{"_type":"span","marks":[],"text":"The ","_key":"d9a7c16be264"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"5aab8321660a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"84efcc202b1e"},{"_type":"span","marks":[],"text":" Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.","_key":"2454ce1e8332"}]}],"perKeywordMapping":["Pharmacy","Health Equity Diversity \u0026 Inclusion"],"cmeType":"per","_createdAt":"2020-04-14T15:02:13Z"},{"name":"Health Care Cost","_id":"topic_healthcare-cost","_updatedAt":"2022-11-29T18:34:38Z","identifier":"healthcare-cost","parent":{"_ref":"15012229-f713-4f0a-8f82-7667530bb382","_type":"reference"},"_createdAt":"2020-05-04T23:46:13Z","_rev":"52vAUxG62nnEnK65ZDnwlC","_type":"taxonomy"}],"_type":"article","body":[{"disableAutoPlayVideo":false,"source":"brightcove","_key":"0598f4182300","videoObject":{"videoDuration":"PT2M23S","videoDescription":"Biosimilars, Formulary Management, IVBM","_type":"videoDetails","videoTitle":"Dr Sophia Humphreys Speaks on Biosimilars in Formulary Management","thumbnail":{"_type":"image","asset":{"_type":"reference","_ref":"image-b0d5d3aac945a97b5115f78767fa29ef92b0ae9d-1280x720-jpg"}}},"experienceID":"6340897300112","_type":"video","videoID":"6340897300112"},{"style":"normal","_key":"14eaef702150","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Sophia Humphreys, PharmD, MHA, BCBBS, spoke about the main takeaways from her panels at the Institute for Value-Based Medicine® (IVBM) conference, including the team approaches and how biosimilars play a role in formulary management.","_key":"0fbe84aebaa6"}],"_type":"block"},{"style":"normal","_key":"bc2184659c87","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"8168d1bdb66a"}],"_type":"block"},{"markDefs":[],"children":[{"_type":"span","marks":["strong","underline"],"text":"Transcript","_key":"7ae559addab3"}],"_type":"block","style":"normal","_key":"80bc87adbe16"},{"children":[{"_type":"span","marks":["strong"],"text":"What role do biosimilars play in formulary management?","_key":"328a4e1aa03a"}],"_type":"block","style":"normal","_key":"30cf43b98dd7","markDefs":[]},{"_type":"block","style":"normal","_key":"0627ce5df3c0","markDefs":[],"children":[{"_type":"span","marks":[],"text":"As you know, biologic medications spend has increased in the past 5 to 10 years, and they're expected to occupy more of our budget in the near future, because they provide an unmet need for many, many conditions. However, they come with a high price because these are large molecule medications made in living organisms, and majority of them have complicated protein structures so there's no way for us to make an identical copy. So generic products are not available for biologics. However, there are biosimilars. These medications are highly similar to the reference product and has no meaningful clinical differences, from the reference biologic medications. We have seen great savings from biosimilar programs, both for health systems as well as patients. Because when a biosimilar product is 50% of the cost of the reference product, our patient's copay would be much lower compared to the reference product as well.","_key":"d7a9649034ec0"}]},{"markDefs":[],"children":[{"text":"","_key":"5648f24581410","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"1fd042855be8"},{"_type":"block","style":"normal","_key":"b95dc1fef788","markDefs":[],"children":[{"text":"What were the main takeaways of your presentation held at the IVBM conference?","_key":"c21f02cf5a150","_type":"span","marks":["strong"]}]},{"children":[{"marks":[],"text":"I'm going to have 2 presentations. One is going to be focused on formulary management, another one is actually focused on biosimilars and our health system financial sustainability. So I would love for our audience to have 2 take-homes. One, there's no set principle for formulary management approach. It takes an entire team and we need to have standardization [and] within the standardization we need to allow flexibility. And also, as we have mentioned, biosimilars will cost much less than reference product, they are highly similar to reference product with no meaningful clinical differences. And they can increase access of care and really help our patients to obtain biologic medication treatment without breaking the bank.","_key":"8dc354bb99df0","_type":"span"}],"_type":"block","style":"normal","_key":"c75d6855065a","markDefs":[]}],"url":{"current":"dr-sophia-humphreys-speaks-on-biosimilars-in-formulary-management","_type":"slug"},"source":null,"is_visible":true,"published":"2023-11-15T17:06:00.000Z","factCheckAuthorMapping":null,"_id":"4fd79120-137d-4ce4-8207-2af2fe54f322","_updatedAt":"2023-11-14T14:48:50Z","_rev":"Nc7f9YRwd7foK7ebuhj1ZS","title":"Dr Sophia Humphreys Speaks on Biosimilars in Formulary Management","articleType":"News","_createdAt":"2023-11-10T21:02:02Z","internalTag":["biosimilars","formulary management","IVBM","biologics"],"link":"/view/dr-sophia-humphreys-speaks-on-biosimilars-in-formulary-management","contentCategory":{"_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB"}},{"internalTag":["ambulatory drug infusion","infusion therapy","biosimilars","cost"],"url":{"current":"dr-jorge-garcia-speaks-about-ambulatory-drug-infusion-infusion-therapy","_type":"slug"},"authorMapping":[{"lastName":"Bonavitacola","_createdAt":"2022-02-23T21:42:42Z","_rev":"sgy4yN0CjmArmRDnE2Khrz","biography":[{"markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/julia-bonavitacola-b5aa63171/","_key":"d45285824c6f"}],"children":[{"_key":"8a55e07516550","_type":"span","marks":[],"text":"Julia is an associate editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2022. She produces written and video content covering multiple disease states, and assists in the screening process for manuscripts submitted to AJMC®."}],"_type":"block","style":"normal","_key":"106fd454900b"},{"markDefs":[{"blank":true,"_type":"link","href":"https://www.linkedin.com/in/julia-bonavitacola-b5aa63171/","_key":"d45285824c6f","nofollow":true}],"children":[{"text":"She has a BA in English language and literature from Rutgers University. You can connect with Julia on ","_key":"c2ef3167786d","_type":"span","marks":[]},{"_type":"span","marks":["d45285824c6f"],"text":"LinkedIn","_key":"8a55e07516551"},{"_key":"8a55e07516552","_type":"span","marks":[],"text":"."}],"_type":"block","style":"normal","_key":"769839c11518"}],"_updatedAt":"2024-05-20T19:27:55Z","firstName":"Julia","displayName":"Julia Bonavitacola","_type":"author","_id":"15b1de57-6a71-4655-ba17-eeaa1c733634","profileImage":{"_type":"mainImage","alt":"Julia Bonavitacola","asset":{"_type":"reference","_ref":"image-fa6d7df41e3dda6f2ed66b65f3313ff5869748c2-430x430-png"}},"url":{"current":"julia-bonavitacola","_type":"slug"}}],"_updatedAt":"2023-11-09T18:58:58Z","seoTag":["ambulatory drug infusion","infusion therapy","biosimilars","cost"],"ExcludeFromPubMedXML":false,"factCheckAuthorMapping":null,"_type":"article","articleType":"News","body":[{"source":"brightcove","_key":"59d69be18795","experienceID":"6340808965112","_type":"video","videoID":"6340808965112","disableAutoPlayVideo":false},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Jorge Garcia, PharmD, MS, MHA, MBA, FACHE, assistant vice president of system oncology and infusion pharmacy services, Baptist Health South Florida, talked about how drug infusion therapy relates to biosimilars and ambulatory drug infusion.","_key":"d5c1a08c7297"}],"_type":"block","style":"normal","_key":"98a38435d542"},{"children":[{"_key":"de94bf19bd9b","_type":"span","marks":[],"text":""}],"_type":"block","style":"normal","_key":"a4b13ddd413f","markDefs":[]},{"style":"normal","_key":"ff367b297023","markDefs":[],"children":[{"_type":"span","marks":["strong","underline"],"text":"Transcript","_key":"1406acf4fedd"}],"_type":"block"},{"_type":"block","style":"normal","_key":"2740edc2a7cd","markDefs":[],"children":[{"_key":"402173283a360","_type":"span","marks":["strong"],"text":"How does ambulatory drug infusion relate to applying cost and evidence to pharmacy coverage?"}]},{"_type":"block","style":"normal","_key":"ad3614f49705","markDefs":[],"children":[{"marks":[],"text":"I think as pharmacists, we play an essential role in promoting cost-effectiveness in the pharmacotherapy that we deliver. Obviously, we have in the infusion space high-cost pharmaceuticals, so understanding where they fit in, and how we make economic choices along the way and the thought process that we follow to make those recommendations is what I look forward to sharing in that session.","_key":"522998d979390","_type":"span"}]},{"_type":"block","style":"normal","_key":"754879583891","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"938febe9b4240"}]},{"style":"normal","_key":"afc4e7ed79e8","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"What do you think the future of infusion therapy is?","_key":"7feae641b7df0"}],"_type":"block"},{"markDefs":[],"children":[{"text":"When it comes to infusion therapy and we look into the future, we see a very robust pipeline of medications that are coming to the marketplace soon. Now whereas immunotherapy has been something of the oncology patient for many years, now we are seeing immunotherapy and gene therapy and other types of biologic therapies that are going to be available for the nononcology patient. So I think it's important understanding that all of that is coming our way, that we prepare, have the capabilities to be able to meet that increase in demand that is headed our way.","_key":"0aa24afdf0b80","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"ca3fce65b0c5"},{"children":[{"_type":"span","marks":[],"text":"","_key":"e40cd83d4fc10"}],"_type":"block","style":"normal","_key":"e1e259168b84","markDefs":[]},{"markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"How do biosimilars relate to ambulatory drug infusion and cost savings?","_key":"abb0dc2e00860"}],"_type":"block","style":"normal","_key":"3dea33a8e70d"},{"_type":"block","style":"normal","_key":"fd431359aad1","markDefs":[],"children":[{"marks":[],"text":"That's a good question. In terms of biosimilars, I think biosimilars deliver an economic benefit, right? We don't bring biosimilars into the marketplace because they're more effective or because they have a safer profile. The reason why we bring them to the marketplace is to deliver on economic value. So I think hopefully now with multiple years of biosimilar experience in the US, we are seeing that there is improved access for these products. And so the way this links into my other presentations is all in the name of increasing access to biologics in general. And so I think biosimilars provide a great way to reduce cost associated with some of those biologics that have biosimilar options by making sure we acquire those products at a fraction of the cost. And that hopefully helps offset some of the innovation and the innovative products that are coming into the space that are more new products that are higher cost to ensure that we can make all of those therapies available to patients.","_key":"c3c6be45e4b30","_type":"span"}]}],"published":"2023-11-10T16:34:00.000Z","link":"/view/dr-jorge-garcia-speaks-about-ambulatory-drug-infusion-infusion-therapy","thumbnail":{"asset":{"mimeType":"image/jpeg","sha1hash":"3c11f2c8755afdbeab5b3972676e6e3032424159","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/3c11f2c8755afdbeab5b3972676e6e3032424159-1280x720.jpg","metadata":{"hasAlpha":false,"lqip":"data:image/jpeg;base64,/9j/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAALABQDASIAAhEBAxEB/8QAGAAAAgMAAAAAAAAAAAAAAAAAAAQBBwj/xAAjEAACAQQCAgIDAAAAAAAAAAABAgQAAwURBhIhQQdRFBci/8QAFAEBAAAAAAAAAAAAAAAAAAAAA//EABoRAQADAAMAAAAAAAAAAAAAAAEAAhIEFFH/2gAMAwEAAhEDEQA/AEE5fxaI+Ri5yGL4e75IbWh63TObyeMxeOsSoq240aZGZbTKujc7DwCaz3kiWkgMSey7OzvdXJ8n20/SuBfqO6ta6n2P5NAccvQVjdlqoEe4bwaxMwVqRNlLGvOxJQIT49HdFT8T5eevDY6/ksQHYDYB+vsUUGfY2p//2Q==","dimensions":{"height":720,"_type":"sanity.imageDimensions","width":1280,"aspectRatio":1.7777777777777777},"isOpaque":true,"blurHash":"MLG[NEW=4.Vr^k~A-;OZng9FI=WBRi%MR+","_type":"sanity.imageMetadata","palette":{"_type":"sanity.imagePalette","darkMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":8.45,"background":"#5a422a"},"muted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":7.88,"background":"#917861"},"lightVibrant":{"title":"#fff","population":2.08,"background":"#f3b49a","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"darkVibrant":{"foreground":"#fff","title":"#fff","population":0,"background":"#7c341c","_type":"sanity.imagePaletteSwatch"},"lightMuted":{"title":"#fff","population":0.76,"background":"#cfb3a7","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"vibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.06,"background":"#be7c54"},"dominant":{"background":"#5a422a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":8.45}}},"uploadId":"VDHs6pTIe3BTfCVVr2vfZ6X6qurLV2Jy","path":"images/0vv8moc6/ajmc/3c11f2c8755afdbeab5b3972676e6e3032424159-1280x720.jpg","assetId":"3c11f2c8755afdbeab5b3972676e6e3032424159","extension":"jpg","size":131506,"_id":"image-3c11f2c8755afdbeab5b3972676e6e3032424159-1280x720-jpg","originalFilename":"Garcia Thumbnail.jpg","_rev":"lr42ZkL95YwmOo7eXKecMW","_type":"sanity.imageAsset","_createdAt":"2023-11-02T17:09:23Z","_updatedAt":"2023-11-02T17:09:23Z"}},"contentCategory":{"_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos"},"taxonomyMapping":[{"_updatedAt":"2022-01-19T10:20:16Z","identifier":"news","_createdAt":"2020-03-30T18:05:45Z","_rev":"OU32WOWh4YetHW0RkWbkso","_type":"taxonomy","name":"News","_id":"39be7351-bd4c-4e98-82b3-0d675ae4671b"},{"name":"IVBM","_id":"d39ec421-0b9c-48cf-874a-1003391b925f","_updatedAt":"2022-02-18T12:08:18Z","identifier":"ivbm","_createdAt":"2020-04-23T19:36:16Z","_rev":"UoosHf5LKj69ImzsXs4QZt","_type":"taxonomy"},{"_updatedAt":"2022-02-22T17:30:46Z","identifier":"ivbm-events","_createdAt":"2022-02-22T17:30:46Z","_rev":"2Cg3jaFTpU6hQKfUrgINsp","_type":"taxonomy","name":"IVBM Events","_id":"abac4670-ca81-4c11-91d1-509e07110acc"},{"_id":"385b1a25-0f07-45fd-906a-410c8acbd92e","_updatedAt":"2023-12-19T21:06:11Z","identifier":"interviews","parent":{"_ref":"d39ec421-0b9c-48cf-874a-1003391b925f","_type":"reference"},"_createdAt":"2020-04-23T19:37:55Z","_rev":"NuKmNEJEtqI7CGtQXk1JuD","_type":"taxonomy","name":"Interviews"},{"identifier":"biosimilars","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"name":"Biosimilars","_updatedAt":"2023-11-03T18:20:52Z","_type":"taxonomy","_id":"compendium_biosimilars","summary":[{"_key":"21a8926c2669","markDefs":[],"children":[{"_type":"span","marks":[],"text":"The ","_key":"d9a7c16be264"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"5aab8321660a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"84efcc202b1e"},{"_type":"span","marks":[],"text":" Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.","_key":"2454ce1e8332"}],"_type":"block","style":"normal"}],"perKeywordMapping":["Pharmacy","Health Equity Diversity \u0026 Inclusion"],"cmeType":"per","_createdAt":"2020-04-14T15:02:13Z","_rev":"rs7eCk0lrr8LMiZP9GDaQL"}],"is_visible":true,"title":"Dr Jorge Garcia Speaks About Ambulatory Drug Infusion, Infusion Therapy","_id":"117d11b9-6cb1-4af4-a240-307b943f722d","updatedOn":null,"source":null,"_createdAt":"2023-11-09T16:33:26Z","_rev":"Fax3BF8xst5hMSusggfB9A","summary":"Jorge Garcia, PharmD, MS, MHA, MBA, FACHE, discussed how infusion therapy can be administered as ambulatory drug infusion and its relation to biosimilars."},{"seoTag":["kimberly maxfield","fda","biosimilars"],"authorMapping":[{"firstName":"Brooke","_rev":"A9UM2QVfJg2GpKiBNGLBGh","biography":[{"children":[{"_type":"span","marks":[],"text":"Brooke is an associate editor for ","_key":"8d68730a8da0"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"730c46c984c9"},{"_type":"span","marks":[],"text":"® (","_key":"0b218fbaa571"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"b1b5b3d9cff0"},{"_type":"span","marks":[],"text":"®). She joined ","_key":"7de919198f04"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"f31a60d737e2"},{"_type":"span","marks":[],"text":" in 2023, where she produces written content covering multiple disease states.","_key":"df11193684f8"}],"_type":"block","style":"normal","_key":"936ecf4b7f0c","markDefs":[]},{"markDefs":[],"children":[{"_key":"5731fbb8e0ae","_type":"span","marks":[],"text":""}],"_type":"block","style":"normal","_key":"9af540ce04de"},{"style":"normal","_key":"98aee68dab9d","markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/brooke-mccormick-1a254b1b6/","_key":"80a1c1a9d7cd"}],"children":[{"_type":"span","marks":[],"text":"She has a BA in journalism from Seton Hall University. You can connect with Brooke on ","_key":"bb68b5e8ee83"},{"text":"LinkedIn","_key":"4bb222fe2840","_type":"span","marks":["80a1c1a9d7cd"]},{"_type":"span","marks":[],"text":".","_key":"c87621477700"}],"_type":"block"}],"profileImage":{"alt":"Brooke McCormick","asset":{"_ref":"image-1fe4e81696463cdd9c1d6b62a2e47c2228d7df99-430x430-png","_type":"reference"},"_type":"mainImage"},"_updatedAt":"2025-01-08T16:42:13Z","lastName":"McCormick","authorType":"author","displayName":"Brooke McCormick","_createdAt":"2023-06-21T17:59:19Z","_type":"author","_id":"00af9d05-a2c4-4451-a6d1-0e28b08cbb65","url":{"current":"brooke-mccormick","_type":"slug"}}],"title":"Dr Kimberly Maxfield Highlights FDA's Education Efforts to Increase Biosimilar Comfort","thumbnail":{"asset":{"url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/4cf6cb481888a7102b78a253bb317a345b32d0d3-2880x1603.png","size":5310091,"_updatedAt":"2023-10-20T20:38:03Z","uploadId":"feImgu4WgDO2jRnOFQ66Uafp55P53TPp","_type":"sanity.imageAsset","mimeType":"image/png","_createdAt":"2023-10-20T20:38:03Z","sha1hash":"4cf6cb481888a7102b78a253bb317a345b32d0d3","path":"images/0vv8moc6/ajmc/4cf6cb481888a7102b78a253bb317a345b32d0d3-2880x1603.png","extension":"png","metadata":{"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"height":1603,"_type":"sanity.imageDimensions","width":2880,"aspectRatio":1.7966313162819714},"isOpaque":true,"blurHash":"MmHg4Gu5XUZ#o~~qZ~n$V@oz#*ayj[XTjE","_type":"sanity.imageMetadata","palette":{"lightMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.04,"background":"#9dbbcc"},"vibrant":{"title":"#fff","population":0.05,"background":"#3c9cc4","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"dominant":{"background":"#857c82","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":5.86},"_type":"sanity.imagePalette","darkMuted":{"background":"#304c57","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.03},"muted":{"population":5.86,"background":"#857c82","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightVibrant":{"background":"#6dc8fc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.02},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.52,"background":"#1e5879"}}},"_rev":"DEP8fOtEq5CxLu2TFZuIzG","assetId":"4cf6cb481888a7102b78a253bb317a345b32d0d3","_id":"image-4cf6cb481888a7102b78a253bb317a345b32d0d3-2880x1603-png","originalFilename":"Screen Shot 2023-10-20 at 4.36.04 PM.png"}},"source":null,"link":"/view/dr-kimberly-maxfield-highlights-fda-s-education-efforts-to-increase-biosimilar-comfort","internalTag":["kimberly maxfield","fda","biosimilars"],"contentCategory":{"_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z"},"_createdAt":"2023-10-20T20:28:27Z","taxonomyMapping":[{"_updatedAt":"2023-10-30T17:48:32Z","identifier":"interviews","_createdAt":"2020-03-30T19:16:54Z","sortOrder":3,"_rev":"xqhc4WIQcOa1P2rns6bqkh","_type":"taxonomy","name":"Interviews","_id":"2d909731-8acf-4e3d-8962-d59b0da85320"},{"_createdAt":"2020-04-14T15:02:13Z","_rev":"rs7eCk0lrr8LMiZP9GDaQL","_type":"taxonomy","_id":"compendium_biosimilars","summary":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"The ","_key":"d9a7c16be264"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"5aab8321660a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"84efcc202b1e"},{"_type":"span","marks":[],"text":" Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.","_key":"2454ce1e8332"}],"_type":"block","style":"normal","_key":"21a8926c2669"}],"perKeywordMapping":["Pharmacy","Health Equity Diversity \u0026 Inclusion"],"cmeType":"per","_updatedAt":"2023-11-03T18:20:52Z","identifier":"biosimilars","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"name":"Biosimilars"}],"published":"2023-10-22T13:00:00.000Z","_rev":"NOhr0886Yd9TLpdNsjEkwE","_updatedAt":"2023-10-23T15:14:25Z","updatedOn":null,"factCheckAuthorMapping":null,"is_visible":true,"body":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"ed157a76dd5d0"}],"_type":"block","style":"normal","_key":"d35d56bf7f4b"},{"_type":"video","videoID":"6339544428112","disableAutoPlayVideo":false,"source":"brightcove","_key":"df5553e45195"},{"markDefs":[],"children":[{"text":"Kimberly Maxfield, PhD, of the FDA explained how the FDA is uplifting the US biosimilar industry. Maxfield expanded upon the biosimilars topic during the AMCP Nexus session, \"Biosimilar Operational Readiness: Marketplace Trends and Regulatory Considerations\" on October 17.","_key":"063448cb22dd","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"d45406f7227e"},{"children":[{"_type":"span","marks":[],"text":"","_key":"150e87ab5f86"}],"_type":"block","style":"normal","_key":"3b6856c10768","markDefs":[]},{"_key":"f9a4b9101287","markDefs":[],"children":[{"_key":"0665fb494ad4","_type":"span","marks":[],"text":"At the FDA, Maxfield currently serves as the scientific lead on the Biosimilar User Fee Act (BsUFA) III regulatory research pilot program in the Office of Therapeutic Biologics and Biosimilars (OTBB). "}],"_type":"block","style":"normal"},{"children":[{"text":"","_key":"95f45f3d7b61","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"2d90f684065f","markDefs":[]},{"markDefs":[],"children":[{"_type":"span","marks":["strong","underline"],"text":"Transcript","_key":"4740ed117198"}],"_type":"block","style":"normal","_key":"8b8ce85bef74"},{"_type":"block","style":"normal","_key":"b7d18c3f6cb5","markDefs":[],"children":[{"marks":["strong"],"text":"What do you wish more people understood about what the FDA is doing to uplift the US biosimilar industry?","_key":"649231b867be0","_type":"span"}]},{"_key":"39ff70f3b8df","markDefs":[],"children":[{"_key":"9cb72cba877b","_type":"span","marks":[],"text":""}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"text":"The biosimilar lifecycle includes many pieces of the health care market and industry. We have the development, we have the marketing, we have the formulary access, we have the clinician comfort. FDA is purview in sort of that lifecycle, at the development phase, and in that education phase. ","_key":"f9406e1797aa","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"a8846847593d"},{"children":[{"marks":[],"text":"","_key":"63237ea774ad","_type":"span"}],"_type":"block","style":"normal","_key":"3a5849058432","markDefs":[]},{"children":[{"_type":"span","marks":[],"text":"The regulatory science program is very focused on the time and cost of licensure, so it's very focused on the actual development program, the data package that's submitted as part of a 351(k) application. ","_key":"7b2a60721201"}],"_type":"block","style":"normal","_key":"366301cc27d8","markDefs":[]},{"style":"normal","_key":"5fa0d5f72c26","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"c673f4e36314"}],"_type":"block"},{"style":"normal","_key":"aac7805361d1","markDefs":[],"children":[{"_type":"span","marks":[],"text":"However, the FDA is also doing a lot of educational efforts that are targeting patients, that are targeting providers, that are targeting pharmacists to inform them about what a biosimilar is and how it is different from a generic; that's just to increase comfort. ","_key":"9f89578aefbb"}],"_type":"block"},{"_type":"block","style":"normal","_key":"de987906f291","markDefs":[],"children":[{"_key":"e3f690c1da68","_type":"span","marks":[],"text":" "}]},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"There's a lot of confusion between biosimilarity and interchangeability, and even in FDA's efforts to streamline the development process, we're never compromising on the statutory requirements or the safety and efficacy. Everything we're doing is trying to build on our experience, to build on others' experience. In the product quality information for biosimilars, every biosimilar and every interchangeable is exactly the same.","_key":"b65111a84b4c"}],"_type":"block","style":"normal","_key":"6478286c76ef"}],"url":{"current":"dr-kimberly-maxfield-highlights-fda-s-education-efforts-to-increase-biosimilar-comfort","_type":"slug"},"articleType":"Commentary","_id":"80d184b7-f732-4304-b7e0-2b1e33a5a889","summary":"Kimberly Maxfield, PhD, of the FDA reflected upon how the FDA is uplifting the US biosimilar industry.","ExcludeFromPubMedXML":false,"_type":"article"}],"topArticlesData":[{"_id":"c1ee57b7-5303-4b5b-b488-9499039385ee","url":"fda-approves-celltrion-s-tocilizumab-anoh-biosimilar-to-actemra","summary":"Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, potentially expanding treatment access for patients. ","title":"FDA Approves Celltrion’s Tocilizumab-anoh, Biosimilar to Actemra","thumbnail":{"_type":"mainImage","alt":"FDA approved. | Image Credit: Olivier Le Moal - stock.adobe.com ","caption":"Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, potentially expanding treatment access for patients. | Image Credit: Olivier Le Moal - stock.adobe.com","asset":{"_ref":"image-a0cb6495daeaee9e3fb7822d0e083c4ace68041e-6000x4000-jpg","_type":"reference"}},"published":"2025-01-31T06:45:00.000Z","updatedOn":null,"source":null,"authors":[{"displayName":"Cameron Santoro","url":"cameron-santoro"}],"factCheckAuthors":null},{"_id":"a48a4bdd-8118-49cd-a028-0536ce535acb","url":"embracing-eom-enhancing-collaboration-and-cost-management-dr-kirollos-hanna","thumbnail":{"caption":"Kirollos Hanna, PharmD","asset":{"_ref":"image-f698018f94ae99ba6f548f81a15462f47765951b-1280x720-png","_type":"reference"},"_type":"mainImage","alt":"Kirollos Hanna, PharmD"},"source":null,"authors":[{"displayName":"Kyle Munz","url":"kyle-munz"},{"displayName":"Kirollos Hanna, PharmD","url":"kirollow-hanna-pharmd"}],"factCheckAuthors":null,"title":"Embracing EOM, Enhancing Collaboration and Cost Management: Dr Kirollos Hanna","summary":"The design of the Enhancing Oncology Model (EOM) was a perfect fit for Minnesota Oncology. ","published":"2025-01-29T15:11:00.000Z","updatedOn":null},{"updatedOn":null,"authors":[{"displayName":"Cameron Santoro","url":"cameron-santoro"}],"url":"ustekinumab-biosimilar-launches-in-france-shifts-the-autoimmune-disease-market","thumbnail":{"caption":"An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving the way for its US launch | Image Credit: lazyllama - stock.adobe.com","asset":{"_ref":"image-67ae50f595958a4eed000662539d417cc02de7f4-4230x2815-jpg","_type":"reference"},"_type":"mainImage","alt":"France | Image Credit: lazyllama - stock.adobe.com"},"published":"2025-01-27T14:13:00.000Z","source":null,"factCheckAuthors":null,"_id":"ea0bfd17-40cb-4307-a604-1f0fb9c240a9","title":"Ustekinumab Biosimilar Launches in France, Shifts the Autoimmune Disease Market","summary":"An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving the way for its US launch."},{"_id":"217e5e24-3532-4051-8ad0-32c87a36c6a3","url":"biosimilar-market-share-growth-and-price-trends-in-q1-2025","authors":[{"displayName":"Cameron Santoro","url":"cameron-santoro"}],"factCheckAuthors":null,"title":"Biosimilar Market Share: Growth and Price Trends in Q1 2025","thumbnail":{"_type":"mainImage","alt":"Market share. | Image Credit: sirichai - stock.adobe.com ","caption":"Samsung Bioepis' Q1 2025 report shows oncology, ophthalmology, and pegfilgrastim biosimilars have gained significant market share, while immunology, filgrastim, epoetin alfa, and insulin glargine biosimilars have grown more slowly. | Image Credit: sirichai - stock.adobe.com","asset":{"_ref":"image-b0ba6e9ce73571eb664a160694081ebd5573c86c-8191x4672-jpg","_type":"reference"}},"summary":"Samsung Bioepis' Q1 2025 report shows oncology, ophthalmology, and pegfilgrastim biosimilars have gained significant market share, while immunology, filgrastim, epoetin alfa, and insulin glargine biosimilars have grown more slowly.","published":"2025-01-23T17:30:53.608Z","updatedOn":"2025-01-23T17:05:20.821Z","source":null},{"title":"Patent Litigation Impacts on US Biosimilar Market Entry","updatedOn":null,"source":null,"authors":[{"displayName":"Cameron Santoro","url":"cameron-santoro"}],"_id":"e1e9a47b-ce50-480a-9bc6-e94b7e94276f","thumbnail":{"_type":"mainImage","alt":"Patent litigation. | Image Credit: LALAKA - stock.adobe.com ","caption":"Earlier patent litigation can be reformed to reflect similar success across Europe, resulting in accelerated US biosimilar market entry. | Image Credit: LALAKA - stock.adobe.com ","asset":{"_ref":"image-35552823be3bf28539562545d1d65e2aad82fe15-8256x5504-jpg","_type":"reference"}},"summary":"Earlier patent litigation can be reformed to reflect similar success across Europe, resulting in accelerated US biosimilar market entry.","published":"2025-01-22T17:00:00.000Z","factCheckAuthors":null,"url":"patent-litigation-impacts-on-us-biosimilar-market-entry"}],"features":[],"cmeData":{"msg":"","data":[{"id":"2bfeb2a2-17ae-49a2-9a42-f5875df7fb07","brandName":"Ajmc","dataType":"ptce","title":"New and Approved: FDA’s 2024 Drug Lineup","thumbnail":"https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/d2afb412-3c3e-4f73-b3d6-2388078622a3/f1up0oihf0qd-PTCE_FDA-PT_Article_012725v2_800x385.png","description":"1.5 Credits / General Pharmacy","releaseDate":"2025-01-06T05:00:00.000Z","expirationDate":"2026-01-07","creditType":"On-Demand","creditAmount":"1.5","created_at":"2025-02-10T12:05:52.295006+00:00","TI_id":"8572b94f-ea24-40ed-aa64-2b208dcbc6c3","slug":"new-and-approved-fdas-2024-drug-lineup","delReference":true,"contentTypeLabel":"Online Article","activity-type":null,"specialty":"[\"General Pharmacy\"]","creditCertificate":null,"courseEndDate":"2026-01-07T04:59:59.999+00:00","cventUrl":"","eventData":null,"imageUrl":null}],"fail":false},"videoData":{}},"queryString":{"slug":["compendium","biosimilars"]}},"host":"www.ajmc.com"},"__N_SSP":true},"page":"/[...slug]","query":{"slug":["compendium","biosimilars"]},"buildId":"IRrGcHGbYOSE-7JrEGg8a","isFallback":false,"gssp":true,"appGip":true,"scriptLoader":[]}</script></body></html>